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Abstract 
Aims and objectives 
Substance misuse is a chronic relapsing condition associated with high morbidity and 
mortality. Treatment attempts to reduce harms associated with drug use and to promote 
recovery and has developed considerably in the last 30 years. Opioid substitution therapy 
using methadone (OST-M) is an effective treatment for opioid dependency. Though the 
effectiveness of OST-M in delivering harm-reduction is well evidenced, evidence 
demonstrating recovery is limited as is understanding of those factors influencing progress. 
In this context, national policy makers and stakeholders have repeatedly questioned the 
value of OST-M as a substance misuse treatment and, at times, have sought to limit its use. 
Rigorous, long term outcome studies of UK subjects are required to improve clinical 
outcomes in OST-M subjects and to ensure ongoing availability of evidence-based 
treatments.  
 
In this context, the study had two main objectives: to demonstrate that standard clinical 
information systems can deliver rich, valid datasets to support outcome research; to use 
these data to explore the relationships between a selection of baseline variables (patient 
characteristics, comorbid conditions, the nature of substance misuse and the treatment 
received), the clinical process and long term outcomes achieved in a large cohort of OST-M 
patients in a standard NHS treatment setting.  
 
Methods and materials 
Standard clinical information, collected over 7 years, was linked with validated data from a 
range of databases. A large representative sample (76% of the OST-M treatment population 
in a region) was described in detail. Follow-up data were retrieved from clinical casenotes (4 
years) and linked datasets (4-7 years) and collated to create a database for analysis. 
Variables for analysis were selected following a review of the published literature. 
Univariate analyses were undertaken to demonstrate statistically significant associations 
between baseline and follow-up variables. Significant variables were then entered into 
multiple regression analyses to develop predictive models for selected outcomes. Any 
ix 
 
predictive models were then subjected to cross-validation to determine their predictive 
power in novel datasets. 
 
Key results 
Many highly significant associations were shown. Significant personal (demographic) factors 
included:  age, gender, having children, having conflict in personal relationships, educational 
level achieved and being in employment. It was notable that the area lived in (of three 
districts) was strongly associated with a wide variation in clinical process and outcomes 
achieved. Whether treated in primary care or specialist services, the medical treatments 
received, the level of non-NHS support and patient satisfaction showed strong associations 
with outcome. Baseline illicit drug use was also strongly associated with outcome. 
 
Multiple regression analyses found that despite these highly significant associations, strong 
predictive models of long terms outcome could not be demonstrated. Where weak models 
were created - predicting drug use (by self - report); drug use (positive tests); family stability 
- cross validation showed these had no predictive value in novel datasets. 
 
Conclusions 
Standard clinical information, linked with relevant NHS datasets can give rich and 
comprehensive data suitable for research of large representative samples over long time 
periods. This study represents one of the largest OST-M populations ever described in the 
UK with longer follow-up periods than most of the published literature.  
 
In this study strong associations were found between a range of independent and 
dependent variables over 4-7 years. These findings broadly reflected the evidence base. 
However, the associated variables could not generate strong useful predictive models of 
long term outcome. This could reflect issues of study design or data quality. 
 
This type of approach should be further developed in the field of substance misuse research. 
Issues of data quality would require to be addressed to maximize the value of these 
datasets. Further research is required to develop better understanding into key factors 
influencing long term outcomes of treatment in substance misuse.  
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Chapter 1. The treatment of opiate dependency in the UK – a political 
analysis 
 
No science is immune to the infection of politics and the corruption of power.… The time has come to consider 
how we might bring about a separation, as complete as possible, between Science and Government in all 
countries. I call this the disestablishment of science, in the same sense in which the churches have been 
disestablished and have become independent of the state.  
 
Jacob Bronowski - Encounter (1971) 
 
 
Dogbert: So, Since Columbus is dead, you have no evidence that the earth is round. 
Dilbert:  Look. You can Ask Senator John Glenn. He orbited the earth when he was an astronaut. 
Dogbert: So, your theory depends on the honesty of politicians. 
Dilbert:  Yes... no, wait 
Scott Adams -Dilbert comic strip (1989). 
 
 
A strategic approach to problem drug use in the UK 
 
Introduction 
 
The use of psychoactive substances precedes recorded history and some suggest may even 
have contributed to human neurodevelopment (Hill & Newlin 2002). The problematic use of 
such substances has also been described for centuries but from the second half of the 20th 
century has been acknowledged as a large and increasing public health problem across the 
world, evoking responses from international and national institutions aiming to reduce the 
harm caused by substance use (United Nations Office on Drugs and Crime [UNODC], 2008; 
Babor et al 2010). Substance misuse can have complex impacts on the individual, with 
potential effects on physical and psychological health as well as social functioning. Its worst 
effects often impact on the most excluded and disadvantaged in society. Central to any 
response to address substance misuse, it is important that policy-makers take cognisance of 
the best available information and research evidence, use this objectively and avoid the 
temptation to bring moral or political judgements to bear. 
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Addressing substance misuse in the United Kingdom (UK) 
In its final report, the independent UK Drug Policy Commission (UKDPC) states: 
“Drug policy is currently a mix of cautious politics and limited evidence and analysis. This is 
coupled with strident and contested interpretations, both of the causes of problems and the 
effects of policies. In fact, for as long as there has been a drug policy, there have been gaps 
in the evidence as well as uncertainty about how to understand and act on the evidence that 
we do have” (UK Drug Policy Commission [UKDPC] 20121) 
This statement is extremely relevant when we consider the current state of flux around the 
treatment of opioid dependency in the UK.  
 
The way we manage people experiencing substance use problems in the UK has changed 
dramatically over the last 25 years (Kidd & Sykes 1999; Kidd 2010). This change has often 
been driven by fears regarding the safety and health of society as a whole rather than 
specific concerns for the individual’s needs or wishes. Large changes in policy direction, 
service capacity or clinical process can occur swiftly – reflecting political will or the 
emergence of a new drug-related threat.  The inconsistent quality of information available 
to inform how we should best manage such problems raises challenges at all levels. Simply 
understanding the magnitude of the problem to be addressed is problematic. Assessment of 
the size of “hidden populations” is innately complicated and uses indirect sampling models 
to estimate prevalence (Frischer & Taylor 1999; Hickman et al 1999; Hay 2000). In the UK, 
information about those who are accessing services is supplied by the Criminal Justice 
System (CJS), National Health Service (NHS) and various social care agencies. But the 
different countries, regions and even districts within the UK have developed diverse 
methods of data collection or have in place differing mechanisms of governance for such 
systems (Information Services Division [ISD] 2012; Health & Social Care Information systems 
2011). This makes the interpretation of findings or comparison between geographical areas 
or treatment approaches challenging – even in the UK, where one major service element, 
the NHS, has traditionally delivered a substantial element of the care process – medical 
treatments.  
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Substance misuse brings many detrimental effects on health and society. During the last 
quarter of a century, the substance misuse problem in the UK has increased greatly in terms 
of raw numbers as well as its effect on society (ISD 2012; Health & Social Care Information 
systems 2011). The demands this places on key public institutions including the NHS and CJS 
make it imperative that scientific scrutiny of the available interventions and clinical 
treatments to address the problem is as robust and objective as possible. 
 
Information, experimental change and evaluation 
The 2012 UKDPC report, cited above, goes on to give a critique of the current state of 
information systems to inform the best way to manage drug problems in the UK. The report 
states: 
“The way we collect analyse and use evidence in UK drug policy has often been inadequate 
and this has held back cost-effective policies that could have improved the lives of millions of 
people” (UKDPC 20121).  
 
They recognise that full blown Randomized Controlled Trials (RCTs) may not always be 
required to demonstrate effectiveness but also acknowledge that, when such scientific 
rigour is seen as less relevant, “too often we have slipped to the other extreme and relied 
simply on anecdote”.  The report authors have the view that, in the drugs field, evidence is 
not given the same position as in other health and social care areas. Instead, “evidence is 
often treated as a stakeholder whose interests should be taken into account, rather than a 
tool that is useful for all participants.” This is clearly an issue which could stand in the way of 
progress and the UKDPC makes a plea for a “new and more mature relationship with 
evidence”. Examples of the change required would include:  having a willingness to be 
guided by evidence and avoidance of “cherry-picking” of the evidence when the outcomes 
are politically challenging; recognising different levels and forms of evidence; being clear 
regarding the objectives of any intervention being evaluated and accepting both negative 
and positive results from evaluations of new initiatives or pilot studies. 
 
The issues raised by these examples echo a long-standing view, expressed in numerous 
advisory documents for successive governments, that good quality information, a culture of 
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evaluation and objective analysis and support for a coordinated programme of research 
would place policy–makers in a stronger position when difficult strategic decisions are 
required.  
 
In Scotland, for example, significant increases in service funding were supported by the first 
Scottish Executive in 1999 after a long period when new funding for treatment was largely 
unavailable.  The Scottish Advisory Committee on Drug Misuse  (SACDM) set up a research 
sub-committee, supported by the Effective Interventions Unit (EIU) – a newly created and 
innovative support unit, tasked with producing authoritative evidence for the substance 
misuse field in Scotland - and co-opted leading Scottish academics to advise on how best to 
evidence the government’s strategic aims. Regarding treatment, this final report stated: 
“There is a commitment within the UK and Scottish drug misuse strategies to develop 
effective drug misuse treatment services. This aim is currently hampered by the lack of 
detailed information on the effectiveness of drug misuse services within Scotland. Where 
research has been undertaken into the provision of methadone this would appear to have an 
important role in the treatment of opiate dependent drug misusers. However, it is not 
possible to say within Scotland what the long term impact of drug misuse treatment services 
is. There is a need to develop a programme of drug misuse treatment evaluation that is both 
comprehensive in its coverage across Scotland and in its inclusion of the range of treatment 
modalities that are currently available within Scotland.”  (McKeganey & McIntosh 2000) 
 
Despite this advice, some 13 years later, Scottish ministers have continued to struggle when 
questioned regarding the effectiveness of Scottish treatment services (Chief Medical officer 
for Scotland, 2012). There is clearly a need to address this deficit in information and 
intelligence. 
 
The changing political map in the UK 
At the same time as the treatment of substance misuse has been evolving so dramatically, 
there has been a shift in the political balance in the UK, with disaggregation of national 
governments to Scotland, Wales and Northern Ireland in the late 1990s. As responsibility for 
local government, health, social care and criminal justice policy has been devolved, to some 
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degree, to these new national administrations, there has been a divergence in the 
approaches taken to prevent the development of substance use problems or to intervene to 
manage them. In 2012 the implications of this political divergence has been highlighted 
further, with six different political parties – including two coalitions -  in power across four 
administrations. Meantime, the Westminster (UK) government retains responsibility for all 
UK legislation regarding controls over drugs with abuse potential (Crown Office 1998). With 
substance misuse an area which is strongly influenced by socio-political drivers, this 
situation raises risks regarding the consistency of service delivery across the UK. 
 
It is important to recognise that, as this political turmoil is acted out in the UK, there is a 
broad consensus around the world regarding how substance misuse is best understood and 
addressed (UNODC, 2008). However, even with this consensus in place, in the UK there is 
ongoing debate regarding the nuances of what services should be achieving when they treat 
substance misusers – at times coloured by a moral judgement within society expressed 
through the media and periodically influenced by politicization of the drugs debate. This is 
not a new phenomenon. Indeed, there has been a tension between clinical opinion and 
political will in the UK for over 100 years with regard to these issues. There is also a long-
standing trans-Atlantic perspective, with consecutive US governments keen to publicly 
support a “war on drugs” and an approach to drug treatment which is more skewed towards 
abstinence and rehabilitation than harm reduction or risk management.   
 
European approaches have, as a rule, engendered a more pragmatic approach. For example 
the European Union Drugs Strategy (2005-12) stated its [demand reduction] aims as 
achieving: 
“Measurable reduction of the use of drugs, of dependence and of drug-related health and 
social risks through the development and improvement of an effective and integrated 
comprehensive knowledge-based demand reduction system including prevention, early 
intervention, treatment, harm reduction, rehabilitation and social reintegration 
measures within the EU Member States. Drug demand reduction measures must take 
into account the health-related and social problems caused by the use of illegal psychoactive 
substances” (Council of the European Union 2004) 
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It is in this strategic context that the new devolved administrations in the UK have recently 
redefined their expectations of treatment for substance misuse. 
 
Current UK and Scottish Government Strategies 
In the last 4 years, both the Scottish and UK Governments have brought forward new 
strategies to address the drug problems experienced across the country. These strategies 
have some similarities – with both seeing the status quo as in need of major change and 
claiming to aspire to deliver an enhanced culture of recovery for drug users seeking 
treatment.  
 
When considering what can be achieved, the Scottish strategy – The Road to Recovery – 
states: 
“In practice recovery will mean different things at different times to each individual… 
[It]... might mean developing the skills to prevent relapse…rebuilding broken 
relationships... Milestones may be as simple as gaining weight... or building self-
esteem. What is key is that recovery is sustained.” (Scottish Government 2008) 
There is acknowledgement of the achievements to date of the long-established harm 
reduction approaches but also an aspiration to move the balance of care towards more 
individualized progress which better supports the reintegration of substance misusers into 
their own communities.  
 
The UK (Westminster) Government’s strategy - Drug Strategy 2010. Reducing Demand, 
Restricting Supply, Building Recovery: Supporting People to Live a Drug-Free Life – addresses 
drug problems in England and Wales. It places more responsibility on the legal system to 
control illegal drug availability. It does also point towards a recovery agenda for treatment-
seeking individuals, stating:  
“A fundamental difference between this strategy and those that have gone before is that 
instead of focusing primarily on reducing the harms caused by drug misuse, our approach 
will be to go much further and offer every support for people to choose recovery as an 
achievable way out of dependency…..The causes and drivers of drug and alcohol dependence 
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are complex and personal. The solutions need to be holistic and centred around each 
individual, with the expectation that full recovery is possible and desirable.” (Home Office 
2010) 
 
These strategies make it clear that, during this period, the focus of treatment is changing 
substantially in the UK for the first time since the 1980s. If we do not put these current 
developments into an historic context we are in danger of revisiting old arguments – pitting 
the pragmatism of “harm reduction” against the aspiration of “abstinence” - repeatedly 
with no likelihood of resolution. At worst, this could mean that evidence-based treatments, 
known to be effective at reducing drug-related harms and death, may become less available 
to substance misusers in the UK, largely for socio-political reasons. At best, it points to a 
continuation of the shabby stigmatization of a highly vulnerable group within society which 
is at high risk of a range of morbidities, social disadvantage and premature death. 
 
The following section will briefly summarize how policy has evolved in the UK in recent 
decades. 
 
UK Drugs policy: a recent  history 
 
The approach to managing drug problems in the UK has long been the subject of political 
and clinical debate. The main points of this discussion are summarised briefly below. A more 
detailed analysis is contained in a number of publications (e.g. Royal College of Psychiatrists 
1987; Stark, Kidd & Sykes, 1999; Strang & Gossop 2005).  
 
20th Century – opium and the British System of care up to the 1960s 
The main illicit drug problems in the UK have been dominated by the use of opioids in 
recent years. Opioids can be defined as: 
“any of a group of substances that resemble morphine in their physiological or 
pharmacological effects, especially in their pain-relieving properties”  
https://wwwcollinsdictionary.com/dictionary/english/opioid  
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Opiates are naturally occurring opioids, specifically associated with the opium poppy. 
Opiates can be defined as: 
“ an addictive drug made from the opium poppy that has morphine-like, soothing effects”  
http://www.yourdictionary.com/opiate 
 
For over a century, the problems associated with illicit opioid use in the UK were managed 
under an approach known as The British system. The British System could be seen as having 
been in place as early as the 18th century. At this time Britain was a global superpower and 
its active opium trade in the east meant that opium and its derivatives were readily 
available within the UK. Inevitably, British subjects became addicted to opiates, and doctors 
would attempt to alleviate their suffering, often by prescribing opioid drugs. This practice 
was not seen as problematic by society and was essentially free of governance until the 
early 20th century.  The first world war saw initial governmental controls appearing which, 
for the first time, made the possession of some substances, such as cocaine, illegal for the 
general public, though doctors were still seen as legitimate suppliers of these substances if 
they were medically required (Berridge, 1984).  
 
However, it is felt that the modern view of the British System is best captured in the work of 
the Rolleston Committee of 1926 (Departmental Committee on morphine and heroin 
addiction, 1926). The British System is often understood to be an approach to the problem 
of opioid addiction which was person-centred, avoided the kind of confrontational 
difficulties seen in the USA (where there had been a strong abstentionist bias) and allowed 
doctors to help people to overcome any problems associated with their substance use, 
often by offering them a safe and legal supply of prescribed opioid drugs.  An alternative 
analysis suggests that at its start, the problem to be addressed was minimal - as there were 
very few problem substance users - and the approach of replacement prescribing which was 
embodied in the British System has been described as “a system of masterly inactivity in 
face of a non-existent problem” (Downes, 1988). What is clear, is that the drug users 
accessing medical care at that time – which continued up to the 1960s - were 
demographically very  different from the current stereotype, described as “more likely to be 
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female, middle-aged or elderly, and from the middle classes; a substantial minority were 
themselves doctors or allied professionals.” (Strang & Gossop 2005). 
 
There is no doubt of the tidy pragmatism contained in the British System.  But there is also 
the worrying seed of a reductionist approach to dealing with the complex problems 
associated with substance misuse by using simply medical approaches.  When the Rolleston 
Committee recommendations are examined it is clear that replacement prescribing by 
doctors of opioid drugs is proposed as only a part of the solution and not the solution in 
itself.  There is an assumption that the physicians will also be helping individuals to address 
associated problems and a sense that improvement (or recovery) is implicit in this approach. 
This important point becomes relevant in the context of the current debate. 
 
The 1960s – social control of an expanding challenge 
The British System was the basis of the approach to address substance use problems until 
the 1960s when a sudden increase in problematic drug use – particularly through injecting  
in younger people and centred on London - saw a reaction from the UK Government to 
increase controls over this new and expanding problem. In response, two Department of 
Health committees within 4 years made recommendations to government on how to 
address heroin and cocaine use – reflecting the speed of this change (Ministry of Health 
1961; 1965). A Home Office committee also considered responses to reports of increasing 
cannabis use during the same period (Home Office cannabis report, 1968). From this point, 
increasing controls over the manufacture, storage and movement of a range of “controlled” 
drugs and a move to reduce General Practitioners’ prescribing of opioids became the norm. 
Instead, replacement prescribing of opioids – such as prescribed pharmaceutical 
diamorphine (heroin) - became a more specialist activity and government strategy became 
more aimed at helping individuals detoxify from their addiction (Royal College of 
Psychiatrists, 1987).  Though a group of individuals continued to access prescribed heroin 
from doctors, a drive towards detoxification/abstinence was broadly supported through the 
1960s and 1970s until the appearance of blood borne virus problems in injecting drug users 
heralded another change of direction.   
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1980s: Blood-borne virus infection, HIV and AIDS – the re-birth of UK harm reduction 
Hepatitis B infections had raised initial public health concerns in the late 1970s, but it was 
the link with HIV which drove real change in the strategic approach to drug misuse. In the 
face of compelling evidence that injecting drug users had a high prevalence of HIV infection 
in parts of Scotland (Robertson et al 1986; Robertson, Bucknall & Wiggins 1986), the 
McLelland Committee recognised that the public health risk of HIV was potentially greater 
than the risk of substance misuse. In response their landmark report made 
recommendations to increase availability of prescribed opioid replacement treatments – 
such as methadone – and to take forward the delivery of limited needle exchange schemes 
for injecting drug users (Scottish Home & Health Department, 1986).  In England, a similar 
process was proposed and in the name of harm reduction – a pragmatic treatment 
approach which promoted the achievement of a range of intermediate goals rather than 
focussing solely on the achievement of abstinence -  new community treatment teams were 
developed to address the rapidly increasing challenge (Advisory Council on the Misuse of 
Drugs [ACMD], 1988). General Practitioners (GPs) were again encouraged to prescribe 
opioids to reduce the likelihood of illicit substance use (ACMD, 1989). The first substantial 
UK treatment guideline in 1991 made replacement prescribing with methadone a real 
consideration for all doctors if dealing with injecting opioid dependent drug users 
(Department of Health, Scottish Home & Health Department, Welsh Office 1991). 
 
The next 15 years saw a c-change in delivery. Achieving a reduction in drug-related harm 
was now the focus of treatment interventions for illicit drug users. As this approach 
developed and clinicians, service commissioners and politicians grew more comfortable with 
the concept of harm-reduction, the idea spread into more and more areas of the substance 
misuser’s life. Clinical professionals moved their focus away from the goal of rehabilitation 
of substance users, instead developing a more pragmatic focussed approach which aimed to 
reduce injecting, and the associated biological, psychological and social risks that this 
activity brought with it. 
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The 1990s to the new Millennium – Expansion of “harm reduction” into social care 
As the 1990s progressed, the prescribing of replacement opioids started to become a 
credible solution for a widening range of social ills – such as drug-related criminal activity. 
Criminal Justice departments started to invest in treatment services for criminals. For 
example, Arrest Referral Schemes were first launched in the UK in 1996 and focussed on 
hard-to-reach individuals, with the aim of giving immediate access to treatment 
[prescribing] which was thought to have potential in reducing criminal activity (Effective 
Interventions Unit [EIU], 20021). Recognising the close link between recidivist crime and 
illicit drug use, Drug Treatment and Testing Orders (DTTOs) were initially piloted in the UK in 
1998. They linked sentencing with mandatory treatment (meaning opioid replacement 
prescribing and testing) – often as an alternative to custody.  Though, following evaluation 
(Home Office 2000; Scottish Executive 20022) they were superseded in England, they have 
been retained in a modified form in Scotland. Another huge development was that in the 
mid-1990s it became more acceptable for medical staff inside Scottish prisons to treat drug 
users using treatments more in line with available community treatments when they had 
previously received only symptomatic relief if treated at all (Scottish Prison Service [SPS], 
1994). 
 
Nor was this move towards broadening harm reduction limited to the Criminal Justice 
System. Concerns about pregnant drug users, their children and the broader child & family 
implications of substance misuse also drove a change in the area of child protection. Soon 
opioid replacement was being proposed as an essential element of managing risk to children 
in the families of drug misusers (Scottish Executive, 2001).  
 
There followed a clear change of emphasis in the treatment process. Previously, the process 
of care for substance misusers involved a comprehensive assessment of need. Experienced 
professionals would determine the nature of the substance use disorder through objective 
assessment and would offer one of a range of treatment approaches, tailored to that 
person’s needs and strengths as part of an ongoing programme of care. Now there was an 
expectation that services would give rapid access to (mainly) opioid substitution therapies 
aimed at stabilisation of drug use and harm reduction rather than detoxification or 
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abstinence. Opioid substitution therapy had become the treatment of choice for a whole 
range of physical, psychological and social issues which may be affected by drug use. 
 
But early in the new millennium, this harm reduction approach, which seemed to herald a 
significant change in the nature of the debate around how best to address substance 
misuse, was gradually seen by some in the UK as part of the problem rather than the 
solution.  New performance management structures for English services were set up by the 
English National Treatment Agency (NTA) – a special health authority tasked with improving 
effectiveness of treatment for substance misusers. Aiming to improve substance misuse 
services in England, the NTA focused its attention on reducing delays to accessing treatment 
and measures of treatment retention - rather than the delivery of improved outcomes. 
Training of doctors (such as General Practitioners) and other professionals in the field 
almost exclusively emphasized the medical (prescribing) aspect of care with training 
concerning the development of skills around psychological support and delivery of social 
interventions given little prominence.  Indeed, the 1999 updated national treatment 
guideline gave little mention of the place for so-called “wraparound services” (Department 
of Health et al, 1999). Reports of activity showed that more and more people were starting 
on opioid replacement therapy – mainly with methadone - in the UK, with services being 
accessed by record numbers (ISD, 2002).  
 
Critics of harm reduction in general and methadone in particular began to publicly portray 
this approach as detrimental to progress, claiming that users received methadone – the 
most commonly used substitute drug - but no additional support to progress – becoming 
“parked” on methadone.  This negative view started to gain media and political support.  
With very high proportions of drug users in treatment on methadone (and by the 
millennium, the newly introduced alternative, high dose Buprenorphine) and availability of 
detoxification, abstinence orientated approaches or non-prescribed alternatives reducing, a 
sense of confrontation developed (Kidd, 2010).   
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“The New Abstentionists” and “The Great Debate” 2008 
In 2008, the journalist Mike Ashton published his critique The New Abstentionists as a 
special insert in Druglink the house journal of the organisation Drug Scope (Ashton, 2008).  
This followed an interview on the BBC Radio 4 “Today” programme, in which the Chief 
Executive of the NTA – following publication of that organisation’s annual report - had been 
asked how many people had successfully completed treatment in England in the previous 
year. His answer of “3%” had become a major news story, with the media debate suggesting 
that the UK drug treatment programme was failing. Ashton’s article critically analysed the 
evidence to date on treatment effectiveness and, concluding that the evidence for harm 
reduction approaches was sound, raised concerns that there was a political shift around the 
UK, with politicians of all colours struggling to hold a firm line in support of harm reduction - 
instead being beguiled by claims that abstinence-based approaches could turn the tide of 
increasing numbers of problematic drug users and improve treatment effectiveness.   
 
The article stimulated considerable interest and rekindled the previously dormant 
‘either/or’ - abstinence or harm reduction - debate in the UK.  In response, the Drug Scope 
charity organized three Great Debates across the UK. The purpose of these events was to 
allow those dealing with these issues – service delivery staff, commissioners, service users 
and their families - to hear opinions from those who held polarized views - and to 
participate in a facilitated discussion on the topic. It is questionable whether these events 
were successful - in that the records of the discussions suggest they simply allowed rather 
fixed views to be aired in, what was at times, a hostile and polarized environment.  A 
summary document was published which tried to ensure the discussion was articulated in 
an objective and balanced manner (Roberts, 2009). The Great Debate may however, have 
ensured that, as UK governments developed their plans, they had some awareness of the 
potential pitfalls of holding simplistic views regarding the relative merits of abstinence or 
harm reduction approaches. 
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An international perspective – the recovery consensus statements 2007/8 
In 2007 The Betty Ford Institute in the USA had carried out a process to develop a consensus 
statement on “recovery” - aiming to give a working definition which people involved in the 
field at all levels could see as relevant to their practice (Betty Ford Consensus Panel, 2007).  
In the context of the new invigorated (but polarized) discussion in the UK, this initiative gave 
an opportunity for those from the different schools of thought in the UK to work together to 
develop a consensus view of what all services should be trying to deliver. The UK Drug Policy 
Commission progressed this work, publishing their consensus statement in 2008 (UKDPC, 
2008). The following draft statement was agreed by the UKDPC group: 
“The process of recovery from problematic substance use is characterized by 
voluntarily sustained control over substance use which maximizes health and 
wellbeing and participation in the rights roles and responsibilities of society”  
The statement was then taken into the field for comment by a wide group of stakeholders - 
including service users, professionals and strategists. A consistent view from this process 
was that the statement did seem to capture the correct tone - allowing many views of 
addiction to be seen as relevant - and potentially opening the discussion to allow a more 
diverse range of interventions, with more individual significance, to become available. The 
Royal College of General Practitioners' (RCGP) consulted its own membership. They found 
that 74% of their members, who had involvement with and training in the treatment of drug 
users, were supportive of the statement (RCGP, 2008). 
 
In summary, the ability of substance misusers to recover was being actively debated and a 
focus of this debate became the value (or otherwise) of Opioid Substitution Therapy – OST – 
and the drug most commonly used in the UK for this purpose, methadone.  
 
The treatment of opioid dependence – Methadone and Opioid Substitution Therapy (OST) 
 
Opioid Substitution Therapy has been a central element of the medical response to opiate 
dependency for many years and, as described earlier, had formed the basis of the “British 
System”, in which doctors pragmatically supported their patients, who had become addicted 
to opioid drugs, by prescribing a safe supply of these drugs to allow them to carry out their 
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responsibilities. The early days of the British System saw doctors prescribing opium and 
morphine, and later diamorphine. In recent years however, the most prominent prescribed 
medication used in OST across the world and in the UK is 6-Dimethylamino-4, 4-Diphenyl-3-
Heptanone - or methadone – a long-acting synthetic opioid.  
 
Methadone 
Methadone was first developed in 1937 in Germany (Figure 1) by scientists seeking a 
synthetic opioid analgesic to address an acute shortage of opium in that country at a time 
when there was a strong political drive to make the German state more independent of 
world trade. However, it was not widely used as in early tests it was found to promote 
behaviours which were not desirable in the military environment.  Nor was the drug made 
freely available to the civilian community. These early developments and links with Fascism 
have developed to an almost mythological level. It was named Dolophine in the USA by the 
Eli Lilly company – and opponents to its use still mis-name it Adolphine, believing (wrongly) 
that it was named after Adolf Hitler, seeing this as a reason to be doubtful about its place in 
clinical care (Herman, Stanclif & Langrod 2000; Gerlach 2004). 
 
Figure 1. early German Methadone patent 
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After the Second World War, all German patents and research records were requisitioned 
and expropriated by the allies. The records of the research work on methadone and other 
opioid drugs were confiscated by the U.S. Department of Commerce Intelligence, 
investigated by a Technical Industrial Committee of the U.S. Department of State and taken 
to the USA. (Council on Pharmacy and Chemistry of the American Medical Association, 
1947). In 1949 researchers in Kentucky showed methadone to be effective at helping heroin 
addicts in short term detoxification programmes (Isbell &  Vogel 1949). However, trials 
repeatedly showed high levels of relapse once an addict had detoxified and it was some 
years before methadone’s potential was realised (Brecher, 1972).  
  
In the post war period, heroin addiction flourished in some parts of the USA – such as New 
York City (Andima, Krug & Bergner,  1973). Opiate overdose became the most common 
cause of death for young adults in New York and criminal activity relating to heroin use was 
widespread (Halpern & Rho 1966). Debate regarding a policy to address this issue in the USA 
progressed through the 1950s and early 1960s. In 1964, investigation of methadone 
maintenance therapy began as a research project at The Rockefeller University under the 
direction of Drs. Vincent Dole and Marie Nyswander whose seminal work progressed 
understanding of the potential of methadone OST and its potential mode of action (Dole & 
Nyswander, 1965; Dole, Nyswander & Kreek, 1966; Dole, 1988).  
 
Early use in the UK 
Methadone use was reported as early as the 1940s in the UK – when it was being trialled as 
a potential analgesic (Prescott & Ransome, 1947).  In the 1960s use of illicit drugs was 
increasing and raising concerns for the government. Illicit methadone use was one feature 
of this change. By the end of 1968, when Home Office notification of addicts became 
compulsory in the UK, 297 people had been notified as addicted to methadone. By 1969, 
this number had risen to 1687. In the UK at this time, methadone was not subject to 
significant controls over prescribing and by the end of 1969, in central London, there were 
serious concerns about availability of illicit methadone. This may have originated from 
poorly controlled medical prescribing and diverted supplies of injectable methadone were 
being extensively used alongside diamorphine tablets (or “jacks”) also prepared for injecting 
- “jacking up” (Edwards & Busch, 1981).  Previous sections of this chapter have shown how 
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national strategic responses aimed to reduce availability of prescribed opioid drugs – with a 
move towards less OST and more detoxification or abstinence-orientated treatments.  
Coincidentally, in some areas of the UK, clinicians began to reconsider maintenance 
prescribing. For example a Glasgow study in 1975 reported that when new patients were 
not prescribed methadone they did as well as those who were prescribed - except for 
criminal behaviour (Paxton, Mullin & Beattie 1978). The value of OST was being brought into 
question. 
 
But in the 1980s a second step-change in illicit drug use occurred in the UK. This time there 
was a much broader geographical spread, beyond the cities and also associated with a much 
wider population of poorer, working class drug users who were less prone to inject drugs – 
smoking them instead – “chasing the dragon” (Home Office, 1986).  The initial national 
response was to continue to offer detoxification programmes – often using short term or 
time limited prescribed  methadone. However, blood-borne virus infection – in particular 
the appearance of HIV/AIDS in the public consciousness changed how drug use would be 
managed for decades (Figure 2).   
 
Figure 2. AIDS Public Health Poster (c1987) 
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The emergence of a potential link between HIV infection and injecting drug use – first 
identified in Edinburgh – re-energized the place of OST in general and methadone in 
particular (Robertson et al 1986). An expert committee reviewed the evidence with a view 
to identifying effective interventions to address this threat in Scotland and the resulting 
McLelland report (Scottish Home and Health Department [SHHD], 1986) proposed that 
services should aim for intermediate goals on the path to abstinence, in order to reduce 
drug-related harms. These goals included: stopping or reducing injecting with unsterile 
equipment; taking drugs more safely (by mouth or inhalation); and taking prescribed (legal) 
rather than illicit drugs. Echoing the Mclelland Committee findings, the 1988 ACMD report 
on HIV prevention stated that: 
“...HIV is a greater threat to public and individual health than drug misuse. The first goal of 
work with drug misusers must therefore be to prevent them acquiring or transmitting the 
virus. In some cases this will be achieved through abstinence. In others, abstinence will not 
be achievable for the time being and efforts will have to focus on risk reduction. Abstinence 
remains the ultimate goal but efforts to bring it about in individual cases must not jeopardise 
any reduction in HIV risk behaviour which has already been achieved.” (ACMD 1988) 
 
This phenomenon reversed the abstinence-orientated prescribing policy of the preceding 
years as it legitimised longer-term opioid prescribing (OST) to enable users to stop injecting.  
As described above, the concept of “harm reduction” in the UK later developed to 
encompass other emerging potential injection-related health risks – such as Hepatitis C 
infection – but also to include more social outcomes such as attempts to reduce criminal 
activity or improve employability.   
 
International opinion and OST 
International debate continues regarding how society may balance the needs of illicit drug 
users and their families or communities with other national priorities or philosophies – 
especially with regard to the use of OST. Though a review of the research evidence base is 
contained in Chapter 3, in-depth analysis of the broader policy debate is beyond the scope 
of this thesis. A helpful summary is contained in the publication Drug Policy and The Public 
Good (Babor et al 2010). In the Summary and Conclusions chapter, a number of potential 
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mechanisms – including medical, social, criminal justice and legislative approaches – to 
address drug-related harm are summarized. They however specifically address the place of 
OST. Making the importance of OST as part of an effective drug policy clear, the authors 
state: 
“We emphasise services for opiate dependent individuals because our review found that: 1. 
the services available for this population, especially OST, have the strongest supporting 
evidence; 2. opiate use poses a high risk of overdose death; and 3. injection drug use has in 
many societies produced an ensuing epidemic of AIDS and other infectious diseases. Services 
for opiate users therefore could have a relatively large effect on population indicators of 
drug-related harm.” (Babor et al 2010) 
 
Evidence-based clinical practice in the UK 1991-2007 
 
Any discussion about recovery in the context of problematic substance use must be 
considered against considerable recent development in terms of evidence-based clinical 
practice in the UK. The UK has developed clinical guidance for medical and other staff since 
1991, when the first “Orange Guideline” made it clear that methadone prescribing was 
appropriate as a harm reduction measure and outlined the best practice for delivery of 
replacement prescribing and detoxification treatments (Department of Health et al., 1991). 
This guideline saw many changes in services across the country – but also revealed 
inconsistencies from area to area. For example, in Scotland the services available in the two 
largest cities – only 40 miles apart - were completely different. Edinburgh, in the wake of 
their HIV epidemic, was developing comprehensive services incorporating specialist 
psychiatry services and GP-based OST services (Greenwood, 1990). In Glasgow however, 
GPs were unlikely to consider delivery of OST (Kidd & Ralston 1993).  
 
The guidance for clinicians was updated in 1999 (Department of Health et al., 1999). That 
version reflected a much improved evidence base as treatment was evolving rapidly across 
the world and UK experience in the newly-developed services across the country was 
identifying the potential challenges around such services and offering practical solutions. 
Requirements that doctors delivered appropriate types of treatments which reflected their 
training and experience were emphasised, as were the implications should doctors not fulfil 
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their obligations to the drug using population. As the evidence base developed further a 
new guideline for clinicians appeared in 2007 (Department of Health et al., 2007). This is the 
current live guidance for clinicians in the UK. 
 
2007 “ Orange Guidelines” 
The 2007 UK treatment guideline was the most comprehensive yet. It was produced by a 
diverse committee of clinicians (from a range of professions), as well as service users and 
treatment providers from a range of philosophies and backgrounds. Government officials 
and advisors were also involved in the process. Though in essence the guideline represents a 
report by an expert group, for the first time in the UK, the process of guideline development 
was supported by the commissioning of systematic reviews of the research evidence base. 
These were taken forward by the National Institute for Health and Clinical Excellence (NICE). 
NICE Guidelines and Technology Appraisals covering all the key medical and psychological 
interventions were considered by the guideline group (NICE, 2007a; 2007b; 2007c; 2007d). 
The group also took into account any live guidance or evidence bases in other associated 
areas of work, such as pain management and mental health dual diagnosis. In this 
environment of scrutiny, this was the first national treatment guideline to comprehensively 
address the evidence base for the effectiveness of psychosocial interventions for substance 
misusers. It was also timely that, at a time when medical care for drug users was under 
public scrutiny, the guideline emphasised the need for high levels of clinical governance and 
quality standards in this area of work.  
 
England: NTA - Models of Care 2002-6 
Paradoxically, at the same time as it was being criticised for failing to deliver recovery, the 
NTA had been developing high quality guidance for commissioners, services and staff to 
improve delivery of a more person-centred approach to care in England.  First published in 
2002 - but continuously evolving - the “Models of Care” guidance had the potential to 
address some of the concerns, voiced by service users, that all roads led to methadone. 
Instead, the guidance required services to fully and holistically assess need and help service 
users to access the interventions they required (NTA, 2006).  Advice about improved care 
planning ensured that staff would regularly review a person's progress against their agreed 
goals and created an environment in which commissioners were required to ensure a full 
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range of options was available in their area.  The NTA commissions treatment services for 
substance misuse across England and holds services to account against tight standards 
regarding access to services.  At the same time, they have developed validated, useful 
clinical tools which can be used to assess improvement - even in those for whom abstinence 
is a challenge. They have also published additional reports which signpost how future 
service delivery may be improved in the UK.  
 
Example (England) - NTA – outcomes for those leaving services 2010 
In 2010, the NTA produced a report based on follow up data relating to nearly 50, 000 cases 
in treatment in England (NTA, 2010). This report had used novel methods to follow up 
people in treatment. The NTA had required treatment providers across England to supply 
reports using a common format – thus allowing the NTA to collate the data collected from 
many diverse agencies. The system (NDTMS – the National Drug Treatment Monitoring 
System) could then supply key data on follow-up over many years. In this study, the NTA 
had linked these clinical data to criminal justice data in central data systems as well as 
testing/screening data in the Drug Test Records allowing them to identify where people re-
entered either a treatment or justice system after discharge.  The 2010 report contains data 
on two cohorts discharged in 2005/6 and 2006/7.  
 
In 2005/6, they found that they could include 41,475 cases who had been discharged. Of 
these, 3353 had been discharged having completed a programme as drug free; 6417 had 
completed a programme but were not drug free. The vast majority - 31,705 - had an 
unplanned discharge. In the next 4 years, however, 19,047 (46%) did not return to either 
treatment or the criminal justice system while some 22,428 (54%) did return. Of those who 
did, 11, 641 (52%) had returned via a treatment route while 10,787 (48%) returned via a 
criminal justice route. Of the criminal justice cases, 7,025 (65%) had re-entered treatment as 
part of this contact. The report concluded that the nature of discharge (planned/unplanned) 
seemed to be less important than may have been expected. In 2006/7, 43,893 cases were 
included in a repeat of this analysis.  
 
As well as giving indications of the outcome of treatment over time, these reports hint at 
mechanisms which could be used to manage clinical information across the treatment 
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system, using routine clinical data, to more comprehensively assess outcomes and the 
effectiveness of treatment interventions. 
 
UK 2010: A new government and a new strategy 
 
In 2010, a new UK government was elected – a Conservative/Liberal Democrat coalition. The 
previous Labour government had been in power for over 12 years and had inherited the 
harm reduction approaches put in place by the previous Conservative government in face of 
the HIV epidemic in the 1980s. This approach had been strongly supported across the 
political divide with high levels of investment from consecutive governments seeing huge 
developments in the field in England and Wales.  This new coalition government quickly 
brought forward a new national strategy Reducing Demand, Restricting Supply, Supporting 
Recovery (Home Office, 2010). In the context of a government focused on dealing with 
austerity by cutting public spending, this strategy emphasised the enforcement aspect of 
drugs strategy as well as the potential of returning recovering drug users to productive 
work. Regarding treatment there was more bullish language regarding recovery. The 
strategy was the first in the UK for nearly 20 years to play down the harm reduction aspect 
of treatment. It stated:  “instead of focusing primarily on reducing the harms caused by drug 
misuse, our approach will be to go much further and offer every support for people to choose 
recovery as an achievable way out of dependency.”  
The strategy made it clear that there was to be a stronger emphasis on more people 
progressing from treatment with OST, stating: “Our ultimate goal is to enable individuals to 
become free from their dependence; something we know is the aim of the vast majority of 
people entering drug treatment. Supporting people to live a drug-free life is at the heart of 
our recovery ambition.”  
However, there does seem to be some acknowledgement that OST is a strong component of 
the system, stating: “Substitute prescribing continues to have a role to play in the treatment 
of heroin dependence, both in stabilising drug use and supporting detoxification. Medically-
assisted recovery can, and does, happen. There are many thousands of people in receipt of 
such prescriptions in our communities today who have jobs, positive family lives and are no 
longer taking illegal drugs or committing crime.” 
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“Recovery Orientated Drug Treatment” 
In this setting the NTA was asked to set up a new expert group to bring forward advice on 
the delivery of a more recovery-orientated approach to treatment. This work was published 
in the summer of 2012 (NTA, 2012). The task of this group was: “to describe how to meet 
the ambition of the Drug Strategy 2010 to help more heroin users to recover and break free 
of dependence”.  
Acknowledging the progress made in the previous 10 years, the report also recognised that 
this report was timely. It stated: “Previous drug strategies focused on reducing crime and 
drug-related harm to public health, where the benefit to society accrued from people being 
retained in treatment programmes as much from completing them. However, this allowed a 
culture of commissioning and practice to develop that gave insufficient priority to an 
individual’s desire to overcome his or her drug or alcohol dependence.”  
 
The report emphasised those significant harm reduction achievements of previous 
strategies, including the achievement of less drug deaths and BBV infections than many 
neighbouring countries. However, the report intended to “ally safe, evidence-based 
recovery-orientated practice to the public health and wider social benefits we already accrue 
from treatment.” It went on to describe how this could be achieved – emphasising the need 
for quality assurance of OST treatments to ensure consistent high quality prescribing; 
introducing the need to build “recovery capital”; delivering individualised, tailored care 
programmes based on individual need; using the techniques of “phasing and layering” of 
interventions – essentially delivering the most relevant interventions at the correct time as 
part of an individual’s recovery plan. 
 
So through considerable investment in a central governance structure, delivered by the 
NTA, English services had seen improvements in performance – but crucially had also 
started to produce detailed information on outcomes. The emphasis was now on improving 
the quality of service delivery to improve the likelihood of substance misusers progressing 
through treatment towards re-integration and recovery. 
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Scotland: development of “The Road to Recovery” 
 
While the English system of care was evolving as described above, Scotland was also 
responding to the drivers of concerns over Blood Borne Virus spread and the criminal justice 
pressures relating to substance misuse. Devolution of powers to the newly formed Scottish 
Parliament in 1998 brought direct control for much of drug policy to Scotland. 
 
A brief history of strategy in Scotland 
Scotland’s strategic drive to managing substance misuse began with the HIV epidemic of the 
1980s. Prior to this, there were clear parallels with the UK in terms of how services were 
arranged and delivered. The McLelland Committee report (SHHD, 1986) had introduced the 
expectation that harm reduction interventions would be made available in Scotland. 
However, the subsequent development of services was patchy across even those areas in 
which injecting drug use was rife.  
 
In 1994, a Task Force report formed the basis of the first national strategic approach to drug 
use in Scotland (Drugs in Scotland. Meeting the Challenge, 1994). Under a Conservative 
Secretary of State, the Task Force report strongly reiterated the prominence of harm 
reduction in general and opiate replacement therapy in particular in the Scottish response. 
It required the creation of local Drug Action Teams – partnership groups involving senior 
accountable public officers, with responsibility to address local need – with the aim of 
improving consistency of delivery across the country. The report also launched an advisory 
committee for ministers – the Scottish Advisory Committee on Drug Misuse (SACDM). 
SACDM aimed to ensure and policy development was supported by up to date expert 
opinion.  There was little new funding to support developments however, and at a time 
when the public sector in Scotland saw little growth, there was minimal coordinated 
improvement nationally.   
 
The Labour party took power in the UK government in 1997 and quickly moved to introduce 
a Scottish Parliament (Crown Office, 1998).  Drug misuse was placed in the Justice 
Department and the first Scottish “drugs minister” – Angus Mackay, Deputy Justice Minister 
- successfully argued for a huge investment to improve services to address drug problems in 
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Scotland. In 1999, “Mackay’s Millions” – a total new investment of £100m  - was announced 
alongside a new Scottish Strategy – Tackling Drugs in Scotland - Action in Partnership 
(Scottish Executive, 1999). This strategy was closely aligned with the UK strategy and 
essentially aimed to sharpen up local accountability, reflected in the new administration. 
However, it made no moves to change the harm reduction ethos of treatment services. The 
considerable financial investment had a huge impact on Scottish services for substance 
misuse. Year on year increases in available spending saw massively increased service 
capacity and activity until 2010.  
 
SACDM Methadone Review 2007 
In 2007, in response to the methadone-related death of a child, the Labour first minister, 
Jack McConnell, announced a review of the use of methadone in Scotland. The Scottish 
Advisory Committee on Drug Misuse (SACDM) convened a process involving three elements: 
a survey of service users' views of their methadone treatment; a query to all NHS Boards in 
Scotland regarding numbers in treatment, outcomes achieved and governance of practice; 
an expert review group to assess these findings as well as the international evidence and to 
produce a report for ministers. The review was published in 2007 (SACDM Methadone 
Project Group, 2007). It found that few NHS Boards could be clear how many people were in 
treatment nor had any real means of demonstrating how effective their programmes were.  
Service users mainly reported that they found access to methadone treatment helpful - but 
were concerned about a lack of choice in terms of treatment options – either to allow 
progress from prescribed methadone or to give access to detoxification. The expert group, 
citing the 2007 National Treatment Guideline and associated NICE reviews, re-iterated the 
place for methadone in treatment. It also made clear that inconsistency of delivery and 
quality issues needed to be addressed to ensure optimal care was being offered in Scotland. 
The methadone review was delivered to the new minority SNP administration [following 
Scottish elections in 2007] and its findings were welcomed by ministers.   
 
The document points towards an improved mechanism for the delivery of care in which the 
service user’s need is central but it also acknowledges that a high proportion of Scottish 
treatment seeking substance misusers are opioid/opiate dependent and, for them, 
substitute prescribing remains the treatment of choice. It stated: “ ...replacement 
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prescribing with methadone remains the main plank of medical treatment for opiate 
dependency…The challenge with methadone is to optimize delivery of harm reduction whilst 
ensuring that progress to recovery is encouraged, facilitating a way out of methadone 
treatment whenever appropriate.”  
 
Recognising that the report had brought an opportunity to refresh the approach to 
substance misuse in Scotland, SACDM then requested a further review, which would 
consider more broadly the full range of treatment elements required to improve the 
prospects of recovery for substance misusers in Scotland. This next report would aim to put 
replacement prescribing into the context of a person with a holistic range of needs.  
 
Essential Care 2008 
The result was Essential Care (SACDM, 2008). This was published in 2008 as the product of a 
large multi-disciplinary and multi-agency expert group. The report echoed a number of 
international guidance documents in the substance use field - but also considered learning 
from other areas facing similar challenges in effecting change - such as the mental health 
recovery field. The report had a number of key messages. It expected that all substance 
misusers should be able to access a full range of evidence-based interventions. These should 
be consistent across the country but would be locally commissioned. Availability of services 
supporting a continuum of care was essential, with improved processes of service 
commissioning, effective performance-management improving delivery and an expectation 
that a full range of specialist services should be available in every locality.  The role of more 
generic services – such as mental health services, pain services and social work - in 
addressing the needs of substance users was also emphasized. The Executive Summary of 
the document stated:  “Substance users have the right to the same quality of care as the rest 
of us.”  
 
The Road to Recovery – 2008 Achieving political consensus 
The Scottish Government published its new strategy to address problematic substance use 
in 2008 (Scottish Government, 2008). At this time, the SNP had formed a minority 
government. Yet, in this period where polarization around the philosophy of drug treatment 
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was the norm, the SNP administration successfully took their strategy through the Scottish 
Parliament - it was accepted unanimously - suggesting the pragmatic approach it contained 
was acceptable to a broad range of political opinions.  This achievement was a striking 
contrast with the sense of political struggle in England. The document used the new 
language of recovery but clearly rejected the view that this was a move away from support 
for harm reduction. To make this point they quoted the United Nations Office on Drugs and 
Crime:  
“Harm reduction has often been made an unnecessarily controversial issue, as if 
there were a contradiction between treatment and prevention on the one hand and 
reducing the adverse health and social consequences of drug use on the other. This is 
a false dichotomy. They are complementary.” (UNODC, 2008) 
What was new about the strategy was a practical approach to addressing the apparent lack 
of availability of treatment, the sense of a reduced range of options (medical, psychological 
and social) available for users and the concern about people being ‘parked’ on methadone 
without any attempt to better engage these people in approaches which could improve 
their prospects. There was an expectation that service users should be encouraged to 
engage in their own recovery, based on their own needs and strengths. Services needed to 
become more aspirational for their patients. Asserting the need for a more personalized 
approach to care, the strategy stated: 
“In practice recovery will mean different things at different times to each individual… 
[It]... might mean developing the skills to prevent relapse…rebuilding broken 
relationships... Milestones may be as simple as gaining weight... or building self-
esteem. What is key is that recovery is sustained.”  
The treatment strategy was based on the key Scottish documents described above, which 
aligned Scottish practice with the national and international evidence base. At this point, 
Scottish strategy was seen as leading the move towards improving the prospects of 
delivering real recovery to more people in treatment while deftly balancing the harm-
reduction needs of many accessing treatment. 
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Delivering Outcomes – Scottish Delivery Reform 2009 
So often, Government Strategies are published and expectations run high - before faltering 
as the next political wave pulls the attention of officials towards another initiative. The 
publication of The Road to Recovery however, heralded the initiation of a major process of 
reform in the way services would be coordinated and delivered.  A ‘Delivery Reform Group’ - 
comprising members of key Advisory Committees - embarked on a redesign of delivery 
arrangements, culminating in the publication of the new Framework for Delivery report 
(Scottish Government, 2009). This document was endorsed by the NHS Scotland Executive 
and Health Minister, Drugs Minister (Deputy Justice Minister) and Confederation of Scottish 
Local Authorities (COSLA). In tandem, the national audit office - Audit Scotland - published a 
critique of the effectiveness of the local Drug and Alcohol Action Teams (DAATs), 
highlighting their inconsistencies and recommending improved local commissioning based 
on needs assessment. In response, a new arrangement - requiring DAATs to be transformed 
into Alcohol and Drug Partnerships (ADPs) was required by October 2009 (Audit Scotland, 
2009). Reporting of performance was to be aligned with generic performance management 
systems for the first time. Previously, DAATs had reported separately to government 
officials on specific areas of performance, relating specifically to the use of ring-fenced 
resources, earmarked by central government for local use. The new system acknowledged 
that action to address substance misuse was unlikely to be effective if not closely linked to 
broader local strategies to address areas such as social exclusion and health inequalities. 
Consequently, the new arrangements placed ADPs inside local Community Planning 
Partnerships, with the NHS partner becoming subject to new “HEAT” targets on access to 
services (NHS Scotland's performance management tool) and local authorities required to 
report on delivery of local outcomes as part of their new “Single Outcome Agreements”. The 
Government had also made available a Substance Misuse Outcomes Toolkit to aid local 
outcome development (SACDM, 2009). This would allow performance in the area of 
substance use to be seen alongside performance in more mainstream areas of the local 
plan. This major development aimed to ensure that such areas as housing, education and 
broader community services would participate more vigorously in the response to problem 
substance use. 
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New financial resources to support improvements continued to increase significantly in 
Scotland for the years 2008/9 and 2009/10 to support the proposed changes. Meantime the 
Government reviewed all governance structures to ensure they were fit for purpose 
(increasing potential to release funds to improve care). A number of specific national 
initiatives were also launched. They created a specialist “support function” – employing 
experienced substance misuse staff to work as national delivery officers- to help local ADPs 
to deliver on their new agenda. National voluntary sector providers were funded to deliver 
and develop a Scottish Drugs Recovery Consortium which aimed to increase the profile of 
the recovery movement and, through working with local systems of care, improve recovery 
opportunities for substance misusers across Scotland. Finally, in a bold change, signalling a 
desire to see government policy scrutinized objectively, the Scottish Government 
announced the creation of an independent Scottish Drug Strategy Delivery Commission 
(DSDC). This body would replace SACDM and hold the Government to account on its own 
strategic delivery. DSDC would set its own agenda – reflecting priorities contained within 
the 59 objectives in the Road to Recovery strategy.  
 
The DSDC published its first report in 2011 (Scottish Drug Strategy Delivery Commission 
2011) and has engaged government in a process aimed at improving performance in key 
priority areas such as child protection, effective prevention activity and the criminal justice 
response to the new “legal highs”. Regarding recovery, this report acknowledged that the 
aspirations contained in the Road to Recovery were proving slow to be realised. The DSDC 
gave clear recommendations to the Scottish Government to improve prospects for those in 
treatment for substance misuse. These included the need to develop better information 
systems to report on activity, performance and outcomes (DSDC 2011). At this stage, the 
Scottish strategic process had appeared objectively to be progressing well and though there 
was a delay in delivering adequate information on recovery, the SNP Government was 
supported by a strong cross-party consensus in the Scottish Parliament. 
 
Re-politicization of the Scottish debate 2012 – coming full circle 
In the late summer of 2012 the Registrar General’s office published its annual report on 
drug deaths in Scotland for the year 2011 (General Register Office for Scotland [GROS], 
2012). Drug deaths had been increasing steadily in Scotland for many years and in 2011 
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deaths increased by 20% from the previous year to a total of 584. Crucially, GROS reported 
that heroin and/or morphine were implicated in, or potentially contributed to, 206 (35%) of 
the deaths while methadone was implicated in, or potentially contributed to, 275 (47%) of 
the deaths. For the first time, methadone (the treatment) was associated with more deaths 
than heroin (the problem).  
 
There was an immediate political and media backlash.  Having initially reported the drug 
deaths figures objectively, a number of media outlets, led by the Daily Record newspaper 
reported a coordinated series of strong anti-methadone stories. They stated that: “State 
prescribed heroin substitute is not the answer. Drug and drink related deaths reach record 
levels” - emphasising that methadone had contributed to more deaths than heroin (Daily 
Record 18th August, 2012). This quickly moved into a confrontational position and was 
reporting negatively on many aspects of methadone prescribing. Focusing on the profits 
made by community pharmacies, the Daily Record stated: “Revealed: £36million bill to 
provide methadone to drug users. Chemists across Scotland are raking in tens of thousands 
of pounds of taxpayers' money to dish out the heroin substitute to addicts.” (Ferguson,  
2012, 12th August).  
 
Within a month this stance had developed into the clearly stated view that the Scottish drug 
strategy was failing. At this stage, opposition politicians were also being quoted as having 
concerns.  In September 2012, efforts in the Scottish press to portray methadone 
treatments negatively included citing examples of tragedies from England. For example, on 
5thSeptember the Daily Record reported on a toddler’s death in Bristol (Daily Record 
050912). They were soon able to report a rift in the national political consensus. On 10th 
September, the Daily Record stated: “Majority of MSPs believe Scotland is losing the war on 
drugs. A study has revealed 60per cent of MSPs believe the current approach is ineffective in 
tackling drug misuse. Only 35per cent think it is working” (Daily Record 100912). This piece 
cited a report based on a survey of 55 MSPs which had been carried out by the UK Drug 
Policy Commission prior to the publication of the Scottish Drug death statistics. The UKDPC 
had published its report on 9th September (UKDPC, 2012). The report had stated that: three 
in five (60%) MSPs felt that Scotland’s current policies were not effective in tackling the 
problems caused by illicit drugs; more than two thirds (70%) of MSPs said that drug policy 
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did not make enough use of evidence and research, and a similar majority (68%) agreed that 
Scotland should have more powers over policy about drugs. The UKDPC report and 
associated media coverage heralded a new period of political unrest regarding the direction 
of drug strategy in Scotland. MSPs from the main opposition parties began a concerted 
effort to gather information from Government sources and NHS Boards regarding activity 
and outcomes in the treatment of substance misuse. The situation worsened as it became 
clear that the Government still struggled to supply valid information regarding activity and 
outcomes. The media campaign also continued and by October, the BBC was reporting 
“Political unity 'broken' on Scotland's drugs policy” (BBC 31/10/12). 
  
This pressure on government was effective. In October 2012 the current Minister for 
Community Safety and Legal Affairs, Ms Rosanna Cunningham, announced that she was to 
ask the Chief Medical Officer for Scotland to commission a review of the use of methadone 
in Scotland (Scottish Government News Release 051012). The Minister seemed to continue 
to support methadone replacement therapy when she stated:  
“Prescribed drug treatment has saved many thousands of lives in Scotland. It is the 
responsibility of the professionals to determine the most appropriate treatment for each 
person seeking medical help with addiction problems”.  
News reports were less balanced, however (Figure 3). The Daily Record reported that:  
“Scottish Government order review of £36m methadone programme thanks to Daily Record 
campaign. An independent expert panel will review the use of the controversial heroin 
substitute after a Record campaign revealed how addicts were left stuck on methadone for 
more than 30 years” (Daily Record 051012).  
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Figure 3. Screenshot of Daily Record online article 051012 
Scottish Government order review of £36m methadone programme 
thanks to Daily Record campaign 
AN independent expert panel will review the use of the controversial heroin substitute after 
a Record campaign revealed how addicts were left stuck on methadone for more than 30 
years 
 
 
 
Methadone 
THE Government have ordered a top level review of Scotland’s scandalous 
£36million methadone programme, thanks to the Daily Record. An independent 
expert panel led by Chief Medical Officer Sir Harry Burns will probe the use of the 
controversial heroin substitute. 
 
The BBC was more balanced in its coverage, stating:  
“Ministers have ordered a review of the way heroin addicts are treated. It will gather 
evidence on substitute drugs such as methadone, and is part of the Scottish government's 
national drugs strategy.  It emphasises recovery from addiction - rather than the previous 
policy allowing addicts to use alternatives to heroin to stabilise their lives. It is hoped the 
review will help doctors offer a full range of treatments, including methadone.  Since the 
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1980s, methadone has been at the heart of the drug treatment strategies of successive 
governments” (Alderson, 2012 October 5th). 
 
In an attempt to clarify the concerns and to restore consensus in parliament, a 
parliamentary debate took place in November 2012. (Scottish Parliamentary debate 
081112). This debate showed that the previous consensus regarding the facts around harm 
reduction and recovery was, in fact, largely intact. One political party – Scottish Labour - was 
an isolated critic of the current government approach but was already reducing the 
inflammatory and stigmatizing language it had used over the previous months. The 
proposed methadone review was already underway and was welcomed by the political 
majority.  The following day the Daily Record reported:  
“Daily Record's methadone campaign tops the agenda at Holyrood. Taxpayers are being hit 
for more than £36m a year - with no record of whether it is working or not” (Daily Record 
091112).  
The second report in the same day stated:  
“The methadone problem is causing huge devastation but we must look at it in a rational 
manner. Millions of pounds of public money are spent administering methadone to more 
than 22,000 drug abusers across Scotland. There are currently no accurate statistics to tell us 
what success – or not – the programme is having. No one knows how many addicts are 
helped to kick heroin. But we do know methadone contributed to 275 of the 584 drug deaths 
in Scotland last year – more than heroin itself.” 
 
Further example screen shots of the online media coverage of this debate are contained in 
Appendix 8. 
 
Lessons learned - the place of evidence 
 
The socio-political debates around substance misuse and the focus of drug strategies have 
repeatedly shown themselves to be relatively immune to what evidence and scientific study 
does exist. Regarding policy, the recent UKDPC report A Fresh Approach to Drugs (UKDPC 
34 
 
2012) cites repeated UK government reports over a long period, highlighting a lack of 
availability of evidence across the drugs field (House of Commons Science and Technology 
Committee, 2006; Wagstaff & Maynard, 1988). In Scotland repeated reports on [for 
example] drug deaths (Zador et al, 2005), methadone effectiveness (SACDM, 2007) and the 
delivery of services more conducive to recovery (DSDC, 2011) have recommended that the 
Scottish Government should support research and evaluation using improved information 
systems. The DSDC report specifically highlighted for ministers and officials the risks of not 
having this information available. It was in this hiatus that the most recent political attack on 
evidence-based treatments has occurred, bringing the place of OST into question.  
 
Even if evidence is available, governments may find it difficult to respond to advice which, 
though evidence-based, is felt to be unsavoury politically. This issue was demonstrated 
clearly during the public disagreement between the Chairman of the Advisory Council on the 
Misuse of Drugs (ACMD) and the (then) Home Secretary over drug classification.  Ultimately 
the Chairman, a leading academic in the field of addictions research, was relieved of his 
position and accused ministers of "devaluing and distorting the scientific evidence over illicit 
drugs by their decision last year to reclassify cannabis from class C to class B against the 
advice of the ACMD” (Travis, 2009 30th October). But there are more worrying 
consequences. After the 2010 General Election, the new Coalition government brought 
forward proposals to amend legislation which had previously required them to seek 
scientific advice when developing drugs policy (Jha, 2010 5th December). 
 
This problem regarding the balance of evidence and policy, could however be readily 
resolved. The UKDPC report gives a valid framework which, if applied, would facilitate a 
more objective approach to drug policy generally in the UK. The authors state: “To make 
progress on tackling the problems associated with illicit drug use, we need a new and more 
mature relationship with evidence”. They identify 5 areas where they feel improvements are 
necessary. These are: 
 Willingness to be guided by evidence – requires avoidance of “cherry picking” 
evidence to avoid difficult political issues 
 Recognition of different forms of evidence – requires policy makers to be able to 
distinguish between better and poorer quality evidence 
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 Clarity on objectives – this requires those considering evidence to be aware of the 
specific objectives an intervention is aiming to deliver on 
 Overcoming the desire for trials to deliver positive results – this reflects the political 
sensitivity of trials or pilot projects. these can be seen as the first wave of 
government policy and if they “fail” can be seen as a negative outcome. 
 Awareness of alternative policies – this reflects the need for governments to be 
aware of opportunity costs and to be prepared to invest in what they know while 
researching what they don’t. 
 
This statement is moot. A first expectation is that policy-makers are prepared to agree on 
the quality of the evidence base – including its strengths and weaknesses. The second is that 
they have an understanding of what this evidence base is relaying. The third is to encourage 
a culture of objectivity. However, it is equally important that the academic and clinical 
establishment are able to acknowledge when the evidence base is less compelling and, in 
such circumstances, should promote the development of an improved evidence base, open 
to objective scrutiny and debate, which ensures the treatments available are those most 
likely to deliver the best outcomes. 
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In Conclusion 
 
This introductory chapter has set this thesis in context. In particular, it has made the 
following points: 
 The use of psychoactive substances is a common activity since pre-history 
 Substance misuse has been known to be hazardous for centuries but has evolved 
into a major international public health challenge in the 20th Century 
 International consensus is in place, supported by international institutions, regarding 
the treatment approaches most likely to reduce the harms associated with opioid 
misuse. Opioid Substitution Therapy (OST) is a key element of this approach and 
methadone, a synthetic opioid developed in the 1930s, has been shown to be  a 
highly effective substitute drug since the late 1960s 
 Over 20 years, the UK has developed evidence-based treatment guidance and 
created standards of care, reflecting the international evidence base 
 The purpose of treatment of substance misuse in the UK has evolved considerably 
over the last 25 years as the evidence base has developed. From the 1980s, 
consecutive governments of all political types have supported the broad thrust of 
harm reduction.  Now, there is a drive to better facilitate progress towards recovery. 
 Politically, the UK is becoming more diverse as legislative power and governance is 
devolved to local administrations, more accountable to their own populations.  Local 
area developments bring variation.  
 Alongside this devolution, local expert groups have produced advice for successive 
governments regarding how the evidence base can best support their aspirations.  
As these political systems diversify further, local data will be essential to inform 
locally relevant developments.  
 Valid, high quality information is essential if outcomes are to improve. This includes 
information on activity and process, evaluation of service effectiveness and 
hypothesis-driven research.  The evidence available must be evaluated objectively 
with policy makers capable of determining when evidence is robust or not. The 
recent UKDPC framework gives a helpful guide on the issues to be addressed if 
evidence is to positively influence treatment effectiveness. 
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Chapter 2. The Key Longitudinal Studies   
 
Things do not change; we change. 
Henry David Thoreau (1817 - 1862) 
 
For one swallow does not make a summer, nor does one day; and so too one day, or a short time, 
does not make a man blessed and happy 
Aristotle (384-322 BC) 
 
Hardly had the glow been kindled by some good deed on your part or by some little triumph over 
your rivals or by a word of praise from your parents or mentors when it would begin to cool and fade 
leaving you in a very short time as chill and dim as before.  
Samuel Beckett (1906–1989) 
 
Introduction 
 
Substance misuse is a chronic relapsing condition and achieving long-term recovery  
requires people to make major changes in their lifestyles, behaviours and relationships 
(McLellan, Lewis, O’Brien & Kleber, 2000). As in any behavioural change, this process is 
cyclical and involves periods of contemplation/preparation, action and relapse. Recovery 
may be influenced by biological, psychological and social factors and the recovery cycle may 
be repeated for many years – even for a lifetime (Koob & Volkow 2010). For some, it has 
been suggested that this process can be spontaneous and may not require additional 
support from services (Best et al, 2010). There is however, clearly a view, supported by the 
evidence base, that for many, making effective care and treatment available can influence 
the outcome, reducing drug-related harms and facilitating recovery (Vielleux et al, 2010).  
 
If we are to understand the factors which may be important in promoting success, it is 
essential that treatment programmes are evaluated in a meaningful way. One key aspect of 
the research required to demonstrate recovery will be that it is longitudinal and follows up 
subjects over a sufficient time period – often for many years.  As the treatment of substance 
misuse has evolved from the late 1960s, national programmes of research around the world 
have attempted to inform the development of effective treatment approaches through 
prospective longitudinal studies which have followed, sometimes very large cohorts of 
treatment – seeking substance misusers, over long periods in the UK, USA, and Australia.  
 
38 
 
Longitudinal studies 
 
Types of study 
Longitudinal studies can help understanding of the natural history of any chronic relapsing 
condition. This approach also has the potential to bring improved insights into the potential 
long term risks and benefits of treatments for these chronic diseases.  The studies can be of 
two types.  
 A prospective study identifies the subjects at the beginning of the research process, 
before treatment is initiated and then follows them up over time, with changes 
observed over this time period. Often hypotheses are in place to be tested, using 
valid scientific methods.  
 A retrospective study identifies subjects at a later stage and retrospectively assesses 
factors or processes which may have influenced an observed outcome.  
There are clearly, however, potential problems in longitudinal studies - issues of Internal 
validity (reflecting methodological challenges) and issues of external validity (reflecting 
challenges of interpretation of any findings). 
 
Internal validity 
Prospective studies  - Key methodological challenges with these studies include selection 
bias, issues regarding comparisons – comparing different clinical groups - and the length of 
the study required to be able to determine meaningful outcomes (especially in chronic 
conditions). This final issue becomes more relevant in relapsing conditions as any 
observation at one time point (for example abstinence) may be followed by a significant 
change (relapse). The research method applied may mean such changes are not identified 
or measured accurately. 
 
Retrospective studies - Retrospective studies bring additional issues which can raise 
questions regarding the quality of the research and challenge its findings. Often, the data 
collected in retrospective studies were not collected for the study purpose, or the 
mechanism of collection did not take a future research project into account. This can mean 
that studies are hampered by missing data. There can also be the challenges of “recall bias” 
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– if subjects are being interviewed about aspects of their past history or bias regarding the 
interpretation of the information supplied. 
 
External validity  
The interpretation of findings must recognise that the research should be relevant to a 
particular population or environment to be a valuable evidence base which can inform 
practice. Studies carried out at different times, using particular subjects in different cultures, 
systems or environments will mean that findings are not necessarily generalizable to the 
population of interest and they should therefore be interpreted with caution. For example, 
in the substance misuse field, studies of male ex-servicemen in the 1970s in the federally-
controlled substance misuse systems of the USA, will have limited relevance to the 
management of a modern GP-based UK shared-care scheme, supported by a small local 
voluntary sector provider. 
 
There are additional challenges when we try to interpret the findings of these studies. What 
definitions are chosen and the means of measuring the key factors or outcomes may bias 
the results. For example, in substance misuse, clarity regarding the drugs being used or 
assessing the extent of any addiction or dependence may not be straightforward. Reported 
drug use may not be reflected in objective assessments. Self-reports of avoidance of 
injecting behaviour or risk may be challenged by presence of active injection sites on 
physical examination. Reported abstinence from benzodiazepines may be challenged by 
positive drug screens.  This is well illustrated by the fact that different researchers and 
studies have tackled one of the few apparent absolutes in this field – abstinence–differently. 
Studies have measured abstinence through direct objective assessment through urine 
testing (Hser, Hoffman, Grella & Anglin, 2001); some have used more indirect measures of 
the supposed consequences of drug use (Haastrkup & Jepsen, 1988) or have recorded 
subjects’ self-report of drug use/abstinence  (Simpson, 1981). These differing dependent 
variables mean that comparison is impossible between studies. This issue has been regularly 
identified in a number of recent Cochrane reviews of substance misuse treatments and will 
be discussed further in Chapter 3. 
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The studies 
This chapter will focus in some detail on the three large UK prospective studies of recent 
years. This section will consider the National Treatment Outcome Research Study (NTORS), 
Drug Treatment Outcomes Research Study (DTORS) and Drug Outcomes Research in 
Scotland (DORIS) studies. The second section will very briefly summarize the main findings 
of the large prospective studies carried out in the USA and Australia – the Drug Abuse 
Treatment Outcome Study (DATOS) and the Australian Treatment Outcome Study (ATOS). It 
is also valuable to consider earlier work from the USA which preceded the DATOS study and 
informed early quality improvement in the field of opiate replacement therapy such as the 
Drug Abuse Reporting Programme - DARP (1969-73) and Treatment Outcome Prospective 
Study - TOPS (1979-81). The chapter will describe the main findings of these key longitudinal 
studies and consider how their findings may inform the current thesis. The studies are 
summarized in Tables 1 and 2. 
 
As well as these studies, there have been a number of additional cohorts described of 
treatment – seeking, opiate dependent subjects in the UK and across the world in the last 40 
years. Some (e.g. Stimson & Oppenheimer, 1982) describe the treatment of substance users 
prior to the modern development of harm-reduction concepts and, though of considerable 
historic interest, offer little to the development of current clinical practice. Others (e.g. Hser 
et al, 2001) are cited elsewhere in the thesis as they have comprehensively observed the 
course of substance users’ careers over decades and informed the development of more 
focused prospective studies and RCTs considering the relative merits of specific 
interventions or treatment approaches.  
 
One aspect of the current study was to test the concept of using standard clinical data to 
objectively assess outcomes over time as well as the potential predictive value of those 
characteristics commonly assessed by clinicians. The cohort studies chosen in this review  
were selected as they aimed to address similar issues, in modern clinical settings and with 
specific consideration of OST with methadone. 
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Table 1. Longitudinal Studies - UK 
Study Country Dates & duration Notes 
The National Treatment Outcome Research 
Study – NTORS  
UK (England) 1996-2001 
5 year follow up 
Prospective Longitudinal cohort study of 1075 subjects 
inducted from 54 services in 4 treatment modalities: 
 specialist in-patient treatment 
 residential rehabilitation programmes 
 community-based methadone maintenance  
 methadone reduction/detox programmes 
Data collected: at intake; 6/12; one year and at 2-3 years and 
4-5 years after intake. 763 reviewed at 1yr. 496 at 5 years. 
Conclusions: “Treatment works”. Showed improvements in 
terms of reduced drug use and crime, increased abstinence, 
and health. 1year improvements were maintained at 5 years. 
Time in treatment was an important positive factor. Concern 
regarding poor outcomes on alcohol and stimulants. 
The Drug Treatment Outcomes Research 
Study -DTORS 
UK (England) 2009 
13 month follow up 
Prospective longitudinal study of 1796 subjects from 342 
agencies across England. Type of agencies not defined – but 
in line with NTA “menu” of treatment options. Also 
qualitative study and cost-effectiveness element 
Data collected : intake, 3-5/12 (1131 cases) & 11-13/12 (504) 
Assessment is essentially of process and not outcome 
Conclusions: Despite increased demand and changes in drug 
use patterns since NTORS, services still effective and reducing 
harms, improving health and wellbeing. Services responsive 
and patients satisfied. Cost effectiveness high. 
Drug Outcomes Research in Scotland  - DORIS  UK (Scotland) 2001-2004 
33 month follow up 
Prospective longitudinal study of 1033 subjects in a range of 
treatments (including prison). These were: 
 Opiate replacement 
 Other replacement 
 Counselling/non-medical 
 residential rehabilitation 
 detoxification 
Data collected : at baseline (MAP), 8, 16 and 33 months 
Also qualitative element to the study 
Conclusions: Mainly focussed on achievement of abstinence 
and not harm reduction. Concluded Scottish services poorer 
than English (NTORS) at achieving abstinence.  
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Table 2.  Longitudinal Studies – USA and Australia 
Study Country Dates & duration Notes 
Drug Abuse Reporting Programme - DARP  USA 1969-1972  
(select data <1981) 
12 year follow up for 
some elements 
Mean 6yr follow up 
of over 6000 cases 
Prospective Longitudinal Cohort Study of 43,943 subjects 
from 52 agencies in 4 modalities (+controls): methadone 
maintenance; therapeutic communities; out-patient drug – 
free; out-patient detoxification 
Data collected at intake and then 2 monthly 
Conclusions: Demographic and sociological characteristics 
only limited importance. Length of time in treatment and 
behaviour in treatment most important 
Treatment Outcome Prospective Study - TOPS  USA 1979-1981 
Maximum  
5 years follow up for 
some elements – up 
to 4270 cases 
Prospective longitudinal study of 11,759 subjects from  41 
services (10 cities) in 4 treatment groups: methadone 
maintenance; detoxification; residential care; op drug-free.  
Subjects interviewed: intake &  1, 3, 6, 9 and 12 months. 
After leaving treatment, follow-up at 3/12, 1,2 & 3-5years.  
Conclusions: Drug abuse treatment reduces illicit drug use 
and criminal activity. Time in treatment important factor 
Drug Abuse Treatment Outcome Study - 
DATOS  
USA 1991-1993 
3 month follow up & 
12 month s follow up 
post discharge 
5 year follow up of 
2966 cases 
Prospective longitudinal study of 10,010 subjects from 96 
services in 4 treatment groups: methadone maintenance; 
residential long term; residential short term; out-patient 
drug-free.   
Data collected: 1 & 3/12  in treatment and 1yr post 
treatment 
Conclusions: Drug use reduced >50% in all groups with 
methadone treatment affecting opiate use most. Retention 
and aspects of engagement (influenced by service 
characteristics) also affected outcomes 
The Australian Treatment Outcome Study - 
ATOS  
Australia 2003-2006 
3 & 12 month follow 
up with a 3 year 
follow up for one 
sample (NSW) 
Prospective longitudinal study of ~615 new patients – 535 
entering 3 treatment types: methadone maintenance - 201 
cases; detoxification – 201 cases; residential settings – 133 
cases 
Data collected: 3 & 12/12 (and 24 & 36/12 for NSW sample) 
Conclusions: Drug use associated risks and crime reduced 
across all modalities at 3 months and was maintained to 3 
years. Time in treatment positively affected outcome except 
in detoxification. Depression negatively affected outcome. 
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National Treatment Outcome Research Study (NTORS) – UK (England) 1996-2001 
 
NTORS was the first major prospective study in the UK and is clearly relevant today. It must 
be recognised that the study commenced at a time when recovery was not a priority for 
services – harm reduction was seen as the clear goal and national strategies across the UK 
were focussed on increasing capacity of harm reduction services – in particular Opioid 
Substitution Therapy using methadone (OST-M). The 1999 National Treatment Guideline 
was still 3 years from publication and service development was at an early stage, with large 
inconsistencies in service delivery across the UK. 
 
NTORS was a UK government (Department of Health) funded national prospective study 
which followed from and was modelled on, prospective studies in the USA that in the 1980s 
and 90s had demonstrated the impact of a range of treatments on outcomes in substance 
use. NTORS recruited 1075 subjects who were at the point of entering 54 different drug 
treatment programmes across England.  The study recognised the difficulties in terms of 
generalising US research in the UK – citing potential differences in terms of UK substance 
users as well as the variation in treatment modalities available in different localities. The 
research design was a prospective, longitudinal cohort study of new self-selecting 
treatment-seeking subjects recruited as they entered four different residential or 
community-based treatment modalities across the UK. These modalities were: specialist in-
patient treatment; residential rehabilitation programmes; community-based methadone 
maintenance and methadone reduction (detoxification) programmes. The modalities were 
chosen to best represent the modes of treatment delivery commonly available across the 
UK. There were no controls. The study was described as naturalistic with causal 
relationships inferred through measurement of key variables in the different treatment 
modalities at different points through the treatment journey. Data were collected at intake 
to the study, six months, one year then subsequently at 2-3 years and 4-5 years after intake. 
 
Purpose of NTORS 
The study aimed to address a very wide range of questions, including: describing the 
characteristics of those entering treatment; types and severity of problems experienced by 
subjects; changes in substance use problems in treatment; any changes in other drug-
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related problems; were these changes maintained over time; relationships between the 
characteristics of substance misusers and the outcomes they achieved in treatment; 
describing the main components of treatment programmes; assessing relationship between 
treatment structure and process and outcome achieved? 
 
Recruitment 
Some 54 services were recruited to the study, comprising 8 in-patient units; 15 residential 
rehabilitation facilities; 16 methadone maintenance services and 15 methadone 
reduction/detoxification services. The study recruited subjects based on set criteria. These 
were: this was a new treatment episode; the subject had a primary drug problem (not 
alcohol); they had a UK contact address; they were not a previous client of that project.  
NTORS recruited 1075 subjects. Their distribution was: 122 (11.3% of cohort) in specialist in-
patient facilities; 286 (26.6%) in residential rehabs; 458 (42.6%) in methadone maintenance 
programmes; 209 (19.4%) in methadone reduction programmes. 
 
Description of the study population – baseline data 
The study population has been described in detail (Gossop et al, 1996; Gossop et al, 1998). 
The population was 74% male and the vast majority defined as “white-UK”. Nearly half were 
in relationships/co-habiting and nearly half had child-care responsibilities. Some 20% were 
in temporary accommodation and 80% were unemployed. The most commonly reported 
substance use problem was long-term opioid dependence with heroin the most frequently 
used drug (>80%) while 49% had used illicit methadone in the 90 days prior to intake. Some 
81% used two or more types of drugs and over 50% used stimulants. The average duration 
of use was 9 years while 25% had used heroin for 13 years or more. Three quarters were 
using “regularly” – weekly or more. Mean heroin use was reported as 2/3g daily but 25% 
used 1g or more daily. Some 62% were injecting drugs. In the 3 months prior to recruitment 
68% had drunk alcohol with an average weekly alcohol consumption of 51 units for men and 
45 units for women. Three quarters of daily drinkers used 10 units per day or more with the 
average for this group being 24 units per day. Criminal activity was assessed. Some 61% of 
the cohort were responsible for a reported 70,728 crimes. Over half (52%) reported at least 
one non drug-dealing offence. The most common reported offence was shoplifting. Three 
quarters had been arrested in the previous 2 years – a total of 4,466 arrests.  Health issues 
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were assessed. Of the NTORS cohort, 48% had been to A&E and 25% had been admitted to a 
general hospital bed in the previous 2 years. Depression and anxiety were described as 
“common” with 29% reporting suicidal thoughts in the 3 months prior to recruitment. Some 
10% had received in-patient psychiatric care in the previous 2 years for problems other than 
addiction while 14% had been treated by community psychiatric services. Some 70% had 
seen their General Practitioner in the 2 years prior to recruitment.  
 
Client differences by modality at intake (p<0.05) 
There were no gender differences. Those choosing to enter methadone reduction, however, 
were younger, had shorter drug histories and more simple/less complex drug use histories 
associated with less risk-taking. Those accessing residential facilities were found to describe, 
in general, a more serious range of problems with longer heroin careers. They were more 
likely to use stimulants or have a heavy alcohol intake and showed evidence of more needle 
sharing/risk taking behaviours. This latter group also had worse offending histories. 
 
Follow up studies – 6 months and One year 
Six month follow up saw considerable improvements in all groups (Gossop et al 19971; 
Gossop et al 19972). At one year outcome data was available on 769 subjects (71% of the 
original cohort), of whom 753 successfully completed a follow up interview. A further 16 
subjects had died during that year (Gossop, Marsden & Stewart, 1998).  There were 
significant improvements in drug use and risk-taking across the cohort.  There were 
significant differences in outcome, reflecting treatment modality attended. The residential 
facilities often saw greater improvements – particularly regarding alcohol use.  There was 
huge variation in service performance however, in all modalities, with the worst performing 
services showing virtually no impact on drug use.  There were 16 deaths - mainly attributed 
to overdose. There was one suicide and one AIDS-related death. Crime fell in both groups to 
similar amounts. 
 
Authors’ conclusions – 1 year follow up 
The authors concluded that at 1 year, treatment was effective with subjects more likely to 
be abstinent and to reduce their use of drugs and risk-taking as well as criminal activity. 
They raised concerns regarding the poor general impact of treatment on drinking behaviour 
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and health outcomes. They discussed why different individuals access different types of 
services and considered the way that treatment pathways could better facilitate 
engagement and retention. They particularly emphasised that methadone maintenance 
programmes had more success in this regard. The issue of the huge service variation (3 fold 
from best to worst) raised issues of consistency of practice and quality of commissioning in 
the UK. This finding also makes interpretation and generalization of the results a challenge. 
 
Follow up studies - Five years (Gossop, Marsden & Stewart, 2001) 
A sample of 650 cases from the NTORS cohort was defined using a degree of scientific rigour 
to ensure proportions represented, as closely as possible, the original cohort for 5 year 
follow up. Some 496 of the 650 selected cases were interviewed (76%). This represents 46% 
of the original cohort. With regard to drug use, the 1 year success already described was 
maintained at 2 and 5 years. Less subjects were using any drugs and those still using were 
using less frequently in all settings.  Injecting fell overall by nearly half, as did sharing of 
injecting equipment. Alcohol use reduced in the residential group but showed no change in 
the methadone group. 
 
The Drug Treatment Outcomes research Study (DTORS) – UK (England) 2009 
 
This study could be seen as a follow-up from NTORS – but was more focused on short term 
service performance, aiming to determine how treatment services were responding to 
changing demographics, developments in drug use presentations to services and higher 
numbers presenting for treatment in England since NTORS. The study recruited  a weighted 
representative sample of 1796 subjects presenting to 342 different agencies across England 
and followed them up twice: at 3-5 months after induction - 886 (49.3%) subjects and at 11-
13 months - 504 subjects (28%). A qualitative assessment and economic evaluation were 
included in the study report (Barnard et al, 2009). 
 
Subjects 
The subjects are described in the baseline report (Jones et al, 2007). Again they were mainly 
described as male and white UK - though more subjects were presenting form other ethnic 
groups. Descriptive analyses found that ethnicity and recent drug use at presentation 
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showed some associations. Those describing crack cocaine as their primary drug problem 
were less likely to be White (77%) and more likely to be Black (12%) than those whose 
primary problem drug was reported as heroin (91% White, 2% Black).  Compared to NTORS, 
Criminal Justice was now a more common source of referrals with 35% referred by this 
route. Balance of drug use had also changed since NTORS. In the four weeks prior to 
baseline interview 62% of subjects had reported using heroin, 44% had used crack cocaine, 
25% benzodiazepines and 50% alcohol. Some 37% reported injecting drugs recently, and 
48% of the injectors (17.9% of respondents) had shared equipment in the past four weeks. 
Seventy-six per cent of opioid users reported poly-drug use in combinations with other 
opioids, benzodiazepines or alcohol with over a third injecting. Some 9% had overdosed in 
the previous 3 months. Crime was common. In the previous 12 months, 73% reported 
committing an offence. 
 
Follow up findings (Jones et al, 2009) 
The study was essentially an audit which explored the standards expected from services as 
part of the treatment process. It reported that services were responding well to increased 
demand. Over 80% of subjects had an agreed care plan in place within 3 weeks of 
assessment, and the majority reported being happy with the care process. At first follow-up 
89% had started at least one treatment modality/episode or completed treatment with a 
median wait of just 7 days to starting. Some 75% had started their treatment within 22 days. 
At 2nd follow up (11-13 months) 81% were retained or had completed their treatment. 
However, new or inexperienced patients did less well in structured treatment approaches. 
Improvements were greatest in the first 12 weeks though some improvement continued for 
3-8 months. Little significant improvements were identified thereafter. Regarding outcomes 
achieved, this study addressed relatively short term outcomes and found that, overall, drug 
use and drug-related harms reduced in that early period. Employment, home stability and 
ability to take on childcare responsibilities also improved (by self-report only) at each stage 
while crime reduced. 
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Conclusions 
The main findings of the study were that “drug treatment is still effective in reducing a range 
of harmful behaviours associated with problem drug use and it is cost-effective.”   
Commenting on the care process, the authors stated that “the majority of treatment seekers 
received care-co-ordinated treatment, expressed satisfaction with their care, were retained 
in treatment beyond three months”. All outcomes were based on patient self-report with 
reports not offering any objective assessments or measures to confirm the reported 
outcomes. However, the report stated that treatment was associated with “significant and 
substantial reductions in drug use and offending as well as improvements in social 
functioning.”  
 
Drug Outcomes research in Scotland (DORIS) – UK (Scotland) 2001-2004 
 
This Scottish outcome study started in 2001 and had a research design similar to the earlier 
National Treatment Outcome Research Study (NTORS) in England. DORIS recruited a cohort 
of 1033 drug misusers who were entering a range of 5 types of drug treatment services. A 
baseline assessment was undertaken using a standardized assessment tool. Subjects were 
then reviewed in “sweeps” at 8, 16 and 33 months thereafter. Additional qualitative data 
were also collected. The aim of the study was to establish whether drug users in treatment 
progressed, what outcomes were being achieved and what types of treatment services were 
associated with the best outcomes. 
 
On entering the DORIS study, researchers accessed a sample representing some 1 in 12 of all 
substance misusers entering treatment in Scotland in 2001. Of those invited to participate, 
89% accepted and undertook a baseline interview. Using a standardized assessment of 
dependence, they found (unlike NTORS) that there were no significant differences in the 
groups accessing different treatment types. 
 
Outputs& reports 
A number of reports and publications were produced from the DORIS study. These included   
papers on drug users’ aspirations from drug treatment (McKeganey, Morris, Neale & 
Robertson, 2004), the treatment needs of prison and community based drug users (Neale & 
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Saville, 2004; Neale, Robertson & Saville, 2005), employability (Kemp & Neale, 2005), 
experiences of trauma and abuse amongst treatment-seeking drug misusers (McKeganey, 
Neale, &Robertson, 2005), drug users’ life problems and overdose (Neale &Robertson, 
2005), drug users and assault (Neale, Bloor, & Weir, 2005). 
 
Results 
Unlike the NTORS publications, none of the reports addressed changes in drug use from the 
perspective of a harm-reduction outcome (i.e. assessing changes in drug use and drug-
related harms). One paper in particular - Abstinence and drug abuse treatment: Results from 
the Drug Outcome Research in Scotland study (Mckeganey et al 2006) – reported only on 
achievement of abstinence in different treatment modalities at 33 month follow up.  This 
paper reported 33 month outcomes on 695 subjects (67% of the DORIS cohort). The authors 
reported that 88% of respondents had used heroin in the 90 days prior to 33 month follow 
up assessment. Some 60% had injected and 11% overdosed in that period.  They found that 
only 5.9% of females and 9% of males were abstinent at 33 months follow up and this group 
was heavily skewed towards those who had been accessing residential rehabilitation 
programmes. When the definition of “abstinence” was aligned with that used in NTORS, the 
authors reported that, of residential rehabilitation patients, 35.9% (NTORS) and 33.3% 
(DORIS) would be abstinent for 90 days. For OST (methadone replacement) patents, 24.3% 
(NTORS) compared with only 11% (DORIS) would be abstinent for 90 days. 
 
Conclusions 
The authors focused on abstinence outcomes concluding that “There is a need to establish 
why so few drug users in contact with the methadone programme in Scotland appear able to 
become drug free 33 months after having contacted this service.” They went on to plea for 
improved access to residential rehabilitation in Scotland and felt there was a need to 
address “why it is that such a small proportion of drug users receiving methadone 
maintenance within Scotland appear to be able to achieve a 90-day drug-free period.” 
 
Discussion – conclusions from large longitudinal studies in the UK 
Both NTORS (1996-2001) and DTORS (2009) were commissioned by UK Government 
departments to assess effectiveness of treatment services in England. NTORS remains the 
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study which has contributed the longest follow-up period and its positive findings have 
guided UK treatment policy for over ten years. Implications regarding treatment retention 
and time in treatment are important at delivering improved outcomes and that these should 
be areas of improvement for services. The study also recognises the continuing challenge of 
ongoing alcohol use and gives a sense of different interventions better matching an 
individual’s needs – with more complex cases seeming to do better in more intensive (often 
residential) environments. The follow up study, DTORS, focused on treatment process and 
showed that the major changes in service delivery in England in the intervening 10 years had 
not seen an overt deterioration in service performance. Indeed, in the relatively brief follow 
up period of up to 13 months, people presenting to services seemed to be accessing their 
treatment of choice very quickly and were being retained well with positive outcomes 
reported – though improvements did not continue beyond 8 months.  
 
In contrast, the DORIS study in Scotland was not Government funded – but was 
commissioned by an independent trust. The Scottish Executive Effective Interventions Unit 
(a unit whose aim was to improve the quality of information and evidence available to 
frontline staff) supported the project in kind through a steering group and practical support 
regarding recruitment and delivery. The outputs from the project have tended to focus on 
the issue of abstinence and have asserted that Scottish services may not be meeting the 
expectations of service users. This view has resulted in the DORIS outputs becoming a focus 
for dispute between those supporting differing philosophies – harm reduction or 
abstinence. Criticism of the authors’ interpretation of their findings by international 
authorities (e.g. Newman, 2005) has reduced the influence of this work – one of the few 
substantial longitudinal studies reported on Scottish subjects. 
 
In conclusion – these UK studies have given an indication of the effectiveness of the 
treatment system in England and NTORS in particular has laid down a strong baseline from 
which more detailed research questions could be developed regarding treatment outcome. 
The emphasis on process in DTORS (it is essentially a service quality audit), its short 
timeframes and the absence of objective, measureable outcome assessments make it less 
powerful and it clearly adds little to the evidence base regarding treatment outcomes.  The 
differing treatment and service commissioning environment in Scotland during the same 
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period makes generalising some of the English findings questionable. The DORIS study 
reports have not addressed key questions about effectiveness of Scottish treatment systems 
in terms of levels of drug use or drug-related harm.  
 
International Longitudinal studies 
 
A number of international longitudinal studies have given an indication of treatment 
effectiveness. Though they are now historic and have issues regarding the generalizability of 
their findings to UK practice, they do address issues of principle, have the advantage of very 
large numbers followed up for long periods and should inform hypothesis-driven research in 
the UK. 
 
Drug Abuse Reporting Programme (DARP) USA (1969-72 – with some subjects to 1981) 
 
This early longitudinal study examined data from 4 treatment groups – methadone 
maintenance, therapeutic communities, outpatient drug-free (counselling & abstinence), 
outpatient detoxification – and non-treatment controls. Some 43,943 clients from 52 
services were assessed at intake and 2 monthly thereafter (with post-treatment follow ups 
for up to 12 years for some samples). This was a large comprehensive and carefully 
constructed naturalistic longitudinal study, supported by Federal funding and assessing 
services across the USA. For the first time, DARP identified factors influencing outcome and 
in particular showed that time in treatment (retention) was a key factor. There are over 100 
reports describing the process and various findings. A summary is available (Simpson & Sells, 
1982). 
 
Findings at 1 year: Among the group of daily opioid users, post-treatment prevalence for 
daily drug use declined in all groups, including controls. Non-opioid use (excluding marijuana 
and alcohol), criminal involvement and employment levels also improved following 
treatment across the modalities. Time spent in any treatment significantly predicted post-
treatment outcomes. 
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Findings at 6 years: The longer term follow-ups revealed a challenge for this type of project 
as people moved in and out of different modalities and it became difficult to attribute any 
change to a specific modality. Any significant differences between the treatment modalities, 
observed in the first 3 years after DARP, became insignificant by Year 6.  Some 61% of the 
original sample had ceased daily opioid use for at least a year by this time and this 
improvement in drug use was accompanied by improvements in other outcome indicators 
including crime, employment, non-opioid drug use and alcohol use. (Simpson, Joe & Bracy, 
1982). 
 
Findings at 12 years (Simpson & Sells, 1990): This follow up study examined a number of 
outcomes and process measures. Treatment history: the sample had averaged more than 6 
treatment episodes in their lifetime. Subsequent treatment episodes saw a “gravitation” 
towards methadone maintenance as the treatment of choice. Relapse rates: Almost three 
quarters of the sample reported at least one relapse to daily opioid use though only 41% 
ever had a continuous episode of daily use lasting over 2 years. Relapse was most likely in 
the first 3 months after ceasing to use, but of those who abstained for 3 months or more, 
80% were still abstinent 12 months later. Ceasing illicit drug use: At Year 12 of DARP, 75% 
had not used any illicit opioids daily for at least one year, 67% had not used opioids for at 
least 3 years and 61% had not used opioids at all.  Criminal involvement: Some 95% of the 
males had been arrested during their lifetime, 91% had been imprisoned at some point in 
their lifetime, with 60% having spent a year or longer imprisoned. 
 
Conclusions: The main findings of this study were: 
 the length of treatment was extremely important with at least 3 month contact 
required to instil positive changes in outcome 
 post -treatment outcome improved with increased time in treatment 
 Methadone maintenance, therapeutic communities and drug-free groups showed 
no differences in outcome – but all showed better outcomes than those not in 
treatment (controls) or the detoxification groups.  
 Differences between treatment groups diminished over time  
 At 12 years 63% of subjects had not used illicit opioids daily for 3 years 
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This study is large and has follow up elements over several years for some subjects making 
its findings powerful indicators of treatment effectiveness. Its weaknesses (in terms of UK 
practice) include that it is set in a US sample and care system – making generalizability 
limited. Also, as the study progressed, subjects accessed a range of treatments, essentially 
“infecting” specific groups and making interpretation of relevant factors very difficult. The 
study did show that many patients reduce their drug use and that retention is an important 
factor influencing positive outcomes. 
 
Treatment Outcome Prospective Study (TOPS) USA (1979-81) 
 
The TOPS study was again Federally funded and aimed to expand on the findings of DARP by  
providing  a framework for more specialized studies, such as those dealing with changing 
drug use patterns, the effect of comorbidity on outcomes, the impact of legal involvement 
on treatment and the overall cost-effectiveness of drug abuse treatment.  This study 
examined data from 4 treatment groups – methadone maintenance, detoxification, 
residential care and outpatient drug-free. Some 11,759 clients entering 41 services were 
recruited. Subjects were interviewed on accessing the service and then at 1, 3, 6, 9 and 12 
months. After leaving treatment, some selected subjects were followed-up at 3 months 1 
year, 2 years and 3-5 years.  
 
Findings (Hubbard, Rachal, Craddock & Cavanaugh, 1984) 
Treatment was found to be effective in reducing daily opiate use and other illicit drug use 
during and after treatment, a finding that supported DARP results. Drug use patterns in the 
USA had changed in the decade following DARP, with less daily use of opioids and more poly 
substance use (primarily involving stimulants and cocaine). However, 77% of the TOP 
sample still reported opioids as their primary drug problem. The study found that subjects 
with legal involvement or where there was legal pressure to enter treatment were just as 
likely as those without such pressure to benefit from that treatment. Indeed, the study 
showed that those with legal involvement stayed in treatment slightly longer. When costs 
associated with crime were calculated, drug misuse treatment was found to be cost 
effective. Among methadone maintenance programmes, some specific factors of 
programme delivery were associated with more positive findings. Programmes with flexible 
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dosing policies, specialized personnel, frequent urine monitoring, and more comprehensive 
services - in terms of frequency of contact and more favourable patient satisfaction reports - 
were more likely to have higher client retention rates.  
 
Conclusions 
The detoxification cohort was removed from study due to persistently poor outcomes. All 
remaining treatment modalities showed dramatic reduction in drug use and criminal activity 
over the first 3 months. At 1 year after treatment there was a clear reduction in drug use, 
crime and mental health issues if subjects were retained in treatment for 3 months or more. 
There were no differences reported in outcomes comparing those in methadone 
maintenance or residential programmes. Over 50% of subjects were abstinent from heroin 
at 1 year post treatment. The researchers concluded that time in treatment was the most 
important predictor of outcome. Significant changes in regular heroin use were seen only 
after 1 year in treatment. 
 
This study has the same strengths and limitations overall as DARP when its findings are 
applied to UK practice. However, the study has duplicated the finding of DARP that 
detoxification was significantly less effective than other interventions in these subjects. 
Also, time in treatment – especially the first 3 months – was a strong indicator of future 
outcome. Significant changes in illicit opioid use took over one year to appear.  
 
Drug Abuse Treatment Outcome Study (DATOS) – USA (1991-1993) 
 
Following on from the lessons of DARP and TOP, DATOS was designed to “capture a 
longitudinal snapshot of drug abuse patterns and treatment responses in the USA” (Simpson 
& Curry, 1997). A naturalistic design recruited from a large number of treatment 
programmes with the aim of identifying changes in treatment populations and service 
delivery over the study period. Key observations included: reductions in opiate use and 
increases in cocaine use in the treatment-seeking population; considering the implications 
of an emerging ageing treatment population; reductions in the availability of a range of 
health and social care services for this population across the USA (Flynn et al 1997).   
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Subjects 
Intake Sample: A total of 10,010 clients entering 96 different treatment programs, offering 
four treatment types – methadone maintenance; residential long term; residential short 
term; out-patient drug-free - during 1991-1993. Follow-up Sample: Some 4,229 (42%) of the 
eligible clients who completed the two-stage intake interviews were selected for follow-up 
(using a stratified random design to ensure they were representative of the baseline 
sample). Some 2,966 subjects were successfully interviewed at follow up, representing 52% 
of the proposed follow up sample and 22% of the baseline sample. No significant differences 
were found between intake and follow-up samples with regard to gender, ethnicity, and 
age. Data was collected at 1 and 3 months while in treatment and then at 12 months post 
treatment.  
 
1 year findings (Hubbard et al 1997) 
Clients treated in all modalities studied in DATOS showed large and significant 
improvements during the 1-year follow-up period. Overall, major outcome indicators for 
drug use, illegal activities, and psychological distress were each reduced on average by 
about 50%. There were significant outcome differences between those admitted to 
different types of treatment (as well as variations between programmes of the same type). 
Outcome differences also reflected the length of time subjects remained in treatment. 
Again, the length of time in treatment (retention) was directly related to improvements in 
follow-up outcomes for all modalities except short-term in-patient care. 
 
A model to explore essential elements of “treatment readiness” and “engagement 
indicators” as potential predictors of retention and outcomes was tested in the different 
therapeutic settings (Joe, Simpson & Broome, 1999). They demonstrated that well-
motivated clients developed better relationships with their counsellors and stayed in 
treatment longer.  Those who attended more counselling sessions and discussed a broader 
range of topics stayed longer in the out-patient drug free and long term rehabilitation 
groups. Those with more severe background problems (hostility or cocaine use) had 
difficulty developing a working relationship with their counsellors, attended fewer sessions, 
and discussed fewer topics. One study also examined client “confidence in treatment” and 
“commitment to recovery” as indicators of engagement after 3 months and found that those 
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with higher motivation at admission developed more confidence and commitment to 
treatment, as did those who had better relationships with counselling staff and who 
attended more counselling sessions. (Broome, Simpson & Joe, 1999).  
 
Conclusions: The main findings of this study were: 
Again the study is based on a US sample and treatment environment. Again the original 
sample is substantial – though the follow up elements are small and the follow up periods 
more limited than in DARP and TOP. Overall, they found that most treatment approaches 
had an effect on illicit drug use with methadone maintenance having the main effect on 
opioid use specifically. Treatment retention was again strongly associated with positive 
outcomes – longer periods in treatment had the most effect. The study looked in-depth at 
“softer” issues relating to the client or treatment process. Aspects of patient motivation and 
engagement seemed to have some effect on treatment outcomes (Simpson & Brown, 1999). 
 
Australian Outcome Treatment Study (ATOS) 2003-6 
 
ATOS was the first large-scale longitudinal study of treatment outcome for heroin 
dependence to be conducted in Australia. This longitudinal prospective study aimed to 
describe the characteristics of people entering treatment for heroin dependence. The study 
examined the treatments received and 3 and 12 month outcomes achieved – in terms of 
drug use, criminal behaviour and mental health as well as assessing the associated costs. 
Longer term outcomes at 24 and 36 months were also examined in a specific follow up 
sample. The sample sizes reported as assessed in various associated publications vary from 
495 (Darke et al, 2009) to 615 (Williamson, Darke, Ross & Teesson, 2007), 745 (Ross et al, 
2006) and 825 (Teesson et al, 2006). IT is not clear why such variation is observed. Of these 
publications, the Teesson paper gives the most detailed description of the methods used 
and states that the sample was some 825 active heroin users entering 38 agencies offering 
three treatment modalities: 277 entering maintenance; 288 detoxification and 180 
residential rehabilitation. Eighty non-treatment controls were also assessed. The clinical 
measures used examined drug use and risk behaviours, treatment history, criminality, 
general health, health service utilisation, and psychopathology – using the Opiate Treatment 
Index tool (Darke et al 1992). Self-report was used to determine changes in illicit drug use – 
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there is no report of objective testing. A health economic evaluation was also included. 
After baseline assessment, subjects were followed up at 3 months. The various reports give 
differing follow up rates which range from 80% at 12 months to 70% at 3 years.  
 
Findings at 1 year 
Some 80% of the original sample were interviewed at 1 year. There were substantial 
reported reductions in heroin and other drug use across all treatment modalities. The 
majority of those who had entered treatment reported being heroin abstinent at 1 year 
compared to the non-treatment controls. Reductions in poly drug use were also reported in 
the treatment samples. Major reductions in risk-taking, crime and injection-related health 
problems were reported across all treatment groups with less marked reductions reported 
in the control group. Psychopathology was assessed to be significantly reduced among the 
treatment modalities compared to controls. Positive outcomes at 1 year were associated 
with more treatment days experienced over the 1 year follow-up period - described as 
'treatment dose' and fewer treatment episodes - described as 'treatment stability'. 
 
Findings at 3 years 
Some 94.5% of the baseline sample completed at least one follow-up interview over a 36-
month follow-up period. The proportion reporting heroin use in the preceding month 
decreased from 99% to 35% from baseline to 24 months. This rate then remained stable to 
36 months. This reduction in reported heroin use was accompanied by reductions in self-
reports of other drug use and in risk-taking, crime and injection-related health problems. 
There were also improvements in assessed general physical and mental health. Positive 
outcomes were associated with more time in maintenance therapies and residential 
rehabilitation and fewer treatment episodes. Time spent in detoxification was not 
associated with positive outcomes. Major depression was also associated consistently with 
poorer outcome (Teesson et al 2008).  
 
Conclusions: The main findings of this study were: 
The study reflects a treatment sample in Australia – which, it could be argued has more 
similarities in terms of service delivery with the UK than the US services. The numerous but 
diverse published reports make sample sizes difficult to clarify – but there seems to have 
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been at least 70% of the sample followed up at 3 years. Only self-report was used to 
determine drug use outcomes, apparently with no objective drug testing. From these 
reports, reductions in drug use, associated risks and crime were observed at 3 months and 
maintained over 36 months. These outcomes were related to time in treatment (except in 
the case of the detoxification group). Depression appeared to negatively affect outcome in 
all groups.  
 
Summary and commentary - the national longitudinal studies 
 
What do these studies tell us? 
There are consistent finding in all of these studies. They generally show that being in 
treatment is associated with clinical improvements. In most modalities, those in treatment 
do better than those not in treatment in terms of drug use and the associated risks, overall 
health and crime. Staying in treatment seems to be an important indicator of better 
outcomes. In NTORS, improvements are generally seen at 1 year and seem to be broadly 
maintained to 5yrs for those reviewed. DORIS raises differences between Scotland and 
England regarding abstinence-based outcomes. DATOS has raised the issues around the 
drug user’s ability to engage with treatment services (or the services’ ability to facilitate 
engagement). ATOS shows that co-morbid mental health issues (in this case depression) 
may impact on the outcome achieved. 
 
Limitations 
There are limitations to the conclusions which can be drawn from such research. The 
limitations include: 
 Relevant to the UK? – The UK health system is very different from that in the USA or 
Australia. While some findings of these national studies should inform study 
development in the UK, it is essential that UK research – reflecting the specifics of 
the delivery of services locally – demonstrates that any findings are generalizable to 
the UK treatment system. 
 
Also, the NHS across the UK is now taking on very different characteristics. This reflects 
different and diversifying government priorities. National governance of drug treatment has 
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been the norm in England for some years. Local governance remains the Scottish 
government’s preferred approach – though recent HEAT targets have seen considerable 
improvements in measureable performance nationally. Also, it is now likely that General 
Practice contracts will vary across the UK, with a Scottish General Medical Services contract 
now being discussed with doctors’ representatives. The care of substance misusers is not 
part of the GP “General Medical Services” (GMS) contract currently and this is likely to be an 
area for debate in future negotiations in Scotland. In such circumstances, generalizability of 
research from different health systems in the UK becomes a serious issue. 
 
 Size and representativeness of the sample - While the total numbers of individuals 
entering these studies is high, the number entering each intervention is relatively 
low. For example, those entering an OST programme in NTORS is 458. Some 279 
entered OST in DORIS and in ATOS this group consists of only 201 cases. By follow up 
(even in the early stages) these samples reduce considerably.  
 
In the case of NTORS, these subjects were recruited from 54 different services increasing the 
likelihood that factors relating to specific service culture, process or performance (the issues 
touched on in DATOS) can impact on outcome. Though sampling processes are described, 
which aim to ensure that the groups are representative at each stage, in some of the 
studies, the issue of sample size and representativeness impacts on the generalizability of 
any findings. ATOS appears to have achieved high levels of follow up though the associated 
reports are difficult to interpret regarding final numbers. 
 
 Selection of participants – The samples are generally drawn from self-selecting 
populations presenting themselves to discrete treatment modalities – not 
randomized to a different treatment or condition as would normally be the case in 
primary research. The studies do not differentiate whether the intervention being 
accessed would best match to that individual’s clinical presentation. If local services 
are not comprehensive – for example offer only detoxification or OST- M options, 
subjects may be accessing inappropriate treatment for their needs.  [This would not 
be an unusual situation in parts of the UK – especially in the 1980s and 90s. In 
Glasgow, for example, formal OST programmes were only commenced in 1994. Prior 
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to this, few patients would receive OST and all from general practice.] Those involved 
in the studies must give informed consent – adding a further selection bias to the 
study of what is a relatively small proportion of a very heterogeneous population. 
Since DARP, the US studies commented specifically on the effects of each treatment 
episode contaminating the final outcome at follow up, making interpretation 
regarding which intervention was driving any observed change very difficult. 
 
 Follow-up periods – NTORS is the only UK study to have a substantial follow up 
period – 5 years - which can realistically reflect the natural history of a treatment-
seeking substance misuser.  DTORS has a follow up period of only 13 months while 
DORIS achieves 33 month follow-up for some selected elements of the study. In 
Australia, ATOS’ main study report relates to a 12 month follow up – though one 
geographical area followed a sub-sample up for 3 years. The report generalises from 
these findings which may overstate the significance of their results. The US studies 
follow a similar approach – with the main analyses relating to relatively short follow 
up periods (DATOS 15 months) but with sub-samples followed up for longer periods 
– up to 5 years in DATOS and 12 years in DARP. 
 
 Controls – These studies generally lack matched control groups. Only ATOS had a 
non-treatment control. This may be inevitable in such studies for ethical or practical 
reasons – though some more localised research of large numbers of subjects has 
used waiting-list controls to assess effectiveness of forms of OST- M delivery (e.g. 
Schwartz et al, 2006). This lack of controls prevents comparison with the 
experimental results (i.e. the proposed effect of the intervention) and weakens the 
power of the scientific findings. The observations from such studies should be used 
to inform the design and execution of hypothesis-driven controlled trials to give 
strong research evidence of what does and does not work. 
 
Discussion - limitations 
The limitations reflect many issues. It must be recognised that these national studies were 
one element of a research process which was “catching up” with a potential global disaster 
– the spread of HIV in the intravenous drug using population. Harm reduction approaches 
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had a developing evidence base as well as pragmatic face validity and national governments 
were responding to the public health challenge. Support for research exploring treatment 
effectiveness was welcomed by clinicians and academics and was often driven by clinical 
pressure and lobbying. However, when a clinical challenge also has substantial political 
perspectives – for example, cash-strapped health services investing in delivery of 
interventions to reduce harm in an excluded and stigmatized patient group - clinicians and 
researchers may overplay their hand. Nor has this challenge abated. 
 
Evidencing treatment effectiveness in Scotland and England 
Demonstrating treatment effectiveness may be complicated by the difficulty in determining 
the best way to measure positive outcomes in a harm-reduction environment or one where 
patients progress along a recovery continuum which may take several years and be 
characterised by fluctuating periods of progress and relapse. In such a chronic relapsing 
condition, even demonstrating the outcome “drug free” offers a challenge to researchers 
who may demonstrate improvement in a narrow area of drug use but little effect in terms of 
broader recovery. Consequently, measures of drug use and injecting risk must be enhanced 
by attempts to describe improvements in social functioning or health status or are replaced 
by measures of service use or “proxy” outcomes – such as treatment retention. Objective 
and consistent measurement of these outcomes presents a real difficulty for researchers in 
this field in terms of obtaining comparable data as well as interpreting complex findings.  
 
The direct challenge to the Scottish Government strategy, described in Chapter 1, reflects, 
to some extent, a lack of convincing evidence – from formal research or local/national 
reporting - for the effectiveness of Scottish treatment services and specifically, a lack of 
prioritization of high quality research into the effective treatment of substance misuse in 
Scotland.   
 
This deficiency can be further illustrated by reviewing research activity in this field. The 
Chief Scientist’s Office (CSO) for Scotland publishes reports of all research funded by CSO on 
an annual basis (Chief Scientist for Scotland [CSO], 2012). This report shows that, since the 
publication of the Road to Recovery in 2008, the CSO has received reports of only 6 research 
studies, funded by that office, relating to substance misuse. Of these, one was focused 
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specifically on Hepatitis C - but in a drug using population. During this same period, the CSO 
received reports of 216 studies on other topics. Only 2.7% of CSO funding, under all 
headings, was in the area of substance misuse. 
 
Also, a gap in availability of valuable routine clinical information has been identified in a 
recent report by the Information Services Division (ISD) of the NHS which undertook a 
consultation on information needs in the field of substance misuse across Scotland (ISD, 
20122). When interviewing a range of stakeholders, the issue of treatment effectiveness was 
high on the agenda. The report states: “Effectiveness of interventions was a prominent 
response to this question... Some interviewees focussed on knowing interventions’ effects 
while others discussed ways to determine effectiveness. Effectiveness can be measured in 
several ways and different interviewees had different priorities. A common concern was that 
at present there was a lack of awareness of the effectiveness of interventions that are being 
used across Scotland.” 
 
In particular, there were real concerns about demonstrating meaningful outcomes. One 
interview clearly raised the question of ISD – who collate national statistics on behalf of the 
government - supporting an ongoing process of service evaluation (not unlike the studies 
cited above): “For large cohorts of service users, you could evaluate new treatments, in 
effect a natural experiment, which would be valuable given the difficulty in carrying out 
randomised controlled trials for methodological reasons and political reasons.” The ISD 
consultation report concluded that: “Perhaps the most prevalent need identified, one that 
sits at both the population and individual levels, was a clear understanding of what works. 
This could be the effectiveness of interventions; what treatment works and what does not. 
But there was more than this, it extended out to needing to identify which policies worked 
and why, which patient journeys generated positive outcomes, what could be considered a 
‘positive outcome’.”  
 
The NHS in England is advised on decisions regarding which treatments should be available, 
by the National Institute for Health and Clinical Excellence – NICE (National Institute for 
Clinical Excellence Establishment and Constitution Order, 1999). The purpose of the 
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organisation was originally to avoid “postcode lotteries” and to ensure equity of access to 
evidence-based medical treatments across the country. NICE is required to “provide 
independent, authoritative and evidence-based guidance on the most effective ways to 
prevent, diagnose and treat disease and ill health, reducing inequalities and variation” and 
its guidance – which includes an assessment of cost – effectiveness of the intervention in 
question -  is required to be followed by local Health Authorities and Primary Care Trusts in 
England and Wales. 
 
In the case of treatment for substance misuse, the most recent national treatment 
guidelines for the UK (Department of Health 2007) were supported by NICE systematic 
reviews or technology appraisals covering all the main treatment approaches (NICE 2007 a-
d). This should have given a degree of security to treatment availability in this field in 
England and Wales. However, only three years later, in 2010, a new government was 
compelled to further explore the evidence on treatment effectiveness – reflecting their view 
that there was a need to understand better what treatments were most likely to deliver the 
desired outcome of recovery - and how delivery of services would facilitate this. The 
resulting expert report - Medications in recovery: re-orientating drug dependence treatment 
(National Treatment Agency, 2012) re-iterated the existing evidence base – but was unable 
to point to any novel research which promised improved progress towards recovery. The 
document declared: “If we stick closely to the compelling evidence for effective OST, and the 
existing guidance based upon that evidence, we will deliver many of the improvements 
needed”. It went on: “ We strongly support continued reference and adherence to the 
existing NICE drug misuse guidance (reviewed and unchanged in 2010-11) and to the more 
practitioner-orientated 2007 Clinical Guidelines”.  
 
Even the supplementary Appendix C (Bell, 2012) which reviewed the evidence to date, 
recognised that firm evidence regarding recovery was lacking and described in aspirational 
terms the need to better recognise so-called “recovery capital” and some proposed changes 
to improve care planning and review. The evidence of effectiveness of such approaches in 
improving delivery of recovery outcomes is clearly yet to appear.  
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In Conclusion 
 
Large national longitudinal studies can give valuable information about the effectiveness, 
risks and benefits of treatment and can support descriptive research. If well planned and 
constructed, they can also address key research questions. However, the studies to date, 
have many limitations and should be followed by high quality hypothesis-driven research 
which takes forward the many valid issues they raise. Few such studies have been taken 
forward in the UK setting. 
 
In this environment, in the UK, there is clearly an opportunity to develop processes which 
collect high quality clinical information on large numbers of those in treatment. Such 
systems could collect data using validated tools of recognised value to the field. Such data 
collection systems would facilitate the development of programmes of research, addressing 
hypothesis–driven studies to answer the many unanswered questions which must be 
understood if recovery is to become a reality. 
 
The next chapter will describe a review of the research literature, which will inform the 
development of hypotheses for testing. 
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Chapter 3. Predicting outcomes – a literature review 
 
It is a capital mistake to theorize before you have all the evidence. It biases the judgment.  
Sir Arthur Conan Doyle -A Study in Scarlet (1887) 
 
“…Yeah?...well, you know, that’s just like..ah your opinion, man” 
The Dude - The Big Lebowski (Ethan & Joel Coen, 1997) 
 
Introduction 
 
This chapter describes a literature review which aimed to generate hypotheses for testing. 
The published international literature relating to factors impacting on outcome for those in 
receipt of Opioid Substitution Therapy using methadone (OST-M) was reviewed: 
1. To identify key independent variables (predictors) impacting on the outcome of OST-M 
treatment.  
2. To identify relevant dependent variables (outputs and outcomes) which are valid 
indicators of treatment effects in OST-M 
 
Methods 
 
Search terms 
The project planned to use data available in a regional database of methadone-prescribed 
patients in Scotland - the Tayside Methadone Cohort database (described in detail in 
Chapter 4).  The database contained baseline clinical data collected in 2005 and follow-up 
data from a range of sources, collected over the next 7 years. The literature review focused 
on those factors which were available within this database with the aim of generating 
testable hypotheses. The literature review would direct the selection of specific 
independent variables (predictors) and dependent variables (outputs and outcomes). 
 
Identification of studies: 
An electronic keyword search was conducted using the following databases:  
 EMBASE (1974-April 2012 inclusive);  
 Ovid Medline(R); Ovid Medline (R) in-process and other non-indexed citations (1946-
April week 2 2012);  
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 Cochrane library - database of systematic reviews; database of other reviews; Health 
Technology Assessments; economic evaluations; controlled trials.   
Searches were limited to publications relating to research in humans. Though publications in 
all languages were sourced, only those for which an English translation was readily available 
were used. Keywords and results are summarized in Table 3 and Figure 4.  
Table 3. Results of Literature search 
Keywords Databases searched Results 
Opioid related disorders Cochrane Database  
 Cochrane database of systematic 
reviews (contains 7163 articles) 
23 identified and abstracts 
screened 
8 papers selected for review 
 Cochrane database of other 
reviews (contains 16,773 articles) 
30 identified and abstracts 
screened 
10 papers selected for review 
 Cochrane database of Health 
technology Assessments (contains 
10,997 articles) 
12 identified and abstracts 
screened 
4 papers selected for review 
 Cochrane database of economic 
evaluations (contains 11,720 
articles) 
11 identified and abstracts 
screened 
2 papers selected for review 
 Cochrane central register of 
controlled trials (contains 670,154 
articles) 
530 identified and abstracts 
screened 
75 full papers selected for review 
 Cochrane Database totals 99 full papers to be reviewed 
Methadone and outcomes  
 
 
 
 
 
 
 
 
EMBASE 1974-April 2012 inclusive; 
Ovid Medline(R); Ovid Medline (R) 
in-process and other non-indexed 
citations 1946-April week 2 2012 
1358 articles identified. 
350 abstracts selected and 
screened 
294 full papers selected for review 
Methadone and comorbidity 198 articles identified 
81 abstracts selected and screened 
71 papers selected for review 
Substance misuse, opiate/opioid, 
dependency and comorbidity 
393 articles identified 
89 abstracts selected and screened 
62 papers selected for review 
Opiate addiction and comorbidity 
Opioid addiction and comorbidity 
436 articles identified 
93 abstracts selected and screened 
74 papers selected for review 
Methadone and pain 858 articles identified 
61 abstracts selected and screened 
33 papers selected for review 
Methadone and anxiety 325 articles identified 
91 abstracts selected and screened 
71 papers selected for review 
Methadone and ADHD 15 articles identified 
15 abstracts selected and screened 
7 papers selected for review 
Methadone and PTSD 19 articles identified 
14 abstracts selected and screened 
12 papers selected for review 
 EMBASE/MEDLINE totals 624 full papers to be reviewed 
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Figure 4. Consort diagram (summary) of literature review process 
 
  EMBASE 1974-April 2012 inclusive + Ovid Medline(R) + Ovid Medline (R) in-process 
and other non-indexed citations 1946-April week 2 2012 Screened for relevance to study 
[n=3602 abstracts identified] 
  – of systematic reviews; of other reviews; of Health 
technology Assessments; of economic evaluations – and Cochrane central register of 
controlled trials [n=606 abstracts identified] 
 
relevant abstracts further screened 
for focus and quality [n=794] 
 
All abstracts screened for relevance 
focus and quality [n=606] 
 
Abstracts excluded as 
irrelevant to study  [n=2808] 
 
Full text articles retrieved 
 [n=624] 
 
Full text articles retrieved 
 [n=99] 
 
Abstracts excluded on 
quality grounds  [n=170] 
 Abstracts excluded  on 
quality grounds [n=507] 
 
Total of 723 articles identified to be retrieved for review. Duplicates were then excluded.  
Articles for which English translation was unavailable were also excluded. 
Full papers were then assessed for relevance to specific research question. 
 n=180 papers were finally included in the review. 
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Selection of relevant studies/papers 
All outputs from the electronic keyword searches were initially screened online and those 
not relevant to this study excluded. Exclusion criteria included: 
 papers not focusing on OST-M 
 papers in which methadone was not a significant factor in the analysis 
 papers in which the OST-M treatments were clearly intended for short term or 
detoxification purposes 
 papers considering treatment in residential/in-patient facilities 
 
Some articles included community-based OST - M alongside others which were within the 
exclusion groups. In these cases a pragmatic judgement was made based on the relevance 
to the current project. If at this stage an article clearly did not meet these pre-defined 
criteria it was rejected.  Duplicate articles were also removed from the output of each 
electronic search at each stage. Finally, reference lists of the selected papers were searched 
manually for any additional key references not identified from the initial electronic search. 
These additional lists were taken through the same procedures as above and, if required, 
accessed and included in the review.  
 
Review of relevance and quality of retrieved articles 
Full text articles were accessed online via the NHS e-library, sourced directly from local 
university libraries or through the University of Dundee inter-library loan system. Many of 
the retrieved articles identified were purely descriptive in nature. Many published papers 
assessed associations between variables in a cross-sectional sample of a study population 
and addressed a wide range of dependent and independent variables. Few were found to 
have a follow-up element to the study or to test a specific, focused hypothesis. The 
electronic search also identified a large number of “review” or “editorial” articles. Some of 
these had followed a rigorous/systematic method to review the existing research while 
others were less rigorous and more selective. A pragmatic judgement was made regarding 
their inclusion in the literature review. 
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Summary of studies identified 
 
Some 180 articles were ultimately included for critical appraisal as part of in this review.  Of 
these, 19 were systematic reviews. Of the remaining 161 studies, only 90 (55%) had any 
longitudinal follow up element. The remainder were descriptive studies or simply identified 
associations between variables in a cross-sectional survey of subjects at a single time point. 
Of the 90 with follow–up elements, the majority – some 64 studies (71% of the identified 
studies with follow up elements, 39% of the total) - had follow-up periods of up to one year 
(mean 8.64 months; range 3 months-1year). Only 26 studies - 29% of those with follow-up 
and 16% of all identified relevant studies - had follow up periods of more than 1 year (mean 
5.86yrs; range 1.5-30yrs). The most common duration of follow up (mode) was only 2 years.  
 
Although rarely acknowledged as an issue, relatively short follow up periods in the research 
evidence base have been commented on previously in a number of recent Cochrane 
Reviews of OST-M.  For example, in the 2009 Cochrane review of Methadone maintenance 
versus no therapy, follow up periods in the research cited ranged from only 45 days to 2 
years (Mattick, Breen, Kimber & Davoli 2009). The 2011 Cochrane review of the effect from 
added psychosocial interventions reviewed evidence from studies of 6-48 weeks (all under 
one year) duration with a mean of only 17 weeks (Amato, Minozzi, Davoli & Vecchi 2011). 
The 2003 Cochrane review of the relative effect of methadone dose drew its conclusions 
based on evidence from studies of 7-53 weeks duration (Faggiano, Vigna-Taglianti, Versino 
& Lemma, 2003).   
 
Opiate dependency is a chronic relapsing condition with a natural history which suggests 
that at least 5 years of illicit drug abstinence is good indicator predicting future stable 
abstinence (Hser, 2007). In such circumstances, it is surprising that so few well-constructed 
studies have attempted to clarify how treatment can affect long term prospects of recovery. 
 
Effectiveness of Methadone Replacement Therapy  (OST- M) – Systematic reviews 
 
All studies reviewed address the use of methadone as the opioid substitute. For the 
purposes of the review, this will be summarized as OST-M. This term will also be used for 
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those studies using other specific terms - such as methadone maintenance therapy (MMT). 
These reflect the same treatment type – and do not reflect a specific reduction or 
detoxification intervention. 
 
The literature search identified 19 systematic reviews considering the effectiveness of 
Opiate Substitution Therapies. Most of these consider Methadone and Buprenorphine 
(Subutex® and Suboxone®) while a few also consider the drug Levo-alpha acetyl methadol - 
LAAM. The reviews are summarised in Table 4 (p83). 
Patient characteristics affecting outcome 
The reviews identified address a number of key questions. 
 
Is OST-M associated with improved outcomes? 
An early review and meta‐analysis considered the effectiveness of OST-M in reducing illicit 
opiate (heroin) use, HIV risk behaviour and criminality (Marsch, 1998).  Marsch reviewed 43 
studies. Of these:  11 studies (involving 2,056 participants) had used ongoing  illicit opiate 
(heroin) use as the outcome measure;  24 studies (7,173 participants) used criminal 
activities as the outcome measure; 8 studies (at least 1,797 participants) used reports of  
HIV risk behaviours as the outcome measure. The author concluded that there is a 
consistent, statistically‐significant relationship between OST-M and the reduction of illicit 
opiate use, HIV risk behaviours and drug and property‐related criminal behaviours. The 
effectiveness of OST-M was felt to be most apparent in its ability to reduce drug‐related 
criminal behaviours. OST-M was described as having had a moderate effect in reducing illicit 
opiate use and drug and property‐related criminal behaviours, and a small to moderate 
effect in reducing HIV risk behaviours.  
 
A UK-based review of community OST-M (or buprenorphine) considered 48 RCTs – 14 of 
methadone, 20 buprenorphine and 14 comparing both (Simoens et al, 2005). The authors 
concluded that the results supported the effectiveness of community maintenance 
treatments with methadone or buprenorphine. The authors raised issues which they felt 
might bias some of the trials. These included:  use of different treatment groups in the 
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studies; variable drug dosing in different studies; high drop‐out rates; small sample sizes; 
short treatment duration. Despite these concerns, the reviewers felt that the studies 
supported the view that community maintenance treatment with methadone or 
buprenorphine was effective in terms of treatment retention, abstinence and reduction in 
illicit opiate use. However, there was considerable variation between the studies in terms of 
the reported results achieved. They also concluded that both methadone and 
buprenorphine were more effective at higher doses.   
 
In 2007, the UK’s National Institute for Health and Clinical Excellence in the UK published a 
technology appraisal which reviewed the evidence of effectiveness of OST using methadone 
or Buprenorphine (Connock et al 2007; NICE 2007a). This was part of a range of reviews 
being undertaken to support delivery of updated clinical guidance for UK doctors 
(Department of Health, 2007). Following the standardized processes for these exercises, an 
expert group took evidence from a wide range of stakeholders – including the 
pharmaceutical industry, service users and clinicians. They also reviewed 31 existing 
systematic reviews and 28 additional RCTs as well as 11 economic evaluations. They noted: 
there were no RCTs from the UK – with the majority originating in the USA. The RCTs 
reviewed usually used fixed dosing, very restrictive delivery (e.g. supervised consumption), 
had no additional psychosocial interventions and short follow up (<1yr). They commented 
that fixed doses did not reflect normal clinical practice and stated that “none used all of the 
appropriate parameters, effectiveness data, perspectives and comparators required to make 
their results generalizable to the  NHS..”. They also felt there was insufficient evidence to 
draw conclusions regarding cost effectiveness. However, in balance they still felt they could 
conclude that OST-M supports retention, reduced opiate use, reduced HIV risk behaviours 
and sero-conversions, reduced mortality and reduced criminal activity. They also stated that 
higher fixed doses were more effective than lower fixed doses. 
 
In 2009 a Cochrane Review examined all RCTs comparing OST-M with placebo or a non-
pharmacological therapy (Mattick , Breen, Kimber & Davoli, 2009). They reviewed 11 RCTs 
(1969 subjects) of which only two were double blind. Outcomes were assessed from 45 days 
to 2 years maximum. The authors commented on the lack of any evidence on some key 
outcomes of interest (such as deaths, social outcomes) and the relationship between 
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medical and psychosocial treatments. They also felt that the methodological failings of 
much of the research made generalising from the evidence base “impossible”. They 
concluded however, that OST-M does improve retention and does reduce heroin use though 
they could not conclude that it reduces criminal activity.  
 
A systematic review of the evidence for a range of treatment options for opioid dependence 
aimed to “synthesize the current status of opioid dependence treatment” (Veilleux et al, 
2010). They reviewed existing systematic reviews from the Cochrane database and 
supplemented this with additional meta-analyses of RCTs published since the most recent 
Cochrane reviews.  Again the authors raised the challenge of carrying out a meta-analysis as 
studies used a broad range of methods and approaches – including differing subjects, 
outcomes and durations. They felt that there was a need to broaden quality research to 
better scrutinize more clinical outcomes including abstinence. Citing 155 studies, involving 
28,999 subjects, they commented on effectiveness of OST-M. They concluded that OST-M 
improves treatment retention, reduces opioid use and reduces withdrawal symptoms in 
opioid dependent individuals. They identified what they saw as clear evidence of dose 
effects – with higher doses more effective at delivering these desired outcomes.  
 
In 2012, the British Association of Psychopharmacology published an update of its 2004 
advice for UK clinicians on the treatment of a range of substance use disorders (Lingford-
Hughes, Welch, Peters & Nutt, 2012). This advice was based on a rigorous systematic review 
of the literature over 3 years, overseen by an invited expert panel. They sourced previous 
systematic reviews from credible sources (e.g. Cochrane database) and other RCTs when 
possible. The authors commented on the complexity of the evidence base – reflecting the 
heterogeneity of research subjects, lack of clarity of the research question in many studies 
and small sample sizes or short follow up times. The evidence base was also largely from the 
US health system making generalizability to the UK a concern. They acknowledged that at 
times the strength of recommendations made was extrapolated from relatively low grade 
evidence or expert consensus (given an “s” status – a standard of care).  
 
With regard to OST-M, they concluded that it improves treatment retention, reduces heroin 
use, shows a trend towards reducing mortality and reduces injecting related risk behaviours 
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- but not sexual risk behaviours. Higher doses seemed to be more effective at achieving 
these outcomes. There was no evidence for an added effect from psychosocial interventions 
nor for an effect on criminal activity. 
 
In Conclusion – systematic reviews on effectiveness of OST-M 
In summary then, a series of systematic reviews has repeatedly concluded that availability 
of OST-M is associated with improved retention, reduced illicit opioid/heroin use and 
reduced HIV risk behaviours – related to injecting. Higher doses are felt to be more 
effective. There is less consensus, in these reviews, regarding the effect on criminal activity 
and mortality. These reviews have consistently commented on methodological issues 
regarding the studies carried out affecting relevance to the UK. These concerns include: lack 
of UK-based research; research is often lacking a clear research question; studies cited often 
have small numbers with short term follow-up periods; heterogeneous populations are 
offered diverse treatment approaches which are difficult to compare; use of fixed dosing 
and rigid delivery systems (e.g. supervision of methadone dispensing); OST-M is often 
delivered with no additional psychosocial interventions. 
 
OST-M dose effects 
Many of the reviews cited above have commented on a dose effect - with higher doses 
being more effective than lower doses.  
 
A Cochrane review was undertaken in 2008 to comprehensively assess the evidence 
regarding the effect of OST-M dose on outcome (Faggiano et al, 2008). They reviewed 21 
studies including 11 RCTs (all from the USA and using follow up periods of <1yr). The studies 
included some 5994 subjects. Controlled prospective studies (CPS) were also cited. These 
CPS can follow patients up for up to 10 years. Again, the authors acknowledged the issue of 
heterogeneity of subjects, inconsistency of sampling etc. – which affected the quality of the 
research. They also recognised that the short follow up period of RCTs reduced the 
relevance of the review findings. There was insufficient evidence to comment on some 
outcomes – such as mortality, criminal activity and social outcomes. They did, however 
conclude that higher doses OST-M (60-100mg) were more effective at retaining patients and 
reducing opioid and cocaine use. 
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Evidence for specific outcomes – the purpose of treatment 
Some reviews have considered evidence that OST-M can deliver specific outcomes along a 
continuum of progress towards ultimately being entirely drug free (abstinent).  The key first 
step of retention in treatment has been addressed in the reviews cited above. The next key 
(harm reduction) outcome would be reduction in risk behaviours and reduced Blood Borne 
Virus (BBV) infections and sero-conversions. 
 
Preventing blood-borne virus (BBV) transmission 
The effectiveness of drug treatment in preventing HIV spread in intravenous drug users was 
explored in a review by Sorensen & Copeland (2000). They reviewed 33 studies including 
over 17,000 participants. They identified serious methodological problems in the literature 
including: a lack of control groups in many longitudinal studies; questionable validity of self‐
report of risk behaviours (often the basis of reports that treatment is successful); concern 
regarding the representativeness of the samples (differences in demographics between in‐
treatment and out‐of‐treatment IDUs in comparative studies; self‐selected treatment 
samples; highly selected samples; small sample sizes). Other issues included: short follow‐up 
periods in longitudinal studies and high attrition rates. Despite these concerns regarding the 
science, they concluded that there is clear evidence that OST-M reduces HIV risk behaviours, 
particularly needle use.   
 
A recent Cochrane Review aimed to assess the effect of oral OST on risk behaviours and HIV 
sero-conversions (Gowing et al, 2011). They could not be highly selective due to the lack of 
RCTs - so included all types of original studies. Some 38 studies incorporating 12,400 
subjects were included. The authors noted that most studies were “at high risk of bias”. 
They also stated that “The lack of data from randomized controlled studies limits the 
strength of the evidence presented in this review”. They concluded, however, that OST 
reduces opioid use, intravenous use, needle sharing and HIV sero-conversion. They also felt 
there may be an effect on sexual risk behaviours for HIV. 
 
Though not technically a systematic review, a recent UK study aimed to examine the effect 
of harm reduction availability and Hepatitis C (HCV) sero-conversion (Turner et al, 2011). 
The researchers carried out a meta-analysis and pooled analysis on data for 2986 subjects 
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from six areas in the UK over 8 years. They used questionnaire information to determine 
availability of OST and needle exchanges locally. Some 40 new HCV cases were identified in 
the period. The study concluded that improved access to both OST and needle exchange 
was associated with a considerably reduced rate of HCV sero-conversion. 
 
Reductions in Illicit drug use and abstinence 
A meta-analysis was carried out to identify risk factors for continued drug use in patients 
treated for “opiate abuse” in a range of interventions, including OST-M (Brewer et al, 1998). 
Some 69 studies were examined. Ten variables were felt to show statistically significant and 
longitudinally predictive relationships with continued use while in treatment. These 
included: high level of pre-treatment opiate/drug use; having a history of prior treatment 
for opiate addiction; having a treatment history where there has been no prior abstinence 
from opiates; abstinence from/light use of alcohol (heavier use of alcohol was more likely to 
be associated with at least a period of abstinence from opiates than light use or abstinence 
from alcohol); history of depression; describing experiencing high levels of stress; being 
unemployed or having  employment problems; the level of association with substance 
abusing peers; only having a short period of  treatment; leaving treatment prior to 
completion.  
 
One review specifically explored abstinence from opioid use in subjects on OST-M 
programmes (Kornor  & Waal 2005).  This review estimated opioid abstinence rates and 
explored possible relationships with characteristics of the patients or treatment 
programmes they had received. There are quality issues regarding the clarity of this review 
and the conclusions drawn. Twelve studies (incorporating 9,718 subjects) met the inclusion 
criteria for the review. The designs of these studies, however, were not clear from the study 
report, although the authors did report that most were “follow‐up studies”. Two of the 
studies appeared to be randomised controlled trials. Follow‐up ranged from 1 month to 
103.2 months. Overall, 33% of patients in the studies had a period of abstinence from 
opioids for an average of 2 years following detoxification. The rates of abstinence ranged 
from 22% to 86%. It is not clear how the authors appraised the evidence retrieved, but they 
concluded that OST maintenance programmes may be suitable for a subgroup of patients. 
They did state that further research was needed to better tailor programmes to achieve the 
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goal of abstinence from illicit opioids.  Regarding the characteristics of the treatment 
programmes - abstinence rates were higher in patients who volunteered to participate in 
detoxification programmes. Methadone dose and psychosocial support were not found to 
be related to abstinence rate in this review. Regarding the characteristics of the subjects - 
age, ethnicity and educational level were shown to have a positive relationship with 
abstinence rate in some studies, but not others. Similarly, duration or severity of 
dependence, detoxification difficulties, social problems and involvement in criminal 
behaviour were shown to have a negative relationship in some studies, but not others.   
 
Recovery and broader treatment outcomes 
A review of the evidence regarding improvements in the Quality of Life (QoL) of drug users 
in treatment was reported in 2010 (de Maeyer, Vanderplasschen & Broekaert, 2010). The 
authors reviewed 38 studies which had assessed QoL as at least one measure of treatment 
effectiveness. Some 16 studies followed up those on some form of OST. A further 11 studies 
compared QoL in opioid users and non-opioid users while 8 longitudinal studies considered 
changes in the QoL over time in various treatment modalities. The OST studies found that 
QoL was very low on entry but improved with treatment. This improvement occurred early 
but then deteriorated again after only a few months (though normally not to pre-treatment 
levels). There were no definitive differences between OST types/drugs in the nine studies 
which made these comparisons. The authors concluded that services must address more 
than the drug use as other factors are likely to affect QoL. They felt that OST has a 
significant effect on QoL in the early stages of treatment and though this tends to 
deteriorate, improvement is sustained beyond the level found on entry. 
 
There have been two recent publications, which are relevant to the use of OST-M in the UK 
treatment setting, specifically reporting reviews of the evidence supporting recovery. Both 
are highly selective and were commissioned by new governments launching new drug 
strategies which had emphasised a recovery ethos over harm reduction. 
 
One published review explored the research evidence for improved recovery (Best et al 
2010). This review was commissioned by the Scottish Government to support their national 
drug strategy which had the stated aim of improving recovery outcomes for substance 
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users. The authors described a systematic review of the published literature which  
identified 205 relevant articles. The process of critical appraisal was not well defined in this 
review and a number of descriptive articles by experts in the recovery field are widely cited. 
The authors note that much of the evidence is from overseas (almost exclusively the USA) 
and is from other areas of addiction such as alcohol  or the broader mental health field – so 
may not translate well into the field of opioid dependence. The authors make a number of 
broad statements regarding their belief around the recovery evidence base and emphasise 
the lack of relevant systematic research in this area in the opioid dependent population in 
the UK. They conclude that in opioid dependency, “sustained recovery is the norm” [though 
there is no evidence presented from quantitative research to support this view]. They point 
out that pathways towards achieving this outcome are “individualistic” and identify the 
phenomenon of  “recovery capital” -  positive attributes in a person’s life - as “the best 
predictor” of recovery outcomes. They also define an identifiable range of “barriers” to 
recovery. They conclude that structured treatment has a part to play but emphasise that 
social support is also required if opioid dependent individuals are to progress from serious 
problem drug use. 
 
The Best review gives a helpful overview of the quality of evidence addressing the elements 
which constitute the specific outcome of recovery from substance misuse. However, the 
report makes statements about recovery which clearly cannot be based on the evidence 
presented. They do conclude that there is a dearth of high quality research evidence 
available to assess potential for recovery in the opioid dependency field in the UK. 
 
In 2012 the English National treatment Agency (NTA) published their report Medications in 
Recovery: Re-orientating Drug Dependence Treatment (NTA, 2012). Like the Best review in 
Scotland, this was commissioned (alongside a number of reviews on various approaches to 
treatment) by the new UK Government in order to respond to a perceived need to 
reconsider how treatment should be focussed in England. [In the UK, though drug control 
legislation is a UK Government responsibility, disaggregation and creation of the Scottish 
Parliament has made Criminal Justice and Health strategies a devolved power. 
Consequently, national strategies and delivery plans for Scottish and English services are 
subject to different governance and accountability arrangements. The NTA oversees 
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treatment delivery in England & Wales only.] The report was sponsored by ministers and 
produced by an invited expert group of stakeholders from a range of backgrounds including 
leading academics in the field in the UK and was supported by authorities from the USA.  
 
As an Appendix to the report, a small sub-group of senior clinicians prepared a review of the 
literature to date - Opioid Substitution treatment and its effectiveness: review of the 
evidence (Bell, 2012). Recognising that recovery may be supported by less sound, high-
quality research, the author states that the review “seeks to integrate, as far as is possible, 
the discourse of evidence-based practice (built on observation and measurement), with the 
humanitarian, recovery-based discourse based on values (such as responsibility, choice, and 
empowerment)”. The approach taken was “to identify the broadly-agreed objectives of 
treatment, and to review the empirical evidence as to the effectiveness of OST. The paper 
then reviews the factors associated with variations in treatment effectiveness..”  
No search strategy or agreed process of exclusion/inclusion of references, nor critical 
appraisal process is included in the review. The review was ultimately attributed to one 
author. As such, the report represents the views of a select group/individual (albeit a group 
including recognised clinical experts in the UK addiction field). 
 
The review re-iterates the published evidence base regarding the many harm reduction 
benefits of OST described in this thesis. However, the authors are less optimistic regarding 
the evidence for improvements in those areas relating to long term recovery. Areas 
addressed include:  
 Quality of Life –They conclude that measureable improvements in quality of life have 
been seen in the short term but there is little evidence for this being sustained 
beyond the early (6 month) phase of treatment; 
 Re-integration to society - The review could identify no compelling quantitative 
research in this area. Qualitative research methods have  raised the ambivalence of 
those on methadone, who recognised that being on methadone may improve the 
conditions for recovery – as users are not in a constant state of withdrawal – but the 
stigma and control associated with methadone treatment has negative effects too. 
Thematic analyses have identified key themes which potentially contributed to 
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improvements in quality of life. These were: availability of good caring relationships; 
having an occupation; independence; having a meaningful life.  
 Achieving abstinence - This issue was contextualised in the review – recognising that 
the philosophy of OST recognises the chronic relapsing nature of addiction and does 
not necessarily hold abstinence at its centre. The review discusses the implications of 
developing a “recovery focus” in OST. The authors acknowledge that “therapy 
requires a rationale” and recognise the paradox of committing an individual to long 
term maintenance medical therapy when one aim is to help them take control of the 
challenge of their own lives. The historic evidence base is cited – and shows the 
challenge of offering effective counselling/therapeutic approaches in this group. The 
authors state that a recovery focus can “provide direction and structure” for the 
service user and clinician. The person’s own community is also seen to have a role to 
play. However, the authors recognise the challenge of delivering recovery. Citing 
Moos (2003), they state “individuals need long-term social supports and personal 
psychological resources to sustain recovery. Formal treatment can be a powerful 
factor in building these social supports and psychological resources to facilitate 
positive change, but on its own it typically does not have a lasting influence.” 
 
What is the effect of how the OST- M is delivered?  
Some reviews have considered whether the mechanisms of treatment delivery affect 
outcomes in OST- M. 
 
One metanalysis reviewed 143 studies to explore the impact of programme [delivery] 
factors on treatment outcomes (Prendergast, Podus & Chang, 2000). They concluded that 
the heterogeneity of the studies led to complexity in terms of interpretation of results. 
Studies examined differing interventions, delivered to different heterogeneous groups of 
subjects and using differing outcomes and timeframes. They did conclude however, that 
some programme factors were found consistently to significantly correlate with better 
outcome. These included treatment exposure (number of appointments) and methadone 
dose. The same research team subsequently used meta-analysis techniques to identify 
methodological factors which may be affecting outcome in 78 studies (Prendergast, Podus, 
Chang & Urada 2002). In this review, they concluded that treatment reduced illicit drug use 
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and criminal activity. The specific factors which predicted better drug use outcomes 
included:  how consistently treatment approaches were implemented (e.g. manualised 
delivery of programmes by well-trained and supervised staff); programmes with less 
“theoretical grounding” – i.e. where the staff were less influenced by the background 
theories; those with strong “researcher allegiance”. Projects for younger adults were felt to 
deliver better crime outcomes. Other factors were not shown to be predictors of outcome 
in this review. 
 
Does inclusion of additional therapies/service delivery elements affect outcome? 
A Cochrane review of the added effect of psychosocial interventions to ORT was undertaken 
(Amato et al, 2011). The review included some 35 studies, incorporating 4319 subjects in 13 
distinct intervention types. Duration of these studies was relatively short term, from 6-48 
weeks with a mean of only 17 weeks. Researchers were unable to demonstrate any added 
effect from the introduction of any psychosocial intervention with regard to the outcomes 
of retention, abstinence, compliance with treatment or improvements in psychological 
symptoms. The researchers however did acknowledge that they “did not evaluate the 
question of whether any ancillary psychosocial intervention is needed when (OST-M) is 
provided, but the narrower question of whether a specific more structured intervention 
provides any additional benefit”. They also acknowledged the issue of short timeframes – 
none of the studies cited assessed outcomes beyond one year. 
 
Some other systematic reviews seem to challenge the conclusions of this Cochrane review – 
at least with regard to specific therapies. 
 
Community Reinforcement Approach - in a review of Eleven RCTs (n=812), Roozen et al 
(2004) considered the effect of the so-called community reinforcement approach (CRA). This 
approach encompasses an holistic bio-psycho-social approach to treatment which 
acknowledges the effect of environmental factors on the care process and tries to 
incorporate these elements into an individual’s care plan. Two of the RCTs addressed the 
effect on opioid treatment - one reporting a greater number of participants achieving at 
least 8 weeks' continuous abstinence with CRA and incentives than “usual care” in a 
detoxification programme. However, this trend was no longer statistically significant at 24 
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weeks post treatment. Another RCT  - the only cited addressing OST-M - reported CRA as 
being statistically significantly better than usual care in a methadone maintenance 
programme (84% of urine samples opiate negative compared with 78%). With regard to 
opioid treatment, the authors' concluded that there is limited evidence that CRA with 
incentives is more effective in an opioid detoxification programme and more effective than 
a standard methadone maintenance programme. 
 
Contingency Management Approach (CM) - Griffith , Rowan-Szal, Roark & Simpson (2000) -  
reviewed 30 studies (n=1,568) in a metanalysis of the effect of Contingency Management on 
outcome in OST-M. CM uses reinforcers – essentially rewards attained for achieving agreed 
goals during the programme. This behavioural approach aims to shape subjects behaviours 
towards normalised behaviour. Based on the type of reinforcer used (i.e. the reward being 
tested), there were: 4 studies of methadone increase or decrease; 1 of methadone increase; 
2 of methadone decrease; 6 of allowing take‐home methadone; 6 of receiving award 
vouchers; and 10 of using mixed interventions. The target behaviour (i.e. the expected 
change in response to the reward) was single‐drug use in 9 studies and multi‐drug use in 21 
studies. The overall estimated effect size (all 30 studies) suggested that the CM 
interventions resulted in better outcomes. The hypothesis of an overall positive CM effect 
(reflected across the literature) was supported, although its magnitude varied considerably. 
The results were felt to confirm that CM was effective in reducing supplemental drug use 
while patients participated in OST-M treatment. Secondly, several parameters were shown 
to be effective in promoting drug‐free urine samples while patients were in treatment. 
These included the following: the use of increases in methadone dose or take‐home 
methadone as incentives; the use of immediate reinforcement; targeting a single drug; 
monitoring urine three‐times a week. 
 
In conclusion – systematic reviews 
 
Quality of the evidence 
Published systematic reviews have consistently commented on the poor quality of the 
research evidence. Studies often have small samples and short periods of follow up. 
Heterogeneous populations are commonly used. Research questions are often unclear and 
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outcomes neither objective nor compatible. The interventions being delivered (e.g. OST-M) 
may be delivered in a way which is unlike normal treatment in the community – for example 
using fixed doses of methadone, not allowing take home methadone or failing to also 
deliver counselling or psychosocial supports. In the context of the delivery of British 
services, little high quality research has emerged from the UK, with most RCTs from the USA 
making the generalizability of their findings to UK practice challenging. 
 
Effectiveness of OST-M 
Despite these concerns, systematic reviews have consistently concluded that OST-M is 
effective in a number of ways. In particular, OST-M has been shown to: improve treatment 
retention; reduce opioid use and injection–based risk–taking. It may also reduce sexual risk-
taking. There is less consensus regarding its effects on death and criminal activity – some 
reviews supporting this effect, others not. 
 
Factors affecting outcome 
Effectiveness of OST-M seems to be affected by dose (higher doses are more effective). 
There is a question over the effectiveness of additional psychosocial interventions, reflecting 
poor quality or short term research. However, there is compelling support for the view that 
amount of treatment exposure – or treatment “dose” may positively affect outcome. A few 
reviews of specific psychotherapies – Contingency Management and Community 
Reinforcement Approach have reported some support from the research evidence base. 
Finally, one review suggested a number of factors which could predict less additional drug 
use. These included: high level of pre-treatment drug use; a history of prior treatment for 
opiate addiction; having a treatment history where there was no abstinence from opioids; 
abstinence from/light use of alcohol; depression; experiencing high levels of stress; having  
employment problems; association with substance abusing peers; a short treatment period 
or leaving treatment prior to completion.  
 
Recovery or abstinence 
Regarding recovery and abstinence – the evidence bases are not compelling and there is 
clearly a need for an approach to develop this research. 
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Table 4. Literature review – Summary of reviews and meta-analyses 
Table 4a. Substance use outcomes  
Source Details of review – summary of methods and conclusions Notes 
Marsch 1998 Focus: GENERAL EFFECTIVENESS OF OST-M 
Methods: 43 studies reviewed. 11 (2056 participants) considered ongoing illicit drug use; 24 (7173 
participants) criminal activity; 8 studies (1,797) HIV risk behaviours 
Conclusions: being in receipt of OST-M reduces drug use, risk behaviours and criminal activity 
 
 
Simoens et al 2005 Focus: GENERAL EFFECTIVENESS OF OST(methadone or buprenorphine) 
Methods: 48 RCTs reviewed 14 OST- M, 20 BRT and 14 both. Issues of quality and consistency of 
review – criteria not clear. 
Conclusions: OST- M and BRT treatment positively predicts retention, and abstinence or reduction 
 
 
Connock et al 2007 
NICE Technology Appraisal 2007 
(TA114) 
 
Focus: RELATIVE EFFECTIVENESS OF OST (methadone or buprenorphine) 
Methods: Guidelines for Clinicians in the UK (report produced to support update of UK National 
Treatment Guidance in 2007). Expert committee took evidence on both OST- M and BRT from a wide 
range of stakeholders. Reviewed 31 existing systematic reviews, 87 additional RCTs and 11 economic 
evaluations. No UK RCTs – 16 from USA. Most studies had fixed dosing, relatively restrictive delivery 
(supervised consumption etc.) no psychosocial interventions and short follow up (<1yr). 
Conclusions (OST-M): 
1. OST-M supports retention;, reduced opiate use; reduced HIV risk behaviours and sero-
conversions; reduced mortality (with 4x increased risk of death on discharge); reduced 
criminal activity. 
2. Higher fixed doses more effective than lower fixed doses 
 
Issues:  
-fixed dose treatments do not reflect 
normal clinical practice 
-evidence not sufficient to draw 
conclusions regarding cost-
effectiveness 
-recognising lack of UK evidence and 
heterogeneity of economic evaluations, 
states: “none used all of the 
appropriate parameters, effectiveness 
data, perspectives and comparators 
required to make their results 
generalisable to the NHS “ 
 
Mattick et al 2009 Focus: GENERAL EFFECTIVENESS OF OST-M 
Methods: Cochrane Systematic Review of all RCTs comparing OST- M with placebo or non-
pharmacological therapy. Reviewed 11RCT - 2 double blind - covering 1969 participants. Outcomes 
assessed from 45 days to maximum of 2 years. 
Conclusions: Methadone increases retention and reduces heroin use. No effect on criminal activity. 
 
Issues: Authors acknowledge 
-lack of evidence in key outcomes (e.g. 
dose and deaths; social outcomes) 
 -no research addressing relationship 
between medical treatment and 
psychosocial treatments 
-methodological concerns in many 
studies make generalising from 
research impossible  
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Veilleux et al 2010 
 
Focus: TREATMENT EFFECTIVENESS SUMMARY (ALL TREATMENTS) Aim to “synthesize the current 
status of opioid dependence treatment”. 
Methods: Systematic review article aiming to address OST- M and forms of detoxification and 
abstinence maintenance in a range of substances. For OST- M - reviewed existing systematic reviews 
plus additional meta-analyses or controlled trials published since the most recent update of each 
Cochrane review. Cited 10 publications, covering 155 studies involving 28,999 subjects. 
Conclusions: OST- M improves retention, reduces opiate use and withdrawal symptoms. There are 
dose effects. There is a need to broaden quality research to address a range of outcomes, including 
abstinence.  
 
Issues: Authors raise issues of  
-difficulty in executing meta-analyses 
due to range of methods and outcomes 
used 
-research questions not covering full 
treatment range 
 
Lingford-Hughes et al 2012 Focus: DELIVERY OF RANGE OF SUBSTANCE MISUSE OUTCOMES Aim - guideline for clinicians – update 
of 2004 guideline by same organisation 
Methods: Three year process overseen by expert panel. Evidence for OST- M reviewed as part of 
comprehensive review of all addictions treatments. Systematic review of existing reviews from 
credible sources (e.g. Cochrane database) or RCTs when possible. Recognition of complexity of 
evidence base - categorization of evidence and strength of recommendation often reflects 
extrapolation from lower grade evidence. If evidence low grade but strong clinical consensus in place 
given “S” status – standard of care.  
Conclusions:  
1. OST- M supports retention in treatment; reduced heroin use; trend regarding reduced 
mortality; reduced drug-related risk behaviours (NOT sexual risk) 
2. Higher dose OST- M more effective at improving retention and reducing heroin and cocaine 
use 
3. NO evidence for an added effect of psychosocial interventions 
4. NO evidence of reduction in criminal justice activity. 
 
Issues:  
Little reference to potential 
confounders: 
-quality of primary evidence base – 
heterogeneity of subjects; clarity of 
research question; sample size and 
representativeness 
-timescales of effects –value in long 
term maintenance and “recovery” 
-largely USA-based evidence base – 
value in UK setting 
Faggiano et al 2008  
 
Focus: METHADONE DOSE AND EFFECTIVENESS IN RANGE OF OUTCOMES Aim was to evaluate the 
efficacy of different dosages of MMT in modifying health and social outcomes and in promoting 
patients’ familiar, occupational and relational functioning. 
Methods: Randomised Controlled Trials and Controlled Prospective Studies evaluating methadone 
maintenance at different dosages in the management of opioid dependence. Non-randomised trials 
were included when proper adjustment for confounding factors was performed at the analysis stage. 
Reviewed 21 studies. 11 RCTs – all from USA (2279 subjects for 7-53 weeks) and 10 CPS (3715 
subjects for 1-10 years).  
Conclusions: Higher dose OST- M (60-100mg) more effective at improving retention, reducing opiate 
and cocaine use. 
Issues: Authors raise issues of 
heterogeneity and inconsistency of 
sampling etc. affecting quality of studies 
 
RCTs all from USA and timeframes are 
<1 year only.  
 
Lack of sufficient evidence to assess 
certain outcomes – e.g. mortality, 
criminal activity and social outcomes 
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Table 4b. Harm reduction outcomes 
Source Details of review – summary of methods and conclusions Notes 
Sorensen et al 2000 Focus: HARM REDUCTION – RISK BEHAVIOUR AND HIV 
Methods: 33 studies with over 17,000 participants reviewed. Numerous methodological issues raised. 
Conclusions: OST- M predicts reduced drug use, risk behaviour and criminal activity. 
 
 
Gowing et al 2011 Focus: HARM REDUCTION – HIV RISK BEHAVIOURS AND SEROCONVERSION Aim was to assess the 
effect of oral substitution treatment for opioid dependent injecting drug users on risk behaviours and 
rates of HIV infections 
Methods: Cochrane Systematic Review of Studies which considered  the incidence of risk behaviours, 
or the incidence of HIV infection related to (any) substitution treatment of opioid dependence. All 
types of original studies were considered. 38 studies involving 12,400 subjects were included. Mainly 
descriptive studies, or studies in which randomisation processes did not relate to the data extracted. 
Most studies “ at high risk of bias”. 
Conclusions: ORT reduces opiate use, IV use, needle sharing and HIV seroconversion. May also affect 
sexual risk behaviours for HIV. 
 
Issues: Authors acknowledge that 
“The lack of data from randomised 
controlled studies limits the strength of 
the evidence presented in this review.” 
Turner et al 2011 
 
Focus: HARM REDUCTION - HEPATITIS C SEROCONVERSION Aim to examine effect of harm reduction 
(needle exchange and ORT) availability and seroconversion. 
Methods: Meta-analysis and pooled analysis of data on 2986 subjects in six areas of the UK from 
2001-9. Questionnaire survey to clarify availability of ORT and needle exchange. Primary outcome of 
new HCV infection. 919 subjects supplied information on interventions. 40 new HCV cases identified. 
Conclusions: Access to harm reduction interventions significantly reduced new HCV seroconversions. 
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Table 4c. Delivering Recovery outcomes 
Source Details of review – summary of methods and conclusions Notes 
Best et al 2010 
 
Focus: RECOVERY Aim to “assess the current state of the evidence base” supporting recovery in the 
field of illicit drug use. 
Methods: Commissioned research by Scottish Government to support their national strategy. 
Systematic literature search and review resulted in 205 articles covering treatment (79 papers), 
children/families (62 papers), criminal justice (27 articles) and prevention/education (37 papers). 
Process of critical appraisal is not well defined and descriptive articles by recovery “experts” are 
widely cited. It is noted that much of the evidence on recovery is from overseas (USA) and is in other 
areas of addiction e.g. alcohol misuse. 
Conclusions: Sustained recovery is the norm but pathways are “individualistic”; “recovery capital” is 
“the best predictor” of recovery outcome; there are an identifiable range of “barriers” to recovery; 
structured treatment has a part to play but social support is also required. 
 
Issues: The authors acknowledge the 
lack of systematic, consistent and 
relevant research in this area – mainly 
foreign research from related care 
areas. Indeed they make a plea for a 
new approach to research – based on 
longer term outcomes. 
 
De Maeyer et al 2010 Focus: QUALITY OF LIFE Aim to examine the relationship between treatment and QoL outcomes. 
Method: Systematic review of the literature. 38 studies identified of which 16 considered QoL 
changes with ORT treatment. They found that QoL was very low on entry, did improve significantly in 
the first few months of treatment but then declined – though not to pre-treatment levels. 
Conclusions: QoL is a measure of success in ORT – but services need to address more than the drug 
use to achieve sustained improvement. 
 
 
Bell 2012 Focus: RECOVERY Aim to “seeks to integrate, as far as is possible, the discourse of evidence-based 
practice (built on observation and measurement), with the humanitarian, recovery-based discourse 
based on values (such as responsibility, choice, and empowerment)”. 
Methods: Part of government-funded expert advice group. Selective review of papers identified by 
sub-group of this national expert panel. Reiterated evidence base for harm reduction effects of OST. 
Also focused on: achieving abstinence; re-integration; quality of life. 
Conclusions: Not optimistic about current state of evidence base. Stated: “individuals need long-term 
social supports and personal psychological resources to sustain recovery. Formal treatment can be a 
powerful factor in building these social supports and psychological resources to facilitate positive 
change, but on its own it typically does not have a lasting influence.” 
Issues: No search strategy defined and 
range of papers reviewed unclear. 
Highly personal selective review 
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Table 4d. Factors impacting on outcome 
Source Details of review – summary of methods and conclusions Notes 
Brewer et al 1998 
 
Focus: REDUCING RELAPSE & IMPROVING OUTCOMES Aim to identify factors which predict  ongoing 
drug use in treatment 
Methods: Systematic review of 69 studies (43% OST- M). Correlations computed over time. 28 
variables identified which may have impacted on substance use – these were from 8 categories: 
demographics; drug use history; non-opiate drug use; physical/mental health; criminal activity; 
employment; psychosocial variables; treatment length and completion. 
Conclusions: Factors associated with more continued use were: High levels of substance use pre-
treatment; history of prior treatment; history of treatment without abstinence; light alcohol use 
depression; high stress levels; unemployed or employment problems; associating with substance 
using peers; short treatment period; leaving treatment before completion 
 
 
Griffith et al 2000 Focus: TREATMENT DELIVERY – CONTINGENCY MANAGEMENT APPROACH (CMA) Aim to assess the 
added effect of Contingency Management Approach to OST- M.  
Methods: Systematic review and meta-analysis of 30 studies involving 1562 patients (range 5-360). 
Conclusions: CMA has a significantly increased effect on outcome in OST- M. Moderators existed – 
relating to the targeting of CM/delivery of the intervention. These had impact on effect size 
 
Issues: Small numbers of studies and 
significant heterogeneity in terms of 
treatment delivery, OST- M dose 
ranges, follow up times etc. meant that 
further research is required 
Amato et al 2011 Focus: EFFECT OF PSYCHOSOCIAL INTERVENTIONS ON TREATMENT OUTCOME IN ARANGE OF 
INTERVENTIONS 
Methods: Systematic review and metanalysis of 35 studies involving 4319 subjects in 13 distinct 
interventions. Studies short term (6-48 weeks duration, mean 17 weeks). 
Conclusions: Unable to demonstrate added effect regarding retention, abstinence, treatment 
compliance or improved psychological symptoms. 
Issues: Authors acknowledge 
- “the review, actually, 
did not evaluate the question of 
whether any ancillary psychosocial 
intervention is needed when 
methadone maintenance is provided, 
but the narrower question of whether a 
specific more structured intervention 
provides any additional benefit to a 
standard psychosocial support” 
-raises methodological questions 
-also issue of USA based evidence 
(relevance to UK practice) 
-issue of short timeframes 
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Table 4e. Patient characteristics impacting on outcome 
Source Details of review – summary of methods and conclusions Notes 
Greenfield et al 2007 
 
Focus: GENDER Aim to examine Factors affecting outcomes in women with substance use disorders. 
Methods: Literature search 1975-2005. 280 articles identified of which 11.8% were RCTs.  
Conclusions: Women less likely to enter treatment. Once in treatment, gender does not predict 
retention, completion or outcome. Gender specific services not necessarily of value but identify need 
for interventions focussed towards specific sub-groups. 
 
Issues: Authors acknowledge small 
sample sizes and lack of RCTs. Potential 
for positive bias from peer-reviewed 
research. 
Ashley et al 2003 
 
Focus: GENDER Aim to examine evidence for effectiveness of treatment programming for women and 
to summarize knowledge around effectiveness of different approaches for women.  
Methods: Systematic review of 38 studies (7 RCTs). The RCTs considered only 253 subjects for a 
timeframe of up to maximum 2 years. They considered specific gender-related treatment 
components: Child care; prenatal care; women only programmes; services addressing women’s 
topics; mental health & comprehensive programming.  
Conclusions: They found evidence for these factors having an  impact on outcomes including Illicit 
drug use reduction; Mental health symptom reduction; Improved birth outcomes; Employment; 
Health status and HIV risk reduction; treatment completion; length of stay 
 
Issues: Authors acknowledge  the lack 
of research evidence from RCTs – most 
is cross-sectional and observational 
research 
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Factors influencing outcomes (Predictors) 
 
The research papers identified in the literature search were critically appraised to identify 
potential predictors and suitable outcomes for scrutiny. Brief descriptions of the findings are 
included below. The results are summarized in Table 5. (p91). 
 
Demographic factors 
 
Age  
A number of studies have assessed the potential impact of age on outcome in substance 
misuse treatment. The literature search identified 3 specific research papers which focussed 
on this issue in the OST-M population. Two of these studies included a follow up element, 
allowing researchers to comment on any effect on outcome. In summary: Despite limited 
evidence (one paper) that retention is affected by age, there are no publications from this 
review which have found age to be a predictor of outcome in substance misuse treatment.  
 
Gender 
Women often appear to be under-represented in drug treatment services. It has been 
hypothesised that gender may impact on clinical process – affecting how services are 
accessed, what treatment options are chosen, retention – or how services are experienced 
by women. This could affect treatment outcomes with the view often expressed that 
women would benefit from dedicated services to address their specific needs. The literature 
search identified 15 specific research papers which focussed on this issue in an OST 
population. Three were review papers. Unusually all but one of the remainder of these 
studies included a follow up element, ranging from 3 months to 30 years, thus allowing 
researchers to comment on any effect on outcome. One paper was excluded as it addressed 
only Buprenorphine (Back et al, 2011).  In summary: gender has been explored in the OST-M 
population – but often as part of other studies, with gender rarely the main research focus. 
Research questions have often been unclear. Unusually, however, much of the research does 
have follow up assessments. Despite this, gender has not been shown consistently to have 
any significant impact on outcome. Some researchers suggest there may be implications for 
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treatment process/delivery but no research to date has explored this in any detail. NIDA has 
raised the need for gender issues to be better addressed in study design. 
 
Personal & social factors 
A number of studies have hypothesized that a range of personal and social factors may 
impact on the effectiveness of substance misuse treatments.  The literature search 
identified 9 relevant papers of which 5 contained a follow up assessment from 35 weeks to 
12 years after initial assessment. One paper was excluded as unavailable for review 
(Copenhaver et al, 2011). In summary: there is some research evidence that social and inter-
personal factors are important in terms of substance misuse treatment outcome. The body 
of evidence often reflects studies which have explored a broad range of factors with 
potential to influence outcome. Few studies address long term outcomes. More definitive, 
focused  study of larger, more representative samples over longer, more relevant timeframes 
is required. 
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Table 5.  Literature review – Summary: Patient characteristics 
Source  Independent Variables Dependent variables Study type Findings 
Burns et al 2009  Age Retention Longitudinal  study 
(retrospective cohort study) 
using Australian national 
data on 42, 960 cases over 
21 years 
Younger age had poorer 
retention.  
Poorer retention not 
associated with poorer 
clinical outcomes 
Rosen et al 2008 Age (>50s v <50) Substance misuse outcomes Retrospective cohort study 
with 24 month follow up 
NSD 
 
Johnston et al 2003; Najavits 
et al 2007 
These studies simply described females accessing particular programmes – there was no specific research question and no 
control group for comparison 
Marsh & Simpson 1986 Gender Behavioural differences 
Psychological status 
Reasons reported for 
stopping drug use 
Retrospective cohort study – 
12 years post DARP 
NSD relating to IV 
Positive gender differences 
found 
Positive gender differences 
found 
Karuntzos et al 1994 Gender Service responses to 
employability requirements 
Prospective descriptive study 
with 3 month follow up 
Positive gender differences 
found 
 
Grella & Lovinger 2012 Gender Illicit drug use 
Chronic health problems 
Psychological distress 
Retrospective cohort study 
with 30 year follow up 
NSD 
Positive gender differences 
found 
Positive gender differences 
found 
Eiroa-orosa et al 2010 , Jones 
et al 2005, Campbell et al 
2009 
Gender Range of substance misuse 
outcomes including 
retention, treatment 
duration illicit drug use 
RCT comparing ORT types  1 
yr, Retrospective cohort 
study (4/12) Retrospective 
cohort study (6yr) 
NSD 
NSD 
NSD 
Burns et al 2010 Methadone/not [in women] Range of reasons for hospital 
admissions 
Retrospective cohort study 
of women on methadone 
with 4 year follow up 
Identified significant 
differences in those on 
methadone/not 
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Havens et al 2009 Employment status; 
psychiatric distress; unstable 
housing; distance form 
treatment site 
Retention RCT of psychosocial 
interventions in needle 
exchange attenders 
Positive associations with 
retention found in all 
factors listed 
Flynn et al 2003 Patient characteristics: 
personal motivation at 
baseline; previous 
treatment; 
religion/spirituality; family 
relationships; employment 
“Recovery” – drug free; 
reduced alcohol use; no 
illegal activity for 1 year 
Retrospective cohort study 
using DATOS data -532 OST- 
M patients 5 year follow up 
Positive associations  found 
with listed factors 
 
Skinner et al 2011 Patient characteristics: 
retention; education or 
employment; less 
relationship disruptions; 
depression; deviant friends; 
poor coping skills 
Recovery and range of 
substance misuse outcomes 
Retrospective cohort study 
of 144 patients 12 year 
follow up 
Positive associations  found 
with listed factors 
 
Stewart et al 2007 With/without children Substance use outcomes Prospective cohort study as 
part of NTORS. 1 year follow 
up  
NSD 
Heinz et al 2009 Relationship closeness Retention and substance use 
outcomes 
9month follow up study of 
635 new OST- M patients 
Positive associations  found   
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Common co-morbidities 
 
Researchers have studied a number of common co-morbid conditions in substance 
misusers. The literature search identified studies relating to the co-morbid conditions which 
were relevant to the Tayside Methadone Cohort baseline assessment. The results are 
summarized in Table 6. (p96). 
 
Pain 
The management of pain in the context of substance misuse is challenging. This reflects a 
number of issues. Many pain medications carry addictive potential which means that in 
managing chronic pain syndromes, doctors must recognise the risk of developing substance 
use disorders, perhaps reflecting the development of hyperalgesia (Fishbain et al, 2009). The 
development of substance misuse issues may be further complicated by other, often 
psychiatric, co-morbidities (Manchikanti et al, 2007). This problem has the potential to be 
hazardous and may even predict overdose death in pain patients (Dunn et al, 2010). Primary 
substance misusers are a group who are prone to injury and may not utilize rehabilitative 
services effectively, resulting in long term pain management challenges. Also, methadone 
patients (or those on any opioid with a long half-life) have been shown to be more sensitive 
to pain (Compton, Charuvastra, Kintaudi & Ling, 2000). This could mean that they have 
increased needs for pain treatment when compared to the general population. Despite this, 
substance misusers are often treated outside normal guidance or are undertreated. Both 
chronic pain and substance misuse can be complex issues, requiring a coordinated approach 
to multi-disciplinary care delivery. This challenge has been recognised in the guidance 
available for doctors in the UK (Department of Health, 2007; British Pain Society, 2007).  
 
Research in this field addresses the problem from both perspectives –the management of 
pain patients (researching the risk of developing a substance use disorder) or primarily from 
the perspective of the management of substance misusers who experience co-morbid pain. 
The literature review described considered the research evidence-base addressing the place 
of pain as a predictor of substance misuse outcome in substance misusers in receipt of OST-
M.  Seven studies were identified of which only one involved a follow up assessment of 
outcome. In summary: Cross sectional studies have described many relationships between 
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the presence of pain and substance misuse status. It has been suggested from these studies 
that substance misusers with chronic pain syndromes are less stable, more likely to use illicit 
drugs and require higher doses of methadone (if on OST-M) to achieve stability. Only one 
longitudinal study has been published to date, in the USA. This found that at 1 year follow up 
those on OST-M who also had chronic pain showed poorer measures of social functioning, 
but did not show any impact on substance use outcomes. 
 
Psychiatric illness - general 
Psychiatric illness is commonly found alongside substance misuse. The 2007 English 
Psychiatric Morbidity Study on adults living in their own home showed that 12% of males 
and 6% of females had some kind of substance dependence concurrent with a psychiatric 
illness (Adult psychiatric morbidity in England, [NHS Information Centre] 2007).  The main 
substances misused by those with mental health problems are alcohol and cannabis. Half of 
those consulting a doctor for an alcohol problem present with mood or anxiety disorders. 
Some 50% of suicides in the UK since 1997 have had a history of alcohol misuse (NICE, 
2011). Such problems are also common in the area of illicit drug dependency.  In Scotland it 
was reported that 40% of new referrals to services (or those re-referred after a 6 month 
absence) did so for mental health reasons (Scottish Executive, 2006). The UK NTORS study 
found that one fifth of those presenting for a range of treatments for substance misuse had 
had previous treatment for psychiatric disorder (Marsden et al, 2000).  
 
The literature review identified 26 studies which directly assessed the relationship between 
substance misuse treatment outcomes and psychiatric comorbidity. Twelve were cross-
sectional studies, involving one off assessments of a sample while 14 were longitudinal 
studies which included a follow up component. These longitudinal studies had follow up 
periods of 6 months to 6 years. In summary: the relationship between presence of co-morbid 
mental illness and substance misuse treatment outcomes for those on OST is complex. Even 
those studies which have shown a significant relationship with outcome have generally done 
so over relatively short timeframes. This could reflect the methodological difficulties in 
carrying out the diagnostic assessments required. However, the GHQ28 is a tool which has 
some merit in many clinical populations and has been shown to be valid and reliable in 
substance misusers. The screening of substance misusers for psychiatric “caseness” has not 
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been well described in the literature but the limited research to date has linked “caseness” 
with short term outcomes. 
 
Research which considers specific diagnoses was not found to be definitive in this literature 
review. Regarding depression – only the ATOS study has brought forward compelling 
evidence regarding the impact on outcome in an OST-M sample. Regarding PTSD - Results 
are conflicting. Follow up studies have not consistently shown that PTSD impacts on process 
nor outcome in OST-M. ADHD seems to be highly prevalent in substance misusers yet little 
research has explored the impact on outcome. In this review, there was no published 
research which has explored impact on substance misuse outcomes in OST-M beyond 9 
months. Anxiety disorders are commonly observed in OST-M populations but this review did 
not identify a definitive evidence base regarding the impact of any anxiety disorder on 
outcome. 
 
Many mental illnesses, like substance misuse are chronic relapsing conditions which 
fluctuate over time. Addressing issues of cause and effect is difficult. Longer term follow up 
and review is required to determine the true relationship with outcomes. 
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Table 6.  Literature review – Summary: Impact of Comorbidities 
Source  Independent Variables Dependent variables Study type Findings 
Ilgen et al 2006 Pain Substance use outcomes Prospective study of 200 
new OST- M patients with 
1yr follow up 
Impact on social functioning  
but NSD with substance use 
Cacciola et al 2001 Comorbid mental illness Substance use outcomes Retrospective cohort study 
of 278 OST- M patients with 
7/12 follow up 
NSD 
Maremmani et al 2000 Axis 1 psychiatric diagnosis Retention Retrospective cohort study 
of 90 OST- M patients with  3 
year follow up 
NSD 
Astals et al 2009 Axis 1 psychiatric diagnosis Retention Retrospective cohort study 
of 189 OST- M patients with  
18/12 follow up 
NSD (but higher OST- M 
dose required for stability) 
Krausz et al 1999; Verthein 
et al 2005 
Comorbid mental illness                                  Substance use outcomes Prospective study of 219 
OST- M patients with 5 year 
follow up 
NSD 
Pani 1997; Pani 2011 Severity of psychiatric 
symptoms      
Substance use outcomes Prospective study of 259 & 
267 new OST- M patients 
with 1yr & 2 year follow up 
NSD 
Schafer et al 2010 Mental health symptoms Substance use outcomes RCT of different ORT types in 
1015 new patients with 1yr 
follow up 
NSD 
Fernandez et al 2001 Psychiatric 
disorders/diagnosis 
OST- M dose and substance 
use outcomes 
6yr follow up study of 132 
OST- M patients. 
Anxiety/affective disorders 
predicted 
heroin/benzodiazepine use. 
Schulte et al 2010 Unidentified/unaddressed 
mental health issues 
Retention Retrospective cohort study 
of  176 OST- M patients with 
90/7 follow up 
If MH problems not 
addressed this impacted on 
retention 
Compton et al 2003 Baseline psychiatric 
disorders 
Substance use outcomes Prospective study of 401 
new OST- M patients with 1 
year follow up 
Positive association with 
outcome 
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Broome et al 1999 Psychiatric symptoms and 
diagnosis 
Substance use outcomes Prospective study (DATOS) at 
1 year 
Current symptoms better 
predictors than lifetime 
diagnosis 
Gelkopf et al 2006 Comorbid mental illness –
symptoms, diagnosis and 
distress 
Substance use disorders - 
SUD (type); Drugs misused; 
retention 
Prospective study of 151 
OST- M patients over 3 years 
Current comorbidity 
associated with SUD. Axis 1 
diagnosis associated with 
better retention and 
outcomes;  distress 
associated with poorer 
outcomes 
Musselman & Kell 1995 Severity of substance use 
disorder 
Improvement in 
psychopathology 
Prospective study of 71 new 
OST- M patients over 24 
months 
NSD 
Gossop et al 2006 Mental health disorder Substance use outcomes Prospective study (NTORS) 
with 5 year follow up 
Association between 
improving mental health 
and SUD outcomes 
ATOS study - Havard et al 
2006; Darke et al 2009 
Major depression A range of process measures 
and outcomes 
Prospective study of 495 
new patients in arrange of 
treatments with 1yr and 3yr 
follow up elements 
Complex association 
demonstrated between 
depression and substance 
use process and outcome. 
Fitzimmons et al 2007 Mood/anxiety disorders Substance use outcomes 3/12 follow up of 106 
pregnant drug users entering 
OST- M 
Mood disorder impacted on 
substance use outcome 
Chilcoat & Breslau PTSD/Trauma Development of substance 
use disorder 
Prospective study of 1007 
subjects screened for 
trauma. 5yr follow up 
PTSD had higher risk of SUD 
Trafton et al 2006 PTSD OST- M treatment process; 
retention 
Retrospective cohort  study 
of 255 new OST- M patients 
– 28% PTSD. 1 year follow up 
PTSD cases worse at intake 
& longer history; also higher 
OST- M dose and better 
retention 
Hien et al 2000 PTSD Retention and substance use 
outcomes 
3/12 prospective study of 96 
new OST- M patients 
PTSD associated with higher 
drug use. 
Retention - NSD 
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Mills et al 2005 & 2007 PTSD OST- M process, substance 
use outcomes 
1 & 2 year follow up study of 
new OST- M patients 
PTSD – worse physical and 
mental disability and 
occupational functioning 
Process NSD 
Kolpe & Carlson 2007 ADHD Substance use outcomes 9/12 follow up of 687 new 
OST- M patients 
58% had ADHD symptoms. 
ADHD associated with 
poorer outcomes 
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Illicit drug use 
The nature of substance misuse as a chronic relapsing condition associated with high risk – 
in particular relating to BBV infections through injecting - has resulted in the development of 
a hierarchy of “harm reduction” measures of progress in treatment. These measures are 
reflected in clinical practice across the world and most of the studies cited use validated 
tools which aim to demonstrate progress in a number of domains (Marsden et al 1998; 
McLellan et al 1992). Using such tools, substance misusers can often show improvement in 
their condition while failing to completely abstain from all illicit drug use. Indeed, in the 
clinical setting, improvements are often seen in areas of social functioning and physical and 
psychological health even while illicit drug use is ongoing. However, the extent of illicit drug 
use on OST-M treatment has consistently been seen to be an important outcome – as 
shown in the systematic reviews above. These systematic reviews have also shown that 
evidence of improvement in areas of social functioning is sparse. 
 
Drug death data in the UK has shown that most deaths involve multiple substances (Zador 
et al 2005; Health & Social Care Information Centre, 2011; ISD, 2012). Over recent years, as 
more substance misusers in parts of the UK have entered OST-M, there seems to be an 
increase in the finding that methadone is a component in these deaths (ISD, 2012). 
Recovery has become a focus for treatment and, for many involved in this debate, moving 
towards objective abstinence is a key component of that recovery process, driving changes 
in guidance for clinicians in the UK (NTA, 2012). But this is inevitably a lengthy process. 
Research into long term abstinence from illicit drugs has suggested that the achievement of 
5 years of abstinence is a strong indicator of success (Hser 2001).  
 
In this context, it is important to consider the relevance of ongoing drug use in terms of the 
broader outcomes we are trying to achieve in OST-M.  The results are summarized in Table 
7. (p146). 
 
Cannabis  
In summary: all of the cannabis studies identified in the literature search had follow up 
components – though never longer than 1 year. Overall cannabis use seems to have little 
impact on these relatively short term treatment outcomes but there are hints that its use 
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may make recovery more challenging – in particular that the amounts used or the nature of 
that use may reduce success. 
 
Benzodiazepines  
At face value, use of benzodiazepines is a serious clinical challenge in OST-M services. 
Guidance is vague regarding how illicit benzodiazepine use should be addressed. In the 
context of recovery – at the very least improvement in social functioning is likely to be 
impacted on by ongoing sedative drug use.  However, it is also clear that benzodiazepine 
use is a significant factor in drug death in the UK (Zador et al 2005; ISD, 2012;  Health & 
Social Care Information Centre 2011). Eight relevant studies were identified exploring this 
issue, of which only 3 had any follow up assessment.  In summary: Benzodiazepine use is a 
common precursor to OST-M and, while on OST-M treatment, ongoing benzodiazepine use 
may affect participation in treatment and short term outcome – though the evidence 
identified is not conclusive. 
 
Prescribed opioids 
The use of opioid drugs – either not prescribed for the individual, or prescribed (for pain for 
example) but used in a way that is not prescribed – is a long-standing problem in those 
traditionally presenting to addiction services. This problem however, has become an issue in 
people attending other medical services and potentially encroaches on new treatment 
populations, not previously seen as substance misusers. Consequently, misuse of prescribed 
opioids is now beginning to be seen as a significant public health issue in the USA and UK 
(Warner, Chen & Makuc, 2009; Volkow et al, 2011; Dhalla , Persaud & Juurlink, 2011). In this 
review, seven studies were found which considered the misuse of other opioid drugs (i.e. 
not illicit heroin) in substance misusers and their potential impact this could have on 
outcomes in OST-M. These studies were often in residential detoxification units. Other than 
the review, all were descriptive and none had a follow up component. In summary – use of 
prescribed opioids/other opioid drugs is clearly extremely common in those presenting for 
substance misuse treatment. There is some evidence that certain factors may differentiate 
those who can be seen as having a “primary heroin” disorder or a “primary prescribed 
opioids” disorder – factors such as previous pain syndrome or mental health disorder. 
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However, there is no research identified in this review into the potential effect of other 
opioid use on outcomes in OST-M. 
 
Cocaine use  
Many studies explore the effect of various treatments on cocaine use. Indeed  
improvements in use of cocaine is often a key outcome reported in systematic reviews of 
OST-M. Only one study was identified in this review, which addressed the specific impact of 
cocaine use on clinical outcomes in OST-M.  In summary: there is only one study identified. 
This showed that use of cocaine predicted more hospitalizations in an OST-M population 
over 2 years.
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Table 7.  Literature review – Summary: Substance use 
Source  Independent Variables Dependent variables Study type Findings 
Raffa et al 2007 Abstinence from illicit drugs Programme adherence – 
process measures 
Retrospective cohort study 
of 60 HIV positive OST- M 
patients with 3 year follow 
up 
Only 4/60 remained 
abstinent. Opiate users 
adhered less well while 
amphetamine and 
benzodiazepine users did 
better 
Budney et al 1998; Weizman 
et al 2004; 
Epstein & Preston 2003 
Cannabis use Substance use outcomes Prospective study of 109; 
283; 408 new OST- M 
patients. 1year follow up 
NSD 
Ghitza et al 2007 Reporting of cannabis use Substance use outcomes RCT of contingency 
management in 690 new 
cases for 6 months 
Under-reporters of cannabis 
more likely to use heroin 
and cocaine 
Brands et al 2008 Benzodiazepine use Substance use outcomes Retrospective cohort study 
of 172 new OST- M patients. 
2year follow up 
Ongoing benzodiazepine 
users more likely to have 
+ve screens for opiates and 
cocaine. In this group 
cocaine use negatively 
affected retention 
Eroia-orosa 2010 Benzodiazepine use Retention and outcomes RCT of ORT types Baseline benzodiazepine use 
correlates with poorer 
retention (not outcome) 
Ongoing benzodiazepine use 
affects outcome (illicit use) 
Ghitza et al 2008  Benzodiazepine use Substance use outcomes 12 week follow up study of 
361 OST- M patients  
Baseline benzodiazepine use 
– even low dose associated 
with poorer outcomes –- in 
OST- M 
Bovasso & Cacciola Baseline cocaine use/not Hospitalization Retrospective cohort study 
of 222 new OST- M patients.  
2 year follow up 
Cocaine use predicted more 
hospitalizations 
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Aspects of service delivery 
 
Researchers have considered how the types of treatment available to substance misusers 
and how these treatments are delivered in practice may impact on outcomes. These issues 
were key aspects of the work progressed in the US prospective studies – especially DATOS. A 
number of studies and reviews have explored the literature relating to a number of these 
factors, including: patient characteristics and programme factors; attendance in services; 
patient satisfaction with the programme;  patient motivation and commitment to 
treatment; locality and travel distance to services; treatment intensity; types of service 
delivery – including setting (specialist or primary care), high/low threshold programmes, 
with/without additional services, delivered within the main service or by an alternative 
provider. Results are summarized in Table 8. (p 104). In conclusion: the way services are 
delivered has been exhaustively assessed in US studies but research has not shown 
definitively that the availability of additional counselling, therapy or practical support, 
focused on (for example) employment, consistently impacts on outcomes achieved. Indeed 
some studies into intensity of delivery give conflicting results. This could reflect the stage of 
recovery subjects are at when treated or assessed. None of the relevant research is UK-based 
and it must be recognise that the US systems for OST-M delivery differ considerably from 
those in the UK.
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Table 8.  Literature review – Summary: Impact of aspects of service delivery 
Source  Independent Variables Dependent variables Study type Findings 
Saxon et al 1996 Patient characteristics; 
Programme philosophy; 
ancillary services offered 
Drug use (weekly urine) and 
ASI scores 
Prospective controlled study 
of 353 new OST- M patients. 
3 conditions. 18/12 follow up 
Complex relationships with 
multiple factors “predicting” 
outcomes. Enhanced 
services gave less cocaine 
+ves but more opiate +ves. 
Simpson et al 1995 Session attendance and 
assessment of quality of 
interactions 
“Behavioural changes” Prospective study of 557 
new OST- M patients 
Session attendance and 
better patient/counsellor 
assessments of interaction 
improved outcome 
Crevecoeur-Macphail et al 
2010 
Attendance  Retention and Substance use 
outcomes 
Prospective study of X new 
OST- M patients(20 
programs) over 9 months 
Better attendance improved 
retention and outcomes  
Kelly et al 2010 Patient satisfaction Substance use outcomes 
assessed by ASI 
Prospective study of 283 
new OST- M patients 
Patient satisfaction 
predicted outcome 
Morris et al 2008 Patient satisfaction (TPQ) Substance use outcomes Prospective study of 841 
existing patients in  arrange 
of treatments (including 
OST- M) 8 month follow up 
Patient satisfaction 
predicted outcome in all 
treatment types 
Broome et al 1999 Patient motivation and 
commitment 
Process measures – 
maintaining motivation; 
establish rapport; 
attendance 
Retrospective cohort study 
of DATOS patients with 3 
month follow up 
Those scoring positively for 
commitment at outset 
maintained this and 
attended better 
Friedman et al 2001 Availability of transport 
provision 
Retention Retrospective cohort study 
of 3175 DATOS patients in 
various programmes (1144 in 
OST- M). Programmes asked 
about travel provision 
Retention better if provision 
in place 
Hubbard et al 1995 Sessions attended Substance use outcomes Retrospective cohort study 
of DATOS subjects 
NSD 
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Avants et al 1995 Intensive day programme v 
standard care 
Substance use outcomes Prospective controlled study 
of 291 new OST- M patients 
in 2 treatment types – 
standard and intensive  
NSD 
King et al 2006 OST- M delivery types – 
degrees of intensity 
Substance use outcomes Prospective controlled study 
of three treatment types – 
own doc; doc + counsellor; 
specialist doc + counsellor 
NSD 
Teesson et al 2006 Treatment “dose” Substance use outcomes Prospective study of 745 
patients in range of 
treatments (ATOS) with 1yr 
follow up 
“Dose”  associated with  
improvements in drug use, 
criminality, 
psychopathology and 
injecting risk 
Corsi et al 2009 Treatment intensity & 
retention 
Substance use outcomes Retrospective cohort study 
of 160 new OST- M patients. 
6/12 follow up 
Intensity and retention both 
impacted on drug use and 
injecting risk 
Rhoades et al 1998 Methadone dose; 
attendances 
Retention and substance use 
outcomes 
RCT of 150 new OST- M pts 
in 4 groups based on dose 
and intensity. 24/52 follow 
up 
Higher dropout in high 
intensity; lower drug use in 
higher dose. HIV risk 
reduced for all and 
older/experienced did best 
Kraft et al 1997 Support services available Drug use; health; work; 
criminal activity; social 
functioning 
RCT of 100 new OST- M 
patients. 6 month 
programme with 6 month 
follow up 
More intensity predicted 
better outcomes in 
programme – only 
abstinence maintained 6/12 
Mclellan et al 1993 Extra counselling; medical 
care; psychological services 
Retention and outcomes CT of 92 new OST- M 
patients to three trial 
conditions with 6/12 follow 
up 
Basic OST- M with no 
counselling ineffective. 
Counselling improved 
efficiency of OST- M 
Wu et al 2010 Additional external support Reported drug use Retrospective cohort study 
of 356 existing OST- M 
patients -  3x assessments 
6/12 apart 
Extra support predicted less 
use 
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Wasserman et al 2001 Focus of counselling – 
“abstinence specific” or 
“general” 
Drug use Prospective study of128 ORT 
patients (OST- M & LAAM). 
3/12 follow up 
Abstinence-specific 
impacted on cocaine use 
NOT opiate 
Schwartz et al 2006 Interim OST- M v waiting list Graduation to full OST- M; 
Substance use outcomes 
RCT of 319 waiting list OST- 
M patients – allocated to 2 
groups. 
Interim group showed 
considerable improvements 
Schwartz et al 2011 3 levels of OST- M intensity 
RCT 
Substance use outcomes 4/12 follow up NSD 
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Prediction of specific outcomes in OST-M 
 
This section describes the results of the literature review regarding those papers considering 
prediction of specific outcomes in OST-M patients. These studies are summarized in Table 9. 
(p 108). 
 
Research on the prediction of positive outcomes 
 
A number of studies have explored prediction of a range of outcomes in OST-M patients. 
Substance use outcomes considered in focused studies have included: substance use (all 
substances); illicit opioid use; dose of methadone, retention or drug death. Blood borne 
virus infection or engagement in risk behaviours have also been specifically considered. 
Development of physical and psychiatric health problems and related use of health services 
have been explored. Limited research has attempted to predict social outcomes. However, 
much of the published literature has not assessed specific research questions or has 
considered the impact of a broad range of factors (predictors) and their potential impact on 
a range of outputs or outcomes.  In summary: This review has found that the identified 
predictive studies add little to the literature already identified. In some published papers, the 
prediction perspective of the work relates to a statistical exercise – usually a regression 
analysis, often examining data generated by a single cross sectional assessment of the data. 
While this may be valuable as preliminary research, it cannot replace a longitudinal 
assessment of relationships over time. There is often no identifiable research programme to 
take forward the findings of many of these preliminary descriptive studies. There is also a 
dearth of helpful information on some key outcome areas in OST-M treatment – such as 
employability and use of health services. This deficit makes assessment of many 
factors/processes potentially affecting recovery impossible. 
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Table 9.  Literature review – Prediction of clinical outcomes in OST-M patients 
Source  Predictor variables Clinical outcomes predicted Study type Findings 
Mclellan et al 1994 Baseline:  Severity of 
substance use; psychiatric, 
employment, family 
problems. 
At 6 months: Services 
received for substance use, 
psychiatric, employment and 
family problems 
Substance use –by  report 
and testing 
“Social adjustment” 
6/12 follow up study of 649 
substance users – mixed 
substances and programmes 
Overall substance use 
outcomes predicted by same 
factors regardless of 
substance. 
Substance use predicted by 
severity of SUD and NOT by 
treatment received 
Social adjustment negatively  
predicted by psychiatric, 
employment and family 
problems and positively 
predicted by receipt of 
services for these issues 
Peles et al 2008 OST- M (2 centres) Retention and abstinence 
from opiates 
302 US and 492 Israel, new 
OST-M patients. 1year follow 
up. Regression analysis.  
Both: higher OST-M dose 
predicted positive outcomes.  
Israel: early abstinence from 
opiates/benzos +ve predictor 
US: not using stimulants and 
age (<30) +ve predictor 
Marsch et al 2005 ORT – LAAM, OST- M,BRT Retention and percentage of 
positive drug screens  - 
opiates and cocaine 
165 new OST-M patients.  
Follow up 119/7 (4/12). 
NO PREDICTORS IDENTIFIED 
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Morral et al 1999 Early treatment 
characteristics 
Retention and positive drug 
tests at 6 & 9/12 follow up 
Retrospective cohort study 
of 59 new OST-M patients. 
Regression analyses. 
Counselling attendance and 
opiate abstinence in first two 
weeks predicted +ve 6&9/12 
outcomes in 80% of cases. 
Friedman et al 2003 Patient characteristics at 
intake 
Health status at 24/12 follow 
up 
2966 new OST-M patients 
(DATOS) followed up for 
24/12. Multivariate linear 
regression model used. 
Poor physical health status; 
presence of comorbid 
conditions;  severity of 
psychiatric symptoms at 
baseline strong predictors. 
Also age, public insurance 
cover and unemployment 
Mancino et al 2010 Patient characteristics at 
intake 
Retention at 3 year follow up 2363 US veterans – new 
OST-M patients 
Younger age, serious mental 
illness, ethnicity (African 
American), race recorded as 
unknown strong predictors 
of negative outcome. 
Peles et al 2010 Patient characteristics  Retention and survival over 
15 years 
613 patients ever on OST-M 
over 15 year period. 93 had 
died. 
Survival predicted by: 
younger age (<40) at 
admission; living with 
partner; hep B negative; not 
using benzodiazepines;  not 
referred directly from 
hospital or discharged from 
programme to hospital. 
Retention predicted by: not 
being referred from hospital 
or discharged to hospital; 
high OST- M dose; no 
opiate/benzo use at 1year; 
psychiatric diagnoses. NB 
Benzodiazepine use reduced 
both outcomes. 
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McCowan et al 2009 Patient characteristics Mortality over 11 years Retrospective cohort study. 
All 2378 OST- M patients  
prescribed in primary care in 
a UK region over 11 years. 
181 dead (60 drug deaths). 
Data linkage and regression 
analyses used. 
“All cause mortality” 
predicted by: overuse of 
Methadone; psychiatric 
admission history; increasing 
comorbidity 
Drug deaths predicted by: 
mental illness history; GP 
prescribing of 
benzodiazepines. 
Protective factors: retention 
and evidence of drug testing 
Kimber et al 2010 Exposure to ORT Injecting behaviour and 
mortality over 26 years 
Follow up study of 655 
injecting drug users from 
historical cohort. 577 had 
received OST- M. 277 had 
stopped injecting. 228 were 
dead. 
ORT exposure did not predict 
reduced injecting but did 
reduce risk of mortality 
Roszell & Calsyn 1986 Dose of OST- M: 
<35mg; 36-59mg; >60mg 
Various outcomes – 
including emotional distress, 
hospitalization; drug use; 
retention at 1 yr. 
1yr follow up of 106 OST- M 
patients. ASI at baseline. At 
6/12 divided into 3 groups 
by dose range. 
High dose group: high 
emotion and more psych 
treatments; also more use of 
barbiturates and stimulants. 
More drug use in treatment  
Medium: low 1 year 
retention 
Low: fewer friends 
Donny et al 2005 OST- M dose & CM Heroin use Volunteers. Existing OST- M 
patients offered increased 
OST- M and CM. No controls. 
Higher doses associated with 
less use and less need for 
CM 
Gerra et al 2004 BRT v OST- M 
Range of patient factors 
Retention 154 new OST- M/BRT 
patients. 12 week outcome 
NSD between ORT types.  
Retention predicted by 
baseline psychosocial 
functioning and Rx dose 
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Kelly et al 2011 A range of baseline 
assessment factors – ASI 
scores 
Retention at 3 months and 
1yr 
Longitudinal study of 351 
new OST- M pts. Regression 
analysis. 248 of these 
reviewed 1yr 
At 3/12: Female gender,  
treatment readiness 
predicted retention. At 1yr: 
ASI scores and MM dose 
Joe et al 1995 Psychological difficulties Engagement /attendance at 
3 months 
90 day follow up of 462 new 
OST- M patients 
More psychological 
problems attended more 
Joe et al 1999 A range of baseline factors Engagement 6 month follow up of 396 
new OST- M patients 
Pre-treatment motivation 
impacted on engagement 
Farre et al 2002 1.OST- M v placebo;  
2.High v low dose 
3.OST- M v BRT 
4. OST- M v LAAM 
Retention and reducing drug 
use 
Review of 13 trials (1944 
subjects – 1282 on OST- M) 
1.High dose OST- M impacts 
on retention/drug use. Low 
dose OST- M predicts 
retention 
2. NSD with retention. High 
dose reduces opiate use.  
3. NSD in comparable doses 
4.High dose OST- M> LAAM 
for retention. Low dose OST- 
M < LAAM for opiate use 
Mattick et al 2009 OST- M v placebo Retention, drug use and risk-
taking 
Review of 11 RCTs, 1969 
subjects. Follow up <2years 
OST- M improves retention, 
use  
Gowing et al 2011 OST- M HIV risk reduction Review of 38 studes (35 with 
OST- M) – 12,400 subjects 
OST- M reduces HIV IV risk 
behaviours.  
Turner et al 2012 Harm reduction provision 
availability 
Hepatitis C seroconversions Metanalysis with pooled 
analysis; 6 UK cities; 2986 
drug users. 
Availability of BBV 
prevention activity reduced 
risk of Hep C conversion 
Soyka et al 2008 BRT v OST- M Retention and substance use 6 month follow up study – 
two treatment groups 
Retention 52.8% NSD 
Drug use reduced NSD 
Britton & Conner 20101 Patient factors Suicide attempts 1 year follow up of 2966 new 
SUD patients (mixed 
treatments). Multivariate 
logistic regression to identify 
predictors 
Risk factors: Previous 
attempts; suicidal ideation; 
depressed; primary cocaine 
use;  OP OST- M/short term 
in-patient Protective: Male; 
age  
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Britton et al 20102 Patient factors Suicide attempts 12 months follow up of 
SUDs after discharge from 
treatment 
3.1% overdosed; Risk 
factors: O/D history; IV 
use; Male; Pain severity 
and H/O sexual abuse 
Gibson et al 2008 Range of factors plus  
BRT v OST- M 
Death RCT of 450 ORT patients. 10 
year follow up. Data linkage.  
OST- M v BRT no difference. 
Increased ORT exposure by 
>7 days is protective. More 
dependent=lower risk & 
more exposure to treatment.  
Hoffmann et al 2001 OST- M Acute hospital admission 175 new OST- M patients. 
Hospital admissions 
recorded 3 years before and 
after OST- M started. 
223 hospitalizations in 
6.5yrs. NSD in before/after 
numbers but types changed  
- less to do with IV use 
NGO et al 2008 OST- M v Naltrexone Hospitalization 522 OST- M v 314 
Naltrexone implant. 
Retrospective cohort study.  
Both groups substantial 
reductions in admissions 
OST- M: less likely to be 
admitted for “non-opioid” or 
“any drug”. More likely to be 
admitted for “opioid” 
NGO et al 2011 Psychiatric comorbidity Hospitalization Same cohort. Psychiatric comorbidity 
increased admissions pre-
treatment. Difference 
reduced after treatment 
Bloor et al 2008 OST- M Drug use 68 OST- M patients over 33 
months 
OST- M reduces “topping 
up” – greater effect than 
other treatments 
Zanis et al 1994 Range of patient factors Employment stages 340 existing OST- M patients. 
Cross sectional study and 
multiple regression 
Low depression score, 
cocaine abstinence, 
education status, marital 
status predicted better 
employment status 
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Discussion – what do we know from the literature review? 
 
This chapter has described the results of a structured review of the literature which aimed 
to scrutinize the published research considering the factors impacting on outcomes in 
patients receiving opioid substitution therapy using methadone (OST-M). 
 
Outcomes assessed 
The review has identified many papers describing primary research findings as well as a 
number of systematic reviews addressing the effectiveness of OST-M. Outcomes considered 
in much of the research are similar across the field. These include: 
 Retention: Many studies and reviews consider treatment retention 
 Reduced drug use - a measure of change in illicit drug use patterns – less 
drugs overall, impact on use of specific drugs (such as opiates, cocaine) 
 Reduced risk-taking - less hazard, either injection-related or sexual activity. 
Deaths. 
 Criminal activity – less theft, violence, drug dealing, arrests and 
imprisonments 
How these outcomes are measured (objective assessments – for example by drug screening 
or “self-report”) may make the validity of findings questionable and difficult to generalize. 
 
There are few studies systematically addressing social outcomes, aspects of physical or 
psychiatric/psychological health or use of health services. This makes assessment of 
recovery progress difficult. 
 
Factors affecting outcome 
Many studies attempt to address the various external factors which may impact on 
treatment outcome. Examples include: demographic factors; previous histories of drug use; 
the nature of a wide range of problems which exist prior to entering treatment; 
psychological and physical health; social stability, housing and family support. Studies have 
also considered aspects of service delivery which may be important. Examples include the 
dose of prescribed methadone received, availability or quality of counselling support, 
practical aspects of service delivery (by whom, from where, how close to a person’s home, 
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low or high threshold) as well as the drug user’s own response – their engagement, 
attendance, therapeutic readiness or ongoing drug use. 
 
Quality 
The quality of the published research is variable. The systematic reviews published in recent 
years by Cochrane and NICE have all commented (with some surprise) the difficulty in 
drawing robust conclusions from the evidence. Citing small sample sizes, short follow up 
periods – often less than one year, poor study design – including the lack of a clear research 
question and a lack of controls – most reviews present their conclusions  tempered with the 
view that more, better quality research is required. Specific areas of concern include:  
 Follow up period - This review eventually identified some 180 articles for critical 
appraisal. Of these, 19 were authoritative systematic reviews which all raised issues 
around the quality of the original research from which they drew their conclusions. 
Of the 161 individual research papers reviewed, only 55% had any longitudinal 
follow up element with the majority of these describing findings at up to one year. 
Only 26 of the studies identified - representing 16% of all identified relevant studies 
in this review - had follow up periods of more than 1 year. Of these, the most 
common duration of follow up was only 2 years.  
 Study design - One obvious area of concern is the fact that the research methods 
often eschew assessment of a condition which is realistic in terms of the clinical 
situation. This may be in an attempt to make research findings more robust. 
Examples include much of the cited OST-M research which uses fixed doses - a 
practice which is not relevant to modern practice and hasn’t been for over 15 years. 
Similarly, longitudinal studies such as NTORS and DORIS were modelled on the US 
studies of the 1970s – and as such sampled subjects who were self-selecting to a 
range of treatment modalities. It is clear that this could reflect what was available 
locally or patient/family preference. This bias makes interpretation of, even high 
quality, studies difficult.  
 
To address the effectiveness of OST-M and the factors which may impact on the outcomes it 
can achieve, research should focus on the relevant populations. Those presenting for 
detoxification in the real clinical world are as a rule very different from those presenting for 
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longer term harm-reduction interventions and future research must reflect this. The NTA 
report on treatment in recovery (NTA, 2012) with its emphasis on personalized treatment 
which is appropriately “phased” or “layered” illustrates this point as does the lack of 
available relevant research on achievement of recovery outcomes.  
 
Generalizability 
A clear issue from the published research is the fact that the vast majority is from large 
studies carried out in the USA.  These studies may give important information regarding 
how American research subjects relate to medications or treatment approaches. But there 
is clearly a need to repeat such studies in the context of the UK health and social care 
system to allow the potential impact of local peculiarities to be fully assessed. As the NHS 
across the UK also starts to diversify this will require researchers to be ever more robust in 
their research methods and will make interpretation of results more complex –even in the 
UK. 
 
The Tayside Methadone Cohort Study 
 
The next chapter describes a naturalistic study which used existing clinical information from 
OST-M patients to create a dataset to allow close scrutiny of the relationship between a 
range of patient characteristics with service delivery (outputs) and treatment outcomes over 
4-7 years.   
 
This study therefore attempts to address many of the issues raised by the literature review 
above. As a proof of concept exercise the project uses everyday information, collected by 
clinical staff in front-line services, to describe those currently receiving OST-M for opiate 
dependency in a Scottish regional service.  It has used standardised, validated tools in the 
context of a clinical service, improving the quality of assessment and review processes. 
Finally, the development effective data-linkage systems has facilitated use of a broad range 
of validated clinical information to give a better understanding of the true impact of 
treatment on OST-M patients’ careers. 
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Chapter 4. Materials and methods 
Introduction 
This thesis describes a naturalistic study which aims to explore the relationship between a 
number of characteristics observed in a baseline (2005) sample of patients on prescribed 
Methadone as an Opioid Substitution Therapy and a range of clinical outcomes achieved in 
these cases 4-7 years later.  The study utilizes information from various sources including: 
NHS clinical casenotes [2005 baseline data and 2009 casenote review] and linked patient-
identifiable records held in the Tayside Health Informatics Centre (HIC) which describe use 
of NHS services – including admissions to hospital – as well as clinical outcomes, including 
drug use [NHS laboratory tests] and death records. 
 
This chapter describes in detail the methods and procedures used in preparation of this 
thesis. Specifically, the chapter will address: 
 the aims and objectives of the study 
 identification and representativeness of the various study samples – including 
baseline (2005) and follow-up (casenote review  - 2009; HIC dataset 2005-12) 
elements 
 retrieval of clinical data and data inputting 
 the use of data-linkage procedures 
 study design and statistical methods applied. 
 
Choice of baseline independent (predictor) variables and dependent (outcome) variables 
 
1. Baseline data: Tayside Methadone Cohort (2005) 
Background 
In 2005 NHS Tayside Board agreed a plan to redesign its community treatment services for 
people experiencing problems with opioid dependency. Historically, as was the case across 
Scotland, Tayside’s specialist treatment services had been developed rapidly in response to 
an HIV outbreak in Dundee in the 1980s (Scottish Home and Health Department, 1986). 
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While there had been some attempts to develop a strategic approach to the further 
development of these services in Tayside, issues of rapid increases in demand and historic 
low levels of investment had meant the services had been inconsistent in their delivery and 
performance. Issues to be addressed by the 2005 service redesign, therefore included: 
 Some sectors in Tayside were experiencing long waits for access to treatment.  
 Treatment options were limited – with the vast majority of patients offered only 
methadone OST with limited access to other treatment types.  Few detoxification 
options were available and access to residential rehabilitation facilities - for which 
gatekeeping was a role of the three local authorities – was used sparingly and 
reflected local custom or funding issues rather than assessed need. 
 Additional community nursing support or access to third sector agencies for 
counselling support was not accessible across the region.  
 The services were also unable to demonstrate that existing patients were 
progressing from the OST programme and “flow” towards recovery – i.e. leaving 
specialist treatment services positively - was limited. A General Practitioner (GP) 
“shared care” programme – to take patients who had stabilized in the specialist 
service - was in place, but was under threat in the face of a new UK GP contract 
which had placed the treatment of substance use problems outside General Medical 
Services (GMS). Instead, GPs would be required to be contracted specifically to 
deliver OST or detoxification and this would be at a significantly increased cost to the 
NHS – based on a national proposed cost, a so-called “Nationally Enhanced Service” 
(NES). In Tayside, the OST programme was already under considerable financial 
pressure, considerably overspending its budget in the shared care element alone. At 
the time of the review, reflecting the national picture, it was threatened by local GP 
negotiators that they would withdraw from any involvement at all. In such 
circumstances all care would have to be delivered by specialist services and service 
gaps were likely. 
 
There was therefore a need for NHS Tayside to address a number of issues: 
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 How to continue to meet the needs of existing methadone patients – many very 
long-term (i.e. in treatment/on methadone 10-20 years). An estimated 8 -1200 
patients were thought to be in treatment at this point. 
 How to improve quality of care and outcomes – by better matching patients to 
appropriate interventions – increasing choice and ensuring that the services were 
also addressing common co-morbid issues (such as chronic pain and a range of 
mental health issues) as well as managing specific substance use issues 
 How to improve access for new patients in need of OST – by increasing capacity and 
improving “flow” – returning stable patients to their GP for ongoing care. 
 
Service redesign 2005 – “Clean team” 
In consultation with specialist and GP clinicians, NHS Tayside agreed a plan to address these 
issues.  The first stage of this process was to assess all existing patients objectively and 
systematically. This assessment would aim to clarify: 
1. Were patients objectively stable or not? 
2. Did the patients have co-morbid problems requiring attention? 
To achieve this it was important to ensure that the service had an understanding of:  
1. Their current status in terms of substance use 
This was assessed using the Maudsley Addiction Profile – MAP (Marsden et al 1998a) and its 
associated questionnaires relating to risk – taking - Injecting Risk Questionnaire (Stimson et 
al 1998) and patient satisfaction - Treatment Perception Questionnaire (Marsden et al 
1998b) as well as recording physical examinations (specifically for evidence of injection 
sites) and taking supervised urine or oral fluid samples for biochemical testing and drug 
screening. 
2. Their current social/demographic situation 
This was assessed using an in-house demographics questionnaire 
3. The presence/absence/severity of a range of co-morbid  health problems: 
a. Pain – assessed using the Brief Pain Inventory – BPI (Keller et al 2004) 
b. Mental health “caseness” - assessed using the General Health Questionnaire - 
28 item version - GHQ28 (Goldberg 1979)   
c. ADHD assessed using the Current  Symptoms Scale – CSS (Barkley & Murphy 
1998) 
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d. PTSD assessed using the Impact of Events Scale – IES (Horowitz, Wilner & 
Alavarez, 1979)  
e. Social phobia assessed using the Social Phobia Diagnostic Questionnaire – 
SPDQ (Newman et al 2003)  
The battery of tools applied reflected: 
 service priorities – those issues or conditions which senior clinicians felt were 
affecting their ability to manage patients or were hindering a patient’s progress 
 advice from local specialists – e.g. Pain and mental health screens (GHQ28, SPDQ, 
CSS and IES assessments) were proposed by local clinical leads in those areas and 
often reflected the tools used in local services. [NB were not chosen with research in 
mind] 
 senior clinicians’ preferences and practical applicability/deliverability in the context 
of a busy working clinical service. Self-completion tools or shorter “screening” tools 
were therefore preferred. 
The rationale for the use of these tools therefore reflected a pragmatic balance of their 
strengths and weaknesses. They were recommended by the relevant senior clinicians and 
then the practicality of their delivery measured against the time available for interviews. 
Copies of the tools used and associated references are contained in Appendix 1. 
 
Process 
Interviewers 
A team of 5 full time experienced senior nursing staff was appointed over and above the 
existing service nursing complement and was made available for 1 year. This team was 
drawn from staff involved in local and national drug and alcohol services. It was managed by 
a newly appointed “team leader” – an experienced service manager from a third sector 
organisation in the substance misuse field – and was given dedicated administration for the 
project. The staff, however, worked in existing clinical facilities meaning there were some 
limitations in terms of availability of clinic space across Tayside for the review process. All 
review staff were trained in the administration of all the tools to be used in the review prior 
to commencing patient contact.   
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Subjects 
All patients currently in receipt of OST- M in the NHS Tayside area at the inception of the 
project were identified from service databases by NHS administrators. Only methadone was 
used in as an opioid substitute in Tayside at this time – though Buprenorphine and 
dihydrocodeine were used in short-term detoxification episodes. Only those on a defined 
substitution therapy programme were included in the review. All had Tayside postcodes. 
This included patients in three main settings:  
1. the NHS specialist service 
2. patients within the criminal justice service – in particular two agencies: 
a. The Tayside Arrest Referral Scheme (TARS) – delivered by a third sector 
organization with access to NHS specialist nursing and prescribing support 
b. The Tayside Drug Treatment & Testing Order (DTTO) service - a partnership 
of the NHS specialist service with the three Tayside Local authority criminal 
justice services. This service had medical staff from the specialist agency 
embedded in the service and nursing staff support consisted of seconded 
specialist nurses 
3. patients within the Tayside Shared Care Scheme – this group was prescribed 
methadone by their own GP, supported by specialist nurses who worked from the 
GP surgery. 
 
The patients were given oral and written information about the review process by their 
keyworkers. They were then offered assessment appointments by post. The team 
concentrated its activity on a rotation of specific geographical areas, allowing reviews to be 
completed in an area so that thereafter normal services could resume as quickly as possible.  
 
Interviews 
The interviews took place in NHS facilities within the patients’ own localities (Dundee city, 
Angus, Perthshire) during the calendar year 2005 - starting in February, with the last 
appointments occurring in December. If patients failed to attend they were offered a further 
appointment at their convenience. Failure to attend this second appointment resulted in a 
more assertive approach through their own locality team with contact made by their own 
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keyworker and communication delivered through the person’s community pharmacy – the 
majority of subjects were attending daily to collect or consume their methadone.  
 
Attendance 
Poor attendance was a significant problem and delayed completion of assessments. This is 
thought to have reflected the fact that the NHS service keyworking staff had very high 
caseloads and were responding to high levels of demand. Consequently patients were often 
offered infrequent appointments (under one per month). The “Did not Attend” (DNA) rate 
was high at normal appointments and staff often asked community pharmacists to “hold” 
prescriptions until a patient was reviewed by the nursing staff if repeated failure to attend 
meant face to face contact had not occurred within one month. This situation unfortunately 
gave some patients the sense that their attendance was not required and this culture clearly 
impacted on the Tayside Methadone Cohort review –especially in its early stages. There was 
a real concern that the required reviews would not be completed in the year planned. In 
response, the project steering group was forced to reduce the amount of data to be 
collected on each case from July 2005, thus reducing the time demand of each interview 
and increasing the number of assessments which could be undertaken by a small team 
within the limited time available.  This meant that a complete dataset was not available for 
all cases. As originally planned, the “clean team” was subsumed into the NHS treatment 
service from January 2006, ending the dedicated review process. At this point 649 of the 
817 cases verified to have been in treatment at the inception of the project had been 
formally assessed. Any remaining cases were then reviewed as part of the normal clinical 
process in each locality. 
 
The sample used in this thesis reflects those patients for whom a substantial dataset was 
obtained during February-December 2005 as part of the Tayside Methadone Cohort review 
process. 
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Data quality 
A weekly steering group meeting involving senior clinical staff from the treatment services 
and the clean team manager collated, reviewed and quality assured the information 
returned by the interviewers. At this (clinical) meeting, patients were also broadly identified 
as “stable” or “unstable”. This was based on a number of factors. These were: 
 Evidence of ongoing regular illicit drug use  - self report; observed behaviour during 
examination; testing; reports from other agencies 
 Evidence of risk-taking  - self report; examination; sequelae of injecting behavior – 
e.g. hospital admissions; overdoses  
 Evidence of complex issues  - self – report; examination; results of co-morbidity 
screens; reports from other agencies 
 
As had been originally planned, depending on this clinical judgement, their future care was 
placed in a specific service element which focussed on stabilization/harm reduction 
(Assessment & Stabilization Service - ASS) or recovery/rehabilitation (Time Tay Change – a 
service designed to facilitate progress from the specialist services, delivered off-site, in 
collaboration with a third sector provider agency – the Scottish Association for Mental 
Health). This was intended to ensure that those in most need would receive the most 
intensive support while those ready to move on from specialist care were supported to 
achieve this. 
 
Data entry  
The clinical data were filed in a specific folder within the NHS casenotes and were referred 
to by clinicians in their care planning and delivery and other clinical  interactions with their 
patients.   
 
In 2006 a successful bid for a small NHS Research & Development (R&D) grant supported 
the development of a database which would contain all the clean team data and support 
the development of outcome measurement systems and audit tools in the service. Local 
Ethics Committee support was obtained. Full ethical committee approval was not required 
though agreement from the NHS Caldicott Guardian was. A bespoke database was built 
using SPSS 16 (SPSS 2003). The 2005 baseline data were input by dedicated and experienced 
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data-entry staff during 2006. The staff were accessed from the Health Informatics Centre – a 
dedicated data management centre jointly managed by NHS Tayside and the University of 
Dundee. Quality assurance was undertaken by a research assistant who checked 10% of 
database inputs against the hard copy information.  
 
These data were then used by service managers and senior clinicians to report on the 
treatment population and to demonstrate progress in aspects of service delivery, quality 
and governance within the local accountability system. Local reports and presentations 
were delivered to the local NHS Tayside board as well as to partners including the local Drug 
and Alcohol Action Teams. 
 
2. Follow up data – 2009 Casenote audit 
In 2009 a further one year grant was obtained through NHS Tayside R&D to carry out a 
follow-up audit project, based on this 2005 baseline cohort.  
 
Initially, it was planned that a sample of patients would be re-interviewed by dedicated 
researchers employed for this purpose. Unfortunately, as available funding was limited and 
this element of the study required full NHS Ethics Committee approval which took some 
months to acquire – delaying commencement of the data collection phase -  data collection 
started very late in the agreed one year timeframe. Once the process for patient interviews 
was in place, attendance for interviews was again very poor with attendance rates below 
10% in the first four weeks of the project.  
 
Consequently, in consultation with the NHS Tayside Ethics Committee, it was agreed to 
modify the audit and instead carry out a casenote-based review. A proforma was created to 
capture a number of process-measures and outcomes from clinical records (Figure 5). These 
data were collected in 2009. An SPSS database was built and data entered for analysis.  A 
service audit report was completed using these data. Further details of this process – 
including prioritization of data sources - are included in Chapter 5. 
  
125 
 
Figure 5 -Data collection form used for 2009 casenote review 
  
Date of data collection  
Name  
Male/Female  
Date of Birth  
Age in 2005  
Locality (Dundee/Perth/Angus)  
Methadone dose in 2005  
Current Prescribed Medications 
[TDPS Rx from methadone database.] 
 
 
 
Key Stability indicators 
 Biochemistry/oral fluid results 
 Results consistent with 
prescribed medications 
 Evidence of injecting/risk 
 Hospital admissions 
 
 
Other: Any objective record of: 
Offending (+arrest+disposals), 
Employment/training/activity,  
Home stability (accommodation) 
Family/relationship stability 
Children/parenting responsibilities 
 
 
 
3. Follow-up data – Health Informatics Centre NHS datasets 2005-2012 
In December 2010, the SUMIT (Substance Misuse Information – Tayside) project was 
launched.   Funded by the three local Alcohol & Drugs Partnerships (ADPs – successor to 
Drug and Alcohol Action Teams,) and delivered by academic staff in the University of 
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Dundee, this was a multi-agency information-sharing project aiming to deliver linked data 
on outcomes in the substance misusing population in Tayside. The data would be collected 
electronically from all services and a new electronic record system in the NHS (MIDIS) would 
supply reports, facilitating clinical governance of care by local commissioning bodies and 
service managers.  
 
Crucially, it was emphasised that the datasets created would also be available for academic 
research and the appropriate ethical approvals, Caldicott Guardian approval and data-
sharing agreements were developed as part of this project. This multiple functionality would 
be achieved by managing all data in a “safe haven” – a virtual electronic environment where 
datasets are linked using unique identifiers and are then anonymised. This element of the 
project was delivered by the Health Informatics Centre (HIC) in Dundee. The SUMIT project 
is described in detail in the papers describing the project – contained in Appendix 2. 
Research governance paperwork is contained in Appendix 3. 
 
The SUMIT project allowed the 2005 baseline data and 2009 follow up data (described 
above) to be linked with a range of other relevant existing datasets held by HIC.  These data 
were then anonymised by HIC and these anonymised linked data given a unique identifier or 
“prochi”. They could then only be accessed through the HIC “Safe Haven” – using a  “virtual 
desktop” which is governed by strict Standard Operating Procedures. HIC processes and 
Standardised Operating Procedures are contained in Appendix 2.   
 
This process supported creation of the comprehensive dataset used as the basis for the 
analyses described in this thesis. 
 
Funding 
Baseline data (2005/6) 
The clinical assessments and record keeping were undertaken by a dedicated clinical 
assessment team - the “clean team” – funded as part of the service redesign by NHS Tayside 
Board.  The staff to develop the baseline SPSS database and carry out data entry were 
funded by a small grant from EASTREN (the local NHS Tayside and Fife Research & 
Development office). 
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Casenote follow-up (2009)  
The casenote review, including proforma development, data collection, SPSS database 
development, data inputting and cleaning were supported by a grant from NHS Tayside 
Research & Development. 
 
HIC data-linkage process (2010-12)  
This element of the study was funded as part of the SUMIT project, supported by dedicated 
funds from the three Tayside Alcohol & Drugs Partnerships. 
 
Subjects & attrition 
A schematic of all subjects’ progress through the study and attrition through the various 
stages of the study is shown in Figure 6 (P129). 
 
Baseline 
The schematic shows that once data was cleaned and invalid Chi-identifiers were removed, 
623 cases were ultimately reviewed as part of the Tayside Methadone Cohort study. 
 
2009 casenote audit 
467 cases were reviewed as part of the casenote audit in 2009 – of whom 251 were active 
ongoing cases (54% of all follow ups) with 216 (46%) having been discharged and currently 
not in treatment. Of discharges, 40 (18.5% of discharges) were described as “planned” – 
representing positive discharges on completion of treatment (i.e. drug free – if in “shared 
care” they would have continued in the OST- M programme) or positive service transfers to 
another area or service. Some 176 cases (81.5% of those discharged, 38% of the casenotes 
available for follow- up) were described as “unplanned” – i.e. discharged before treatment 
completed. This group would include deaths – for whom clinical casenotes would not be 
available. 
  
128 
 
HIC linked datasets 
HIC datasets contained differing sample sizes. Larger datasets were available for out-patient 
attendances in the drug service (giving a measure of “treatment dose”) with data available 
on 607 (97%) of the original cases.  Some 45 cases from the original TMC subjects had died 
in the period from 2005-12. This represents 7.2% of the baseline cohort. Data for other 
service involvement reflects these subjects’ use of these services. For example, General 
Hospital admissions (from national Scottish Morbidity Record  - SMR -  data) were recorded 
for 294 cases (47% of the original cohort). This means that 294 of the TMC cases were 
admitted at any time in the 7 years to 2012. These 294 cases were admitted a total of 907 
times. SMR01 contains details of diagnoses, days in hospital etc. The balance of cases were 
not admitted to a general hospital in that period – and therefore had no SMR01 completed.  
 
It can be seen that, for some of the measures chosen – such as Ambulance Service call-outs 
or A&E attendances – there are only 35 cases (responsible for 293 events) and 32 cases 
(responsible for 723 episodes) recorded respectively. This reflects the fact that these data 
have only become available in recent years though the HIC process – i.e. they do not reflect 
the total follow up period.  
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Figure 6.  Schematic of potential participants (numbers) 
 
 
 
 
 
 
 
 
  
Baseline Population 
All Patients on Methadone ORT 
 in Tayside 
January 2005 
817 cases 
Follow – up 
Health Informatics Centre Data 
January 2005 – December 2011 
 
 
Follow – up 
Clinical Casenote review 
July-December 2009 
467 cases 
Discharged 
216 cases 
Retained  
251 
cases 
Out-patient 
attendance 
607 cases 
Ambulance 
attendance 
Non-fatal 
Overdose 
293 episodes  
by 35 cases 
A&E 
Attendance 
723 
attendances 
by 32 cases 
General Hospital 
Admission 
907 admissions 
by 294 cases 
Psychiatric 
Admission 
133 
admissions  
by 56 cases 
GROS 
Death 
45 cases 
Planned 
Discharges 
40 cases 
Unplanned 
Discharges 
176 cases 
Patients not 
assessed in 2005 
134 cases Details 
unavailable 
60 cases 
Baseline 
Clinical Data Collection  
February-December 2005 
623 cases   
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Ethical considerations & permissions 
Baseline audit 
In 2006 permission was obtained from the NHS Tayside Caldicott Guardian to access and 
organise the baseline clinical information for research purposes. Tayside Research Ethics 
Committee was approached regarding the need for ethical approval. They confirmed that no 
approval was required for this element of the study. 
 
Follow-up casenote review 
In 2009 permission was obtained from the Caldicott Guardian to carry out a follow up audit 
on the casenotes of the original 2005 cohort. Ethical approval was acquired from Tayside 
Research Ethics Committee to carry out follow up interviews. When this was found to be 
unfeasible, permission was formally obtained to proceed to a casenote-based audit. 
 
Health Informatics Centre data-linkage 
In 2010, permission was obtained from the Caldicott Guardian to include the 2005 Cohort 
and 2009 follow up data in the SUMIT project – a multi-agency information-sharing project 
aiming to deliver linked data on outcomes in the substance misusing population in Tayside. 
This allowed the TMC data to be linked with existing datasets held by the Tayside Health 
Informatics Centre (HIC). The total dataset was then anonymised by HIC and these 
anonymised linked datasets given a unique identifier or “prochi”. They could then only be 
accessed by named staff, through the HIC “Safe Haven” – using a “virtual desktop” governed 
by strict Standard Operating Procedures. Tayside Research Ethics Committee confirmed no 
further ethical approval was required to allow the analyses to proceed. Confirmation of the 
approvals from the Tayside Caldicott Guardian and Ethics Committee is contained in 
Appendix 3 (TASC Ref: 2010PY01). 
 
Statistical considerations 
Data were analysed in the HIC safe haven environment and all outputs stored within that 
environment. All analyses used in this thesis were performed in 2012 using SPSS version 18 
(IBM, 2010). 
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Baseline assessment of sample 
Initial descriptive analyses were used to describe the key characteristics of the baseline 
sample.  This included descriptions of: demographics and social circumstances; substance 
use and associated clinical problems (assessed by the MAP, IRQ and TPQ); co-morbid 
conditions – including pain (assessed by the BPI); GHQ caseness (assessed by GHQ28); ADHD 
(assessed by the CSS); PTSD (assessed by the IES); social phobia (assessed by the SPDQ).  
 
Representativeness of baseline sample 
Although the baseline study aimed to deliver a census of OST- M patients in Tayside, it was 
important to ensure that the Tayside Methadone Cohort sample was representative of all 
OST- M patients in Tayside.   
 
A large proportion (76.2%) of the total Tayside OST- M population was assessed in 2005. 
However, in the early stages of the project it had proven difficult to be clear regarding the 
size of the baseline population, from which the sample was drawn. This may have reflected 
the rapid movement of patients into and out of the service. It was also impacted on by the 
poor quality of local administration systems in hard-pressed services which had been 
dispersed from a central base to localities up to 20 miles away. The original assessments 
were undertaken in a clinical setting and management of these clinical casenotes by medical 
records departments in three different NHS sectors meant that original patient lists were 
difficult to validate retrospectively. Any information at all on some 60 of the originally 
identified total of 817 active patients could not be retrieved for the study. Limited 
information from prescribing databases and service patient management systems were 
available for the 134 of the subjects who were not assessed by the clean team in 2005.  
 
Means and standard deviations of a limited range of descriptive demographic variables were 
collected in order to assess representativeness. Variables available for testing were: gender, 
age, methadone dosage. Categorical variables were compared using the chi-squared test. 
Continuous variables were compared using the paired t-test. These results are shown 
graphically in Table 10.  
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Table 10. Representativeness of baseline sample  
Continuous 
variables 
Population 
proportion 
Male 
Sample 
proportion 
Male 
Population 
mean (SD) 
Sample 
Mean 
(SD) 
Statistics 
Age 
 
  30.3 (6.7) 32.7yrs 
(7.8) 
t-test; t=3.4; 
df=692; p=0.001 
Methadone   55.3mg 
(21.5) 
49.3mg 
(25.9) 
t-test; t=2.3; 
df=752; p=0.022 
Gender 
 
57% 69%   Chi-squared test 
χ2(1)=7.064; 
p=0.008 
 
As these figures show, significant differences were found for all three variables chosen, 
raising issues regarding the representativeness of the original sample. In the sample 
assessed, males were over-represented, mean age was older and methadone dose less than 
that in the treatment population as a whole. This may represent the fact that a harder-to-
reach element of the treatment population (one which may have been on higher 
methadone doses) were the most resistant to being invited for review. Though they would 
have been reviewed by their own clinical team later, they were not included in the original 
cohort (or this study) as they were assessed outside the study period.  
 
Selection of baseline (predictor) variables and follow-up (outcome) variables 
The extensive literature review (Chapter 3 above) indicated a number of variables which 
previous research has indicated may be important in influencing outcome of treatment. 
Previous research also informed the outcomes which should be considered. Baseline and 
follow up datasets (2009 Casenote review and 2005-12 HIC datasets) were explored and a 
list of variables for assessment created. Quality of data and potential  missing data were 
important factors in choosing the variables used for these analyses. 
 
Representativeness of the 2009 follow -up sample 
Although follow-up records were available for 75% of those assessed at baseline (467 of 
623), it was important to determine whether this follow up sample was representative of 
the baseline sample. Categorical variables were compared using the chi-squared test and 
continuous variables using the paired t-test. The results are shown in Table 11. 
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Table 11. Representativeness of the follow – up sample 
Categorical variables % Baseline  % Follow-up  Statistic 
Sex    
 Male 69 69 χ
2
(1)=0.026; p=0.873 
 Female 31 31  
Geographical area    
 Dundee 62 63 χ
2
(2)=3.864; p=0.145 
 Angus 23 18  
 Perth & Kinross 16 19  
Frequency of changing address    
 Never 22 22 χ
2
(3)=0.065; p=0.996 
 Sometimes 58 58  
 Frequently 17 17  
 Very frequently 3 3  
Lives alone or with others    
 Alone 37 38 χ
2
(5)=1.383; p=0.926 
 With partner 25 26  
 With family 31 29  
 With friends 5 5  
 Hostel 2 3  
Has children    
 Yes 75 74 χ
2
(1)=0.098; p=0.755 
 No 25 26  
Has physical health problems    
 Yes 51 52 χ
2
(1)=0.011; p=0.915 
 No 49 48  
Has mental health problems    
 Yes 50 47 χ
2
(1)=0.596; p=0.440 
 No 50 53  
Has support from other agencies    
 Yes 30 30 χ
2
(1)=0.011; p=0.915 
 No 70 70  
Literacy / numeracy skills    
 Not good 10 9 χ
2
(2)=2.258; p=0.879 
 OK 38 38  
 Good 52 53  
Educational attainment    
 None 53 52 χ
2
(4)=0.405; p=0.982 
 O’ Grades 28 29  
 Apprentice/SVQ/City & Guilds 2 2  
 Highers 4 5  
 College / university 13 12  
Continuous variables Baseline mean(SD) Follow-up 
mean(SD) 
 
 Age 32.96 (7.746) 36.94 (7.603) t-test t=-0.241; df=446; 
p=0.810 
 
No significant differences were found for the variables assessed. The 2009 follow up sample is found 
to be representative of the baseline 2005 sample. 
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Follow – up assessment: Statistical tests 
 
Normality of data and use of tests -parametric or non-parametric 
It was important to establish whether the available data qualified as parametric or whether 
use of a nonparametric test would be appropriate.  Parametric tests are seen as more 
precise, with greater statistical power but are not robust when there is non-adherence to 
the assumptions associated with parametric testing.  To qualify for parametric testing, the 
data must meet the following assumptions: 
 Data must be continuous (i.e. scalar data with the difference between any two 
points being the same as the difference between any other two points).   
 Data must be normally distributed.   
Normality was tested by visual inspecting of the standard histogram generated by SPSS with 
a superimposed normal curve. If there was some doubt further tests were undertaken. This 
included: a visual inspection of a Q-Q plot (approximation of the distribution of the variable 
in question to a straight line). If required it was also planned to apply further tests of 
normality – Kolmogorov-Smirnov and Shapiro-Wilk tests.  
 
Longitudinal analyses of independent (baseline) and dependent (outcome) variables 
Univariate associations were assessed. Categorical data were compared using the chi-
squared test. Testing of continuous data was determined by normality. If data were 
normally distributed, parametric tests were favoured.  In the initial analyses both 
independent variables (IVs) and dependent variables (DVs) were either categorical or 
continuous. Table 12. shows the tests undertaken, depending on the nature of the data. 
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Table 12. Statistical tests undertaken 
Independent Variable Dependent Variable Statistical test undertaken 
Categorical Categorical Chi square test 
Categorical Continuous If data were parametric: ANOVA 
If data were non-parametric: 
Mann Whitney U-test 
(for 2 variables) 
Kruskall-Wallis H-test  
(for>2 variables) 
Continuous Categorical linear (if data have a linear 
relationship) or quadratic (if not) 
discriminant analysis 
Continuous Continuous linear (if data have a linear 
relationship) or quadratic (if not)  
regression  analysis 
Effect sizes were also assessed using a range of statistical tests: Phi; Cramer’s V; Cohen’s d 
and Partial 2 Levels of effect are described, reflecting Cohen’s “rule of thumb” 
 
Multiple testing 
The effect of multiple testing is an issue with the proposed approach. If a true null 
hypothesis is tested, using (as planned) the 0.05 level as the critical significance level, then 
the probability of coming to a `not significant' (i.e. correct) conclusion is 0.95. If two 
independent true null hypotheses are tested, the probability that neither test will be 
significant is 0.952 = 0.90. So, as the number of independent tests increases, the probability 
that none will be significant reduces to the power of the number of tests. Therefore, if 
twenty hypotheses were tested, the probability that none will be significant is 0.9520 = 0.36. 
This gives a probability of 1 - 0.36 = 0.64 of getting at least one significant result meaning it 
is more likely to find a significant result than not. Multiple testing therefore increases the 
likelihood that a significant finding will appear spuriously by chance alone. This is an 
example of a Type 1 error – a false positive. 
 
Bonferroni correction 
There are a number of so-called Post hoc procedures which can be used to reduce the 
likelihood of a Type I error (Toothaker, 1993). One common example is the Bonferroni 
method. This method divides the significance value (α) by the number of tests undertaken. 
For example, if the proposed significance level (α) is 0.05 and ten tests have been 
undertaken, then using the Bonferroni method [α/10] the likelihood of Type 1 errors can be 
reduced if the proposed significance level is corrected to 0.005. It is, however, important to 
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be aware that this approach is statistically conservative and has the potentially negative 
effect of reducing statistical power. This phenomenon in turn brings an increased probability 
of rejecting a significant finding - a Type II error or false negative. Use of the Bonferroni 
correction in the analysis of these data will be discussed at the appropriate results section. 
 
Effect sizes 
In all cases the effect size was also assessed using appropriate tests. For data which used the 
Cohen’s d and Partial 2 tests, these statistics showed the level of the effect (small; medium; 
Large). In the case of Phi or Cramer's V, a score of >.10 was assessed as providing a 
minimum threshold for the presence of a substantive relationship between the variables.  In 
some analyses (using the Kruskal -Wallis H test) the Monte Carlo estimate of significance 
was reported alongside its confidence intervals for significance. This test can give 
confidence that an apparently significant effect is genuine. 
 
Tables containing the results of the univariate analyses are contained in Chapters 5 and 6. 
The results are reported as significance values (as described in Field 2005). Effect sizes are 
reported for those associations found to be statistically significant.  These results generated 
a list of potential predictors which could then be used to develop and test a predictive 
model of relevance to the known evidence base and clinical experience.  
 
Predictive modelling 
 
This part of the project tested the prediction of 4-7 year outputs (process measures) and 
clinical outcomes using the 2005 baseline data. 
 
A series of univariate analyses had assessed the associations between baseline 
(independent) and follow up (dependent) variables.  The issue of multiple testing had been 
addressed using the Bonferroni Correction. Those associations then found to be significant 
were used to assess their value in predicting key outcomes for the TMC patients.  
 
Reflecting the evidence base already discussed, a group of outcomes to be predicted was 
proposed. These were: 
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 alive/dead  - recorded by Registrar General (Recorded in the GROS data available 
to the HIC dataset) 
 ongoing illicit drug use – 1. by self-report and 2.  +ve tests in 2009 (both from 
2009 casenotes) 
 [NB It was planned that NHS Laboratory test results from HIC should be the basis of this 
analysis. However, these tests were were unavailable in HIC at the time of analysis making 
this analysis dependent on the quality of casenote recording/filing of results] 
 indicator of family stability (as demonstrated in 2009 casenotes) 
 physical health - acute hospital admissions (recorded in 2009 casenotes) and 
nights in acute hospital (SMR01) 
 
Plans to consider other a number of potentially relevant outcomes such as overdoses from 
ambulance or A&E data) psychiatric admissions (casenotes and SMR04 data) and 
incarcerations (casenote data) were not progressed, as the number of cases involved in each 
were very small.  
 
Method of regression analysis  
Details of the analyses are contained in the relevant results section (Chapter 7). For those 
outcomes for which data were categorical, a logistic regression was undertaken. In the case 
of the data used in this analysis, all outcomes were binary meaning that a binary logistic 
regression analysis was required. For the one outcome which was continuous – hospital 
admissions – a multiple linear regression analysis was undertaken. The process involved:  
 
1. Initial selection of Independent variables 
The original group of predictor (independent) variables (IVs) were selected from all available  
variables in the 2005 baseline dataset as they had been identified -  from the literature 
review -  as having evidence to support their predictive value with regard to treatment 
outcomes. 
2. Associations with dependent variables 
The selected IVs were then tested individually and their impact on the selected DVs was 
assessed (Results are shown in Chapters 5, 6). 
138 
 
3. Choice of variables for the multiple regression analysis 
Ideally, factors influencing recovery would have been assessed – but in 2012 the data 
available from the SUMIT dataset was in its early stages and information on social outcomes 
was unavailable in the HIC safe haven at this stage. Data-sharing agreements to access local 
authority and third sector data were in place but technical challenges meant that these data 
were not yet accessible. Variables relating to the broader recovery process had not 
therefore been prominent and more standard substance misuse outcomes relating to the 
extent or risk associated with illicit drug use along with indicators of health - such as  
hospital admission and death  - were selected. Factors implying a high degree of family 
stability from casenotes were also used 
4. Method chosen 
These significant IVs were then placed in a multiple regression analysis in the SPSS statistics 
programme, using a Forced Entry method. A number of rules were followed whenever 
possible: 
 The fewest variables with the best predictive value was the aim.  
 Only variables with a good theoretical grounding were included.  
 A process was undertaken to remove those variables found to be redundant 
5. Sample size  
Sample size was a key consideration (Green, 1991). To test  best fit of the model (testing R2) 
the minimum sample size follows the equation: 
sample size = 50 + 8k (where k is number of predictors) 
For a process to test the individual predictors then minimum sample size is calculated using 
the equation: 
sample size = 104 +k (where k is number of predictors) 
If overall fit and contribution of predictors is required, it is recommended that both tests are 
undertaken – in which case, the equation giving the highest number is used to calculate 
sample size required. 
 
Cross – validation of predictive models 
In order to validate any predictive models identified and ensure these models were 
generalizable  - i.e. the model generated would predict outcomes in novel data - a process 
of cross-validation was undertaken. Cross-validation is a statistical technique for assessing 
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how the results of a statistical analysis on one set of data will generalize to another 
independent data set. It is mainly used in settings where the goal is prediction, and one 
wants to estimate how accurately a predictive model will perform in practice (Geisser, 1993; 
Devyver & Kittler, 1982). 
 
Regression analysis can result in a model which displays so called “over-fitting” – with the 
regression analysis results  incorrectly implying that the proposed model is a better fit to the 
data than it is, or has less prediction error - difference between the model predicted value 
and the actual observed value - than is the case. In a standard multiple regression, this 
prediction error refers to how well the regression equation predicts the outcome variable 
scores of new cases based on applying the original model coefficients to the novel cases’ 
predictor variable scores. In the case of over-fitting, these errors will be biased - implying 
less prediction error - often due to the actual outcome variable values being used to create 
the prediction model – a process known as “double dipping” (Kriegeskorte, Simmons, 
Bellgowan & Baker, 2009). Cross validation techniques are one way which can be used to 
address this over-fitting bias by avoiding double dipping. 
 
In the TMC example, the cross-validation process involved a number of steps: 
 creating a complete dataset – removing all missing data 
 randomly dividing the sample 50/50 into a training and testing dataset 
 the appropriate regression analysis was undertaken in the first half of the dataset – 
the training dataset – generating a predictive model with β coefficients for each 
variable. 
 these β values were then entered into the appropriate equation – this time using the 
novel testing dataset - to  generate a predicted outcome in these novel data. The 
equation used reflected the type of regression being undertaken: 
- Linear regression: Y = β0 + β1X1 + β2X2 +…. βnXn + ε.  
This was used when the DV was continuous 
- Binary logistic regression: P(Y) = 1/1 + e-(β0 + β1X1 + β2X2 +…. βnXn) 
This was used when the DV was binary 
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 the predicted outcome generated, was then compared to the actual observed 
outcome for the testing dataset, using a chi-squared test. A significant difference 
between the observed and predicted outcomes would imply that the proposed 
predictive model is NOT predictive in this novel dataset. 
 
The results of this process are described in Chapter 7. 
 
In conclusion 
 
This chapter has described a process which aimed to develop a large and representative 
research database from existing identifiable clinical data accessed from a number of 
sources: a service review census (2005); a follow-up casenote review (2009) and linked data 
from national datasets (2005-12). 
 
It has described the methods used to collate this database and the statistical plans 
developed for a number of analyses. 
 
Reflecting key questions from the literature review, univariate analyses were then carried 
out  using the 2005 baseline data as independent (predictor) variables and the 2009 
casenote review and HIC linked-data as dependent (outcome) variables.  These analyses 
generated associations which were then to be used as the basis to develop a testable 
predictive model. 
 
The next section of the thesis – chapters 5-7 –describes the results. 
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Chapter 5 
Results: baseline sample - descriptive statistics 
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Figure 7.Results: 2005 Baseline Sample - Descriptive statistics 
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Descriptive statistics 
This section describes the characteristics of the 2005 baseline sample of the Tayside 
Methadone Cohort. Figure 7.  illustrates the data sources used. The data were collected at 
their baseline assessment interview in 2005 using a variety of tools described above 
(Chapter 4). Additional data (e.g. regarding GP, postcodes and deprivation scores) were 
available retrospectively from HIC databases. The variables selected are later used as 
Independent variables/predictors.  Demographic information was collected at baseline. 
Table 13. Baseline Demographics  (n=623) 
 N % Mean Median Range  Min-
max 
SD 
Age 623 100 32.96 32 49 17-66 7.746 
Gender (n=620)        
                           Male 424 68.4      
                       Female 196 31.6      
M:F ratio 2.16:1       
Home (n=620)* 
                      Dundee 382 61.6      
         Perth & Kinross 98 15.8      
                         Angus 140 22.6      
SIM-D Deprivation score (n=607)** 
Quintile 1 311 50.2      
Quintile 2 172 27.7      
Quintile 3 64 10.3      
Quintile 4 45 7.3      
Quintile 5  
(most affluent) 
15 2.4      
Time at current address (N=612) 
<1 month 37 6      
                1-6 months 75 12.3      
          6 months -1 yr 92 15      
                        1-3 yrs 165 27      
                        3-5 yrs 84 13.7      
>5yrs 159 26      
Frequency of changing address (n=500) 
                          never 109 21.8      
                 sometimes 294 58.8      
                  frequently 97 19.4      
*NHS Tayside board area contains three discrete local authority areas – Perth & Kinross, Angus and Dundee 
City. **Health board scores. 1=most deprived.  
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Information regarding home circumstances, childcare/parenting responsibilities and the 
quality of relationships was collected (Table 14). 
 
Table 14. – Family support and Childcare responsibilities 
 N % Mean Median Range  Min-
Max 
SD 
Children (n=585) 
                              Yes 443 75.7      
                               No 142 24.3      
If yes how many? (n=442) 
                                  1 197 44.6      
                                  2 135 30.5      
                                  3 75 17      
                                  4 22 5      
                                  5 7 1.6      
                                  6 6 1.3      
Living circumstances (n=616) 
                          Alone 232 37.7      
             With partner 153 24.8      
                With family 189 30.7      
              With friends 28 4.5      
Days contact with 
partner (604) 
266 no 
contact 
44% 15.01 
days 
 30 days 0-30 14.42 
MAP Partner 
conflict score 
  6.06    18.64 
Days contact with 
Family (606) 
82 no 
contact 
13.5% 18.54  30 days  12.42 
MAP Family conflict 
score 
  5.09    17.59 
Days contact with 
friends (606) 
221 no 
contact 
 12.79  30 days  12.82 
MAP Friends 
conflict score 
  0.67    6.33 
 
The majority of subjects have at least one child though over one third live alone. The 
majority are living with a partner or family but the mean contact with partner family or 
friends is far less than daily. 
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Information regarding the subjects’ educational attainment, self-assessment of their basic 
skills, and employment were collected (Table 15).  
 
Table 15.  Education, skills, training and employment  
 N % Mean Median Range  Min-
Max 
SD 
Self-rating of reading, writing and counting (601) 
Not good 61 10.1      
Okay 227 37.8      
Good 313 52.1      
Educational level achieved (593) 
No qualifications 312 52.6      
Standard grade or 
equivalent 
164 27.7      
Higher 27 4.6      
College 78 13.1      
Days in paid work of 
30 (607) 
  2.19  30 0-30 7.22 
Days sickness 
absence from work 
of 30 (604) 
  0.26  30 0-30 2.519 
Days unemployed of 
30 (595) 
  23.58  30 0-30 12.264 
 
The group self-assessed their basic reading writing and counting skills well though over 10% 
saw these skills as “not good”.  Educational attainment was poor with over 50% having no 
qualifications at all and over 61% of those with qualifications having only standard grades. 
Few were in paid work with those who were working a mean of only 2 days per month. 
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Information regarding physical and mental health problems was obtained. This included 
information regarding registration with a General Practitioner or support from another 
agency outside the NHS treatment service (Table 16). 
 
Table 16. – Care & treatment status (general) 
General N % Mean Median Range  Min-
Max 
SD 
Registered with a GP (n=620) 
Yes 580 93.5      
No 40 6.5      
Physical problems reported (n=567) 
Yes 293 51.7      
No  274 48.3      
Being treated 177 31.2      
MAP Physical health 
score (622) 
  14.2   0-37 7.98 
Mental health problems reported (n=533) 
Yes 265 49.7      
No 268 50.3      
Being treated 184 34.6      
MAP psychological 
health score (620) 
  15.73   0-40 9.22 
Support from other agencies (n=502) 
Yes 152 30.3      
No 300 69.7      
 
Only 87% were registered with a GP. 52% reported having physical health problems of which 
only 60% were receiving treatment. Mean MAP physical health score was 14.2 (SD 7.98) 
suggesting that in general physical health problems were mild/moderate. Some 49.7% 
reported mental health problems of which 69% were being treated. Mean MAP 
psychological health score was 15.73 (SD 9.22) suggesting that mental health problems were 
mild/moderate. Only 30% were receiving additional support from other (Non-NHS) agencies 
for themselves or their children. 
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Information regarding where they received their substance misuse treatment (i.e. which 
agency) and what prescribed treatments they were in receipt of were collected. 
 
Table 17. – Care & treatment status (substance misuse) 
Treatment 
specifically for 
substance misuse 
 
Number 
 
% 
 
Mean 
dose 
 
Mode 
 
Range 
 
Min-
max 
 
SD 
Methadone prescribed (n=608) 
Yes 588 96.7 49.54mg 50mg 170mg 0-170 25.25 
No 20 3.3      
Diazepam prescribed (n=619) 
Yes 178 29 6.84 20 85 0-85 13.65 
No 441 71      
Treatment setting (n=547) 
GP shared care 156 24.8      
TDPS 298 47.4      
DTTO/TARS 93 14.8      
 
At the time of the assessment 97% of the subjects were in receipt of a methadone 
prescription from Tayside services. This may reflect that, having been identified from 
methadone databases, some patients had detoxified or had come off methadone for some 
other reason.  Most commonly prescribed dose was 50mg with the mean dose 49.54mg (SD 
25.25). Maximum dose was 170mg.  
 
Some 29% of subjects were being prescribed diazepam. The most common dose was 20mg 
(range 0-85mg) with a mean dose of 6.84mg (SD 13.65).  
 
Treatment was being delivered in three settings: NHS specialist service (TDPS) – 298 cases 
(47.4%); Criminal Justice services (DTTO and TARS) – 93 cases (14.8%); General Practice 
Shared Care –  156 cases (24.8%). 
 
Details of their baseline drug and alcohol use were obtained (Table 18). This included 
information on injecting risk (Table 19). 
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Table 18. -  Baseline substance use 
 N % mean median range Min-max SD 
Drug screens (n=582) 
Illicit Opiates positive (of 
534) 
289 54      
Benzodiazepines +ve (of 
533) 
314 58.9      
Methadone +ve 
(of 533) 
508 95.3      
Alcohol days/30 (620) 387 no 
days 
62.4 2.92 days Mode 
1 day 
30 0-30 7.030 
Alcohol amounts  - units 
(616) 
  3.49 units Median 8 
units for 
drinkers 
39 1-40 6.39 
Cannabis days/30 
(619) 
186 no 
days 
30% 15.11 Mode 1 or 
16 
30 0-30 13.72 
Cannabis amounts Not recorded in standardised way 
Heroin days/30 (619) 323 no 
days 
52% 4.66 Mode 1 
day 
30 0-30 8.69 
Heroin amounts (623)   0.14g Mode 0.1g 
Median 
zero [or 
0.1g if 
users] 
4g 0-4 ? 
Heroin route (612) 324 none 52.9%      
Snort 7 1.1      
Smoke 190 31%      
IV 90 14.7      
IM 1       
Illicit Methadone 
days/30 (622) 
416 no 
days 
67.1 3.43 Mode 1 
day 
30 0-30 7.88 
Methadone amounts 
(623) 
Amounts poorly recorded in assessment records for methadone 
DHC days/30  (620) 536 no 
days 
86.4 0.64 Mode 1 
day 
30 0-30 3.23 
DHC amounts (619)   28.55 Mode 
60mg 
Median 
150mg 
1200mg 0-1200mg 107.36 
Morphine days/30 (621) 
(618 no days reported) 
 
3 cases 0.5% 0.01  4 days 0-4 0.23 
Morphine amounts (625)   0.78  400mg 0-400 16.256 
MST days/30 (622) 572 92 0.30 Mode 1 
day 
30 0-30 1.946 
MST amounts (616)   14.71mg Mode 
100mg 
Median 
100mg 
1000mg 0-1g 75.06 
Diconal days/30 (622) 
(620 no days reported) 
2 cases 0.3% 0.00 Mode 1 or 
2 days 
2 days 0-2 0.09 
Diconal amounts (629)   0.00   0-2mg 0.09 
Diazepam days/30 (620) 
(409 no days reported) 
211 34 2.96 days Mode 1 
day 
30 0-30 7.21 
Diazepam amounts (620)   13.39mg  450 0-450 32.99 
Temazepam days/30 
(607)  
495 no days reported 
112 18.5 3.48 days Mode 1 
day 
30 0-30 9.23 
Temazepam amounts 
(621) 
  6.28mg  400 0-400 32.47 
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At baseline 54% of patients tested positive for heroin at their review appointment. Some 
58.9% tested positive for diazepam (29% were prescribed diazepam). 
 
Table 19. – Injecting risks (from MAP and IRQ) 
 N % Mean Median Range Min-
max 
SD 
IRQ - Any injecting/28 days (537) 
yes 87 16.2      
never 450 83.8      
Days injected/30 
(616) 
  1.86 
days 
 30 0-30 6.14 
Times/day injected 
(613) 
  0.26 
times 
 5 times 0-5 0.70 
IRQ – sharing/28 days (82) 
Never 67 81.7      
Sometimes 11 13.4      
Frequently 4 4.9      
Days shared/30 
(613) 
  0.08 
days 
 30 0-30 1.24 
 
Only 87 cases (16.2%) reported any injecting at all. Of those who injected, most injected 
rarely with mean injecting days of 1.86 days of the last 30 (SD 6.14). Range was 0-30 days 
meaning that daily injecting was occurring in a minority. Mean frequency of daily injecting 
was 0.26 injections/day (range 0-5 times; SD 0.70). Over 80% stated they never shared with 
only 4.9% stating they shared frequently. 
 
2. Comorbidity assessment at 2005 baseline 
Assessments were undertaken regarding a number of common comorbidities.  Tool used 
were selected by clinical lead staff or were recommended by local experts. 
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Table 20. Pain – Brief Pain Inventory 
 N % mean Median  Mode Min-max SD 
Pain problem (522) 
Yes 300 57.5      
No 222 42.5      
Duration–months  
(295) 
  77.82 48 120 0-384 77.07 
Chronic @ 6/12 (296) 
yes 258 87.2      
no 38 12.8      
Chronic @ 12/12 (296) 
Yes  238 80.4      
no 58 19.6      
Intensity score (624)   76.78 60 50 0-100 21.865 
Severity quintiles (296) 
1st 13 4.4      
2nd 41 13.9      
3rd 97 32.8      
4th 97 32.8      
5th 48 16.2      
Location (299) 
Multiple sites 64       
Back 78       
Head/neck/shoulders 26       
Chest 15       
Abdomen/liver 32       
Arms/hands 9       
Legs/feet 73       
Characteristics 
Pain before SUD? Yes 51 18      
SUD before Pain? Yes 58 20.6      
Affects sleep 233 77.9      
Affects ADL 207 72.1      
Medical treatment 
Saw doctor for pain 227 76.7      
Type of doctor 
GP 134 62.3      
Pain specialist 17 7.9      
Other 64 29.8      
Taken seriously 138 61.1      
Prescribed opiate for 
pain 
41 16.4      
Prescribed 
benzodiazepine  
3 1.2      
 
Pain was common in the baseline population with 57.5% of those asked reporting a problem 
with pain (Table 20). Pain was reported as  long lasting with mean duration of pain reported 
as 77.82 months (range 0-384 months; SD 77.07). Of those experiencing pain, 80.4% would 
be defined as “chronic” using the commonly-used 12 month cut-off. Pain was reported as 
severe. In the BPI intensity score (ranges from 0-100) the mean score was 76.78 (range 0-
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100; median 60; SD 21.87). Pain affected many areas of the body with the back, lower limbs 
and multiple sites the most common. Pain was reported as preceding substance misuse in 
18% with 20.6% reporting substance misuse before onset of their pain. Pain affected many 
activities with 77.9% reporting it affected sleep and 72.1% reporting an effect on basic 
activities of daily living. Some 62.3% reported seeing a doctor to address their pain problem 
but only 7.9% had ever seen a pain specialist. Some 61% of those seen by a doctor felt their 
pain was taken seriously but only 16.4% had been prescribed an opiate for their pain. 
 
Some 300 cases (58.4% of 514 interviewed) scored above the likert threshold for “caseness” 
in the GHQ28 (Table 21). 
 
Table 21. Psychiatric “caseness” - General Health Questionnaire (GHQ28) 
 N % Mean median Mode Min-
max 
SD 
Total score (514)   28.11 26 21 1-78 13.609 
Likert threshold for caseness: 23/24 (514) 
Yes - caseness 300 58.4      
No - caseness 214 41.6      
 
Some 215 (40% of 539 interviewed) received a diagnosis of Social Phobia based on the 
threshold of 21/22 (Table 22). 
 
Table 22. Social Phobia – Social Phobia Diagnostic Questionnaire (SPDQ) 
 N % Mean median Mode Min-
max 
SD 
Total score (539)   6.88 0 0 0-27 8.587 
Likert threshold for social phobia: 21/22  
Yes - caseness 215 40%      
No - caseness 323 60%      
 
 
Using this version of the Impact of Events Scale, 280 cases (48% of the 601 assessed at 
baseline) have a high likelihood of having a form of Post -Traumatic Stress Disorder, based 
on the likert threshold of 26 for caseness (Table 23). 
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Table 23. PTSD - Impact of Events Scale (IES) 
 N % Mean median Mode Min-
max 
SD 
Total score (601)   23.90 19 0 0-75 24.981 
Likert threshold for caseness: 26 
Yes - caseness 280 48%      
No - caseness 299 52%      
Avoidance score    14.04 14.00 0 0-65 13.390 
Intrusion score    13.06 13.00 0 0-35 12.383 
 
ADHD screening was one of the areas lost due to time pressures. Consequently, only 368 
cases were interviewed using the Current Symptoms scale.  Of these, only 59 cases (16%) 
were felt to have symptoms of ADHD with the majority in the “inattentive” group (Table 24). 
 
Table 24. ADHD – Current Symptoms Scale (CSS) 
Presence/type of ADHD N % 
Any ADHD? (n=368) 
No ADHD 309  
ADHD present 59 16% 
Type of ADHD (59) 
Inattentive 31 52.5% 
Hyperactive/impulsive 8 13.6% 
Combined 20 33.9% 
 
 
Discussion and conclusions – descriptive data 
 
The Tayside Methadone Cohort consists of 623 existing cases in OST- M treatment for the 
management of opiate dependency across a Scottish region – Tayside - comprising one city 
(Dundee) and two counties – Angus and Perth and Kinross. The sample represents some 
76% of those in receipt of OST- M in the region. The cases were included if interviewed in 
the calendar year 2005 (February to December). Tests show the sample to differ from those 
not assessed in terms of methadone dose, age and gender distribution. This may reflect that 
those who were difficult to engage differed significantly from the sample. 
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Demographics 
The sample is 68.4% male with a mean age of 32.96 (SD 7.746). 61.6% of the sample lives in 
Dundee City, 22.6% in Angus and 15.8% Perth & Kinross. The sample is exposed to high 
levels of deprivation with 77.7% living in the two most deprived health board area quintiles. 
Some 39.7% have lived at their current address for over 3 years while 33.3% have lived 
there for less than 1 year. Some 443 (75.7%) are parents of 851 children while 232 (37.7%) 
report that they live alone. Some 44% had no contact with their partner in the previous 30 
days. 
 
Educational attainment was poor with over 50% having no qualifications at all and over 60% 
of those with any qualifications having only achieved standard grades. Few were in paid 
work with those who were working reporting a mean of only 2 days per month in active 
employment. 
 
Healthcare 
Only 87% were registered with a GP. Despite this, 52% reported having physical health 
problems of which only 60% were receiving treatment. Mean MAP physical health score was 
14.2 (SD 7.98) suggesting that in general physical health problems were mild/moderate. 
Some 49.7% reported mental health problems of which 69% were being treated. Only 30% 
were receiving support from other agencies (for themselves or their children) outside the 
NHS specialist treatment agencies. 
 
Treatment for substance misuse 
Though the cohort was identified via methadone prescribing information systems, only 97% 
of the cohort was currently prescribed methadone when assessed. This is likely to reflect a 
natural fluctuation of those on prescriptions – either though successful detoxification or loss 
of a community prescription for some clinical reason (e.g. imprisonment; hospital 
admission; failure to attend to access a script etc.). The most commonly prescribed dose of 
methadone was relatively low at 50mg with the mean dose of 49.54mg (SD 25.25). The 
maximum dose was 170mg. Some 29% of subjects were also being prescribed diazepam – 
often as a detoxification agent but some would be “maintenance” prescriptions. The 
information contained within the database could not determine which group an individual 
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patient would be in. Treatment was being delivered in three settings: NHS specialist service 
(TDPS) – 47.4%; Criminal Justice services (DTTO and TARS) – 14.8%; General Practice Shared 
Care – 24.8%. At baseline 54% of patients tested positive for heroin at their review 
appointment. Some 58.9% also tested positive for diazepam (only 29% were prescribed). 
However, only 16% of subjects reported any injecting. Of those, over 80% stated they never 
shared injecting equipment, with only 4.9% stating they shared frequently. 
 
Comorbidities 
Chronic pain: This was a common complaint with 57.5% stating they had a pain issue. Pain 
was long lasting. Mean duration of pain was 77.8 months (SD 77.07) and 80.4% would be 
described as “chronic” at the 1 year cut-off. Pain was severe. In the BPI intensity score, 
mean score was 76.68/100 (SD 21.87). Pain affected many activities of daily living. Over 60% 
had seen a doctor about their pain but only 7.9% had seen a pain specialist. Only 16.4% had 
been prescribed an opiate for their pain. 
 
Mental health “caseness” and other issues: of the 514 assessed using the GHQ28, 300 
(58.4%) scored above the Likert scale threshold for “caseness”. 
 
Social Phobia: Of 539 interviewed, 215 (40%) scored above the SPDQ diagnostic threshold. 
 
PTSD: 601 were interviewed using the IES scale.  Of these some 280 (48%) scored higher 
than the threshold of  26 for “caseness”. Mean score was 23.9 (SD 24.981). 
 
ADHD: The current symptoms scale assessed 368 subjects. Only 16% had symptoms 
suggestive of ADHD. Using this tool, the majority would be classed as “inattentive”. 
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Chapter 6 
Results: Follow – up 1.  
Clinical casenote review, 2009 
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Figure 8. Follow up – Clinical casenote review - 2009 
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Process - Follow up analyses 1. Clinical casenote review 2009 
 
Introduction 
This chapter describes the first follow up element of the study. Figure 8. illustrates the data 
sources of data used in these analyses. 
 
In 2008, NHS Tayside research & Development (R&D) office offered an opportunity to bid 
for small grants to support the development of information systems in specific clinical areas 
seen as NHS priorities. These were generally areas which were experiencing waiting time 
delays or quality concerns. The researchers successfully bid for an R&D grant to deliver a 
follow-up study of the sample described as the “Tayside Methadone Cohort” from 2005. 
 
Process 
The original Tayside Methadone Cohort sample from 2005 was used as the basis of the 
study. It was first planned to use follow up interviews using the Maudsley Addiction Profile 
(MAP), Injection Risk Questionnaire (IRQ) and Treatment Perception Questionnaire (TPQ) to 
demonstrate objective changes in the baseline sample regarding their illicit drug use, risk 
taking and associated sequelae. The study received Ethics Committee and Caldicott 
Guardian approval and proceeded in the autumn of 2009. Unfortunately, attendance at the 
follow up assessments was extremely poor and this issue threatened the value of the study. 
Consequently, the researchers obtained permissions to alter the data collection process 
and, instead, collected data from the NHS clinical casenotes.  
 
Data collection 
The medical records were made available to the researcher in the clinical service bases. This 
reduced the likelihood of the research obstructing clinical practice and also increased 
accessibility of as much information as was available. The clinical information was collected 
using a data-collection pro-forma (Figure 5 – p125). Clinical notes recorded in the calendar 
year 2009 were examined. 
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Data quality and validity 
The quality of clinical casenote recording was found to be inconsistent in many clinical 
services. Some records to be accessed were also from non-NHS services (e.g. Drug 
Treatment & Testing Order and Arrest Referral Schemes) making quality assurance an issue. 
It was recognised that this raised a potential risk to the study. In response, 3 priority levels 
for data collection were created – reflecting the likely quality of data available.  The 
researcher was advised to use the highest level of information available for completion of 
the data collection tool. If conflicting or confusing information was found this was discussed 
with the project lead clinician.  If the true nature of the status of a case could not be agreed 
and this was unresolvable, information was defined as “missing”. 
The priority levels used were as follows: 
 Level 1: The highest level included any validated assessment tools completed by 
staff. Examples included the MAP and associated forms; Treatment Outcome Profile 
(TOP). This tool had been introduced as a follow up measure of outcome in the 
service. It was preferred by clinicians because of its brevity (compared to the MAP). 
New cases (or those returning after an absence of 6 months) would also have a 
Scottish Morbidity Record (SMR) 25 completed. A copy is often held in the 
casenotes. Completion of this document is mandatory across Scotland and is the 
basis of national statistics - making it a likely source of valid information from the 
casenote. 
 Level 2: The next level included formal reports /correspondence relating to hospital 
admissions, the criminal justice system (often a source of background reports) and 
child protection. Included in this level were care plans – completed by keyworkers at 
regular case reviews or on discharge. These were only included if the service 
proforma  – which objectively assessed a number of areas of progress in a case -   
was completed. 
 Level 3:  The lowest level accepted was contemporaneous handwritten notes.  
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Data entry and cleaning 
The information collected on the proforma, which had unique identifiers, allowing matching 
with the Tayside Methadone Cohort baseline data, was input into a bespoke database built 
in SPSS version 18 (IBM 2010). The data was initially held in an encrypted form on a secure 
hard drive which was password protected and stored in a locked cupboard in the 
Department of Psychiatry, University of Dundee Medical School.  
 
Data – linkage: SUMIT project and HIC Safe Haven 
In Autumn of 2010, the SUMIT project was launched. The project is described in detail in 
Chapter 7.  Associated papers are contained in Appendix 3. SUMIT engaged the support of 
the Health Informatics Centre (HIC) and, as part of this project, data were migrated into the 
HIC “Safe Haven” – a virtual environment where data is held securely with a new, unique 
identifier or “Prochi”. The data can then be linked with other relevant clinical data. The 
Tayside Methadone Cohort (2005) data and 2009 casenote follow up data were migrated  
into the HIC Safe Haven in Spring 2011. All subsequent data handling took place in that 
secure environment. 
 
Analyses 
The data used in these analyses were: 
 Data collected at the baseline assessment interview in 2005  
 Data collected at the casenote review of 2009 
The literature review described in Chapter 3, informed the development of an analysis plan, 
using data available in the linked dataset to assess the individual impact of a range of 
predictor variables (independent variables) on a range of process measures or outcomes 
(dependent variables). The variables chosen for this analysis are shown in Tables 25 and 26. 
 
The generic research question being addressed in this case is: 
Does (baseline - independent variable) impact on (follow up - dependent variable)? 
From this, a null hypothesis can be generated: 
Baseline (independent variable) does not impact on follow up (dependent variable) 
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Table 25.–independent and dependent variables – patient characteristics (casenote review) 
 
Predictor Variable (Independent) at baseline Dependent variable (2009 casenote review) 
Demographics Process measures 
Age Retained on treatment  - 4 years 
Gender If discharged positive or negative  discharge  
Home District Methadone dose 
Deprivation score (NHS Board SIM-D) Diazepam dose 
Social stability  Regular drug screen done 
Time at address Outcome measures 
Lives alone Employment status 
Has children Family stability 
Lives with children Any illicit drug use 
MAP Conflict scores –partner; family; friends Heroin use reported 
Educational level achieved Heroin use (days) 
Days in paid work Heroin use (route) 
Treatment status Diazepam use 
Provider (Specialist; GP; CJS) Diazepam days 
Registered with GP Illicit methadone use 
Support from other agency Illicit methadone days 
MAP Physical health score Illicit painkiller (opiate) use 
MAP Psychological health score Illicit painkiller days 
Prescribed methadone dose Test  positive opiates 
Prescribed diazepam dose Test positive benzodiazepines 
TPQ patient satisfaction score Acute hospital admissions reported 
Illicit drug use Psychiatric hospital admissions reported 
Any heroin use Incarceration reported 
Extent of use (“Days used”)  
Route 
Risk taking (IRQ score) 
Illicit benzodiazepine use 
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Table 26. –independent and dependent variables - comorbidities  (casenote review) 
 
Predictor Variable (Independent) at baseline Process (Dependent variable) 
Co-morbidities Process measures 
Psychiatric caseness Retained on treatment  - 4 years 
GHQ 28 Caseness If discharged – positive or  negative 
GHQ 28 Total score Methadone dose 
Chronic Pain Diazepam dose 
BPI-Pain presence Regular drug screen done 
BPI-Pain duration Outcome measures 
BPI-Pain chronicity (12/12 cut off) Employment status 
BPI-Pain intensity (score) Family stability 
BPI-Pain intensity (quintiles) Any illicit drug use 
Anxiety disorders Heroin use reported 
Social phobia diagnosis (as SPDQ) Heroin use (days) 
PTSD caseness (IES cut off 26) Heroin use (route) 
PTSD severity (IES total score) Diazepam use 
ADHD Diazepam days 
ADHD Symptoms (CSS) Illicit methadone use 
ADHD type (CSS) Illicit methadone days 
ADHD impairment (CSS) Illicit painkiller (opiate) use 
 Illicit painkiller days 
Test  positive opiates 
Test positive benzodiazepines 
Acute hospital admissions reported 
Psychiatric hospital admissions reported 
Incarceration reported 
 
Statistics 
When both independent and dependent variables were categorical - Chi-squared tests were 
undertaken. For categorical independent and continuous dependent variables, an ANOVA 
was used (if data were parametric). If not, the Kruskall-Wallis H-test or Mann-Whitney U-
test (for binary data) were used. 
 
For continuous independent variables with categorical dependent variables, discriminant 
analyses were used. If the DV/IV relationship was linear, linear discriminant analyses were 
used. If not, quadratic discriminant analyses were used. 
 
When both independent and dependent variables were continuous – linear regression 
analyses were undertaken. 
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Addressing Multiple Testing 
The issue of multiple testing has been discussed in Chapter 4.  There is a risk of 
overestimating the significance of results when large numbers of tests are being 
undertaken. There are a number of ways a Bonferroni Correction could be applied 
(Toothaker 1993).  
 
As has been described in Chapter 4, the Bonferroni Correction involves dividing the 
accepted significance level (p-value) by the number of repeat tests. In these datasets, there 
are 22 individual analyses being undertaken using each Independent Variable. Statistical 
significance is being defined at the p= 0.05 level. Using the Bonferroni Correction, involving 
all of the analyses, this would require statistical significance to be accepted only at the 
p=0.002 level for all analyses.  
 
Alternatively, however, it could be argued that a number of discrete groups of tests are 
being undertaken and using the Bonferroni Correction as described above would reduce the 
statistical power of the tests – increasing the likelihood of a false negative result (Type 2 
error). In fact only 5 tests per Independent Variable relate to a Dependent Variable (DV) 
regarding measures of the treatment process; 2 tests relate to a social functioning (DV); 12 
relate to any drug use [4 – heroin; 3 diazepam; 2 methadone; 2 other opiates]; 3 relate to 
the outcomes of admissions or incarcerations. If this approach were applied, more 
appropriate significance levels can be determined which reduce the likelihood of  Type 2 
error. The significance levels are shown in Table 27. 
 
These corrections were applied when considering the relevance of any associations 
demonstrated. 
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Table 27. Bonferroni Correction – significance by Dependent Variable 
Dependent Variable Number of analyses Significance level 
Process Measures 
Retained on treatment  - 4 years  
 
5 
 
 
0.01 
If discharged – positive or  
negative 
Methadone dose 
Diazepam dose 
Drug screen done 
Social functioning 
Employment status  
2 
 
0.025 Family stability 
Drug use  
All drugs 12 0.0041 
Heroin 4 0.0125 
Diazepam 3 0.0167 
Methadone (Illicit) 2 0.025 
Other opiates 2 0.025 
Admissions  
General Hospital  
3 
 
0.0167 Psychiatric Hospital 
Prison 
 
Results – Clinical casenote review 2009 
 
This section describes the results of the analyses undertaken using data collected from 
clinical casenotes (n= 467) in 2009. Significant associations are shown in a series of tables – 
Tables 28-42. Tables of negative results (where no significant associations were 
demonstrated in the univariate analyses) are contained in Appendix 5.  
 
Demographic factors 
Neither gender nor deprivation score at baseline was shown to be associated with 4 year 
outcomes. 
 
Age and gender (Table 28) 
Age was found to have a significant association with the treatment process reported in 
casenotes in 2009. Younger subjects were more likely to have a drug screen undertaken 
than older subjects. Age was also associated with the recorded state of family stability. 
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Again being younger was associated with poorer family stability recorded in the casenotes. 
Complete results are shown in table 28. 
 
Table 28.  Associations: age/process & 4 year outcomes  
Independent  Variable Dependent (Process) variable Statistics Effect size 
 
Age 
 
Significant impact set at 
thep<0.05 level 
 
Significant impact at the 
appropriate level once 
Bonferroni Correction applied 
 
Retained in treatment 
Younger = better retention 
LDA X2(1)=4.412; p=0.036 
If NOT retained, +ve or –ve 
discharge (n=198) 
LDA X2(1)=0.001; p=0.977          
Drug screen done 
Younger  = more tests done 
LDA 
X
2
(1)=7.628; 
p=0.006 
Cohen’s d=-.211 
r = -0.105 
small effect size 
Methadone dose QRA t(1)=1.063; p=0.288           
Diazepam dose QRA t(1)=0.845; p=0.399            
Dependent (Outcome) variable 
Employment status LDA X2(1)=0.927; p=0.336          
Family stability 
Younger = less stable family 
LDA 
X
2
(1)=11.321; 
p=0.001 
Cohen’s d = .63 
r = 0.301 
medium effect size 
Any illicit drug use reported LDA X2(1)=1.853; p=0.173          
Heroin use reported 
Younger = more likely to use 
LDA X2(1)=5.429; p=0.020 
 
Heroin days LDAX2(5)=4.285; p=0.509      
 
Heroin route LDA X2(1)=0.092; p=0.762          
Illicit  Diazepam use 
Younger = more likely to use 
LDA X2(1)=5.301; p=0.021 
 
Illicit diazepam days LDA X2(1)=7.549; p=0.183          
Ill meth use LDA X2(1)=0.010; p=0.920          
Illicit methadone days LDA X2(3)=3.322; p=0.345          
Illicit painkillers  LDA X2(1)=1.458; p=0.227          
+ve opiates recorded LDA X2(1)=3.639; p=0.056          
+ve benzos recorded LDA X2(1)=0.439; p=0.507          
Acute admissions reported  LDA X2(1)=1.175; p=0.278          
Psych admissions reported  LDA X2(2)=0.144; p=0.931          
Prison reported  LDA X2(3)=1.331; p=0.722          
 
Place of residence (Table 29) 
Place of residence was strongly associated with a number of process measures and 
outcomes. Regarding process – Dundee residents were retained in treatment best with 
those residing in Angus retained least well.  Prescribed Diazepam dose also differentiated 
the area (despite the whole region using the same prescribing protocols). Angus subjects 
had the highest prescribed diazepam doses, Dundee the lowest. Regarding outcomes – 
Dundee subjects reported less illicit drug use overall (P&K was poorest) and had better 
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recorded family stability (Angus was poorest). Subjects from Dundee & Angus showed more 
illicit diazepam use (through recorded drug testing) than those from P&K.  
 
Table 29. Associations: place of residence/process and 4 year outcomes 
Independent (Predictor) Variable Dependent (Process) variable Statistics Effect size 
 
Residence 
 
Significant impact set at 
thep<0.05 level 
 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention (Yes 156) 
Dundee>P&K>angus= retained 
Chi square 
X
2
(2)=11.352; 
p=0.003 
Cramer’s v=.164 
p=0.003 
Substantial 
relationship  
If NOT= +ve or –ve discharge 
Negative P&K>Angus>Dundee 
Chi square X
2
(6)=14.435; p=0.025 
 
Drug screen done (D>P>A) Chi square X
2
(4)=11.342; p=0.023 
Methadone dose (A>D>P) KWH X
2
(2)=8.409; p=0.015 
Diazepam dose 
Higher dose= Angus>P&K>Dundee 
KWH 
X
2
(2)=9.660; 
p=0.008 
Partial 
2
  = .014 
Small effect size 
 
Dependent (Outcome) variable  
Employment status Chi square X
2
(2)=0.820; p=0.664 
Family stability 
Dundee>P&K>Angus 
Chi square 
X
2
(4)=20.796; 
p<0.001 
Cramer’s v = .157 
P=.004 
Substantial 
relationship 
Any illicit drug use reported 
P&K>Angus>Dundee 
Chi square 
X
2
(6)=18.917; 
p=0.004 
Cramer’s v = .149 
P=.004 
Substantial 
relationship 
Heroin use reported (A>P>D) Chi square X
2
(6)=14.102; p=0.029 
Heroin days (A>P>D) Chi squareX
2
(16)=30.946; p=0.014 
Heroin route Chi square X
2
(8)=14.266; p=0.075 
Illicit Diazepam use 
Dundee=Angus>P&K 
Chi square 
X
2
(6)=21.583; 
p=0.001 
Cramer’s v = .160 
p=0.001 
Substantial 
relationship 
Illicit Diazepam days Chi square X
2
(16)=24.491; p=0.079 
Illicit Methadone use (D=A>P) Chi square X
2
(6)=12.763; p=0.047
 
Illicit Methadone days Chi square X
2
(12)=18.697; p=0.096
 
Illicit painkillers **25 cases 
Angus>Dundee>P&K 
Chi square 
X
2
(6)=16.932; 
p=0.010 
Cramer’s v=.141 
P=0.010 
Substantial 
relationship 
+ve opiates tests Chi square X
2
(8)=14.531; p=0.069 
+ve benzodiazepine tests 
Dundee>Angus>P&K 
Chi square 
X
2
(6)=35.621; 
p<0.001 
Cramer’s v = .160 
P=.004 
Substantial 
relationship 
Acute admissions reported  
Angus>P&K>Dundee 
KWH 
X
2
(2)=2.842; 
p=0.241 
 
Psych admissions reported  
Angus>P&K>Dundee 
KWH 
X
2
(2)=0.776; 
p=0.678 
 
Prison reported  
Angus>P&K>Dundee 
KWH 
X
2
(2)=0.449; 
p=0.799 
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Social stability at baseline 
Most factors describing baseline social stability showed no associations with outcomes. 
These factors included: time at current address; living status (alone/not); living with their 
children; educational level attained; days in paid work. Some factors did show significant 
associations. 
 
Children (Table 30) - Having children recorded at baseline was found to have negative 
associations with 2009 status. Having children was associated with negative discharge being 
recorded and with notes recording poor family stability. 
Table 30. Associations: having children/process and 4 year outcomes 
Independent Variable Dependent (Process) variable Statistics Effect size 
 
Has children 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  Chi square X
2
(1)=0.442; p=0.506 
Pos/neg discharge  
Kids predict negative discharge 
Chi 
squareX
2
(1)=11.194; 
p=0.001 
Cramer’s v=.167 
P=0.011 
Substantial 
relationship 
Drug screen done Chi square X
2
(2)=3.466; p=0.177 
Methadone dose KWH X
2
(1)=1.946; p=0.163 
Diazepam dose KWH X
2
(1)=1.407; p=0.236 
Dependent (outcome) variable 
Employment status Chi square X
2
(5)=7.520; p=0.185 
Family stability  
Kids negative predictor of stability 
Chi square 
X
2
(2)=7.723; 
p=0.021 
Cramers v=.136 
P=0.025 
Substantial 
relationship 
Any illicit drug use reported Chi square X
2
(3)=3.812; p=0.283 
Heroin use reported; days; 
route 
Chi square X
2
(3)=1.634; p=0.652 
Chi square X
2
(8)=12.531; p=0.129 
Chi square X
2
(4)=1.063; p=0.900 
Ill Diazepam use; days; Chi square X
2
(3)=0.856; p=0.836 
Chi square X
2
(8)=14.243; p=0.076 
Ill meth use; days;  Chi square X
2
(3)=0.805; p=0.848 
Chi square X
2
(6)=4.027; p=0.673 
Illicit painkillers days Chi square X
2
(3)=0.864; p=0.834 
Chi square X
2
(4)=1.070; p=0.899 
+ve opiates Chi square X
2
(4)=1.240; p=0.871 
+ve benzos Chi square X
2
(3)=1.1085;  p=0.781 
Acute admissions reported  KWH X
2
(1)=0.590; p=0.443 
Psych admissions reported  KWH X
2
(1)=0.208; p=0.648 
Prison reported  KWH X
2
(1)=0.539; p=0.463 
 
MAP Partner, relative and friend conflict scores (Table 31) - Having higher conflict scores 
recorded at baseline was associated with 4 year outcomes. A higher Friends conflict score 
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was associated with more illicit diazepam and illicit methadone use. A higher partner 
conflict score was associated with more illicit methadone days used recorded at follow up. 
Table 31.  Associations:  MAP conflict scores/process and 4 year outcomes 
Independent (Predictor) Variable Dependent  variable Statistics Effect size 
 
MAP conflict scores: 
1. Partner 
2. Relative 
3. Friends 
 
Significant impact set at the 
p<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  1.LDA  X2(1)=0.146; p=0.702 
2.LDA  X2(1)=0.532; p=0.466 
3.LDA  X2(1)=0.711; p=0.399 
Positive/negative discharge 1. LDA X2(1)=1.814; p=0.178 
2. LDA X2(1)=2.015; p=0.156 
3. LDA X2(1)=0.400; p=0.527 
Drug screen done 1.LDA  X2(1)=0.345; p=0.557 
2.LDA  X2(1)=0.610; p=0.435 
3.LDA  X2(1)=1.667; p=0.197 
Methadone dose 1.LRA t(1)=-1.384; p=0.167 
2.LRA t(1)=-0.387; p=0.699 
3.LRA t(1)=0.798; p=0.425 
Diazepam dose 1.LRA t(1)=-0.597; p=0.551 
2.LRA t(1)=-0.738; p=0.461 
3.LRA t(1)=0.669; p=0.504 
Employment status 1.LDA  X2(1)=0.030; p=0.862 
2.LDA  X2(1)=0.932; p=0.334 
3.LDA  X2(1)=0.249; p=0.618 
Family stability 1.LDA  X2(1)=2.884; p=0.089 
2.LDA  X2(1)=0.648; p=0.421 
3.LDA  X2(1)=0.040; p=0.841 
Any illicit drug use reported 1.LDA  X2(1)=0.039; p=0.844 
2.LDA  X2(1)=0.002; p=0.967 
3.LDA  X2(1)=0.443; p=0.506 
Heroin use reported 1.LDA  X2(1)=0.960; p=0.327 
2.LDA  X2(1)=0.006; p=0.936 
3.LDA  X2(1)=0.277; p=0.598 
Heroin days 1.LDA  X2(5)=8.281; p=0.141 
2.LDA  X2(5)=2.798; p=0.731 
3.LDA  X2(5)=0.649; p=0.986 
Heroin route 1.LDA  X2(1)=0.017; p=0.895 
2.LDA  X2(1)=1.315; p=0.252 
3.LDA  X2(1)=0.897; p=0.344 
Ill Diazepam use; days (of 90); 
 
1.LDA  X2(1)=0.049; p=0.825 
2.LDA  X2(1)=1.279; p=0.258 
3.LDA  X2(1)=2.094; p=0.148 
Illicit diazepam days 
Higher PCS  score predicts less 
days use 
Higher FCS predicts more days 
used 
1.LDA  X2(5)=11.547;  
p=0.042 
2.LDA  X2(5)=4.904; p=0.428 
3.LDA X2(5)=22.927; 
p<0.001 
 
 
 
 
Partial 
2
  = .019 
Small effect size 
Illicit  methadone use  
Higher FCS predicts illicit use 
1.LDA  X2(1)=0.001; p=0.975 
2.LDA  X2(1)=2.684; p=0.101 
3.LDA  X2(1)=11.903; 
p=0.001 
 
 
Partial 
2
  = .017 
Small effect size 
Illicit methadone days 
Higher PC score predicts more 
days used 
 
1.LDA  X2(3)=11.096; 
p=0.011 
2.LDA  X2(3)=7.266; p=0.064 
3.LDA  X2(3)=3.461; p=0.326 
Partial 
2
  = .092 
Medium effect 
size 
 
+ve opiates 1.LDA  X2(1)=0.415; p=0.519;  2.LDA  X2(1)=0.112; 
p=0.738; 3.LDA  X2(1)=0.064; p=0.800 
+ve benzos 1.LDA  X2(1)=0.053; p=0.818; 2.LDA  X2(1)=0.036; 
p=0.850; 3.LDA  X2(1)=0.000; p=0.999 
Acute admissions reported  1.LRA t(1)=-0.419; p=0.676; 2.LRA t(1)=-0.727; 
p=0.468; 3.LRA t(1)=0.831; p=0.406 
Psych admissions reported  1.LRA t(1)=-0.417; p=0.677; 2.LRA t(1)=-0.724; 
p=0.469; 3.LRA t(1)=0.833; p=0.405 
Prison reported  1.LRA t(1)=-0.392; p=0.695; 2.LRA t(1)=-0.704; 
p=0.482; 3.LRA t(1)=0.850; p=0.396  
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Educational attainment (Table 32) - The level of educational attainment achieved was 
recorded at baseline. It was found that this was associated with recording of acute and 
psychiatric admissions in casenotes.  Perhaps surprisingly, those who had attained a level of 
education/training which was an apprenticeship or higher were more likely to have hospital 
admissions recorded in their casenotes. 
 
Table 32.  Associations: Educational level achieved/process and 4 year outcomes 
Independent  Variable Dependent (Process) variable Statistics Effect size 
 
Educational level achieved 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  Chi square X
2
(4)=11.870;p=0.018 
More s =less  retention 
Positive/negative discharge Chi square X
2
(4)=3.133; p=0.536 
Drug screen done Chi square X
2
(8)=9.298; p=0.318 
Methadone dose KWH X
2
(4)=8.631; p=0.0.071 
Diazepam dose KWH X
2
(4)=9.212; p=0.056 
Dependent (outcome) variable  
Employment status Chi square X
2
(4)=2.316; p=0.678 
Family stability Chi square X
2
(8)=12.395; p=0.134 
Any illicit drug use reported Chi square X
2
(12)=17.052; p=0.148 
Heroin use reported Chi square X
2
(12)=18.321; p=0.106 
Heroin days Chi square X
2
(32)=37.535; p=0.230 
Heroin route Chi square X
2
(16)=20.460; p=0.200 
Ill Diazepam use Chi square X
2
(12)=14.883; p=0.248 
Illicit diazepam days Chi square X
2
(32)=22.167; p=0.903 
Illicit methadone use  Chi square X
2
(12)=17.233; p=0.141 
Illicit methadone days Chi square X
2
(24)=17.659; p=0.819 
Illicit painkillers  Chi square X
2
(12)=15.212; p=0.230 
Illict painkillers days Chi square X
2
(16)=19.781; p=0.230 
+ve opiates Chi square X
2
(16)=14.454; p=0.565 
+ve benzos Chi square X
2
(12)=12.245; p=0.426 
Acute admissions reported 
Apprentice= >admissions 
KWH (4)=15.447; 
p=0.004 
Monte carlo sig  
test =.003 
99% CI .002-.005 
Likely effect 
Psych admissions reported 
Apprentice= >admissions 
KWH(4)=14.782; 
p=0.005 
Monte carlo sig  
test =.004 
99%ci=.002-.005 
Likely effect 
Prison reported  KWH(4)=10.638; p=0.31 
Apprentice= >incarcerations 
 
Treatment status (Services received at baseline) 
Factors relating to the service received at baseline were found to be associated with 
outcome at 4 years.  
Treatment setting  (Table 33)  Regarding Process:  specialist services (NHS and Criminal 
Justice) were more likely to retain patients in treatment than GPs.  Criminal Justice services 
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(CJS) recorded more drug screens. Regarding outcomes: specialist services recorded more 
evidence of family stability. GP patients were considerably more likely to have injecting and 
any admissions recorded (including incarcerations). CJS patients were most likely to report 
heroin and illicit diazepam use but least likely to report injecting. Illicit methadone use was 
most likely to be recorded in specialist NHS service whose cases were least likely to test 
positive for opiates or benzodiazepines. 
Table 33.  Associations: treatment setting/process and 4 year outcomes 
Independent (Predictor) Variable Dependent (Process) variable Statistics 
 
GP or specialist setting 
(+CJS) 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention Specialist>GP Chi square 
X
2
(2)=10.902; 
p=0.004 
Cramer’s v=.163 
p=0.004 
Relevant Effect 
Pos/neg discharge Chi square X
2
(2)=3.593; p=0.166 
Drug screen done CJS>TDPS>GP Chi square 
X2(4)=14.019; 
p=0.007 
Cramer’s V=.131  
p=0.007 
Small effect 
Methadone dose Anova F(2,8)=3.093; p=0.046 
Diazepam dose Anova F(2,8)=0.927; p=0.397 
Dependent (outcome) variable  
Employment status Chi square X
2
(12)=20.024; p=0.067 
Family stability Specialist>GP Chi square 
X2(4)=12.301; 
p=0.015 
Cramer’s v=.123 
p=0.015 
Relevant Effect 
Any illicit drug use reported Chi square X
2
(6)=12.093; p=0.060 
Heroin use reported CJS>GP>TDPS Chi square 
X2(6)=20.392; 
p=0.002 
Cramer’s v=.158 
p=0.002 
Relevant Effect 
Heroin days Chi square X
2
(16)=26.067; p=0.053 
Heroin route GP IV ++>TDPS>CJS Chi square 
X2(8)=26.233; 
p=0.001 
Cramer’s V=.179 
p=0.001 
Relevant Effect 
Illicit Diazepam use CJS>GP>TDPS Chi square 
X2(6)=17.906; 
p=0.006 
Cramer’s V=.148 
p=0.006 
Relevant Effect 
Illicit diazepam days Chi square X
2
(16)=25.021; p=0.069 
Illicit methadone use 
TDPS<GP+CJS 
Chi square 
X2(6)=21.325; 
p=0.002 
Cramer’s  v=.162 
p=0.002  
Relevant Effect 
Illicit methadone days  
TDPS <GP/CJS 
Chi square 
X2(10)=22.283; 
p=0.014 
Cramer’s V=.165 
p=0.014 
Relevant Effect 
Illicit painkillers  Chi square X
2
(6)=13.621; p=0.034 
Illicit painkillers days Chi square X
2
(8)=12.559; p=0.128 
+ve opiates CJS>GP>TDPS Chi square 
X2(6)=19.642; 
p=0.003 
Cramer’s V=.155 
p=0.003 
Relevant Effect 
+ve benzos CJS>GP>TDPS Chi square 
X2(6)=22.884; 
p=0.001 
Cramer’s v =.167 
p=0.001 
Relevant Effect 
Acute admissions reported  
GP>TDPS>CJS 
ANOVA F(2,8)=5.619; 
p=0.004 
Partial 
2
  = .027 
Small effect 
Psych admissions reported 
GP>TDPS>CJS 
ANOVA F(2,8)=5.368; 
p=0.005 
Partial 
2
  = .026 
Small effect 
Prison reported  
GP>TDPS>CJS 
ANOVA F(2,8)=4.888; 
p=0.008 
Partial 
2
  = .024 
Small effect 
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Registration with a General Practitioner (Table 34) - Being registered with a GP at baseline 
showed consistent associations with some markers of stability at 4 year follow up. Those 
registered with a GP in 2005 were more likely to be employed, had more evidence of family 
stability recorded in their casenotes and also had less opiate positive drug tests recorded. 
 
Table 34. Associations: GP registration at baseline/process and 4 year outcomes 
Independent  Variable Dependent variable Statistics Effect size 
 
Registered with GP 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  Chi square X
2
(1)=5.353; p=0.021 
Pos/neg discharge Chi square X
2
(1)=0.115; p=0.735 
Drug screen done Chi square X
2
(2)=3.594; p=0.166 
Methadone dose KWH X
2
(1)=0.268; p=0.605 
Diazepam dose KWH X
2
(1)=4.668; p=0.031 
GP predicts lower dose 
Dependent (outcome) variable  
Employment status  
GP predicts better employment 
Chi square 
X
2
(6)=17.800; 
p=0.007 
Cramer’s V=.195 
p=0.007 
Relevant effect 
Family stability  
GP predicts family stability 
Chi square 
X
2
(2)=8.973; 
p=0.011 
Cramer’s V=.139 
p=0.011 
Relevant effect 
Any illicit drug use reported Chi square X
2
(3)=6.792; p=0.079 
Heroin use reported; days; route Chi square X
2
(3)=7.459; p=0.059 
Heroin days Chi square X
2
(8)=9.956; p=0.268 
Heroin route Chi square X
2
(4)=10.551; p=0.032 
GP predicts less injecting 
Illicit Diazepam use Chi square X
2
(3)=5.638; p=0.131 
Illicit diazepam days Chi square X
2
(8)=7.089; p=0.527 
Illicit methadone use  Chi square X
2
(3)=7.344; p=0.062 
Illicit methadone days Chi square X
2
(6)=7.863; p=0.248 
Illicit painkillers  use Chi square X
2
(3)=5.604; p=0.133 
Illicit painkillers days Chi square X
2
(4)=9.063; p=0.060 
+ve opiates  
GP predicts less  +ve tests 
Chi square 
X
2
(4)=11.411; 
p=0.022 
Cramer’s V=.156 
p=0.022 
Relevant effect 
+ve benzos Chi square X
2
(3)=4.750; p=0.191 
Acute admissions reported  KWH X
2
(1)=4.657; p=0.031 
GP predicts more admissions 
Psych admissions reported  KWH X
2
(1)=4.822; p=0.028 
GP predicts more admissions 
Prison reported  KWH X
2
(1)=5.661; p=0.017 
GP predicts more incarcerations 
 
Support from other agencies (Table 35) - Subjects reported if they or their children were in 
receipt of additional support from external agencies in the third sector or from the local 
authority at baseline. The records of those who reported they were being supported 
showed more recorded evidence of family stability at 4 year follow up. 
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Table 35. Associations: agency support at baseline/process and 4 year outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics Effect size 
 
Support from other agencies 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  Chi square X2(1)=1.414; 
p=0.234 
Pos/neg discharge Chi square X2(1)=0.186; 
p=0.667 
Drug screen done Chi square X2(2)=1.101; 
p=0.577 
Methadone dose KWH X2(1)=0.185; p=0.667 
Diazepam dose KWH X2(1)=3.057; p=0.080 
Dependent (outcome) 
variable 
 
Employment status Chi square X2(5)=7.083; 
p=0.215 
Family stability 
>support predicts stability 
Chi square 
X
2
(2)=7.712; 
p=0.021 
Cramer’s V=.149 
p=0.021 
Relevant effect 
Any illicit drug use reported Chi square X2(3)=1.973; 
p=0.578 
Heroin use reported Chi square X2(3)=2.306; 
p=0.511 
Heroin days Chi square X2(8)=5.209; 
p=0.735 
Heroin route Chi square X2(4)=2.944; 
p=0.567 
Illicit Diazepam use Chi square X2(3)=2.886; 
p=0.410 
Illicit diazepam days Chi square X2(8)=11.402; 
p=0.180 
Illicit methadone use Chi square X2(3)=2.170; 
p=0.538 
Illicit methadone days Chi square X2(6)=10.476; 
p=0.106 
Illicit painkillers  use Chi square X2(3)=1.959; 
p=0.581 
Illicit painkillers days Chi square X2(4)=2.636; 
p=0.620 
+ve opiates Chi square X2(4)=4.059; 
p=0.398 
+ve benzos Chi square X2(3)=1.791; 
p=0.615 
Acute admissions reported KWH X2(1)=1.743; p=0.187 
Psych admissions reported  KWH X2(1)=1.726; p=0.189 
Prison reported  KWH X2(1)=2.669; p=0.102 
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Treatment status (Prescribed opiates and benzodiazepines at baseline) 
Doses of methadone and diazepam were associated with 4 year outcomes. Patients on 
higher doses of methadone were more likely to be retained and had more drug screens 
recorded. They were also less likely to screen positive for non-prescribed opioids or to be 
admitted or incarcerated (Table 36). 
Table 36. Associations: baseline methadone dose/process and 4 year outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics Effect size 
 
Methadone dose 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  
↑ dose predicts retention 
LDA 
X
2
(1)=10.643; 
p=0.001 
Cohen’s d = 0.307 
R=0.152 
Small effect size 
Pos/neg discharge LDA X2(1)=0.760; p=0.383 
Drug screen done 
↑baseline dose=↑tests 
LDA 
X
2
(1)=14.916; 
p<0.001 
Cohen’s d = 0.365 
R=0.179 
Small effect size 
Methadone dose LRA t(1)=2.521; p=0.012 
Baselinedose = ↑2009 dose 
Diazepam dose LRA t(1)=-2.119; p=0.035 
Baselinedose = ↓2009 dose 
Dependent (outcome) 
variable 
 
Employment status LDA X2(1)=0.074; p=0.785 
Family stability LDA X2(1)=0.009; p=0.924 
Any illicit drug use reported LDA X2(1)=2.307; p=0.129 
Heroin use reported LDA  X2(1)=5.360; p=0.021 
Baselinedose = ↓use 
Heroin days LDA X2(5)=1.806; p=0.875 
Heroin route LDA X2(1)=0.256; p=0.613 
Illicit Diazepam use LDA X2(3)=1.013; p=0.314 
Illicit diazepam days LDA X2(5)=5.500; p=0.358 
Illicit methadone use LDA X2(1)=0.266; p=0.606 
Illicit methadone days LDA X2(3)=0.278; p=0.964 
Illicit painkillers use LDA X2(1)=0.125; p=0.723 
Illicit painkiller days LDA X2(1)=4.751; p=0.029 
↑baseline dose=↓days 
+ve opiates 
↑baselinedose=less +ve 
LDA 
X
2
(1)=5.569; 
p=0.018 
Cohen’s d=-.321 
R=-0.158 
Small effect size 
+ve benzos LDA X2(1)=0.035; p=0.852 
Acute admissions reported 
Higher dose less admissions 
LRA t(1)=-3.448; 
p=0.001 
Partial 
2
  = .100 
Medium effect 
Psych admissions reported 
Higher dose less admissions 
LRA  t(1)=-3.466; 
p=0.001 
Partial 
2
  = .100 
Medium effect 
Prison reported 
Higher dose less  prison 
LRA t(1)=-3.432; 
p=0.001 
Partial 
2
  = .101 
Medium effect 
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The reverse was generally true for diazepam prescribing. Higher diazepam doses were 
associated with poorer retention and less evidence of drug screening having been 
undertaken. However, for those screens undertaken, a higher dose was associated with less 
positive screens for illicit opioids. Higher baseline diazepam dose was associated with a 
higher follow up methadone dose, with poorer family stability, and increased likelihood of 
admission or incarceration (Table 37).  
Table 37. Associations:  baseline diazepam prescribed dose/process and 4 year outcomes 
Independent Variable Dependent (Process) variable Statistics Effect size 
 
Diazepam dose 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  
Lower dose predicts retention 
LDA 
X
2
(1)=14.522; 
p<0.001 
Cohen’s d=-1.246 
R=-0.529 
Large effect size 
Pos/neg discharge LDA X2(1)=5.344; p=0.021 
Lower dose predicts +ve discharge 
Drug screen done  
Higher dose predicts no test done 
LDA 
X
2
(1)=16.418; 
p<0.001 
Cohen’s d= -1.067 
R=-0.471 
Large effect size 
Methadone dose  
Higher dose predicts higher dose 
LRA t(1)=3.986; 
p<0.001 
Partial 
2
  = .076 
Medium effect 
Diazepam dose LRA t(1)=-0.763; p=0.446 
Dependent (outcome) variable  
Employment status LDA X2(1)=1.437; p=0.231 
Family stability  
Higher dose predicts less stability 
LDA X
2
(1)=4.993; 
p=0.025 
Cohen’s d = 0.081 
R=0.041 
Small effect size 
Any illicit drug use reported LDA X2(1)=0.210; p=0.647 
Heroin use reported; days; 
route 
LDA X2(1)=3.045; p=0.081 
Heroin days LDA X2(5)=0.633; p=0.986 
Heroin route LDA X2(1)=2.203; p=0.138 
Illicit Diazepam use LDA X2(3)=0.000; p=0.985 
Illicit diazepam days LDA X2(5)=4.410; p=0.492 
Illicit methadone use  LDA X2(1)=0.887; p=0.346 
Illicit methadone days LDA X2(3)=0.236; p=0.972 
Illicit painkillers use LDA X2(1)=0.583; p=0.445 
Illicit painkillers days LDA X2(1)=0.131; p=0.717 
+ve opiates  
Higher dose –ve test 
LDA X
2
(1)=5.220; 
p=0.022 
Cohen’s d = 0.060 
R=0.030 
Small effect size 
+ve benzos LDA X2(1)=5.216; p=0.022 
Higher dose  +ve test 
Acute admissions reported 
Higher dose =more admiss 
LRA t(1)=4.183; 
p<0.001 
Partial 
2
  = .974 
Large effect size 
Psych admissions reported 
Higher dose=more admiss  
LRA t(1)=3.963; 
p<0.001 
Partial 
2
  = .974 
Large effect size 
Prison reported  
Higher dose= more incarc 
LRA t(1)=3.990; 
p<0.001 
Partial 
2
  = .966 
Large effect size 
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Treatment status (Perception of treatment (TPQ) on outcomes (Table 38) 
A baseline cross-sectional analysis found a strong association between where main care was 
received and the degree of “satisfaction” as measured by the TPQ total score (ANOVA 
F(2,8)=6.291; p=0.002). Those in the specialist services had higher TPQ  scores than those in 
GP shared care.  At follow up a higher TPQ total score was associated with more illicit 
methadone use. 
Table 38.  Associations: Perception of treatment (TPQ)/process and 4 year outcomes 
Independent Variable Dependent (Process) variable Statistics Effect size 
 
Satisfaction at baseline 
(TPQ total score) 
 
Significant impact set at the 
p<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  LDA X2(1)=0.199; p=0.655 
Pos v neg discharge LDA X2(1)=0.000; p=0.998 
Drug screen done LDA X2(1)=0.114; p=0.736 
Methadone dose LRA t(1)=-1.927; p=0.055 
Diazepam dose LRA t(1)=-1.106; p=0.269 
Dependent (outcome) variable  
Employment status LDA X2(1)=1.002; p=0.317 
Family stability LDA X2(1)=1.788; p=0.181 
Any illicit drug use reported LDA X2(1)=0.490; p=0.484 
Heroin use reported; days; 
route  
LDA X2(1)=1.396; p=0.237 
Heroin days LDA X2(5)=1.606; p=0.901 
Heroin route LDA X2(1)=1.667; p=0.197 
Illicit Diazepam use LDA X2(1)=2.013; p=0.156 
Illicit diazepam days LDA X2(5)=2.279; p=0.809 
Illicit  methadone use  LDA X2(1)=4.848; p=0.028 
Illicit methadone days LDA 
X
2
(1)=12.002; 
p=0.007 
Partial 
2
 = .118 
Medium effect 
Illicit painkillers *use LDA X2(1)=1.111; p=0.292 
Illicit painkiller days LDA X2(1)=1.153; p=0.215 
+ve opiates LDA X2(1)=1.555; p=0.212 
+ve benzos LDA X2(1)=1.170; p=0.279 
Acute admissions reported  LRA t(1)=-0.428; p=0.669 
Psych admissions reported  LRA t(1)=-0.403; p=0.687 
Prison reported  LRA t(1)=-0.441; p=0.660 
 
Illicit drug use at baseline 
Heroin use reported at baseline was strongly associated with a number of outcomes – 
predicting any drug use in 2009 (Table 39). Route of use was also relevant with baseline 
injecting predicting more heroin use and more injecting in 2009 (Table 40).   
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Table 39.  Associations: baseline heroin use/ process and 4 year outcomes 
Independent Variable Dependent (Process) variable Statistics Effect size 
 
Heroin use (baseline test) 
 
Significant impact set at the 
p<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  Chi square X2(2)=5.507; 
p=0.064 
Pos/neg discharge Chi square X2(2)=0.877; 
p=0.645 
Drug screen done Chi square X2(4)=6.389; 
p=0.172 
Methadone dose ANOVA F(2,8)=3.618; p=0.028 
+ve predicts higher dose 
Diazepam dose ANOVA F(2,8)=3.490; p=0.031 
+ve predicts  higher dose 
Dependent (outcome) variable  
Employment status Chi square X2(12)=14.637; 
p=0.262 
Family stability Chi square X2(4)=7.849; 
p=0.097 
Baselin heroin use predicts any 
illicit drug use reported in 2009 
Chi square 
X
2
(6)=20.892 
p=0.002 
Cramer’s V=.154 
p=0.002 
Relevant effect 
Heroin use reported;  
+ve predicts use 
Chi square 
X2(6)=13.867p=0.031 
Heroin days used KWH X
2
(1)=0.140; p=0.904 
Heroin route Chi square X2(8)=8.736; 
p=0.365 
Ill Diazepam use 
+ve predicts use 
Chi square 
X2(6)=13.789p=0.032 
Illicit diazepam days Chi square X2(16)=21.456; 
p=0.162 
Illicit  methadone use Chi square X2(6)=5.450; 
p=0.488 
Illicit methadone days Chi square X2(12)=12.143; 
p=0.434 
Illicit painkillers use Chi square X2(8)=8.559; 
p=0.200 
Illicit painkillers days Chi square X2(8)=11.554; 
p=0.172 
+ve opiates Chi square X2(8)=11.926; 
p=0.155 
+ve benzos Chi square X2(8)=11.043; 
p=0.087 
Acute admissions reported  ANOVA F(2,8)=2.421; p=0.090 
Psych admissions reported  ANOVA F(2,8)=2.336; p=0.098 
Prison reported  ANOVA F(2,8)=2.126; p=0.121 
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Table 40. Associations: baseline heroin route / process and 4 year outcomes 
Independent Variable Dependent (Process) variable Statistics Effect size 
 
Heroin use  - route 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  Chi square X2(4)=1.782; 
p=0.776 
Pos neg discharge Chi square X2(2)=2.707; 
p=0.258 
Drug screen done Chi square X2(8)=3.107; 
p=0.927 
Methadone dose ANOVA F(2,6)=0.415;  p=0.798 
Diazepam dose ANOVA F(4,6)=1.235; p=0.295 
Dependent (outcome) variables 
Employment status Chi square X2(24)=17.751; 
p=0.815 
Family stability Chi square X2(8)=5.462; 
p=0.707 
Any illicit drug use reported Chi square X2(6)=14.207; 
p=0.027 
Injecting predicts less use 
Heroin use reported  
Injecting 05 = use 09 
Chi square 
X
2
(6)=30.699; 
p<0.001 
Cramer’s V=.158 
p=0.001 
Relevant effect 
Heroin days KWH X2(4)=1.240; p=0.872 
Heroin route 
Injecting 05 = injecting 09 
Chi square 
X
2
(8)=49.851; 
p<0.001 
Cramer’s v =.173 
p<0.001 
Relevant effect 
lllicit Diazepam use Chi square X2(12)=10.626; 
p=0.561 
Illicit Diazepam days Chi square X2(32)=20.972; 
p=0.932 
Illicit methadone use Chi square X2(12)=7.546;  
p=0.820 
Illicit methadone days Chi square X2(24)=13.679; 
p=0.954 
Illicit painkillers  use Chi square X2(12)=3.608; 
p=0.990 
Illicit painkillers days Chi square X2(16)=5.876; 
p=0.989 
+ve opiates Chi square X2(16)=22.582; 
p=0.125 
+ve benzos Chi square X2(12)=7.287; 
p=0.838 
Acute admissions reported  ANOVA F(4,6)=0.339; p=0.851 
Psych admissions reported  ANOVA F(4,6)=0.344; p=0.848 
Prison reported  ANOVA F(4,6)=0.372; p=0.829 
 
Comorbidity screening at baseline 
Few associations were found between comorbidity findings and 4 year recorded outcomes. 
GHQ28 total score was associated with more illicit diazepam use and more illicit methadone 
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days used (Table 41). PTSD “caseness” was associated with methadone dose and family 
stability while severity of PTSD symptoms was associated with methadone dose (Table 42). 
Table 41.  Associations: GHQ28 scores and caseness / process and 4 year outcomes 
Independent (Predictor) Variable Dependent variable Statistics Effect size 
 
1. GHQ caseness 
2. GHQ total score 
 
Significant impact set at the 
p<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  
Higher score=lower retention 
1.Chi square X
2
(1)=0.711; p=0.399 
2.LDA X
2
(1)=4.683; p=0.030 
Pos/neg discharge 1.Chi square X
2
(1)=2.077; p=0.150 
2.LDA X
2
(1)=0.042; p=0.837 
Drug screen done 
Higher score=less likely screened 
1.Chi square X
2
(2)=1.652; p=0.438 
2.LDA X
2
(1)=5.218; p=0.022 
Methadone dose 1.KWH X
2
(1)=0.466; p=0.495 
2.QLR t(1)=1.871; p=0.062 
Diazepam dose 1.KWH X
2
(1)=0.007; p=0.931 
2.QLR t(1)=-0.090; p=0.928 
Employment status 1.Chi square X
2
(6)=7.890; p=0.246 
2.LDA X
2
(1)=2.965; p=0.085 
Family stability 1.Chi square X
2
(2)=1.478; p=0.478 
2. LDA X
2
(1)=1.562;  p=0.211 
Any illicit drug use reported 1.Chi square X
2
(2)=1.296; p=0.523 
2.LDA X
2
(1)=1.009; p=0.315 
Heroin use reported 1.Chi square X
2
(3)=2.115; p=0.549 
2.LDA X
2
(1)=0.096; p=0.756 
Heroin days 1.Chi square X
2
(7)=8.756; p=0.195 
2.LDA X
2
(4)=3.973; p=0.410 
Heroin route 1.Chi square X
2
(4)=1.710; p=0.789 
2.LDA X
2
(1)=0.062; p=0.804 
Illicit Diazepam use  
Higher score=more  diazepam use 
1.Chi square X
2
(3)=4.789; p=0.188 
2. LDA 
X
2
(1)=6.686;  
p=0.010 
Cohen’s d = 0.367 
R=0.180 
Small effect size 
Illicit diazepam days 1.Chi square X
2
(8)=9.140; p=0.331 
2.LDA X
2
(5)=4.119; p=0.532 
Ill meth use 1.Chi square X
2
(3)=4.508; p=0.212 
2.LDA X
2
(1)=1.643; p=0.200 
Illicit methadone days  
Higher score=more mm days 
1.Chi square X
2
(6)=7.756; p=0.256 
2.LRA 
X
2
(3)=13.755; 
p=0.003 
Partial 
2
 = .118 
Medium effect 
Illicit painkillers  
 
1.Chi square X
2
(3)=2.331; p=0.507 
2.LDA X
2
(1)=1.720; p=0.190 
Illicit painkiller days 1.Chi square X
2
(4)=2.338; p=0.674 
2.LDA X
2
(1)=0.083; p=0.773 
+ve opiates 1.Chi square X
2
(4)=3.869; p=0.424 
2.LDA X
2
(1)=0.538; p=0.463 
+ve benzos 1.Chi square X
2
(3)=2.380; p=0.497 
2.LDA X
2
(1)=1.734; p=0.188 
Acute admissions reported  
Higher score=more admissions 
1.KWH X
2
(1)=1.74 3; p=0.187 
2. LRA t(1)=2.159; p=0.032 
Psych admissions reported  
Higher score=more admissions 
1.KWH X
2
(1)=1.726; p=0.189 
2.LRA t(1)=2.123; p=0.034 
Prison reported  
Higher score=more admissions 
1.KWH X
2
(1)=2.669; p=0.102 
2.LRA t(1)=2.216; p=0.027 
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Table 42. Associations: PTSD (Impact of Events scale) / process and 4 year outcomes 
623 screened. 601 total scores of whom 271 scored zero.  280 show PTSD “caseness” based on cut off of 26 on 
scale. 321 no PTSD. Severity scale shows 175 “severe” and 105 “moderate” 
Independent (Predictor) Variable Dependent (Process) variable Statistics Effect size 
 
PTSD (IES) 
1. Caseness (>26) 
2. Severity 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention : PTSD = better  
Severity of PTSD=better retention 
1.Chi square X
2
(1)=6.862; p=0.009 
2.LDA X
2
(1)=5.112; p=0.024 
Pos/neg discharge 1.Chi square  X
2
(1)=0.218; p=0.641 
2. LDA X
2
(1)=0.311; p=0.577 
Drug screen done 1.Chi square X
2
(2)=3.657; p=0.161 
2.LDA X
2
(1)=2.322; p=0.128 
Methadone dose 
Caseness and score = higher dose 
1.KWH 
X
2
(1)=5.009; 
p=0.025 
Partial 
2
 = .001 
Small effect 
 
2.QRA  
t(1)=-2.674;  
p=0.008 
Partial 
2
  = .003 
Small effect 
Diazepam dose 1.KWH X
2
(1)=2.395; p=0.122 
2.QRA t(1)=-1.673; p=0.095 
Dependent (outcome) variable  
Employment status 1.Chi square  X
2
(6)=11.589; p=0.072 
2.LDA X
2
(1)=0.315; p=0.575 
Family stability 
PTSD caseness = less family stability 
1.Chi square  
X
2
(2)=6.648; 
p=0.036 
Cramer’s V=.122 
p=0.036 
Relevant effect 
2.LDA X
2
(1)=1.357; p=0.244 
Any illicit drug use reported 1.Chi square  X
2
(3)=3.153; p=0.369 
2. LDA X
2
(1)=0.869; p=0.351 
Heroin use reported; days; route  1.Chi square  X
2
(3)=5.781; p=0.123 
2.LDA X
2
(1)=0.129; p=0.720 
Heroin days 1.Chi square  X
2
(8)=12.703; p=0.122 
2.LDA X
2
(5)=7.302; p=0.199 
Heroin route 1.Chi square  X
2
(4)=5.397; p=0.249 
2.LDA X
2
(1)=0.109; p=0.741 
Illicit Diazepam use Chi square  X
2
(3)=6.407; p=0.093 
LDA X
2
(1)=0.269; p=0.604 
Illicit diazepam days Chi square  X
2
(8)=13.398; p=0.099 
LDA X
2
(5)=8.039; p=0.154 
Illicit methadone use  
PTSD=illicit use 
1.Chi square  X
2
(3)=8.429; p=0.038 
2.LDA X
2
(1)=4.248; p=0.039 
Illicit methadone days 1.Chi square  X
2
(6)=9.911; p=0.128 
2.LDA X
2
(3)=1.713; p=0.634 
Illicit painkillers use 
PTSD=illicit painkiller use 
1.Chi square  X
2
(3)=8.750; p=0.033 
2.LDA X
2
(1)=1.966; p=0.161 
+ve opiates 1.Chi square X
2
(4)=3.162; p=0.531 
2.LDA X
2
(1)=0.009; p=0.925 
+ve benzos 1.Chi square X
2
(3)=3.020; p=0.389 
2.LDA X
2
(1)=0.004; p=0.950 
Acute admissions reported  1.KWH X
2
(1)=3.498; p=0.061 
2.LRA t(1)=-2.312; p=0.021 
Psych admissions reported 1.KWH X
2
(1)=5.167; p=0.023 
2.LRA t(1)=-2.328; p=0.020 
Prison reported  1.KWH X
2
(1)=3.890; p=0.049 
2.LRA t(1)=-2.364; p=0.019 
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Other analyses                                                                                                                          
Following application of the Bonferroni Correction, no statistically significant associations 
were demonstrated between a number of the selected independent baseline variables and 
dependent variables at 4 year follow up. 
 
Factors showing no associations included: Gender; SIMD-local quintile (deprivation score); 
time at current address; lives alone/not; lives with children/not; days in paid work in last 30 
days; MAP Physical Health Score; MAP Psychological Health Score; Heroin days used; 
Positive benzodiazepine tests; Injection risk taking (IRQ); comorbidities – pain, social phobia 
and ADHD. 
 
Full results tables for these negative results are shown in Appendix 5.   
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Chapter 7 
Results: Follow up 2. 
 HIC Linked datasets 2005-2011 
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Figure 9. Follow up – HIC Linked datasets 2005-2011 
 
 
 
 
 
 
 
 
 
  
Baseline Population 
All Patients on Methadone ORT 
 in Tayside 
January 2005 
817 cases 
Patients not 
assessed in 2005 
134 cases 
Follow – up 
Health Informatics Centre Data 
January 2005 - December 2011 
 
Out-patient 
attendance 
607 cases 
Ambulance  
Attendance 
Non-fatal 
Overdose 
293 episodes 
35cases 
A&E 
Attendance 
723 
Attendances 
By 32 cases 
General Hospital 
Admission 
907 admissions 
By 294 cases 
Psychiatric  
Admission 
133 
admissions 
By 56 cases 
GROS 
Death 
45 cases 
Discharged 
216 
Cases 
Planned 
Discharges 
40 Cases 
Unplanned 
Discharges 
176 Cases 
Retained 
251  
Cases 
Follow-up 
Clinical Casenote review 
July-December 2009 
467 Cases 
Details 
unavailable 
60 cases 
Baseline 
Clinical data collection 
February-December 2005 
623 cases 
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Results - Follow up analyses 2. HIC Linked datasets – 2005-11 
This section describes the findings of the follow up review utilizing the linked datasets 
available through HIC. The data used in the analysis were: 
 Data collected at the baseline assessment interview in 2005  
 HIC linked datasets  
The literature review informed the development of a model, using data available in the 
linked dataset, to assess the associations a range of independent variables had with a range 
of process measures or outcomes (dependent variables). The variables chosen are shown in 
Table 43.   
Table 43. Additional dependent variables 
Dependent Variables (HIC linked datasets) 
SMR00 (out-patient) sessions (number) 
SAS (Ambulance) attendances 
Naloxone administrations 
A&E attendances 
SMR01 admissions (acute) - All 
SMR01 duration (acute nights)  - All 
SMR04 admissions (psychiatric) 
SMR04 (psych) emergency/routine 
SMR04 admissions - total days 
SMR04 admissions - longest stay 
GROS dead/alive 
 
Statistics 
As before, for analyses when both independent and dependent variables were categorical - 
Chi-squared tests were undertaken.  For categorical independent and continuous 
dependent variables, an ANOVA was used (if data were parametric). If not, the Kruskall-
Wallis H-test or Mann-Whitney U-test (for binary data) were used. For continuous 
independent variables with categorical dependent variables, discriminant analyses were 
used. If the DV/IV relationship was linear, linear discriminant analyses were used. If not, 
quadratic discriminant analyses were used. When both independent and dependent 
variables were continuous – linear regression analyses were undertaken. 
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Multiple testing and the Bonferroni Correction 
This process did not involve significant multiple testing - making it unlikely that there will be 
false positives as a result. No Bonferroni Correction was applied. 
 
Results – Clinical HIC Linked datasets 2005-12 
This section describes the results of the analyses undertaken using data collected from the 
HIC datasets from 2005-12.  Positive results are shown in a series of tables – Tables 44-59 
below. Tables of negative results (where no associations were demonstrated in the 
univariate analyses) are contained in Appendix 5. 
 
Demographic factors 
Younger age was associated with having more out-patient appointments with the drug 
treatment services and younger subjects were less likely to have died in the 7 year follow up 
period (Table 44). 
 
Table 44.  Associations: Age / HIC outcomes (7 year follow up) 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics Effect size 
 
Age 
 
Significant impact at the 
p<0.05 level 
 
 
 
Out-patient appointments 
SMR00 sessions (number) 
Younger= more appointments 
LRA 
 t(1)=-4.096; 
p<0.001 
Partial 2  = .657 
Large effect size 
Acute services contacts  
Ambulance Service call-outs 
SAS attendances 
LRA t(1)=-0.008; p=0.994 
Naloxone administrations LRA t(1)=-0.201; p=0.843 
A&E attendances LRA t(1)=1.647; p=0.112 
General Hospital Admissions  
SMR01 admissions (acute) - 
All 
LRA t(1)=1.753; p=0.081 
SMR01 duration (nights)  -All LRA t(1)-0.966; p=0.335 
Psychiatric Admisisons  
SMR04 admissions (psych) LRA t(1)=-0.924; p=0.363 
SMR04 total days LRA t(1)=-1.059; p=0.298 
Registrar General Death 
data GROS dead/alive 
Younger = less likely dead 
LDA 
X
2
(1)=19.567; 
p<0.001 
Cohen’s d =.585 
R=0.281 
Medium effect 
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Gender was associated with a number of 7 year process measures and outcomes (Table 45). 
Females attended significantly more appointments than males. Males were more likely to 
be admitted to a psychiatric unit and if admitted, spent more time as an in-patient than 
females. Males were also more likely to have died in the 7 year follow up period. 
 
Table 45.  Associations: Gender / HIC outcomes  
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics Effect size 
 
Gender 
 
Significant impact at the 
p<0.05 level 
 
Out-patient appointments 
SMR00 sessions 2005/10  
Females more attendances 
KWH 
X
2
(1)=11.225; 
p=0.001 
Monte Carlo sig 
test=.002  
99% CI .001-003 
Likely effect 
Acute services contacts  
Ambulance service call-outs 
SAS attendances 2008/11 
KWH X2(1)=0.010; p=0.921 
Naloxone administrations 
2008/11 
KWH X2(1)=1.721; p=0.190 
A&E attendances <2008 KWH X2(1)=0.254; p=0.614 
General Hospital Admissions  
SMR01 admissions (acute) - 
ALL 
KWH X2(1)=0.614; p=0.433 
SMR01 duration(nights)  - 
ALL 
KWH X2(1)=0.126; p=0.723 
Psychiatric Admissions  
SMR04 admissions(psych) 
2005/11 Males more admissions 
KWH 
X
2
(1)=5.046; 
p=0.025 
Monte Carlo sig 
test =.038 
99% CI .033-042 
Likely effect 
SMR04 total days  
Males =  more time as IP 
KWH 
X
2
(1)=5.499; 
p=0.019 
Monte Carlo sig 
test =0.017 
99%CI=.013-020 
Likely effect 
Registrar general Death 
Data GROS dead/alive M>F 
Chi square 
X
2
(2)=17.287; 
p<0.001  
Cramer’s v=.184 
p<0.001 
Relevant effect 
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Markers of social stability 
A number of factors, reflecting a degree of social stability, were assessed.  
 
MAP conflict scores were assessed. The score recording conflict with friends at baseline was 
associated with death – higher conflict score predicting an increased likelihood of dying in 
the 7 year follow up period (Table 46). 
 
Table 46.  Associations: MAP conflict scores / HIC outcomes 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics Effect size 
 
MAP conflict scores: 
1. Partner 
2. Relative 
3. Friends 
 
Significant impact at the 
p<0.05 level 
 
Out-patient Attendances 
SMR00 sessions 2005/10 
1.LRA t(1)=-0.213; p=0.832 
2.LRA t(1)=1.196; p=0.232 
3.LRA t(1)=-0.554; p=0.580 
Acute Services Contacts 
Ambulance Service Call-outs 
SAS call outs 
1.LRA t(1)=-1.181; p=0.242 
2.LRA t(1)=0.398; p=0.692 
3.LRA t(1)=-0.404; p=0.688 
Naloxone administrations 
2008-11 
1.LRA t(1)=-0.831; p=0.413 
2.LRA t(1)=0.227; p=0.822 
3.LRA t(1)=0.548; p=0.589 
A&E attendances <2008 1.LRA t(1)=0.016; p=0.987 
2.LRA t(1)=1.287; p=0.208 
3.LRA t(1)=-0.142; p=0.888 
Acute Hospital Admissions 
SMR01 admissions (acute) - 
ALL 
1.LRA t(1)=0.876; p=0.382 
2.LRA t(1)=-0.953; p=0.342 
3.LRA t(1)=-0.917; p=0.360 
SMR01 duration(nights)  - 
ALL 
1.LRA t(1)=0.517; p=0.606 
2.LRA t(1)=-0.656; p=0.513 
3.LRA t(1)=-0.562; p=0.575 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
1.LRA t(1)=-0.791; p=0.434 
2.LRA t(1)=0.580; p=0.566 
3.LRA t(1)=0.184; p=0.855 
SMR04 total days 1.LRA t(1)=-0.456; p=0.651 
2.LRA t(1)=0.294; p=0.770 
3.LRA t(1)=-0.291; p=0.773 
Registrar General Death 
Data 
GROS death 
1.LDA X2(1)=0.566; p=0.452 
2. LDA X2(1)=2.590; p=0.108 
3. LDA 
X
2
(1)=4.007; 
p=0.045 
Cohen’s d=0.164 
R=0.082 
Small effect size 
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Days in paid work were found to be associated with psychiatric admission – with more days 
associated with more and longer admissions (Table 47). 
 
Table 47. Associations: days in work at baseline assessment /  HIC outcomes 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics Effect size 
 
Days in paid work 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
LRA t(1)=-1.339; p=0.181 
Acute Services Contacts 
Ambulance Service Call-outs 
SAS attendances 2008/11 
LRA t(1)=-0.502; p=0.617 
Naloxone administrations 
2008-11 
LRA t(1)=-0.514; p=0.611 
A&E attendances <2008 LRA t(1)=0.195; p=0.847 
Acute Hospital Admissions 
SMR01 admissions (acute) -  LRA t(1)=-1.490; p=0.137 
SMR01 duration(nights)  -  LRA t(1)=-1.449; p=0.149 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11  
More predicts > admissions 
LRA t(1)=2.730; 
p=0.009 
Partial 2  = .024 
Small effect size 
SMR04 total days  
More work predicts >days IP 
LRA t(1)=5.984; 
p<0.001 
Partial 2  = .001 
Small effect size 
Registrar General death 
Data GROS death 
LDA X2(1)=1.007; p=0.316 
 
Treatment status 
A number of factors relating to the delivery of treatment and care were considered.   
 
The treatment setting (NHS specialist, Criminal Justice or GP) was found to be relevant with 
specialist NHS services seeing patients more frequently in the 7 year follow up period. 
Criminal Justice Services saw patients more often than GP shared-care services (Table 48).  
Registration with a GP (not drug treatment delivery by a GP) was associated with increased 
acute hospital admissions (Table 49).  
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Table 48. Associations: treatment setting / HIC outcome 
Independent Variable Dependent Variable Statistics Effect size 
 
Treatment setting 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
TDPS>CJS>GP 
ANOVA 
F(2,8)=5.305; 
p=0.005 
Partial 2  = .021 
Small effect size 
Emergency Services Contacts 
Ambulance Service Call-outs 
SAS attendances 2008/11 
ANOVA F(2,8)=0.608; p=0.548 
Naloxone administrations 
2008/11 
ANOVA F(2,8)=0.951; p=0.400 
A&E attendances <2008 ANOVA F(2,8)=0.181; p=0.835 
Acute Hospital Admissions 
SMR01 admissions (acute)  ANOVA F(2,8)=1.404; p=0.247 
SMR01 duration(nights)   ANOVA F(2,8)=1.563; p=0.212 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
ANOVA F(2,8)=0.117; p=0.890 
SMR04 total days ANOVA F(2,8)=0.335; p=0.717 
Registrar General Death 
Data GROS death 
Chi square  X2(2)=1.753; 
p=0.416 
 
Table 49. Associations: registration with a GP at baseline / HIC outcomes 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics Effect size 
 
Registered with GP 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
MWU=16739.0; p=0.069 
Acute Services Contacts 
Ambulance service Call-outs 
SAS attendances 2008/11 
MWU=100.0; p=0.488 
Naloxone administrations 
2008-11 
MWU=33.0; p=0.449 
A&E attendances <2008 MWU=45.0; p=0.672 
Acute Hospital Admission 
SMR01 admissions (acute) - 
ALL GP predicts more   
MWU=4096.5; 
p=0.024 
Partial 2  = .017 
Small effect size 
SMR01 duration(nights) MWU=4490.0; p=0.175 
Psychiatric admission 
SMR04 admissions(psych) 
2005/11 
MWU=232.5; p=0.325 
SMR04 total days MWU=246.0; p=0.515 
Registrar General Death 
Data 
Chi square X2(1)=0.236; 
p=0.627 
 
Support services delivered by another (non-NHS) agency increased the likelihood of 
attendance at substance misuse out-patient clinic appointments (Table 50). Satisfaction 
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with treatment – shown by higher Treatment Perception Questionnaire scores at baseline -  
was associated with a reduced likelihood of acute hospital admission during the follow up 
period (Table 51). 
Table 50.  Associations: support from other (non-NHS) agencies / HIC  outcome 
Independent Variable Dependent Variable Statistics Effect size 
 
Support from other agencies 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
Support predicts attendance 
MWU=16441.5; 
p=0.021       
Cohen’s d= -0.307 
R=-0.152 
Small effect size 
Emergency Service Contacts 
Ambulance Service Call-outs 
SAS attendances 2008/11 
MWU=249.0; p=0.127 
Naloxone administrations 
2008-11 
MWU=70.5; p=0.746 
A&E attendances <2008 MWU=93.0; p=0.090 
Acute Hospital Admissions 
SMR01 admissions (acute)  MWU=4680.0; p=0.911 
SMR01 duration(nights)   MWU=4452.0; p=0.503 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
MWU=200.0; p=0.844 
SMR04 total days MWU=177.5; p=0.437 
Registrar General Death Data 
GROS death 
Chi square X2(1)=0.233;  
p=0.630 
 
Table 51. Associations: baseline TPQ total score / HIC outcome 
Independent Variable Dependent Variable Statistics Effect size 
 
TPQ total score 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
LRA t(1)=-0.916; p=0.360 
Emergency Service Contacts 
Ambulance service Call-outs 
SAS attendances 2008/11 
LRA t(1)=-0.642; p=0.523 
Naloxone administrations 
2008-11 
LRA t(1)=-0753; p=0.457 
A&E attendances <2008 LRA t(1)=-0.784; p=0.438 
Acute Hospital Admissions 
SMR01 admissions (acute) 
Higher score =less admission 
LRA t(1)=-
2.247; p=0.025 
Partial 2 = .069 
Medium effect 
SMR01 duration(nights)   LRA t(1)=-1.394; p=0.164 
Psychiatric Admissions 
SMR04 admissions 2005/11 LRA t(1)=-1.107; p=0.273 
SMR04 total days LRA t(1)=-1.563; p=0.124 
Registrar General Deaths  LDA X2(1)=0.130; p=0.719 
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A higher MAP Physical Health Score was associated with acute admissions and increased 
deaths (Table 52).  A higher  prescribed methadone dose was associated with an increased 
likelihood of acute hospital admission and longer admissions (Table 53). Though higher 
methadone dosage was not associated with increased psychiatric admissions, those who 
were admitted had longer in-patient stays. 
 
Table 52.  Associations: baseline MAP Physical Health Score / HIC outcomes 
Independent Variable Dependent Variable Statistics Effect size 
 
Map Physical Health Score 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
LRA t(1)=0.734; p=0.463 
Acute Services Contacts 
Ambulance Service Call-outs LRA t(1)=0.996; p=0.323 
Naloxone administrations  LRA t(1)=0.477; p=0.637 
A&E attendances <2008 LRA t(1)=-0.976; p=0.335 
Acute Hospital Admissions 
SMR01 admissions (acute)  LRA t(1)=2.291; 
p=0.023 
Partial 2  = .145 
Large effect size 
SMR01 duration(nights)   LRA t(1)=1.434; p=0.153 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
LRA t(1)=0.633; p=0.529 
SMR04 total days LRA t(1)=1.349; p=0.183 
GROS death LDA X
2
(1)=4.226; 
p=0.040 
Cohen’s d=.248 
R=0.123 
Small effect size 
 
Table 53.  Associations: baseline methadone dosage / HIC outcomes 
Independent Variable Dependent Variable Statistics Effect size 
 
Methadone dose 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
LRA t(1)=1.796; p=0.073 
Emergency service Contacts 
Ambulance Service Call-outs 
SAS attendances 2008/11 
LRA t(1)=-0.267; p=0.790 
Naloxone administrations 
2008-11 
LRA t(1)=-1.246; p=0.223 
A&E attendances <2008 LRA t(1)=0.084; p=0.934 
Acute Hospital Admissions 
SMR01 admissions (acute) LRA t(1)=2.125; 
p=0.035 
Partial 2  = .951 
Large effect size 
SMR01 duration(nights)   LRA t(1)=2.187; 
p=0.030 
Partial 2  = .997 
Large effect size 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
LRA t(1)=-1.614; p=0.112 
SMR04 total days LRA t(1)=-
2.125; p=0.038 
Partial 2  = .122 
Medium effect 
 GROS death LDA X2(1)=0.172; p=0.679 
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Illicit drug use 
Illicit drug use was associated with a number of outcomes. Those using more heroin at 
baseline were seen less frequently over the follow up period (Table 54). Those using more 
frequently at baseline experienced longer periods of in-patient psychiatric care (Table 55). 
Table 54.  Associations: heroin use at baseline / HIC outcomes 
Independent  Variable Dependent Variable Statistics Effect size 
 
Heroin use 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
More use predicts less 
ANOVA 
F(2,8)=4.050; 
p=0.018 
Partial 2  = .171 
Large effect size 
Emergency Services Contacts 
Ambulance Service Call-outs ANOVA F(2,8)=2.762; p=0.071 
Naloxone 2008-11 ANOVA F(2,8)=1.121; p=0.339 
A&E attendances <2008 ANOVA F(2,8)=0.035; p=0.966 
Acute Hospital Admissions 
SMR01 admissions (acute)  ANOVA F(2,8)=1.993; p=0.138 
SMR01 duration(nights)  ANOVA F(2,8)=0.754; p=0.471 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
ANOVA F(2,8)=1.311; p=0.279 
SMR04 total days ANOVA F(2,8)=0.551; p=0.580 
GROS death Chi square X2(2)=2.707; 
p=0.258 
 
Table 55.  Associations: extent of baseline heroin use (heroin days) / HIC outcomes 
Independent Variable Dependent Variable Statistics Effect size 
 
Heroin days used 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
LRA t(1)=-0.477; p=0.655 
Emergency service Contacts 
Ambulance service call-outs 
SAS attendances 2008/11 
LRA t(1)=-0.193; p=0.847 
Naloxone administrations 
2008-11 
LRA t(1)=1.152; p=0.258 
A&E attendances <2008 LRA t(1)=-0.102; p=0.919 
Acute Hospital Admissions 
SMR01 admissions (acute) - ALL LRA t(1)=1.700; p=0.090 
SMR01 duration(nights)  - ALL LRA t(1)=1.630; p=0.104 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
LRA t(1)=-1.897; p=0.063 
SMR04 total days  
More days= longer stays 
LRA t(1)=2.940; 
p=0.005 
Partial 2  = .018 
Small effect size 
GROS death LDA X2(1)=0.160; p=0.689 
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Comorbidities 
A number of common comorbidities were assessed at baseline and positive associations 
were found with 7 year HIC outcomes.  
 
Comorbid Pain – the presence of any pain was associated with increased stays in acute 
hospital admissions. Increased intensity of pain was associated with an increased likelihood 
of death in the 7 year follow up period (Table 56).  Psychiatric caseness (GHQ28) – Caseness 
had no associations. However, a higher total GHQ28 score was associated with longer 
psychiatric admissions (Table 57). 
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Table 56.  Associations: pain and its characteristics at baseline / HIC outcomes 
Independent Variable Dependent Variable Statistics Effect size 
 Pain 
1. Pain present 
2. Duration 
3. Chronic (12/12) 
4. Severity score 
5. Severity quintiles 
 
Significant impact at the 
p<0.05 level 
 
 
 
Out-patient attendances 
SMR00 sessions 2005/10 
1.MWU=28032.0; p=0.567 
2.LRA t(1)=-0.603; p=0.547 
3. MWU=5243.000; p=0.251 
4. LRA t(1)=-1.839; p=0.066 
5.KWH(4)=8.012; p=0.091 
Emergency Service Contacts 
Ambulance Service Call-outs 
SAS attendances 2008/11 
1.MWU=416.500; p=0.784 
2.LRA t(1)=-0.307; p=0.761 
3.MWU=82.000; p=0.945 
4.LRA t(1)=1.607; p=0.113 
5. KWH(3)=1.468; p=0.690 
Naloxone administrations 
2008-11 
1.MWU=97.500; p=0.379 
2.LRA t(1)=0.181; p=0.859 
3.MWU=19.000; p=0.599 
4.LRA t(1)=1.274; p=0.212 
5.KWH(2)=0.638; p=0.727 
A&E attendances <2008 1.MWU=95.500; p=0.307 
2.LRA t(1)=1.238; p=0.232 
3. MWU=6.500; p=0.700 
4.LRA t(1)=0.961; p=0.343 
5. KWH(4)=6.736; p=0.150 
Acute Hospital Admissions 
SMR01 admissions (acute) - 
ALL 
1.MWU=6068.500; p=0.414 
2.LRA t(1)=-0.957; p=0.340 
3.MWU=1530.500; p=0.299 
4.LRA t(1)=0.155; p=0.877 
5. KWH(4)=4.125; p=0.389 
SMR01 duration(nights)  - 
ALL  
Pain predicts longer stays 
 
1.MWU=5349.000; 
p=0.035 
Partial 
2
  = .032 
Small effect size 
2.LRA t(1)=-1.667; p=0.098 
3.MWU=1347.500; p=0.054 
4.LRA t(1)=-0.611; p=0.541 
5. KWH(4)=2.448; p=0.654 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
1.MWU=235.000; p=0.712 
2.LRA t(1)=-1.452; p=0.160 
3.MWU=23.500; p=0.071 
4.LRA t(1)=0.499; p=0.620 
5. KWH(3)=0.879; p=0.831 
SMR04 total days 1.MWU=214.500; p=0.416 
2.LRA t(1)=-1.462; p=0.157 
3. MWU=22.000; p=0.060 
4.LRA t(1)=0.284; p=0.777 
5. KWH(3)=0.539; p=0.910 
Registrar general Death 
Data 
GROS death  
Pain severity predicts death 
1.Chi square X
2
(1)=1.160; p=0.281 
2.LDA X
2
(1)=0.000; p=0.988 
3.Chi square X
2
(1)=2.330; p=0.127 
4. LDA  X
2
(1)=1.495; p=0.221 
5. Chi square 
X
2
(4)=12.815; 
p=0.012 
Cramer’s V=.208  
Relevant effect 
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Table 57.  Associations: baseline GHQ28  scores and caseness / HIC outcomes 
IndependentVariable Dependent Variable Statistics Effect size 
 
1. GHQ caseness 
2. GHQ total score 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
MWU=25312.5; p=0.160 
LRA t(1)=1.705; p=0.089 
Acute Services Contacts 
Ambulance Service Call-outs 
SAS attendances 2008/11 
MWU=350.0; p=0.422 
LRA t(1)=0.759; p=0.451 
Naloxone administrations 
2008-11 
MWU=63.5; p=0.077 
LRA t(1)=1.563; p=0.129 
A&E attendances <2008 MWU=97.5; p=0.662 
LRA t(1)=1.452; p=0.158 
Acute Hospital Admissions 
SMR01 admissions (acute) - ALL MWU=6052.0; p=0.736 
LRA t(1)=1.705; p=0.089 
SMR01 duration(nights)   MWU=5689.0; p=0.325 
LRA t(1)=1.705; p=0.089 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
MWU=199.0; p=0.634 
LRA t(1)=1.926; p=0.061 
SMR04 total days  
Higher score predicts >days 
MWU=210.0; 
p=0.863 
LRA t(1)=2.643; 
p=0.011 
Partial 2  = .995 
Large effect size 
Registrar general Death Data 
GROS death 
1.Chi square X2(1)=0.181; 
p=0.670 
2.LDA X2(1)=1.566; p=0.211 
 
Table 58.  Associations: baseline PTSD (IES) / HIC outcomes 
Independent Variable Dependent Variable Statistics Effect size 
PTSD (IES) 
Caseness (>26) 
Severity score 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 
1.MWU=36142.000; p=0.181 
2. LRA t(1)=2.022; p=0.155 
Emergency Service Contacts 
Ambulance Service Call-outs 
SAS attendances 2008-11  
PTSD predicts more attendances 
1.MWU=349.500; 
p=0.050 
Partial 2  = .021 
Small effect size 
2. LRA t(1)=1.069; p=0.289 
Naloxone administrations 2008-
11 
1.MWU=124.500; p=0.683 
2. LRA t(1)=-0.395; p=0.696 
A&E attendances <2008 1.MWU=157.500; p=0.685 
2. LRA t(1)=0.922; p=0.363 
Acute Hospital Admissions 
SMR01 admissions (acute) 1.MWU=8987.000; p=0.529 
2. LRA t(1)=-1.511; p=0.132 
SMR01 duration(nights)  1.MWU=9111.000; p=0.754 
2. LRA t(1)=-0.926; p=0.355 
Psychiatric Hospital Admissions 
SMR04 admissions(psych)  1.MWU=362.500; p=0.791 
2. LRA t(1)=-0.756; p=0.453 
SMR04 total days 1.MWU=368.000; p=0.879 
2. LRA t(1)=-1.054 p=0.297 
Registrar General Death Data 
GROS death 
1.Chi square  X
2
(1)=0.253; p=0.615 
2. LDA X
2
(1)=0.575; p=0.448 
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Post Traumatic Stress Disorder (PTSD) – a score of greater than 26 on the Impact of Events 
Scale – indicating “caseness”  was associated with an increased likelihood of emergency 
ambulance call outs (Table 58). 
 
Attention Deficit Hyperactivity Disorder - ADHD – Presence of any type of ADHD (assessed 
using the current symptoms scale - CSS) is associated with administration of naloxone to 
treat overdose during an emergency ambulance call out. The hyperactive type is more likely 
to be offered more appointments (Table 59). 
Table 59.  Associations: ADHD symptoms, type and impairment (CSS) / HIC outcomes 
Independent Variable Dependent Variable Statistics Effect size 
 
ADHD (CSS) 
1.symptoms 
2.types 
3.impairment 
 
Significant impact at the 
p<0.05 level 
 
Out-patient attendances 
SMR00 sessions 2005/10 H>I>C 
type predicts appts 
1.MWU=7232.000; p=0.204 
2.KWH(2)=7.009; 
p=0.030 
Partial 
2
  = .070 
Medium effect 
3.MWU=3235.000; p=0.400 
Emergency Service Contacts  
Ambulance Service Call-outs 
SAS attendances 2008-11 
1. MWU=127.500; p=0.114  
2. KWH(2)=0.478; p=0.787 
3.MWU=67.000; p=0.783 
Naloxone administrations  
2008-11 
1. MWU=20.500; 
p=0.031 
Partial 
2
  = .235 
Large effect size 
2.KWH(2)=1.900; p=0.387 
3.MWU=20.500; p=0.877 
A&E attendances <2008 1.MWU=28.000; p=0.538 
2. KWH(2)=1.000; p=0.607 
3.Not computed (numbers) 
Acute Hospital Admissions 
SMR01 admissions (acute) - ALL 1.MWU=1708.500; p=0.679 
2.KWH(2)=0.323; p=0.851 
3.MWU=8987.000; p=0.529 
SMR01 duration(nights)  - ALL 1.MWU=1538.500; p=0.374 
2.KWH(2)=1.407; p=0.495 
3.MWU=401.000; p=0.170 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
1.MWU=118.000; p=0.850 
2.KWH(2)=0.114; p=0.944 
3.MWU=341.500; p=0.070 
SMR04 total days 1.MWU=110.500; p=0.623 
2.KWH(2)=1.311; p=0.519 
3.MWU=23.000; p=0.253 
GROS death 1.Chi square X2(2)=0.032; 
p=0.858 
2. Chi square X2(2)=4.922; 
p=0.085 
3. Chi square X2(1)=0.021; 
p=0.884 
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Other analyses 
Following application of the Bonferroni Correction, no statistically significant associations 
were demonstrated between the selected independent baseline variables and dependent 
variables at 4 year follow up. 
 
Factors showing no associations included: home district; SIMD-local quintile (deprivation 
score); time at current address; lives alone/not; has children; lives with children/not; 
educational level attained; MAP Psychological Health Score; Prescribed diazepam dose; 
Heroin route; Positive benzodiazepine tests; Injection risk taking (IRQ); comorbidities – 
social phobia. 
 
Full results tables are shown in Appendix 5.   
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Introduction 
This chapter summarises and discusses the positive findings from the univariate analyses 
described in Chapters 6 and 7. Once the Bonferroni corrections were applied, there 
remained a number of highly statistically significant associations over the 4-7 year follow up 
period.  This chapter will collate these findings and discuss the implications.  
 
Demographics (Table 60) 
 
Basic demographics 
Age had an impact on the process of care experienced over the follow up period – with 
younger subjects attending services more frequently and being tested more. The published 
evidence suggests these younger patients would be more likely to be showing clinical 
progress, but no significant differences in terms of specific clinical outcomes were observed 
in this cohort. It was observed that younger subjects were less likely to have died during the 
follow up period, however. Regarding family stability, records of younger patients suggested 
they were less stable.  Gender also showed some associations. Females were better 
attenders at clinics but males were more likely to have been admitted to psychiatric 
hospital, had longer admissions when they were admitted and were more likely to have died 
during the follow up period.  
 
Family and supportive relationships 
Perhaps surprisingly, having childcare responsibilities was associated with negative clinical 
outcomes. Parents were found to be more likely to be discharged negatively from services 
[i.e. poorly retained] and also scored lower for measures indicating family stability. MAP 
conflict scores with friends were associated with a range of poorer outcomes including more 
illicit methadone and diazepam use as well as an increased likelihood of death during the 
follow up period.  
 
Educational attainment and employment status 
Higher educational attainment was associated with more hospital admissions – both acute 
and psychiatric. The small number of subjects who were in work were more likely to be 
admitted to psychiatric hospitals and remained in-patients for more days when they were 
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admitted to psychiatric hospitals. This finding raises questions beyond the scope of this 
study. Recent reports on stigma have highlighted the difficulty experienced by active 
substance misusers who try to access generic healthcare (UKDPC, 2010).  Also, studies of 
comorbid substance misuse and mental illness have reported that this patient group are 
treated differently by mental health services, when compared to those without a substance 
use disorder (e.g. Scottish Executive 2003; Scottish Executive 2006).  The findings of the 
current study could reflect a stigma effect and could illustrate the fact that subjects who are 
more  able to demonstrate “normal” (or acceptable) behaviours were more likely to be 
admitted to hospital – i.e. not “excluded” when experiencing psychiatric distress. However, 
further research is required to explore the significance of these initial findings.  
 
Home – residence and deprivation 
Where people lived and who looked after them was of considerable relevance regarding 
clinical outcomes – though these univariate analyses seemed to reveal some 
inconsistencies.   
 
Angus is a very rural and relatively prosperous district in the NHS Tayside area. Yet it 
showed a higher rate of diazepam prescribing to OST- M patients. Angus patients were also 
the poorest retained in treatment and were most likely to have an admission to hospital or 
incarceration recorded in their casenotes. Paradoxically, Dundee City – the most deprived 
area in Tayside - had the best retained subjects who were the least likely to be using any 
drugs at follow up. They were also prescribed diazepam less and were least likely to have 
admissions or incarcerations recorded in their casenotes. The district of Perth & Kinross was 
the area where subjects were most likely to use any illicit drugs at follow up. It is notable 
that deprivation scores (using national SIM-D data) were found to have associations with 
these outcomes – a surprising finding. 
 
There may be an issue regarding clinical processes  although all the services managing OST-
M patients in Tayside are governed by a single set of clinical standards and guidelines which 
define clearly how OST-M patients should be assessed and treated. It must also be 
acknowledged that the observed differences could have been impacted on by variation in 
the quality of clinical casenotes across a large area service. 
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Table 60. Univariate analyses results: Demographics  
Independent variable Dependent variable Statistics 
Age Family stability (p=0.001) Younger  less stable 
Death (p<0.001) Older>Younger 
Drug tests done (p=0.006) Young more 
OP attendances (p<0.001) Young more 
Gender Psychiatric admissions (p=0.025) Male>Female 
Psychiatric days admitted (p=0.019) Male>Female 
death (p<0.001) Male>Female 
Out-patient attendance (p=0.001) Female> Male 
District 
D=Dundee 
P=Perthshire 
A=Angus 
Family stability (p<0.001) D>P>A 
Any drug use  (p=0.004; P>A>D) 
Diazepam use (p=0.001; D=A>P 
Illicit painkillers (p=0.010; A>D>P) 
Morphine specific +ves (p<0.001; A>P>D) 
Benzo +ves (p<0.001; D>A>P) 
Acute admissions (p=0.013; A>P>D) 
Psychiatric admissions (p=0.006; A>P>D) 
Incarcerations (p=0.003; A>P>D) 
Retention (p=0.003; D>P>A) 
Diazepam dose Rx (p=0.008; A>P>D) 
Has children Nature of discharge (p=0.001) Children= -ve d/c 
Family stability (p=0.025; Children=less stable 
Conflict scores (Partner) 
 
Conflict score (Family) 
Methadone (days) (p=0.011) High score=more 
Diazepam (days) (p<0.001) High score=more 
Methadone use (p=0.001) High score=use 
Death (p=0.045) Higher score=death 
Educational level Acute admissions (p=0.004) qualifications= more 
Psychiatric admissions (p=0.005) qualifications= more 
Days in paid work Psychiatric admission (p=0.009) days=  admissions 
Psychiatric admission days (p<0.001) days=  days work 
 
Treatment - providers and additional support (Table 61) 
The nature of the medical treatment provider for delivery of OST- M – person’s own GP, 
Criminal Justice (CJS) or NHS specialist service – raised conflicting associations.  Specialist 
services (both CJS and NHS) saw patients more frequently, tested them more often and 
retained patients in treatment better than GPs. There were no consistent differences 
between CJS and NHS – which suggests that more intensive support by a service with low 
caseloads (the DTTO has average caseloads for nursing staff of 10 cases at any one time – 
the NHS has average caseloads of over 40 cases) had little effect on outcome. This is 
perhaps even more surprising as the DTTO is an “alternative to custody” scheme and 
therefore has an added incentive to demonstrate improvement. Comparing the outcomes 
achieved in all three elements, the specialist CJS element demonstrated more illicit 
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diazepam use than specialist NHS – supported by positive tests for these drugs. The NHS 
patients did, however, show more illicit Methadone use – “topping up” - while in OST- M. 
Regarding clinical outcomes, both of these specialist services, compared to primary care, 
were associated with more family stability. The GP – treated group showed more injecting, 
and had more admissions – both psychiatric and acute - and more incarcerations recorded 
in their casenotes. Additional support from external agencies was associated with better 
clinic attendance and more evidence of family stability.  Regardless of the methadone 
provider, GP registration (for general medical services) showed a strongly  positive 
association with better employment status, improved family stability and reduced likelihood 
of positive drug tests. GP registration was, however, also associated with more acute 
admissions – potentially a positive finding in light of the many health problems prevalent in 
this population. The MAP physical health score predicted both acute admissions and death 
in the follow up period. 
Table 61.  Univariate analysis results: Healthcare support 
Independent variable Dependent variable Statistics 
Non NHS support Family stability (p=0.021) support=stability 
Out-patient attendance (p=0.021) support=attendance 
Registered with GP (GMS) Employment status (p=0.007) GP=better 
Family stability (p=0.011) GP=stable 
Opiate positive tests (p=0.022) GP=less +ve 
Acute admissions (SMR) (p=0.024) GP=more 
Treatment provider Family stability (p=0.015; Specialist>GP) 
Heroin use (p=0.002; CJS>GP>TDPS) 
Heroin route (p=0.001; GP IV++) 
Diazepam use (p=0.006; CJS>GP>TDPS) 
Methadone use (p=0.002 TDPS ) 
Methadone days (p=0.014 TDPS ) 
DF118 use (p=0.038; CJS>TDPS>GP) 
Opiate positive tests (p=0.003; CJS>>GP>TDPS) 
Benzodiazepine +ve tests (p=0.038; CJS>GP>TDPS) 
Acute admissions (p=0.004) GP>TDPS>CJS 
Psychiatric admissions (p=0.005) GP>TDPS>CJS 
Incarcerations (p=0.008) GP>TDPS>CJS 
Retention (p=0.004) Specialist>GP 
Screens done (p=0.007; CJS>TDPS>GP) 
Out-patient attendance (p=0.005; TDPS>CJS>GP) 
MAP Physical Acute admissions (SMR) (p=0.023) >score=admissions 
Death (p=0.040) >score=death 
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Substance use and treatment (Table 62.) 
Substance use at baseline shows strong associations with treatment outcome.  Previous 
reports  have found that  the nature and extent of illicit use and injecting/risk-taking on 
commencing treatment is a strong predictor of outcomes. In this cohort of existing OST- M 
patients, higher levels of heroin use at 2005 baseline were associated with poorer 
attendance at services and more illicit drug use at follow up as well as more psychiatric 
admissions during the follow up period. More injecting at baseline was associated with 
ongoing injecting during the follow up period and more heroin use at follow up.  
 
Medical treatments for substance misuse 
Also as expected and reflecting the evidence base, higher prescribed methadone doses at 
baseline were associated with positive effects in terms of treatment processes. The current 
study found higher doses were associated with better treatment retention, more frequent 
testing - and better (harm reduction) outcomes, in terms of less drug use (fewer positive 
drug tests) and fewer incarcerations. It is notable that acute admissions reported in SMR 
data and those recorded in casenotes show a difference here, implying that admissions are 
not reported/recorded consistently through the patient self-report process.  
 
Higher diazepam doses (recorded in MAP) had almost universally negative associations. 
These included:  poorer retention in treatment with fewer drug screens performed and, 
though this group were often prescribed higher methadone doses (often viewed by service 
providers as positive process measures of treatment quality) they were also found to have 
more opiate positive drug screens on follow-up. Higher diazepam doses also correlated with 
poorer measures of family stability along with more recorded admissions and 
incarcerations.  
 
Patient satisfaction with the treatment they received (measured by the TPQ) was associated 
with fewer recorded admissions but more illicit methadone use by self-report. This could 
reflect that those with a more positive (or less challenging) relationship  with the services 
are more likely to admit to illicit use of methadone (which is impossible to detect unless 
patients are using heavily and are seen to be over-sedated).  
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Table 62. Univariate analysis results: Substance use and treatment 
Independent variable Dependent variable Statistics 
Methadone dose at baseline Opiate positive tests (p=0.018) baseline= +ves 
Acute admissions (notes) (p=0.001) baseline= admiss 
Acute admissions (SMR) (p=0.035) baseline= admiss 
Acute nights (SMR) (p=0.030) baseline= nights 
Psychiatric admission (notes) (p=0.001) baseline= admiss 
Psychiatric days (SMR) (p=0.038) baseline= days 
Incarcerations (notes) (p=0.001) baseline= admiss 
Retention (p=0.001) baseline=retention 
Screens done (p<0.001) baseline= tests 
Baseline diazepam dose Family stability (p=0.025) baseline =less stable 
Opiate positive drug screens (p=0.022) baseline=neg tests 
Acute admissions (p<0.001) baseline=more 
Psychiatric admissions (p<0.001) baseline=more 
Incarcerations (p<0.001) baseline=more 
Retention (p<0.001) predicts retention 
Methadone dose (p<0.001) baseline= dose 
Drug screen done (p<0.001) baseline=less tests 
Patient satisfaction (TPQ) Illicit methadone days (p=0.007) satisfaction=less 
Acute admission (SMR) (p=0.025) score=less  
Heroin use Any illicit use (p=0.002) +ve test predicts use 
Heroin days (p=0.005) +ve test predicts use 
Out-patient attendance (p=0.018) +ve predicts less 
Heroin use (days used) Psychiatric admission (days) (p=0.005) use predicts days 
Heroin route Heroin use (p=0.001) injecting predicts use 
Heroin days (p=0.014) injecting =more 
Heroin route (p=0.001) injecting persists 
 
Co-morbidities (Table 63.) 
The total GHQ score at baseline (n.b. but not “caseness” status) was associated with 
diazepam use, illicit methadone days used and psychiatric days admitted during follow up. 
Presence of any Pain was associated with longer acute hospital stays while Pain Intensity 
was associated with death.  PTSD “caseness” was associated with lower family stability, 
more ambulance callouts and higher prescribed methadone doses. PTSD score (severity) 
was associated with a higher prescribed methadone dose and better retention. The 
presence of ADHD symptoms was associated with more episodes of naloxone requirements 
following overdose (though numbers were very small). ADHD type was associated with out-
patient attendances with the hyperactive type reviewed more frequently.  
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Though they are commonly observed in clinical practice, this study has not found these 
common comorbidities (as assessed in clinical services) to be strongly associated with the 
longer term outcomes measured in this cohort.  
Table 63. Univariate analyses results: Comorbidity 
Independent variable Dependent variable Statistics 
GHQ score Illicit diazepam use (p=0.010) score=more use 
Illicit methadone days (p=0.003) score=more days 
Psychiatric admissions (days) (p=0.011) score=more days 
Pain presence Acute admission nights (SMR) (p=0.035) pain=longer stays 
Pain intensity quintiles Death (p=0.012) intense= deaths 
PTSD Caseness Family stability (p=0.036; PTSD=less) 
Ambulance callouts (p=0.050)  PTSD=more 
Methadone dose (p=0.025) PTSD=higher 
PTSD severity score Retention (p=0.010) severity=retention 
 Methadone dose (p=0.008) PTSD=higher 
ADHD symptoms Naloxone administrations (p=0.031) ADHD predicts use 
ADHD type Out patient attendance (p=0.030) H>I/C predicts 
number of attendances 
 
In conclusion 
 
These univariate analyses have revealed a number of strong associations between the 
selected independent and dependent variables measured at 4-7 years . 
 
Some of the associations replicate previous research findings. Examples include: 
 higher baseline heroin use and risk-taking was associated with poorer outcomes 
 higher prescribed methadone dose was associated with better outcomes 
 more diazepam use was associated with poorer outcomes 
 more external support and GP registration was associated with better outcomes 
 
Some of these associations challenge the published evidence base or have shown conflicting 
results. Examples include: 
 being a parent was actually associated with poorer clinical outcomes 
 the comorbidities chosen did not show many strong or consistent associations 
 the “area” effect was unexpected. The most affluent Tayside area (Angus), is 
associated with poor process measures and outcomes while the most deprived 
204 
 
(Dundee City) shows the reverse. Meanwhile, the SIM-D deprivation scores showed 
no significant associations at all. Tayside is a diverse region and many factors may 
have been important. Issues relating to local services and consistency of practice 
may also be relevant – though Tayside-wide standards were in place to ensure 
consistency of all elements of the OST- M prescribing programme. Further study is 
required to explore the many factors which may be influencing these results. 
 
It is important to recognise that data quality may be important here – with recorded 
admissions and incarcerations, for example, seeming to be discrepant from the findings of 
analyses using validated SMR data on admissions.   
 
The next chapter describes a series of multiple regression analyses and cross-validation 
exercises, undertaken to determine whether these data could successfully predict clinical 
outcomes and whether the predictive models developed were generalisable – i.e. effectively 
predict outcomes in novel datasets.  
 
 
 
 
 
 
  
205 
 
 
 
 
 
 
 
 
Chapter 9 
Results: 
Prediction of Outcomes 
  
206 
 
Figure 13. Results: Prediction of outcomes 
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Introduction 
This chapter describes attempts to test the ability of the Tayside Methadone Cohort clinical 
data to predict clinical outcomes. It also describes a process of cross-validation, which aimed 
to test the ability of any predictive models generated to predict clinical outcomes in a novel 
dataset. 
 
Univariate analyses 
A series of univariate analyses have been described. Using a group of baseline 
(independent) variables and outcome (dependent) variables, identified from the literature, 
it was shown that there are significant associations between some variables over time.  
 
Multiple testing – the Bonferroni correction 
The issue of multiple testing had been addressed by using the Bonferroni method as 
described in the methods chapter.  
 
The next phase was to introduce these variables into a model which could be tested in 
terms of its ability to predict specific outcomes. A multiple regression analysis would be 
undertaken to achieve this.  
 
Process 
 
Choosing variables to test 
Again using the literature review, a series of relevant outcomes of clinical significance were 
identified. The outcome variables chosen are shown in Table 64. 
Table 64. Outcome variables for multiple regression 
Outcomes Data source 
Death (2005-2009) HIC data - GROS 
Opiate positive drug screens 2009 casenotes 
Self-report of opiate use 2009 casenotes 
Family stability 2009 casenotes 
Acute admissions 2005-9 HIC data – SMR01 
 
The relevant independent variables, found to have a highly significant association with these 
outcomes were identified. These are shown in Table 65. 
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Table 65. Predictive model – variables for multiple regression analysis 
DV (outcome) IV (Predictor) Statistics (Chapters 6,7) 
 
Death (2005-2009) 
GROS (HIC) 
No  of medical admissions LDA X
2
(1)=41.053; p<0.001 
Age LDA X
2
(1)=19.567; p<0.001 
Gender Chi square X
2
(2)=17.287; p<0.001 
Retention (2009) Chi square X
2
(1)=19.224; p<0.001 
Drug screen done 2009 Chi square X
2
(2)=20.620; p<0.001 
Number of SAS attendances LDA X
2
(1)=9.985; p=0.002 
Number of SU OP attendances  LDA X
2
(1)=7.659; p=0.006 
BPI Pain severity (quintile) Chi square X
2
(4)=12.815; p=0.012 
MAP friends conflict score LDA X
2
(1)=4.007; p=0.045 
MAP physical health score LDA X
2
(1)=4.226; p=0.040 
 
Opiate positive drug screens in 
2009 casenotes 
Treatment setting Chi square X
2
(6)=19.642; p=0.003 
Baseline Methadone dose LDA X
2
(1)=5.569; p=0.018 
Registered with GP Chi square X
2
(4)=11.411; p=0.022 
Baseline Diazepam dose LDA X
2
(1)=5.220; p=0.022 
 
Self - report of opiate use  
in 2009 casenotes 
Route of heroin use - baseline Chi squareX
2
(6)=30.699; p<0.001 
Treatment setting Chi square X
2
(6)=20.392; p=0.002 
Age LDA X
2
(1)=5.429; p=0.020 
Baseline Methadone dose LDA X
2
(1)=5.360; p=0.021 
Days heroin use at baseline LDA X
2
(1)=5.231; p=0.022 
Area lives in Chi square X
2
(6)=14.102; p=0.029 
Any heroin use at baseline Chi square X
2
(6)=13.867; p=0.031 
 
Family stability recorded in 
2009 casnotes 
Age LDA X
2
(1)=11.321; p=0.001 
Area lives in Chi square X
2
(4)=20.796; p<0.001 
Registered with GP  Chi square X
2
(2)=8.973; p=0.011 
Treatment setting Chi square X
2
(4)=12.301; p=0.015 
Has children Chi square X
2
(2)=7.723; p=0.0.021 
Support from other agencies Chi square X
2
(2)=7.712; p=0.021 
Baseline prescribed diazepam 
dose 
LDA X
2
(1)=4.993; p=0.025 
Illicit diazepam use Chi square X
2
(4)=10.699; p=0.030 
PTSD caseness Chi square  X
2
(2)=6.648; p=0.036 
Acute admissions 2005-9 
SMR01 (HIC) 
 
Presence of pain MWU=5349.000; p=0.035 
Methadone dose LRA t(1)=2.187; p=0.030 
 
Key:  from univariate analysis (following Bonferroni Correction) P<0.001 
 from univariate analysis (following Bonferroni Correction) P<0.005 
 from univariate analysis (following Bonferroni Correction) P<0.05 
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Multiple regression analysis. 
Where the outcome to be assessed was categorical, a multiple logistic regression was 
undertaken. Where the outcome was continuous – in this case, only the number of acute 
admissions – a multiple linear regression was undertaken.  
 
Independent variables were placed in the appropriate multiple regression analysis in the 
SPSS18 computer programme (IBM, 2010), using a Forced Entry (ENTER) method. Stepwise 
methods were avoided as it has been argued that these computer-based approaches rely on 
the computer selecting variables statistically - i.e. not based on their theoretical importance 
– and are more likely to result in over/under fitting - a process of including variables with 
little effect or excluding some which are clinically relevant (Field, 2009).  A number of rules 
were considered when developing the model: 
 Finding a model with the fewest variables but with the best predictive value 
was the aim.  
 Only variables with a good theoretical grounding were included – the 
variables chosen reflected the evidence base explored in the literature review 
and the results of the univariate analyses.  
 A process was undertaken to remove variables found to be redundant – 
provided this did not reduce the predictive power of the model.  
 
Sample size 
Sample size was another important consideration (Green, 1991). The sample size 
recommended depends on the size of the effect (i.e. how well a variable predicts an 
outcome). It is generally felt that the larger the sample the more generalizable is the 
predictive model. Simple rules are often applied suggesting 10 or 15 cases are required for 
each predictor in the model (Field, 2009). However, more specific approaches to agreeing 
sample size in a multiple regression analysis can be used, depending on the purpose of the 
analysis. 
 To test best fit of the model to the data (testing R2) the minimum sample size is 
calculated by using the following equation: 
sample size = 50 + 8k (where k is number of predictors included) 
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 For a process intended to test the role of the individual predictors within a model 
then minimum sample size is calculated using the equation: 
sample size = 104 +k (where k is number of predictors) 
 
Green states that, if both a measure of overall fit to the data and a test of the contribution 
of all predictors are required, it is recommended that both tests are undertaken – in which 
case, the equation giving the highest number is used to calculate sample size required for 
the regression to be successful.  
 
Multicollinearity 
The purpose of the regression analysis is to be able to draw conclusions about the 
population of interest based on the sample. For this to be accurate (or unbiased) it is 
important that a number of assumptions are true. One key assumption is that there should 
be no perfect linear relationship (correlation) between two or more predictors. Though 
perfect collinearity is rare, a degree of correlation is very common. As the degree of 
correlation increases, there are a number of potential impacts: 
 the standard error of the β coefficient rises (i.e. is more variable and therefore less 
representative of the population as a whole) 
 the size of R (degree of correlation between predicted and observed outcome) is 
limited 
 the importance of specific predictors is difficult to assess 
 
In this analysis plan, should a strong predictive model be identified, it was planned that the 
degree of multicollinearity would be assessed using the SPSS collinearity diagnostic function 
as described by Field (2009). Two characteristics would be examined:  
1. The tolerance value. Menard (1995) suggests a tolerance value of less than 1 indicates a 
significant collinearity problem. 
2. The Variance Inflation Factor (VIF). A value of 10 would be taken to indicate a high level of 
collinearity (Myers 1990).  
 
Outputs from the multicollinearity process undertaken are contained in Appendix 7. 
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Cross – validation of the predictive models 
A process of cross-validation was also undertaken to determine whether the findings of the 
regression analysis would produce a valid predictive model when applied to an unrelated 
dataset. 
 
The process undertaken is described in Chapter 4 (Materials and methods). To summarize, 
the following steps were planned: 
 a complete dataset was created - all subjects with any missing data in the relevant 
fields were removed from the analysis 
 dividing the sample 50/50 into a training and testing dataset 
 a test of sample size was applied 
 the appropriate regression analysis was undertaken in the first half of the dataset – 
the training dataset – generating a model with β coefficients for each variable. 
 these β values were then applied to the novel  testing dataset - to  generate a 
predicted outcome in these novel data. The equation used reflected the type of 
regression being undertaken: 
- Linear regression: Y = β0 + β1X1 + β2X2 +…. βnXn + ε.  
This was used when the Dependent Variable was continuous 
- Binary logistic regression: P(Y) = 1/1 + e-(β0 + β1X1 + β2X2 +…. βnXn) 
This was used when the Dependent Variable was binary 
 the predicted outcome generated, was then compared to the actual observed 
outcome for the testing dataset. A significant difference between the observed and 
predicted outcomes would imply that the proposed predictive model is NOT 
predictive in this novel dataset. 
 
The next section describes the results of these multiple regression analyses. 
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Regression 1: Death 2005-2009 (from HIC GROS death data) 
The initial analysis had found a number of associations between independent (predictor) 
variables and the outcome variable, DEATH. Many of these associations were significant at 
the p<0.001 level. These are summarized in Table 66.  
 
Table 66. Statistically significant associations – dependent variable DEATH 
DV (outcome) IV (Predictor) Statistics 
 
Death (2005-2009) 
No  of medical admissions LDA X2(1)=41.053; p<0.001 
Age LDA X2(1)=19.567; p<0.001 
Gender Chi square X2(2)=17.287; 
p<0.001 
Retention (2009) Chi square X2(1)=19.224; 
p<0.001 
Drug screen done 2009 Chi square X2(2)=20.620; 
p<0.001 
Number of SAS attendances LDA X2(1)=9.985; p=0.002 
Number of SU OP attendances  LDA X2(1)=7.659; p=0.006 
BPI Pain severity (quintile) Chi square X2(4)=12.815; 
p=0.012 
MAP friends conflict score LDA X2(1)=4.007; p=0.045 
MAP physical health score LDA X2(1)=4.226; p=0.040 
 
Methods 
As outcome variable is dichotomous (Dead v not dead) a binary logistic regression was 
carried out.  
 
Developing a predictive model - Binary Regression Analysis  
First a complete dataset was created by removing all missing data. The complete dataset 
contained 184 cases of which 15 had died between 2005 and 2009.  
 
Initial sample size was assessed. The two equations proposed by Green (1991) would 
suggest: 
 Best fit equation - sample size = 104 +k (where k is number of predictors = 10) – 
sample size of 114 was required 
 Individual variables equation - sample size = 50 + 8k (where k is number of predictors) 
– sample size of 130 is required. The complete dataset of 184 cases was, 
theoretically, sufficient. 
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Using the complete dataset, a series of binary logistic regressions were undertaken to 
identify the relevant IVs to include in the most powerful predictive model.  
 
Results 
Table 67. shows the results of the first multiple binary regression undertaken. In this 
analysis only the 6 highly significant (P<0.001) associations were included. This would also 
reduce the required sample size to 110 (Best fit) or 98 (Variables).  
 
Table 67.  Death: Complete dataset - all highly significant predictors 
Predictor Β (SE) Significance 
Constant 6.581 (56841.828)  
No  of medical admissions -0.175 (0.104) P=0.093 
Age -0.145 (0.042) P=0.001 
Gender 19.881 (40193.110) P=1.000 
Retention (2009) -0.725 (1.050) P=0.490 
Drug screen done 2009 -15.308 (40193.887) P=0.052 
R2 = 0.585 (Hosmer&Lemeshow), 0.209 (Cox & Snell), 0.484 Nagelkerke. Model X2(7)=43.121; p<0.001. Model classifies 94% correctly [40% 
of deaths v 0 before model applied; 98.8% of living v 100% before. Before model, prediction 91.8% correct] 
It is clear that in this regression, some variables are not contributing to the predictive power 
of the model.  The variables Gender and Retention were excluded and the analysis repeated. 
The results are shown in table 68. 
 
Table 68.  Death: Complete dataset – selected highly significant predictors 
Predictor Β (SE) Significance 
Constant 26.125 (40192.968)  
No  of medical admissions -0.227 (0.096) P=0.018 
Age -0.134 (0.040) P=0.001 
Drug screen done 2009 -15.453 (40192.968) P=0.036 
R2 = 0.630 (Hosmer&Lemeshow), 0.189 (Cox & Snell), 0.437 Nagelkerke. Model X2(4)=38.492; p<0.001. Model classifies 93.5% correctly. 
Before model, prediction 91.8% correctly. 
The small number of cases of death make the overall prediction level - 93.5% - seem high. 
However, the  “before” model (i.e. the prediction before a model is applied) predicts 91.8% 
of the variance. This apparent high level of prediction, reflects the high correlation with the 
the state “not dead”. Death is a rare event and even though the TMC dataset is large – if all 
deaths were included there would only be 45 events in 623 cases. The creation of a 
complete dataset has reduced the number of cases even further – making accurate 
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prediction impossible. There is little improvement achieved by adding the proposed model 
as less than 2% of the variance would be explained by the model. 
 
Multicollinearity was not found to be a concern with tolerance levels ranging from .973 to 
.999 and VIF close to 1 for all factors. 
 
Conclusion: The model has therefore not been demonstrated to be useful at predicting 
death in this sample. As the model was not a useful predictor of outcome, no cross-
validation was undertaken. 
 
Regression 2:   Drug use – record of positive opiate screens recorded in casenotes - 2009 
 
The significant variables identified from the longitudinal analyses are shown in table 69. 
 
Table 69. Statistically significant associations – DV positive drug screens 2009 
DV (outcome) IV (Predictor) Statistics 
 
Opiate positive drug screens 
in 2009 casenotes 
Treatment setting Chi square X2(6)=19.642; 
p=0.003 
Baseline Methadone dose LDA X2(1)=5.569; p=0.018 
Registered with GP Chi square X2(4)=11.411; 
p=0.022 
Baseline Diazepam dose LDA X2(1)=5.220; p=0.022 
 
Developing a predictive model - Binary Regression Analysis  
First a complete dataset was created by removing all missing data. The complete dataset 
contained 200 cases of which 66 had positive tests recorded in their casenotes in 2009. As 
the number of predictors was small, rather than use the whole dataset to develop the 
model to be tested, it was decided to use all of the predictors in the regression and cross 
validation process. This complete dataset was therefore divided into two elements each 
with 100 cases.  
 
Sample size an issue. According to Green (1991) – sample sizes of 90 (best fit) or 108 
(variables) cases would be required. Small sample size is therefore a potential weakness. 
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A Binary Logistic regression was undertaken using the first half of the dataset – ML=1. This is 
the training dataset. The results are shown in Table 70. In this case, we can see that the 
model is a good fit to the data, the model chi-squared test is highly significant (p<0.001) but 
the proposed model predicts only 13% of the variance. Two variables - being registered with 
a GP and the baseline methadone dose in 2005 are the stronger predictors in the model. 
Multicollinearity was not a concern with tolerance levels  of .982- to .990 and VIF close to 1 
for all factors (details can be found in Appendix 7). 
 
Table 70. Positive drug screens: Complete dataset –highly significant predictors 
Predictor β (SE) Significance 
Constant -1.785 (0.784)  
Treatment setting 0.837 (0.534) P=0.117 
Baseline Methadone dose 0.046 (0.020) P=0.020 
Registered with GP -3.303 (1.268) P=0.009 
Baseline Diazepam dose 0.096 (0.050) P=0.056 
R2 = 0.824 (Hosmer&Lemeshow), 0.215 (Cox & Snell), 0.287 Nagelkerke. Model X2(5)=24.164; p<0.001. Model classifies 67% correctly [54% 
of +ve& 78% of –ve]. Before model, classifies 54% correctly. 
Cross validation 
The β values from this first regression were inserted into the following equation: 
P(Y)= 1/1+e-(b0+b1X1+b2X2+….+bnXn) 
When applied to the dataset ML=2  - the testing dataset,  this generates a series of 
predicted outcomes  for that dataset.  The predicted outcomes and observed outcomes in 
this novel dataset – ML=2 - can then be compared using a Chi-squared test, using the 
predictive model generated using the original dataset ML=1. The results are shown in Table 
71. 
Table 71. Cross validation: Observed and predicted outcomes – opiate +ve drug tests 
 Observed positives Observed negatives 
Predicted positives 29 28 
Predicted negatives 18 25 
Chi squared test: X
2
(1)=0.800; p=0.371. 
 
Though the chi-squared test has produced a non-significant result, observation of Table 100 
shows that this comes about because there is no discrimination between 
predicted/observed positive and predicted/observed negative outcomes. There is no 
relationship between observed and predicted outcomes. 
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Conclusion: Despite the univariate analyses suggesting these factors were strong predictors 
of illicit drug use (measured by positive tests recorded in casenotes), multiple regression 
analysis found the model to be a weak predictor of this outcome. When this weak model 
was applied to a novel dataset there was no relationship between observed and predicted 
outcomes, showing that the model was not generalisable.  
 
Regression 3:  Drug use – DV self-report of opiate use recorded in casenotes 
The significant variables identified from the longitudinal analyses are shown in table72. 
 
Table 72. Statistically significant associations – DV self-report of opiate use 
DV (outcome) IV (Predictor) Statistics 
 
Self - report of opiate use  
in 2009 casenotes 
Route of heroin use - baseline Chi squareX2(6)=30.699; 
p<0.001 
Treatment setting Chi square X2(6)=20.392; 
p=0.002 
Age LDA X2(1)=5.429; p=0.020 
Baseline Methadone dose LDA X2(1)=5.360; p=0.021 
Days heroin use at baseline LDA X2(1)=5.231; p=0.022 
Area lives in Chi square X2(6)=14.102; 
p=0.029 
Any heroin use at baseline Chi square X2(6)=13.867; 
p=0.031 
 
Developing a predictive model - Binary Regression Analysis  
In this case, as there were 7 potential variables to be included in the model – making sample 
size a significant issue if attempting to create a valid predictive model - the whole sample 
was used initially to develop a predictive model. 
 
First a complete dataset was created by removing all missing data. The complete dataset 
contained 193 cases of which 91(47.2%) had reported opiate use recorded in their 
casenotes in 2009. Some 102 (52.8%) did not have a self-report of illicit heroin use recorded. 
Sample size was adequate -106 (variables) or 111 (best fit) cases would be required. 
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Step 1 Regression analysis – whole dataset with selected predictors 
An initial binary regression analysis was undertaken using the two most significant 
predictors (p<0.005) – these were:  route of heroin use at baseline and treatment setting. 
The resulting model predicted 16.2% of the variance observed, was a good fit to the data (R2  
of 0.868) and the model Chi-squared test was highly significant (p<0.001) (Table 73). 
 
Table 73. Self – report: Complete dataset – selected highly significant predictors 
Predictor β (SE) Significance 
Constant 19.941 (40192.587)  
Treatment setting 1.319 (0.417) P=0.002 
Baseline route of heroin use -20.153 (40192.587) P<0.001 
R2 = 0.868 (Hosmer&Lemeshow), 0.167 (Cox & Snell), 0.223Nagelkerke. Model X2(6)=35.009; p<0.001. Model classifies 69.3% correctly 
[77.8% of +ves& 61.8% of –ves]. Before model, classifies 53.1% correctly. 
Step 2 Regression analysis – whole dataset with remaining predictors introduced 
All remaining predictors were then introduced to determine whether any improvement in 
the model was achieved. 
 
When all significant predictors (from the univariate analyses) were included this new model 
predicted only 68.6% correctly (65.6% of positives and 71.3% of negatives). The baseline 
model predicted 52.9% correctly – 15.7% of the variance is accounted for by the model. 
Also, R2 reduced to 0.835 (Hosmer & Lemeshow). The model Chi-square remained 
significant (X2(8)=43.526; p<0.001). Three factors were found to be significant contributors 
to the predictive model: Treatment setting (p=0.011); Baseline route of heroin use (p=0.012) 
and Age (p=0.042). 
 
Step 3 Regression analysis – whole dataset with only significant predictors 
These three significant predictors were then included in a new model. This only predicted 
67.2% correctly (67.8% of positives and 66.7% of negatives). R2 increased to 0.852 (Hosmer 
& Lemeshow). The model Chi-square remained significant (X2(7)=39.322; p<0.001). 
Though it had only predicted some 16.2% of the variance, it was felt that the original model 
was a more powerful predictor of self-reported opiate use, and showed better goodness of 
fit to the data. It also used only variables which objectively contributed to the model- 
reducing the number of predictors and increasing compliance with the rules set initially. This 
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model was therefore used as the basis for the cross validation process. Multicollinearity was 
not found to be a concern as tolerance levels were low and VIF 1.000 for all factors. 
 
Cross validation 
The complete dataset was divided into two elements ML=1  and ML=2 with 97 and 96 cases 
respectively.  
 
Sample size: this may not be adequate – Green’s equation for best fit would imply a sample 
of 108 is required. For assessment of variables’ contribution it would be 74.  
 
Training dataset (ML=1) 
A Binary Regression Analysis was performed using the preferred predictive model. The 
results are shown in Table 74. The model predicts 17.5% of the variance observed.  
 
Table 74. Training dataset (ML=1) – self-report of opiate use 
Predictor β (SE) Significance 
Constant 21.068 (40192.789)  
Treatment setting 0.868 (0.596) P=0.251 
Baseline route of heroin use -19.993 (40192.789) P=0.002 
R2 = 0.819 (Hosmer&Lemeshow), 0.221 (Cox & Snell), 0.295 Nagelkerke. Model X2(6)=24.181; p<0.001. Model classifies 71.1% correctly 
[75.6% of +ves& 67.3% of –ves]. Before model, classifies 53.6% correctly. 
 
Cross validation 
The β values from this first regression were applied to the dataset ML=2 - the testing 
dataset, generating a series of predicted outcomes for that dataset.  The predicted 
outcomes and observed outcomes in this novel dataset – ML=2 - were then be compared 
with the original dataset ML=1. The results are shown in Table 75. 
 
Table 75. Cross validation: Observed and predicted outcomes – self-reported drug use 
 Observed positives Observed negatives 
Predicted positives 26 42 
Predicted negatives 19 8 
Chi squared test: X
2
(1)=8.005; p=0.005 
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Again, observation of the table shows that there is no relationship between predicted and 
observed outcomes. The model was found not to be generalisable when applied to these 
novel data.  
 
Regression 4:   Positive record in casenotes indicating family stability  
 
The significant variables identified from the longitudinal analyses are shown in table 76. 
 
 
Table 76. Statistically significant associations – DV family stability 
DV (outcome) IV (Predictor) Statistics 
 
Family stability recorded in 
casenotes 2009 
Age LDA X2(1)=11.321; p=0.001 
Area lives in Chi square X2(4)=20.796; 
p<0.001 
Registered with GP  Chi square X2(2)=8.973; 
p=0.011 
Treatment setting Chi square X2(4)=12.301; 
p=0.015 
Has children Chi square X2(2)=7.723; 
p=0.0.021 
Support from other agencies Chi square X2(2)=7.712; 
p=0.021 
Baseline prescribed diazepam 
dose 
LDA X2(1)=4.993; p=0.025 
Illicit diazepam use Chi square X2(4)=10.699; 
p=0.030 
PTSD caseness Chi square  X2(2)=6.648; 
p=0.036 
 
Developing a predictive model - Binary Regression Analysis  
First a complete dataset was created. This complete dataset contained 189 cases of which 
114 (60.3%) had a positive report of factors indicating family stability recorded in their 
casenotes in 2009. 75 (39.7%) contained data suggesting poor family stability. Sample size is 
adequate. If all predictors were included, sample size should be between 113 and 122. 
 
Step 1 Regression analysis – whole dataset with selected predictors 
Using this complete dataset (n=189) an initial regression analysis was undertaken using the 
four most significant predictors– these were age, area lived in, registered with GP and 
treatment setting. The results are shown in Table 77. While it appears to be a reasonable fit 
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to the data, with the model Chi-squared test significant (p=0.002), the proposed model only 
predicted 7.4% of the variance observed. 
 
Table 77.  Family stability Complete dataset – selected most significant predictors 
Predictor β (SE) Significance 
Constant 3.900 (1.289)  
Age -0.067 (0.024) P=0.005 
Area lives in 0.930 (0.654) P=0.012 
Registered with GP -0.118 (1.722) P=0.946 
Treatment setting 0.073 (0.403) P=0.631 
R2 = 0.917 (Hosmer&Lemeshow), 0.105 (Cox & Snell), 0.143Nagelkerke. Model X2(6)=21.038; p=0.002. Model classifies 67.7% correctly. 
Before model, classifies 60.3% correctly. 
 
Step 2 Regression analysis – whole dataset with all significant predictors 
All 9 predictors from the univariate analyses were then entered into the model to determine 
whether any improvement was achieved. Results are shown in table 78. 
 
Table 78.  Family stability Complete dataset – all significant predictors 
Predictor β (SE) Significance 
Constant 3.391 (1.293)  
Age -0.067 (0.024) P=0.005 
Area lives in 0.930 (0.654) P=0.012 
Registered with GP -0.118 (1.722) P=0.946 
Treatment setting 0.073 (0.403) P=0.631 
Has children -1.257 (0.539) P=0.020 
Support from other agencies -0.395 (0.455) P=0.385 
Baseline diazepam dose 0.032 (0.022) P=0.146 
Illicit diazepam use -1.447 (1.037) P=0.015 
PTSD caseness -0.013 (0.408) P=0.975 
R2 = 0.806 (Hosmer&Lemeshow). Model X2(12)=39.131; p<0.001. Model classifies 72.8% correctly. Before model, classifies 60.3% correctly. 
 
When all significant predictors were included the new model showed some improvement. It 
predicted 72.8% correctly, representing 11.9% of the variance observed. Also, R2 reduced to 
0.806 (Hosmer&Lemeshow). The model Chi-squared test was highly significant 
(X2(12)=39.191; p<0.001). Two of the factors included, however, were found to be highly 
insignificant contributors to the model. These were registered with a GP (p=1.000) and PTSD 
caseness at baseline (p=0.975). These factors were then excluded for step 3. 
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Step 3 Regression analysis – whole dataset with insignificant predictors removed 
 All remaining significant predictors were then included in a new model. This new model 
predicted 72.4%  - explaining 12.1% of the variance observed. R2 was unchanged from step 2 
= 0.805 (Hosmer & Lemeshow) and the model Chi-square remained highly significant 
(X2(10)=40.926; p<0.001). The next two factors which were least significant were then 
removed from the model. These were treatment setting (p=0.610) and support from other 
agencies (p=0.385).  
 
Step 4 Regression analysis – whole dataset with further insignificant predictors removed 
Only significant predictors were then included in a new model. This model predicted only 
10.5% of variance observed. R2 increased to 0.841 (Hosmer & Lemeshow) while the model 
Chi-square remained  highly significant  (X2(7)=38.148; p<0.001). 
 
As model 3 predicted the highest proportion of the variation (albeit only 12.1%) with the 
least number of factors and acceptable goodness of fit, this model was used as the basis for 
the cross validation process. Multicollinearity was again not found to be a concern with 
tolerance levels ranging from .697 to .956 and VIF from 1.067 to 1.435. 
 
Cross-validation process 
The complete dataset was divided into two elements ML=1 (94 cases) and ML=2 (95 cases). 
Sample size is lower than required. For best fit sample sizes of 111 would be required while 
for variables, 106. 
 
A Binary Regression Analysis was performed using the preferred predictive Model 3. The 
results are shown in Table 79. In this subset, the proposed model is less of a good fit with R2 
reducing to 0.630. Model Chi-squared remains highly significant (p<0.001). The model 
however, predicts an increased 20.8% of the variance observed. 
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Table 79. Family Stability: training dataset  ML=1 (n=94 cases) 
Predictor β (SE) Significance 
Constant 6.057 (1.962)  
Age -0.093 (0.052) P=0.072 
Area lives in -20.594 (27710.084) P=0.335 
Has children -2.333 (0.962) P=0.012 
Baseline diazepam dose 0.014 (0.036) P=0.704 
Illicit diazepam use -4.027 (1.770) P=0.015 
Treatment setting -1.023 (0.761) P=0.179 
Support from other agencies -0.444 (0.687) P=0.518 
R2 = 0.630 (Hosmer&Lemeshow), 0.394 (Cox & Snell), 0.531 Nagelkerke. Model X2(10)=41.135; p<0.001. Model classifies 79.3% 
correctlyBefore model, classifies 58.5% correctly. 
The β values from ML=1 were then used to generate a series of predicted outcomes in ML=2 
using this predictive model.  A Chi-squared test was then undertaken to compare the 
predicted and observed outcomes in the novel dataset ML=2, using the predictive model 
generated using the original dataset ML=1. Results are shown in Table 80. 
 
Table 80. Cross validation: Observed and predicted outcomes – family stability 
 Observed stable Observed unstable 
Predicted stable 46 25 
Predicted unstable 0 3 
 Chi squared test: X
2
(3)=5.137; p=0.162.  
Though the chi-squared test has produced a non-significant result, observation of Table 80 
shows that this comes about because there is no discrimination between predicted and 
observed outcomes.  The proposed model is found not to be generalizable when applied to 
novel data.  
 
Regression 5:  Measures of Health status – NHS service use (Acute hospital admissions) 
Two proxy measures of “health status” were available in the database and were considered. 
These were:  
1. admissions to hospital (recorded in casenotes in 2009 – either contemporaneous 
notes or discharge letters) 
2. SMR01 records of number of nights in the acute hospital. 
 
Recorded admissions to acute hospital (casenotes) 
The variables to be used in developing this predictive model are shown in Table 81. 
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Table 81. Statistically significant associations – DV Admissions recorded in casenotes 
DV (outcome) IV (Predictor) Statistics 
 
Recorded acute admissions 
2009 
 
RX methadone dose LRA t(1)=-3.448; p=0.001 
Rx diazepam dose LRA t(1)=4.183; p<0.001 
Educational level achieved KWH(4)=15.447; p=0.004 
Treatment setting ANOVA F(2,8)=5.619; 
p=0.004 
Area KWH X2(2)=8.696; p=0.013 
Pain intensity LRA t(1)=2.366; p=0.018 
PTSD severity LRA t(1)=-2.312; p=0.021 
Registered with GP KWH X2(1)=4.657; p=0.031 
GHQ total score LRAt(1)=2.159; p=0.032 
 
As the outcome variable was continuous a linear regression analysis was planned. 
First, a complete dataset was created. All subjects with missing data relating to the relevant 
variables were removed. The resulting complete dataset contained only 17 cases. It was felt 
that no generalizable findings could be generated in this case. No further analysis was 
therefore undertaken using this outcome variable. 
 
SMR01 Acute hospital nights 
The two variables to be used in developing this predictive model are shown in Table 82. 
 
Table 82. Statistically significant associations – DV SMR01 Acute admissions 
DV (outcome) IV (Predictor) Statistics 
SMR01 – acute admissions 
2005-9 
Presence of pain MWU=5349.000; p=0.035 
Methadone dose LRA t(1)=2.187; p=0.030 
 
As the outcome variable was continuous a linear regression analysis was planned. 
First, a complete dataset was created - all subjects with missing data relating to the relevant 
variables were removed. The resulting complete dataset contained 96 cases with an SMR01 
record of admissions and no missing data.  Sample size recommended would range from 66 
cases to 106. 
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A multiple linear regression was undertaken on the complete dataset. The predictor 
presence of pain is categorical. In order to include this in the analysis it was recoded to zero 
and one as a “dummy variable”. The results of the regression analysis are shown in Table 83. 
 
Table 83. SMR01 admission nights: Complete dataset 
Predictor β (SE) Significance 
Constant -3.442 (16.550)  
Methadone dose 0.100 (0.133) P=0.455 
Presence of pain (BPI) 11.751 (7.055) P=0.099 
 
The fit of the regression model was assessed. R2 was 0.036 – showing that only 3.6% of the 
variance is explained by the model. ANOVA gave a result of F(2,8)=1.740; p=0.181. This 
shows that the model is not a significant fit of the data overall.  There is an assumption that 
any errors in the regression are independent. This is tested using the Durbin-Watson 
statistic which in this case this was 1.406. This statistic should be close to 2 (and between 1 
and 3). This assumption is therefore met. Multicollinearity was not a concern as VIF was 
1.003. 
 
Conclusion: It was concluded that the model proposed by these data is not a good 
predictive model of nights in an acute hospital ward as recorded by SMR01 returns. In such 
circumstances, no cross validation was undertaken. 
 
Discussion 
 
The multiple regression analyses have shown that, despite apparently strong associations 
found in the univariate analyses, it has not been possible to create strong predictive models 
for the selected outcomes. This could reflect a number of issues.  
 
Data quality and sample size 
The quality of available data - in particular the amount of missing data - meant that the 
creation of a complete dataset removed a large proportion of certain variables. For 
example, in the regression attempting to predict deaths, the complete dataset contained 
only 15 of the 45 deaths on the database. Death is a rare event – and prediction is difficult - 
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but clearly, this level of missing data is likely to have influenced the result. The loss of 
subjects could also have affected the sample size which, especially as the dataset was split 
into training and testing groups, fell below the recommended levels.  
 
Multicollinearity of predictors 
One effect of multicollinearity is to reduce the potential size of R. It was possible that this 
could have reduced the overall predictive value of the models generated. In order to 
determine whether this was an issue, the degree of multicollinearity was assessed for all 
models using the Variance Inflation Factor output from SPSS and the associated tolerance 
levels. This assessment found no evidence of a significant influence from multicollinearity. 
SPSS diagnostic outputs are shown in Appendix 7. 
 
Cross-validation 
The process of cross-validation adds more rigour to the regression analysis process. 
However, by splitting the dataset in half any statistically significant findings become more 
difficult to achieve. If they are achieved – and a valid predictive model is found – the process 
of cross-validation could demonstrate more robustly the predictive value of the model by 
testing the model on observed outcomes in a novel (untested) dataset.  
 
In this project, however, none of the models generated were found to be strongly predictive 
– even when univariate analyses had shown individual predictors to have highly significant 
relationships with outcomes over time. Those models generated, which were found to have 
some limited predictive value, were further assessed using a cross-validation exercise. But in 
none of these three outcomes – drug use (self - report); drug use (positive tests filed); family 
stability – was the model found to be generalisable to a novel dataset.  
 
Testing the cross-validation approach 
It is important to determine whether there has been any error in executing the cross-
validation exercise. If it is clear that the method used would have been successful if a strong 
predictive model were tested then the failure to positively discriminate outcomes reflects 
the weakness of the model - i.e. the lack of predictive value - and not some methodological 
failing in the study. 
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In order to determine whether the cross-validation exercise was appropriate (i.e. was likely 
to demonstrate generalisability) a multiple regression and cross-validation exercise was 
undertaken using a correlated novel dataset.  A comprehensive description of this test is 
contained in Appendix 6.  
 
This test demonstrated that the approach taken was valid. 
 
 
In conclusion 
 
The multiple regression analysis has shown that even in relatively large samples of OST-M 
patients (compared to many in the published literature), highly statistically significant 
findings from univariate analyses may not form the basis of a strong predictive model. Even 
when a reasonable degree of prediction can be demonstrated by the multiple regression, 
this model may not be capable of predicting outcomes in novel datasets. The cross- 
validation exercise has demonstrated that more rigorous testing is a valuable addition when 
testing the predictive value of these models. 
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Chapter 10. Discussion 
 
All that is gold does not glitter, Not all those who wander are lost.  
J.R.R. Tolkien 
It is good to have an end to journey toward; but it is the journey that matters, in the end. 
Ernest Hemingway 
Introduction 
This chapter will discuss the strengths and weaknesses of the research described in this 
thesis. It will also consider the clinical relevance of the project – in terms of the process 
(using clinical data to assess longer term outcomes in a large, UK – based clinical sample) 
and implications for future research and development. 
 
The thesis describes a series of separate studies in the same treatment sample. The initial 
baseline review was stand-alone work, undertaken for clinical reasons, but developed to be 
more systematic by the introduction of validated tools. This was then used as the basis for 
identification of the follow up study cohort in 2009. Finally, the SUMIT project delivered 
access to additional validated datasets and also an environment – the HIC Safe haven – 
within which the separate datasets could be linked and anonymised, with appropriate 
governance and security in place – delivering the complete Tayside Methadone Cohort 
database.   
 
This naturalistic approach brings strengths and weaknesses. 
 
Strengths of the study 
 
Setting 
This study is set in NHS treatment services in the UK. The services involved in the project 
represent a common example of the treatment approach/environment in Scotland and 
across the UK as a whole. Specialist NHS services deliver medical treatments and specialist 
counselling or psychological interventions, supported by a General Practice “shared care” 
scheme (for those less complex patients who are in no need of specialist care). Additional 
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dedicated Criminal Justice Services are available to some patients involved with the justice 
system as a result of their drug problem. All of these services are supported by a range of 
local authority and third sector services offering specific interventions to address a broad 
range of relevant issues including childcare, family stability, employability and 
homelessness. As in many parts of the country, the services being accessed by the subjects 
of this study are not located in one discreet locality – instead being delivered in a range of 
urban, rural and semi-rural settings in three very different local authority areas. However, 
the protocols overseeing service delivery (e.g. prescribing practice) are standardised across 
the NHS Board area – meaning observed variation should reflect more specific patient 
differences and be less affected by variation in practice by locality services. The geographical 
area of “Tayside” is often seen in Scottish terms as “representative” of many of the Scottish 
NHS Board regions – encompassing inner city areas of high deprivation, small and large 
towns and a considerable rural hinterland with patchy levels of social exclusion. The Tayside 
Methadone Cohort sample is therefore likely to be more representative of “standard” UK 
service users than those seen in some studies. 
 
In the Scottish context, the research and service-evaluation evidence available to plan 
services has been dominated by work done in the two large cities – Edinburgh and Glasgow. 
The services in which that work is set, has reflected local history, however. For example, the 
HIV epidemic in Edinburgh in the 1980s generated the opportunity for very long term 
follow-up of a specific cohort of individuals in one deprived area of the city (e.g. Kimber et 
al, 2010). Simultaneously, Glasgow specialists and GPs resisted harm reduction approaches, 
only launching a GP-led methadone service in 1994. This has grown into one of the largest in 
Europe and its standards are often described as being of the highest level. Despite this 
apparent success in terms of the care process – access and retention - Glasgow still sees the 
highest levels of drug death in the UK (ISD, 2012). It seems likely that this reflects local 
phenomena. It is important to consider the degree of generalisability of research findings. 
 
Over 70% of substance misusers in Scotland are not found in Edinburgh or Glasgow. There is 
an urgent need for research which is more relevant to those services outside the major 
conurbations where service delivery is less concentrated and the controls available in the 
inner city (easy access to 7 day dispensing, for example) may be unachievable. 
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This study is one of the first large studies of long-term outcomes in substance misusers in 
treatment delivered in Scotland.  
 
International relevance 
This study has been based in a UK treatment system and has emphasised the need for 
longitudinal research with relevance to UK practice. As well as being important in terms of 
the Scottish and UK treatment system, however, the study also has international relevance. 
There is a strong, long-standing international consensus regarding the place of OST-M in the 
treatment of opioid dependency and any challenge to this view has historically been 
perceived to be hostile (e.g. Newman 2005). However, on reviewing the international 
evidence, it is clear that significant gaps remain in our understanding of the strengths and 
weaknesses of this treatment – especially when the existing evidence-base is challenged 
regarding the delivery of Recovery outcomes and progress from OST-M (NTA, 2012). 
Consolidation and development of the evidence base is required to ensure that the use of 
OST-M is scrutinised objectively, its potential risks reduced and its effectiveness maximised. 
The current study addresses some of the weaknesses in the international evidence, 
identified by previous systematic reviews (e.g. Lingford-Hughes, Welch, Peters & Nutt, 
(2012). 
 
Sample size & cases available for follow up 
One of the main strengths of this study is the size of the sample. Initially 647 of a total 
treatment population of 817 patients in a Scottish regional service were assessed using a 
validated assessment tool (the Maudsley Addiction Profile). When data were cleaned and 
invalid identifiers removed this still left a large baseline sample of 623 cases. This represents 
more subjects than most long term studies carried out in the UK. A high proportion of cases 
were also available for the follow up study. Some 467 of Tayside OST-M cases were followed 
up at 4 years – 75% of the baseline sample. NTORS - a good comparison as a longitudinal UK 
study following patients up for 5 years – had a baseline population in Methadone 
Maintenance [OST-M] of 458 cases (plus a further 209 described as being in Methadone 
reduction) of which 46% were followed up at 5 years. DORIS, the main comparable Scottish 
study recruited less than 300 cases in OST-M with some 47% followed up at 33 months.  
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Other recent UK studies have examined large samples over longer periods. McCowan, Kidd 
& Fahey (an earlier study using the data held in the Dundee Health Informatics Centre) had 
tested the use of linked datasets to examine a sample of 2378 Tayside GP-prescribed OST-M 
patients who were followed up over 11 years using SMR-linked data to imply outcomes. No 
rich in-depth clinical information was collected in that study, however. The researchers 
simply utilized data available in standard NHS databases – but the size of the sample and the 
long follow up period gave valuable information regarding potential future research to 
better understand risk/protective factors for death in these patients (McCowan, Kidd & 
Fahey, 2009). Another large Scottish sample was reported by Kimber et al (2010). This 
sample consisted of injecting drug users initially recruited in the 1980s and followed up in 
depth for over 30 years. Some 557 of that sample were reported to have had some OST at 
some stage in that period (Kimber et al 2010).  
 
The approach described in this thesis offers a potential model to further develop rich 
datasets, describing large representative samples which could be tracked over long time 
periods, allowing more consistent and relevant outcomes to be measured in these 
populations than is often the case in the international literature. This would also create the 
environment within which original research could flourish – allowing assessment of the 
impact of a range of factors on development of addictive behaviours, associated risks and 
long term clinical outcomes. 
 
Length of follow up with a representative sample 
The follow up period of 4 years (for clinical data from casenotes) and up to 7 years (for the 
HIC linked datasets) is a real strength of this study. Many research studies in this field are 
descriptive, with no longitudinal element. Those that do tend to report on short term 
outcomes – often less than one year – and this has been cited as a weakness for even the 
more well-constructed and more rigorous research studies, cited in recent systematic 
reviews (e.g. Lingford-Hughes et al 2012; Gowing et al 2011; Faggiano et al 2008; Mattick et 
al 2009). In the context of a chronic relapsing condition in which 5 years’ stability is seen as 
a reasonable indicator of success (Hser, 2007) it is valuable to take a long view of progress 
to allow an understanding of the natural history of the condition as well as progress through 
treatment. Indeed the early US longitudinal studies acknowledged that the effectiveness of 
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individual treatments is difficult to discern in the context of patients in the clinical setting 
moving through different treatments over time.  
 
While research into short term outcomes give an indication of the challenges experienced in 
the early stages of treatment, it is clear that those in treatment for longer periods - years or 
even decades - face different challenges. As clinicians are challenged to evidence the 
recovery outcomes delivered by OST-M, these deficits in supporting evidence have become 
a vulnerability. Developing research programmes based on the type of approach used in this 
thesis would allow the impact of treatment to be more comprehensively and meaningfully  
assessed. 
 
Outcomes not process 
The study has taken care to collect data on a range of treatment outcomes – as well as some 
process measures. Many studies in the published literature focus simply on treatment 
processes. On occasion aspects of process can be seen as helpful proxy measures of 
treatment success – for example retention in treatment has been described as an outcome 
by many in original research. However, it is important that meaningful valid clinical 
outcomes are reported if the effectiveness of treatment is to be demonstrated. This study 
has, for example, shown a disparity between different outcome measures which would be 
expected to show a high degree of correlation - with self-report of heroin use not consistent 
with the laboratory findings on drug screens. Previous reviewers have commented on this 
weakness – and it may be important that researchers – at the very least acknowledge that 
some of the outcomes measured (perhaps adopted as they are more readily available in the 
research setting) require closer scrutiny.  The outcomes chosen also need to include more 
socially-orientated measures of success to better inform the developing recovery 
aspirations of those in treatment across the world. 
 
Ultimately, political and social concern about these programmes reflects, to some extent, an 
inability to demonstrate measureable change in substance misusers in those aspects of their 
condition in which society expects to see progress. Academics should consider how best to 
address these information deficits – by constructing high quality research projects which 
address specific testable hypotheses in representative samples.  
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Co-morbidities – novel research 
This thesis addresses some common co-morbidities and presents initial findings. Pain and 
substance misuse are common bedfellows and are problematic clinical syndromes to 
manage, even when they present in isolation (BPS, 2007). Yet no longitudinal studies in the 
UK have to date, reported on the relationship between co-morbid pain and substance 
misuse outcomes. The most recent UK national treatment guidance could only cite cross-
sectional descriptive research from the USA (Department of Health et al, 2007). Little 
longitudinal research exists in the international literature with regard to the relationship 
between pain and outcomes on OST-M. Although one US study has assessed 1 year 
outcomes in small sample of OST patients (Ilgen et al 2006), there is a need to duplicate and 
develop this work in the UK health system. 
 
Other co-morbidities also require more in-depth investigation if their role in the 
development, maintenance of and recovery from substance misuse is to be understood. A 
range of mental health problems are common in the substance misuse population – but it is 
unclear what relevance they have in affecting an individual’s ability to recover and progress. 
Mental disorders could drive the development of substance misuse. Alternately, substance 
misuse might lead to development of a mental disorder or both conditions could develop in 
the context of common vulnerabilities. Managing mental disorder in substance misusers 
could be a crucial area of work required to maximise recovery outcomes for those in OST-M.  
 
The Tayside Methadone Cohort has demonstrated that the routine assessment of these co-
morbid conditions can be achieved in standard NHS services and has delivered initial 
research into their associated outcomes. 
 
Casenote process  
The rigour of the casenote follow-up process managed to collect a valuable dataset which 
was quality assured and only recorded those findings which could be validated. If there 
were discrepancies or conflicting information in the casenotes, a “missing” status was given 
in this case. The main disadvantage in this element of the study was the poor quality of the 
casenotes themselves. Missing information or poor filing meant that in some fields, missing 
data were recorded. Though a challenge during this project, this issue could be addressed 
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when the SUMIT project systems are fully operational – as access to higher quality data 
from SMR forms as well as more use of standardised data collection “forms” in the clinical 
casenotes would reduce the gaps in data. 
 
SUMIT and data-linkage 
The data-linkage process, brought to the study by the SUMIT project and supported by the 
Health Informatics Centre, has shown that it is possible to develop operational data 
management systems which have multiple uses but maintain data security. SUMIT was in 
development during the data collection and analysis phase of this project and early 
difficulties – such as the lack of availability of key data due to slow development of the NHS 
MIDIS system – meant that validated data from the Treatment Outcome Profile or SMR25b 
as well as comprehensive laboratory data and virology information (HIV and Hepatitis C 
status) could not be included in the analysis.  
 
In future there is an expectation that local authority and third sector data will also be 
available to make our understanding of each case richer and more complete. Data-sharing 
agreements are in place to allow this within SUMIT and local authority data from two of the 
three areas is currently being fed into the HIC safe-haven where it will be available for 
future analysis. Such an approach will remove the need to use self-report data on housing, 
criminal justice, parenting/child protection, employability and other key outcome areas 
potentially impacted on by OST-M treatment. 
 
Comprehensiveness of the analysis – use of multiple regression and cross-validation 
Many studies proposing predictive models in the published literature describe less rigorous 
approaches than that undertaken in this study.  Some do perform multiple regression 
analyses, but often in datasets collected in a single cross-sectional study at one time point, 
drawing conclusions about the ability of these models to predict future outcome despite no 
follow up component. Others describe a series of univiariate analyses, essentially mining 
large datasets to find a range of associations over time. Both approaches are valuable initial 
steps but cannot demonstrate the ability of any predictive model to predict true outcomes 
in novel data. These pilots should be followed by more systematic research projects, which 
scrutinize the true predictive value of any associations demonstrated. 
234 
 
This study has adopted a more rigorous method. A systematic literature review informed 
the selection of independent and dependent variables and testing was underpinned by a 
series of hypotheses relating to the current understanding of relationships between 
predictors and outcomes. The findings of these univariate analyses were then used to 
inform multiple regression analyses which aimed to produce models to predict key, clinically 
relevant outcomes. This process was in turn exposed to a cross-validation exercise which 
demonstrated which models were potentially generalisable and which were not. Essentially, 
the predictive value of the model was tested against the actual outcomes observed in a 
different/novel sample.  
 
It is an important finding of this study that strong, statistically significant, associations over 
time, demonstrated in the univariate analyses, did not result in useful strong predictive 
models. The few weak models developed did not generalise to novel datasets. Using 
generated data it has been possible to show that the approach taken is valid and would be 
expected to demonstrate predictive power if it were present.  
 
This is an approach which would greatly improve the evidence base in these complex cases 
and help us to understand the relative importance of the many factors which may affect 
outcomes in OST- M patients. 
 
Weaknesses of the study 
 
Study design - Retrospective cohort study 
Study design has reflected the way data became available during the study process. 
Consequently the study design reflected data which had emerged from clinical processes 
and did not reflect a standard hypothesis – driven prospective study. However, the study did 
generate testable hypotheses regarding the relationships between factors identified in the 
evidence base as being influential regarding outcome and undertook initial testing of these 
hypotheses. These effects were then included in regression analyses. While it could be 
assumed that some of the factors tested – such as gender or age – may be confounding 
variables – confounding “by indication” – it is likely that this would have resulted in 
unacceptable levels of multicollinearity  during the regression analyses. Tests did not show 
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this to be the case.  Alternative statistical approaches  - such as causal modelling - could be 
considered which would reduce the likelihood of bias in future studies, allowing 
identification of confounders and specific hypotheses to be tested. 
 
Clearly the retrospective nature of the study is a weakness. The ideal approach would have 
been to identify new treatment-naïve patients and follow them-up over time in a 
prospective longitudinal study. However, it could be argued that one of the key current 
issues to be addressed in this field is how best to adjust the approach to treatment for those 
who have been on OST-M for many years. It is this very population – longer term opioid 
prescribed patients [often described as “parked on methadone”] who are the basis of much 
of the socio-political debate of the present day. In the recovery literature, it is clear that the 
current research evidence base is of little value in understanding how best to improve 
outcomes for this group.  The current study would have been strengthened if data on 
previous treatment or length of time in treatment data were available.  Neither of the 
recent reviews of the recovery literature in substance misusers (Best et al 2010; Bell, 2012) 
could cite rigorous and convincing research to inform the development of services more 
likely to deliver progress in treatment beyond the standard harm-reduction outcomes. 
 
Research into how best to improve patient outcomes and progress towards recovery is 
urgently required. The basic infrastructure in place from this project could be used to 
generate hypotheses which will be the subject of prospective longitudinal follow up studies 
in the future to address these issues. 
 
In a future study using similar linked datasets it would be valuable to include other datasets 
which would offer a richer understanding of each individual’s progress through the 
treatment process. 
 
Baseline sample 
There are a number of specific weaknesses in the baseline element of the study. 
Representativeness – it was disappointing and surprising that the large baseline 
sample was found not to be representative of the treatment population as a whole using 
the demographic variables chosen. This may have reflected the data collection process 
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during the 2005 review, meaning that a particular group, who were ‘hard to reach’ or 
resistant to attending, were only seen late in the process – by which time the database used 
in this study was already completed. It is, however, important to recognise that this remains 
one of the largest OST-M samples described in the UK and world literature. It has been the 
case in the international literature that sample size or representativeness is difficult to 
determine. Many publications citing large samples may have a similar issue of selection bias. 
Indeed, studies such as NTORS and DORIS have clear selection bias as subjects were self-
selecting to a particular treatment intervention. In future studies it would be useful, if time 
was available, to carry out an additional data collection process to access more detailed 
information on the cases unavailable at baseline. 
Missing information – The study was limited by being based on existing data 
collected in the clinical setting. There was no opportunity in this study to return to collect 
data on subjects not included in the original clinical exercise- though some data on 
demographic characteristics was available from HIC linked datasets – allowing tests of 
representativeness. Some information which would have been very valuable, therefore, was 
not available without a further data collection exercise which was not feasable. For 
example: richer data on the duration and outcomes of previous treatment episodes or 
experiences would have been extremely useful and clearly has relevance; the duration of 
the current OST-M episode; valid data on criminal justice outcomes; more detailed 
information on other service involvement – including mental health services. This 
information clearly has the potential to strongly influence outcome and mechanisms to 
reduce this deficit would be included in any future study design. If missing data remained a 
challenge – a common problem with large datasets using routine data – statistical 
approaches such as a form of imputation of data could be used to resolve these issues. This 
may be unsuitable for some variables where a large proportion  of data were missing. 
Indeed, since the completion of this pilot, as SUMIT has become the basis for clinical 
information management in Tayside, much of these data are now available routinely on new 
cases, if requested and missing data may be less of an issue. 
Tools used - Not all the data-collection tools used were ideal. This reflected the 
“clinical” nature of the initial data collection and the local opinions regarding the tools best 
suited to the task. For example, a range of screening tools for ADHD in adults were not 
available in 2004 when the study was being developed. The Current Symptoms Scale 
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(Barklay & Murphy 1998) – a screening tool for symptoms suggestive of ADHD in children – 
was recommended by local Child & family Psychiatrists with expertise in the ADHD field as 
the most useful and adaptable tool available for use with adults at the time which was also 
quick and easy to use. Since then, new, rapid, adult screening tools have become available – 
such as the WHO screener (WHO, 2003).  The Impact of Events Scale (Horowitz, Wilner & 
Alvarez, 1979) was recommended by local clinical psychologists, who regularly screened 
individuals for trauma using this tool in the NHS addiction services. This tool is regularly 
used to screen for PTSD in a range of populations. It was at the database development and 
data entry stages of the study that it became apparent that the tool used in the Tayside 
study had been superseded by an extended version, not used in the local services (Weiss & 
Marmar, 1997) – making the findings for this work less valuable in the research field. 
Process of baseline data collection – lack of complete data - The time pressures 
during the original review reflected the fact that the process was a clinical one and had 
clinical drivers and timescales. This meant that the “clean team” was forced to reduce the 
information collected on some subjects. This inevitably reduced available data for some 
variables. 
 
2009 follow up data – casenote information issues 
Though the process of data collection was rigorous and quality assured, the quality of 
casenotes meant that follow up clinical information was sub-optimal. This meant that the 
researcher recorded data as “missing” – for example when there was conflicting information 
in different casenotes on a particular subject. This becomes clear when “hard” data from 
(for example) laboratory tests is at odds with “self-report” data on illicit drug use. 
 
SUMIT – timing – delays in delivery of key reports: TOP,  SMR25b and MIDIS forms 
The planning of this study coincided with the creation of the SUMIT system. This system has 
great promise – but its early stages coincided with the development of the NHS MIDIS 
electronic casenote system.  MIDIS allows clinicians to complete validated forms - such as 
the Treatment Outcome Profile – TOP (NTA, 2007) or Assessment of Recovery Capital – ARC 
(Groshkova, Best & White 2012) - as part of their normal clinical work. It was planned that 
such data would be collected in 2011 as part of standard clinical processes – making patient 
identifiable outcome data, collected using validated tools, an element available for the 
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current thesis. However, the MIDIS data system took much longer to deliver than 
anticipated – meaning that these data were not available as the research project reached 
key milestones.  
If these data had been available then the 2009 casenote review data would have been seen 
as a pilot – with the stronger data in place for the final analysis, alongside the already-
validated HIC data. It is likely that this would have removed some of the need to interpret 
ambiguity in the recordings in casenotes and would have ensured more complete datasets. 
Crucially, it would also have allowed assessment of more recovery-orientated data than was 
available in normal clinical recording. 
 
HIC late delivery of laboratory results 
As well as the MIDIS issues described above, HIC were also challenged by this project 
regarding availability of data. Project timeframes coincided with key HIC technical staff 
leaving their posts and delays were experienced in accessing some of the datasets and 
linking them with TMC. In particular, two datasets planned to be part of the linked dataset 
were not available when required – GP prescribing data (data is available on all GP 
prescriptions in Tayside – as was used in McCowan, Kidd & Fahey, 2009) and laboratory 
tests (which would have included all drug screens undertaken in any setting as well as HIV 
and Hepatitis C test results). It is clear that use of hard valid measures of outcome would 
provide stronger evidence of the effectiveness or otherwise of treatment and BBV sero-
conversion would be a valuable addition. 
 
Proof of Concept 
Clearly the strength of these analyses and the ability to scrutinize more comprehensive and 
recovery-orientated data would have made the final study outputs more powerful. 
However, the sample size, length of follow up and strength of much of the data used make 
this study an important proof-of-concept which may be developed further as a research tool 
as the clinical systems become more reliable and the data more valid. 
 
Clinical significance of this research 
This research has used data from standard NHS clinical systems to develop a comprehensive 
dataset which has allowed hypotheses to be tested and outcomes to be validated. It has 
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given access to a large sample of OST-M patients and has followed them up over a long 
period. The failings of the study, described above, perhaps make the conclusions of this 
work of less relevance than the implications of the process which has been piloted for the 
first time here. 
 
Substance misuse is a chronic relapsing condition which can take a lifetime to overcome 
(Hser, 2007). It is a hazardous activity associated with high levels of morbidity and mortality 
and is a high profile area of clinical work, often raising political and social debates about 
how best to manage the problem. Harm reduction has altered the course of substance 
misuse, and in-particular the impact of injecting heroin use in the UK. This has not been 
associated with a coordinated drive to consolidate the evidence base, however. Now, as 
political concerns drive the direction of treatment, yet again, it is more important than ever 
that good quality research underpins the evolution of clinical practice. This can only occur in 
the presence of UK-relevant, long-term prospective studies of representative samples in 
treatment.  The process piloted here has the potential to deliver this. 
 
Recommendations for future research 
 
Process 
The study has given a proof-of-concept regarding the use of the SUMIT system to bring 
together relevant data to allow longer term research, addressing a wide range of outcomes, 
in large representative samples.  The deficits reflect the available data and it is clear that, 
now the SUMIT project has the ability to deliver more consistent data in a range of fields – 
many more relevant to the recovery agenda – a prospective, longitudinal follow-up study 
should be planned and delivered. 
 
Hypothesis-driven research 
The hypothesis – driven element of this study has re-iterated some of the facts already 
known from the international literature. The univariate analyses have shown that previous 
drug history (in this case illicit heroin use at baseline) was associated with 4-7 year 
substance use outcomes. Higher methadone dose at baseline was associated with better 
clinical outcomes and certain aspects of service delivery - such as having support from 
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external agencies or being registered with a GP for General Medical Services – were also 
associated with positive treatment outcomes. Use of illicit diazepam was associated with 
poorer outcomes. It is striking that the nature of the service delivery – e.g. primary care or 
specialist care - and, to some extent, the locality in which a person resided - were associated 
with considerable variation in outcomes. This inconsistency is a finding which has been 
commented on by previous researchers (Gossop, Marsden & Stewart, 1998). The 
longitudinal US studies commented on the importance of the nature of therapeutic delivery. 
Further study of this factor would be an important element in improving the ability of 
services to deliver recovery. 
 
Unfortunately, as a result of deficits in the final dataset, the study has not been able to 
explore in depth the relationship with a number of outcomes, including social outcomes - 
relating to family life or work. These are areas in which further high quality longitudinal 
research is required if recovery is to be realised.  
 
Choosing alternative statistical approaches – such as causal modelling – and, where 
appropriate, considering development of clinical trials (for example in those areas where 
specific treatment interventions can be tested) would be useful developments of these 
data-collection systems.  Trials could focus on aspects of treatment delivery – setting, 
therapies offered, etc.  
 
The recovery agenda in the UK requires that research should focus on long term recovery 
outcomes. This does not mean that harm reduction outcomes are irrelevant. Indeed, some 
opponents of the move towards recovery seem to see it as, in some way, a challenge to 
harm reduction and therefore a backward step. It is clear, however, that one important 
measure of success in the area of recovery would be an ability to demonstrate that new 
treatment approaches were not associated with deterioration in harm reduction outcomes 
and achievements. 
 
In Conclusion 
The treatment of substance misusers in the UK continues to be in need of a convincing 
evidence base which can demonstrate that patients in the UK are receiving treatments 
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which deliver the progress they are seeking and secure socio-political support for the 
treatments that work. 
 
The Tayside Methadone Cohort study, described in this thesis, has demonstrated that it is 
possible to use standard clinical data to generate hypotheses, test these using univariate 
analyses and then use these results to develop a testable predictive model for clinical 
outcomes in an OST-M sample. 
 
Future research using a similar system – such as the SUMIT system in Tayside – would 
ensure that research addressed long term outcomes in large representative UK samples. 
This, in turn, could generate evidence around the recovery agenda and would influence the 
debate regarding the future balance of substance misuse treatment services in the UK. 
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Appendix 1 Rating scales used and coding process  
Choice of instruments/tools 
The project uses data collected using instruments which were chosen by the clinical team 
for reasons of applicability in the original baseline data-collection exercise. Issues which 
influenced choice of instrument included its brevity or ease of use, availability for self-
completion, familiarity with front line clinicians and evidence of validity and specificity. 
Demographic and substance misuse information 
The baseline assessment by the “clean team” included elements of the assessment which 
used standardised instruments with some applicability in research. The tools used, however, 
primarily reflected standard clinical practice in the clinical service (e.g. the use of the 
Maudsley Adiction Profile, Injecting Risk Questionnaire and Treatment Perception 
Questionnaire).  A tool was also created to collect basic demographic information in a 
standardised way during the interviews – as at the time basic information on family 
circumstances etc. was lacking in the clinical records. 
Co-morbidities 
Psychiatry and psychology staff requested that specific tools be used to assess common co-
morbidities. These included:  
 the Impact of Events Scale – IES -  (to assess trauma and PTSD and help to direct 
treatment of trauma issues);  
 the Social Phobia Diagnostic Questionnaire – SPDQ  -  (to assess presence of Social 
Phobia with a view to offering Cognitive Behavioural Therapy interventions) 
Psychiatrists within services were concerned about diagnosis of ADHD in some patients. No 
routinely – used brief screening tools were available for use with adults in 2005. It was 
unlikely that staff would have time to administer larger diagnostic tools. The team consulted 
a local child/adolescent psychiatrist with special expertise in the diagnosis and treatment of 
ADHD in children and adolescents. The Current Symptoms Scale (CSS) was recommended for 
the exercise. 
Specialist services/professionals, also involved in jointly managing opiate dependent 
patients with the clinical teams, requested specific assessments. Examples include the 
Chronic pain questionnaire. This is based on the Brief Pain Inventory (BPI) but also includes 
specific fields used by local pain services).  
The main instruments used are discussed briefly below. Examples/illustrations  of the data 
collection tools are included. 
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Maudsley Addiction Profile (MAP) Plus Injection Risk (IRQ) and Satisfaction (TPQ) 
Introduction 
The MAP is a brief, interviewer administered questionnaire which is useful in treatment 
outcome research. It measures problems in four domains: substance use, health risk 
behaviour, physical &psychological health, and personal/social functioning.  It was 
developed in the UK for assessing people with drug and alcohol problems and was designed 
as a core research instrument and to be a resource for treatment services wishing to 
undertake outcome studies (Marsden et al 1998). 
 
Key advantages of the MAP: 
 Developed in the UK - relevant to UK practice 
 Brief to administer – when compared to other research tools (e.g. Addiction Severity 
Index – ASI (McLellan et al. 1980; 1992) and Opiate Treatment Index - OTI (Darke, 
Ross & Teesson, 1992).  
 Can be used repeatedly for outcomes research. All measures can be repeatedly 
administered at points after an index treatment episode. allowing observation of 
changes while in treatment 
 Previously used in UK research – allowing comparison with existing findings 
 
Domains assessed 
Three problem domains are assessed in the MAP: 
 drug and alcohol consumption 
 injecting and other health risk behaviours (Strang, 1992). 
 health problems 
 personal/social functioning (Including relationships, employment and crime) 
 
Practical applications 
The authors recommend a “modular approach” is taken to allow comparison of data 
between services and over time. They also endorse use of additional tools to measure 
needle/syringe sharing - Injecting Risk Questionnaire (Stimson, et al., 1998) and patient 
satisfaction - Treatment Perceptions Questionnaire  - TPQ (Marsden et al., 1998). 
 
Use of the instrument 
Detailed information on the use of the MAP, its scoring and analysis is contained within: 
Marsden J,  Gossop M,  Stewart D, Best D, Farrell M, Strang J (1998) The Maudsley 
Addiction Profile. A brief instrument for treatment outcome research. Development and 
User manual. London. National Addiction Centre/Institute of Psychiatry 
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NHS Pain Services Chronic Pain Questionnaire (includes the Brief Pain Inventory – BPI) 
 
Introduction 
The Brief Pain Inventory (BPI) is a brief, self-administered questionnaire to assess pain 
severity. It was developed for use in cancer patients but had been used in published studies 
of patients with both cancer pain and non-cancer pain. The BPI was shown to be reliable and 
valid when used in non-cancer pain patients (Keller et al 2004). Cronbach alpha reliability 
ranges from 0.77 to 0.91 
 
Key advantages of the BPI/NHS data collection tool 
The BPI was available in two formats: the BPI short form (used for clinical trials) and the BPI 
long form, which contains additional detailed descriptive items  - e.g.  pain descriptors. For 
brevity’s sake and for the patient’s ease of use, the short form was recommended as used in 
local pain services. 
 
Domains assessed 
The BPI tool collects information on the severity of pain, location of pain, impact of pain on 
daily function, pain medications received and amount of pain relief in the past 24 hours or 
the past week . 
 
Practical applications/Use of the instrument 
The BPI can be used in any patients with pain from chronic diseases or conditions such as 
cancer, osteoarthritis and low back pain, or with pain from acute conditions such as 
postoperative pain. The questionnaire is completed by either self-report or interview and 
takes five minutes (short form) or 10 minutes (long form) to complete. There is no scoring 
algorithm, but "worst pain" or the arithmetic mean of the four severity items can be used as 
measures of pain severity. The arithmetic mean of the seven interference items can be used 
as a measure of pain interference. 
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General health Questionnaire – 28 item (GHQ28) 
Introduction 
The GHQ is a self-administration screening tool designed to detect probable psychiatric 
disorder in primary care settings (Goldberg, 1972).  The tool has evolved in response to 
demand from researchers as well as greater understanding of the role of its components  - 
resulting in the development of the Scaled GHQ (GHQ28)  which has become a popular 
screening tool in a range of settings (Goldberg & Hillier, 1979).  
 
Key advantages of the GHQ28 
The GHQ 28 is a shorter version of the original 60 item GHQ questionnaire but has also been 
shown to  more clearly address the 4 main components. 
 
Domains assessed 
Depression; anxiety; social performance; somatic complaints 
 
Practical applications/use of the instrument 
Self -completion questionnaire – used in a wide range of clinical settings and well tolerated 
by patient groups. In drug users potential issue of literacy. Short questionnaire allows time 
to support completion. 
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General Health Questionnaire (GHQ-28) 
Please read this carefully:We would like to know if you have had any medical complaints and how your health 
has been in general, over the last few weeks. Please answer ALL the questions by ticking the answer which best 
applies to you. Remember that we want to know about PRESENT and RECENT complaints, not those that you 
have had in the past. It is important that you try to answer ALL questions. 
Have you recently….. 
A1.  Been feeling well and in 
good health?  
Better than 
usual  
Same as 
usual  
Worse than 
usual  
Much worse 
than usual  
A2.  Been feeling in need of a 
good tonic?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
A3.  Been feeling run down and 
out of sorts?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
A4.  Felt that you are ill?  Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
A5.  Been getting pains in your 
head?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
A6.  Been getting a feeling of 
tightness or pressure in the 
head?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
A7.  Been having hot or cold 
spells?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
B1.  Lost much sleep over worry?  Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
B2.  Having difficulty staying 
asleep once you are off?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
B3.  Felt constantly under strain?  Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
B4.  Been edgy and bad 
tempered?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
B5.  Been getting scared and 
panicky for no good reason?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
B6.  Found everything getting on 
top of you?  
 
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual 
B7.  Been feeling nervous and 
strung-up all the time?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
PLEASE TURN OVER 
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Have you recently….. 
C1.  Been managing to keep 
yourself busy and 
occupied?  
More so than 
usual  
Same as 
usual  
Rather less 
than usual  
Much less 
than usual  
C2.  Been taking longer you over 
things you do?  
Quicker than 
usual  
Same as 
usual  
Longer than 
usual  
Much longer 
than usual  
C3.  Felt on the whole you were 
doing things well?  
Better than 
usual  
About the 
same  
Less well than 
usual  
Much Less 
Well  
C4.  Been satisfied with the way 
you carry out a task?  
More satisfied  About the 
same as 
usual  
Less satisfied 
than usual  
Much less 
capable  
C5.  Felt that you are playing a 
useful part in things?  
More so than 
usual  
Same as 
usual  
Less so than 
usual  
Much less 
useful  
C6.  Felt capable of making 
decisions about things?  
More so than 
usual  
Same as 
usual  
Less so than 
usual  
Much less 
capable  
C7.  Been able to enjoy your 
normal day-to -day 
activities?  
More so than 
usual  
Same as 
usual  
Less so than 
usual  
Much less 
than usual  
D1.  Been thinking of your self as 
a worthless person?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
D2.  Felt that life is entirely 
hopeless?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
D3.  Felt that life is not worth 
living?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
D4.  Thought of the possibility 
that you might do away with 
yourself?  
Definitely not  I don’t think 
so  
Has crossed 
my mind  
Definitely 
have  
D5.  Found at times you couldn’t 
do anything because your 
nerves were so bad?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
D6.  Found yourself wishing you 
were dead and away from it 
all?  
Not at all  No more than 
usual  
Rather more 
than usual  
Much more 
than usual  
D7.  Found that the idea of taking 
your own life kept coming 
into your mind?  
Definitely not  I don’t think 
so  
Has crossed 
my mind  
Definitely has  
Copyright© General Practice Research Unit 1978Published by NFER Publishing Company 
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Social Phobia Diagnostic Questionnaire (SPDQ) 
Introduction 
Social phobia is an intense, irrational fear of social situations. Most sufferers fear only 
specific social situations, though those with generalized social phobia fear most social 
encounters. The DSM-IV (Diagnostic and Statistical Manual; 4th Ed.) provides a specific list 
of diagnostic criteria for social phobia. These are listed as: 
 Marked and Persistent Fear: A persistent, intense fear of social situations, due to a fear of 
showing anxiety symptoms or acting in an embarrassing way. 
 Anxiety Response: Exposure to the situation results in an intense anxiety reaction 
 Recognition That Fear is Irrational: Adults with social phobias recognize that their fear is 
out of proportion. 
 Avoidance or Distress: The sufferer goes out of his or her way to avoid the situation 
which  can only be endured with great distress. 
 Life-Limiting: The phobia severely impacts the sufferer’s life. 
 Six Months Duration: In children and teens, the phobia has lasted at least six months. 
 Not Caused by Another Disorder: Many anxiety disorders and physical illnesses cause 
similar symptoms.  
 Not Related to a specific Physical Disorder: If the sufferer also has a physical condition, 
the phobic response is not limited to anxiety about displaying the effects of that 
condition in public.  
 
Key advantages of the SPDQ 
The SPDQ is a brief self-report questionnaire which takes only a few minutes to complete 
and can help diagnose social phobia. It has been shown to be reliable and valid in a number 
of populations (Newman et al, 2003) 
 
Domains assessed 
The SPDQ addresses questions relating to the DSM1V criteria above. The scores are collated 
to give a Fear score, avoidance score and a total score of overall severity 
 
Practical applications/Use of the instrument 
Can be completed by the subject or at interview.  
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Current Symptoms Scale (CSS) 
Introduction 
This diagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults can be a 
challenging process because it includes making judgments based on clinical interviews, 
rating scale results, informant ratings, and objective supporting. Patient evaluation should 
gather information on: 1. severity /frequency of symptoms; 2. establishment of childhood 
onset of symptoms; 3. chronicity and pervasiveness of symptoms; 4. the impact of 
symptoms on major life activities (Barklay & Murphy 1998). 
 
Many rating scales may be helpful, including: the Conners' Adult ADHD Rating Scale; the 
Brown Attention-Deficit Disorder Scale for Adults; the Wender Utah Rating Scale, the ADHD 
Rating Scale and ADHD Rating Scale-IV; the Current Symptoms Scale, and the recently-
developed Adult ADHD Self-Report Scale-v 1.1 Symptom Checklist. However, specialists 
agree that more research is needed to establish the usefulness of self-administered rating 
scales compared with investigator-administered scales (Murphy & Adler 2004).  
 
Key advantages of the CSS 
The CSS was included in the battery of tests as it was (in 2004) one of only a few self-
completion questionnaires seen as a useful screener - which could be completed rapidly by 
patients and was free to use in the public domain.  
 
Domains assessed 
There are 3 sections in the questionnaire – assessing inattention and hyperactivity as well as 
the degree of impairment.  There are 4 possible answers - Never/Rarely=0; Sometimes=1; 
Often=2; Very Often=3. There is an assessment of when problems began (though clearly 
there is no possibility of recording collateral history).  
 
Practical applications 
This tool has been used a s a useful screening tool in a range of populations in the past. 
 
Use of the instrument 
“A” scores (relating to symptoms experienced)  are calculated into A-odd (inattentive – 9 
questions) and A- even (hyperactive/impulsive – 9 questions).  High scores in these areas 
indicate that type of ADHD may be present. An A-total score adds these two components. If 
there are 6/9 questions answered and high scores chosen for both odd/even questions, 
then the individual likely to have combined ADHD. The “B” score (relating to impairment)  is 
given as a total. If an individual is scoring 3 points (very often) on at least 2 questions there 
is impairment in at least 2 areas of life 
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Impact of Events Scale (IES) 
Introduction 
The Impact of Event Scale (IES) is a 15 item questionnaire that measures the amount of 
distress a person associates with a specific event. It was developed 1979 (Horowitz, Wilner 
& Alavarez, 1979).  In 1997, the scale was revised by adding seven additional questions 
(Weiss & Marmar 1997).  The earlier version (used and proposed by the clinical psychology 
staff in the substance misuse services locally) was used in this study. 
 
Key advantages of the IES  
The test is used to measure the impact experienced following a traumatic event. Studies 
show the IES can be valuable in spotting both trauma and less intense forms of stress and is 
capable of detecting Post Traumatic Stress Disorder (PTSD). It is recommended for use in a 
clinical setting as a measure of symptom severity or symptom change. It is a descriptive 
rather than a diagnostic tool. It is well tolerated by patients and has been used as a 
screening tool in a range of general populations.  
 
Practical applications & Use of the instrument 
The IES is a self-completion questionnaire. It consists of 15 questions and has two subscales 
which look separately at intrusion and avoidance. Together these scales give a total impact 
of event score and serve as a useful indicator of the extent to which a traumatic event is 
reverberating in the mind. 
 
There are 4 possible responses to this questionnaire- not at all, rarely, sometimes, often. 
Intrusion, avoidance and total scores are recorded. A total score cut-off  of 24 can be a 
valuable indicator of PTSD “caseness”. 
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Appendix 1.2  Tayside Methadone Cohort   - Coding for Databases 
 
Data entry staff were given the following coding guidance to ensure consistency of data 
entry 
 
 
General scores 
0 = No 
1 = Yes 
88 = Not known/not applicable 
99 = Missing information (if no information has been given and it ought to have been 
IDCODE = for each database- enter 10 digit chi number [converted to prochi] 
Date refers to date of assessment – enter as dd.mm.yy only 
 
Demographic information form 
 
Id code (chi)        10 digits 
Date (date of assessment)      dd.mm.yy 
Dob  (date of birth)         dd.mm.yy 
Age put in age (work out from date of assessment and DOB)   
Sex (sex)      1 = male2 = female 
 
Q1. How long have you lived at your present address?   
1 = less than 1 month; 2 = less than 6 months; 3 = less than 1 year; 4 = less than 3 years 
5 = less than 5 years; 6 = 5 or more years; 88 = not known  
 
Q2. How often do you usually change address?    
0 = never; 1 = sometimes; 2 = frequently; 3 = very frequently; 88 = not known 
 
Q3. Do you live:0 = alone; 1 = with partner;  2 = with family; 3 = with friends; 4 = hostel 
88 = not known 
 
Q4a. Do you have any children?     
0 = no; 1 = yes; 88 = not known 
Q4b. If yes, how many?  Write in number e.g 3 
Q4c. Male or Female?  Write in  (e.g  2 males and 1 female) 
Q4d. Age of children.  Write in e.g  8, 16, 20 
Q4e – 4j   Put in age ranges of children for each child 
0-4 years=0; 5 -12 years=1; 13 – 18years=2; 18 + years=3; Not applicable 88 
(e.g if 3 children aged 1, 8 and 19 then - 4e  = 0, 4f = 1 and 4g = 3. 4h and 4i = 88) 
 
Q5a. Do your children live with you?  0 = no; 1 = yes; 88 = not known 
Q5b.If your children don’t live with you, do you have access?0 = no; 1 = yes 
88-not known/not applicable 
 
Q6a. Do you have any physical problems? 0 = no; 1 = yes; 88 = not known 
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Q6b. If yes, what are these?  Write in response(s) e.g back pain  
Q6c. Do you currently have any mental health problem? 0=no; 1=yes; 88 = not known 
Q6d. If yes, what are these?  Write in response(s)e.g  PTSD 
 
Q7a. Are you receiving any treatment for physical condition?0=no; 1=yes; 88 = not known 
Q7b. If yes, please detail treatments Write in response(s) e.g physio 
Q7c. Are you receiving any treatment for MH problems? 0 = no; 1 = yes; 88 = not known 
Q7d. If yes, please detail treatments Write in response(s) e.g anti-depressants 
 
Q8a. Do you or your children receive support from any other agency? 0=no; 1=yes; 88 = NK 
Q8b. If yes, which agency? Write in response(s) e.g SW 
 
Q9. How do you rate your writing, reading and numeracy skills?  0=not good; 1=OK; 2 = good 
Q10. If answered ‘not good’ are you interested in improving? 0=no;1=yes; 2=don’t know; 
88=Not known/not applicable 
 
Q11. What level of education have you reached? 0=none; 1= O’Grade; 
2=apprentice/C&G/SVQ; 3 = Higher;  4 = College/University 
 
Q12a. Have you ever had a head injury?0 = no; 1 = yes; 88 = not known 
Q12b. If yes, did you attend hospital? 0 = no; 1 = yes; 88 = not known 
 
Q13a. Have you ever been unconscious?0 = no; 1 = yes; 88 = not known 
 Q13b. Did you receive medical attention?0 = no; 1 = yes; 88 = not known 
            
  
Maudsley Addiction Profile (MAP) 
Id code 
Date of assessment 
 
4 columns added to account for certificate of analysis screening tests. (These are stapled on 
the front of assessment pack).  
 
Benzodiazepines/ Methadone/ Opiates/ Morphine- Specific.  
Codes- 0 = No,   1 = Yes   2 = Not screened for substance. 
If screen has not been done e.g individual only screened for 2/4 use code 2 for not 
screened. 
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Section B: Substance Use 
 
Codes are as follows:   
Card 1 
 
None 1 
day 
only 
2 
days 
only 
3 
days 
only 
1 day 
a 
week 
2 
days 
a 
week 
3 
days 
a 
week 
4 
days 
a 
week 
5 
days 
a 
week 
6 
days 
a 
week 
Every 
day 
Other 
number 
0 1 2 3 4 9 13 17 21 26 30  
 
 
Card 2 
 
Oral Snort/Sniff Smoke/Chase Intravenous Intramuscular 
1 2 3 4 9 
 
 Enter number of dates used in past 30 days. Enter ‘0’ for none (Card 1) . Enter amount used 
on a typical day in the past 30 days (verbatim). Record routes of administration (Card 2) 
SUBSTANCE DAYS USED AMOUNT USED ON 
TYPICAL DAY 
ROUTE(S) 
B1. Alcohol    
B2. Heroin    
B3. Illicit Methadone    
B4. Cocaine Powder    
B5. Crack Cocaine    
B6. Amphetamine    
B7. Cannabis    
B8. Prescribed 
methadone 
   
B9. Prescribed DF118’s    
B10. Illicit DF118’s    
B11. Morphine    
B12. MST    
B13. Diconal    
B14. Amphetamine Base    
B15. Ecstasy    
B16. Prescribed diazepam    
B17. Illicit Diazepam    
B18. Prescribed 
Temazepam 
   
B19. Illicit Diazepam    
Other:    
 
Review team have not consistently used Card 1 for scoring, therefore this section cannot be 
scored according to MAP instructions.  
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Section C: Health Risk Behaviour 
 
If no illicit drugs injected in past 30 days enter ‘0’ in C1- C3. Use response from card 1 to 
complete C1 (see above).If some answers have not been completed e.g if C1 has been 
answered but C2, C3 have not, enter 88 for ‘not known.’ 
 
If no penetrative sex in past 30 days enter ‘0’ in C4 and C5.If some answers have not been 
completed enter 88 for ‘not known’ 
 
Section D: Health Symptoms 
Card 3 
 
Never Rarely Sometimes Often Always 
0 1 2 3 4 
D1: How often experienced the following physical health symptoms. (total score 0-40) 
D1score. Total scores from D1a- D1j and add to get total.  
A-J has 5 possible responses (Card 3). Each should be completed with one of the 5 choices.  
If not completed enter ‘99’ for missing response. 
 
D2: How often experienced the following emotional or psychological symptoms.(total score 
0-40). D2scrore. Total score from D1a – D1j and add to get total. 
 
A-J has 5 possible responses (Card 3). Each should be completed with one of the 5 choices. If 
not completed enter ‘99’ for missing response. 
 
Section E: Personal/Social Functioning 
Card 1 
 
None 1 
day 
only 
2 
days 
only 
3 
days 
only 
1 day 
a 
week 
2 
days 
a 
week 
3 
days 
a 
week 
4 
days 
a 
week 
5 
days 
a 
week 
6 
days 
a 
week 
Every 
day 
Other 
number 
0 1 2 3 4 9 13 17 21 26 30  
 
If not in a relationship enter ‘0’ in E1 and E2. 
Use Card 1 responses to complete responses for E1-E7.  
E8 and E9 should be written in verbatim e.g days formally unemployed (E9) write 30. 
E10: Crimes committed in past 30 days.  
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Card 1 
None 1 
day 
only 
2 
days 
only 
3 
days 
only 
1 day 
a 
week 
2 
days 
a 
week 
3 
days 
a 
week 
4 
days 
a 
week 
5 
days 
a 
week 
6 
days 
a 
week 
Every 
day 
Other 
number 
0 1 2 3 4 9 13 17 21 26 30  
 
Responses for this question should use Card 1 for ‘days committed’ from A-F and other 
crimes. 
Responses for ‘number of times committed on a typical day’ should be written in verbatim. 
 
Total score for E1-E6 are totalled by calculating conflict days/contact days x100 = % time in 
contact. Add score to columns partnerc (E1-E2), relationc ( E3- E4) and friendco ( E5-E6). 
 
General health Questionnaire (GHQ28)  
 
The GHQ scores can be interpreted in 3 ways: 
1. Severity of psychological disorder 
2. Estimate prevalence of psychiatric illness 
3. Indicator of morbidity. 
 
Complete:  Idcode;  Date 
 
There are 4 sections in the GHQ: A 1-7, B1-7, C 1-7 and D 1-7.  
Total of 28 questions in this version. There are 4 possible answers per question.  
 
e.g A1 ‘ been feeling perfectly well and in good health? esponses :- better than usual, same 
as usual, worse than usual , much worse than usual. 
 
All responses in all sections should be score 0, 1, 2, 3 (Likert scale) from left to right.  
Better than usual=0; Same as usual=1;Worse than usual=2;Much worse than usual=3 
Total score for each section will be between 0 and 21. 
Each section score should be totalled and added to variable ascore, bscore, cscore, dscore 
and total score. 
 
ADHD (current symptoms  scale- self report - CSS) 
Id code 
Date of assessment 
 
On database there are 3 sections.  There are 4 possible answers. Each response should be 
circles and coded in the database as follows: 
 
Never/Rarely=0; Sometimes=1; Often=2; Very Often=3If no response is indicated enter ‘99’ 
for missing. 
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A1-18- This section asks individual to circle the number next to each item that best 
describes your behaviour. 
 
B 0- this refers to when problems began. ‘ I was approximately ____ years old’ Complete 
this by entering age, if given. If not, enter 99 for missing information.  
 
B1- 10 – To what extent do the problems you may have circled on the previous page 
interfere with your ability to function in each of these areas of life activities 
 
C1-9 – List of items that describes people. Please tick the boxes that best applies to you. 
 
SCORING 
 
A scores are calculated into A-odd (inattentive) and A- even (hyperactive/impulsive) 
 
So in A-odd column add up all odd scores and total. There are 9 odd questions 
In A-even column add up all even scores and total. There are 9 even questions 
In A-total column add scores for both odd and even. If there are 6/9 questions answered 
and high scores chosen for both odd/even questions, individual likely to have combined 
ADHD. 
 
B-total (impairment) are all scores from b1- 10. Total all scores given. If individual is scoring 
3 points (very often) on at least 2 questions there is impairment in at least 2 areas of life. 
 
Injecting Risk Questionnaire (IRQ) 
 
Idcode 
Date of assessment 
 
There are 18 questions in this questionnaire. Apart from Q1 and Q18 all questions have 4 
possible responses and are coded as set out below e.g (Q2).  
 
If Q1 is answered ‘no’ which is 0, complete all other questions by inputting ‘88’ – not 
known/not applicable. 
 
Q1. Have you injected a drug during the last 4 weeks? No=0; Yes=1 
e.g Q2. During the last 4 weeks, how often have you shared Injecting equipment?  
  
Answer all other questions Q2-Q17 using same codes: 
Never= 0; Rarely=1; Sometimes=2; Frequently=3; Not known/not applicable=88 
 
Q18. During last 4 weeks, with how many different people have youd one any of the things 
on this page? Complete this by inputting verbatim response e.g . 2. 
 
Total score. Calculate the scores from questions 2, 4 – 17. Total will be from 0 –45. High 
score = greater injecting risk. 
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Chronic Pain Questionnaire (BPI plus additional fields from NHST Pain services) 
 
Id code 
Date of assessment 
 
CHRONIC PAIN ESTABLISHED FROM Q2 IF LONGER THAN ONE YEAR. 
 
Q1. Do you have a problem with pain? No=0; Yes=1; Not known=88 
Q2. For how long have you had this pain? Enter response e.g months/years 
Q3. Where is your body do you have this pain?   
Head=0; Neck=1; Shoulders=2; Upper back=3; Lower back=4; Chest=5; Abdomen=6; Liver=7; 
Arms=8; Hand(s)=9; Legs=10; Feet=11; Not known/not stated=88 
Q4. What do you think caused this pain? Trauma=0; Disease=1; Drug Use=2; other=3; NK=88 
Q5. Have you ever seen/are you seeing a doctor for this pain? No=0; Yes=1; Not known=88 
Q6. Which doctor did you see? GP=0; Pain specialist=1; Other consultant =2; NK=88 
* The name of the doctor is likely to be given Therefore to code appropriately is a question 
of Interpretation – check with BK.        
Q6b. When was this?     Type in date e.g. mmm.yy (APR 02) 
Q7. Do you feel your pain problem was taken seriously?No=0; Yes =1; Not known=88 
Q8a. What are you taking for this pain? PRESCRIBED 
Opiates=0; Benzo’s=1; NSAID’s=2; Anti-inflammatories=3;  Other=4 (list) 
No prescribed drugs= 5; 2 prescribed drugs =6; 3 or more prescribed drugs=7 
Not known=88 
Q8b. Non-prescribed drugs: Opiates=0; Benzo’s=1;  NSAID’s=2; Anti-inflammatories=3; 
Other= 4; No non- prescribed drugs= 5; 2 non prescribed drugs=6;  
3 or more non- prescribed drugs=7;  Not known=88 
Q8c. Over the counter (OTC) drugs :  Opiates=0; Benzo’s=1; NSAID’s=2;  
Anti-inflammatories=3; Other=4; No OTC drugs=5; 2 OTC drugs=6 
3 or more OTC drugs=7; Not known= 88 
Q9. Is any of this pain due to withdrawal from drugs?No=0; yes=1; Not known=88 
Q10a. Did you first have a pain problem which lead you to use drugs/medication?  
No=0; Yes=1; Not known=88 
Q10b. Did you have a problem with drug/medication use, then developed pain?   
No=0; Yes=1; Not known=88 
Q10c. Do you feel that your drug/medication use and pain are unrelated?  
No=0; Yes=1; Not known=88 
Q11. Does your pain problem cause you disturbed sleep? No=0; Yes=1; NK=88 
Q12a. Does your pain problem affect your ability to go about daily activities?   
No=0; Yes=1; Not known=88 
Q12b. If yes, how does it affect you? Work= 0; Shopping=1; Walking=2; Standing =3 
Self care=4; Social activities=5; multiple activities=6; Not known=88 
Q13. Please indicate pain intensity (0-100) Input as a number e.g 60 
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Treatment Perceptions Questionnaire (TPQ) 
 
ID codeDate of assessment 
Specify where the patient receives his/her main treatment: TDPS= ;1; GP= 2; other=3 
 Strongly Agree Agree Disagree Strongly 
Disagree 
Question 1 0 1 2 3 
Question 2 0 1 2 3 
Question 3 3 2 1 0 
Question 4 3 2 1 0 
Question 5 3 2 1 0 
Question 6 0 1 2 3 
Question 7 3 2 1 0 
Question 8 3 2 1 0 
Question 9 0 1 2 3 
Question 10 0 1 2 3 
Question 11 0 1 2 3 
Question 12 0 1 2 3 
Question 13 3 2 1 0 
Question 14 3 2 1 0 
 
Total scores 0-42. 
HIGHER TOTAL SCORE REFLECTs GREATER SATISFACTION WITH TREATMENT. 
 
Stress/ PTSD (Impact of Events Scale - IES) 
 
IdcodeDate of assessment 
88 – not known (i.e if some answers are missing) 
 
The IES used here consists of 15 questions and has two subscales which look separately at 
intrusion and avoidance. Together these scales give a total impact of event score and serve 
as a useful indicator of the extent to which a traumatic event is reverberating in the mind. 
Recommended for use in a clinical setting as a measure of symptom severity or symptom 
change. It is a descriptive rather than a diagnostic tool. 
 
In a general stress clinic population, the intrusion subscale mean was 21.4 (SD 9.6) and 
avoidance subscale mean was 18.2 (SD 10.8) N.B this can be taken as a guide. 
 
There are 4 possible responses to this questionnaire- not at all, rarely, sometimes, often. 
 
Intrusion questions are Q1, Q4, Q5, Q6, Q10, Q11, Q14 
Avoidance questions are Q2, Q3, Q7, Q8, Q9, Q12, Q13, Q15 
 
The responses for all questions are: Not at all= 0; Rarely=1; Sometimes= 3; Often= 5 
 
There are 3 stand alone questions 1,2, 3 (labelled a,b,c) on the database. No = 0, yes= 1 
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Total score for intrusion (questions Q1, Q4, Q5, Q6, Q10, Q11, Q14) put in INTSCOR column 
Total score for avoidance (questions Q2, Q3, Q7, Q8, Q9, Q12, Q13, Q15) put in AVOSCOR 
Total score to be inputted into TOTALSCO column all at end of database. 
Social Phobia Diagnostic Questionnaire (SPDQ) 
 
Id codeDate of assessment 
 
There are 3 primary questions to be completed. If ‘yes’ is answered to any of these first 3 
questions, continue and input particular choices for the rest of questionnaire. If ‘no’ to first 
3 questions input ‘88’ for not known/not applicable for all remaining questions.  
 
The database is numbered A, B and C for initial questions. Followed by q1- 23. There are 
parts A and B for questions 1-17 inclusive as demonstrated on questionnaire form.  
 
Responses are part A (Fear)    part B (avoidance) 
0 – no fear      0 – never avoid 
1 – mild fear      1 – rarely avoid 
2 – moderate fear     2 – sometimes avoid 
3 – severe fear     3 – often avoid 
4 – very severe fear     4 – always avoid 
However, the numbering is odd. It jumps from 10 to 12. Therefore database has followed 
same numbering and omitted number 11 (be careful)!! 
 
Q18- 20 and Q23 have yes/no/ not known/N.A choice 
Q21 and Q22 have 5 possible answers (and also 88- not known/NA) 
 
SCORING 
 
The SPDQ is scored using a sum total response. This scoring system was devised in an 
attempt to create a score that would best enable detection of the presence of social phobia.  
 
To create total score all ‘yes’ answers (A, B, C and q 18, 19, 20) to be computed in TOTALYN 
column 
 
A – in social situations where it is possible that you will be noticed or evaluated by others do 
you feel excessively nervous, fearful or uncomfortable? 
 
B – Do you tend to be overtly worried that you may act in a way that night embarrass or 
humiliate yourself in front of other people or that others may not think well of you? 
 
C – Do you try to avoid social situations? 
 
Q18 Do you tend to experience fear each time you are in feared social situations? 
Q19 Does the fear come on as soon as you encounter feared social situations? 
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Q20 Would you say that your social fear is excessive or unreasonable? 
 
Additional items e.g. fear responses (q1a- 17a) only are each divided by four and total 
scores for these are to be computed in FEARTOT column. 
 
Q21 and 22 (interference and distress) are divided by two.  
 
All yes/no, fear responses and q21 and 22 totals are added to make final total. (total 
column) 
 
Total scores range from 0 –27. 
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Appendix 2. – SUMIT  Scoping Document 
 
 
SUbstance Misuse Information – Tayside:  “SUMIT” 
A 2 year, Time-Limited Project to Deliver a Functioning Care, Treatment & Recovery Information 
System for Substance Misuse in Tayside. 
Background 
Organisational support 
In 2008 NHS Tayside Board and the three Tayside DAATs agreed to prioritise funding the purchase of 
an information system to support delivery of the substance misuse care and treatment pathway. 
Funds were identified and committed from ring-fenced care & treatment resources for drugs and 
alcohol. Tayside Substance Misuse Services are leading on this project and have support from key 
partners to progress the deployment of a system based on the new MIDIS system. 
HAF Information Working Group 
On 14th October 2009, the NHST Health Advisory Forum (HAF) discussed the need to ensure that any 
new information systems must support effective commissioning. A working group was formed - the 
Information Working Group (IWG)  – and a process commenced to develop an options paper for 
consideration.  At a meeting on 18th February 2010, the IWG considered the paper “Tayside 
Substance Misuse Information Systems. Opportunities to maximize performance: an Options Paper – 
draft 4” and supported “Option 3” which proposed that “the HAF sets up a working group to develop 
a proposal in partnership with NHST/ADPs/ and University of Dundee (UoD) to maximize the 
potential value of the new system using resources already committed for this purpose.” The 
membership of the IWG and Executive Summary of the options paper are included in Appendix 1.  
Delivery plans 
Following the decision of the IWG, this paper describes an initial plan for delivery of a fit-for-purpose 
substance misuse information system for Tayside’s care treatment & recovery pathway. In line with 
the aspirations described by the HAF IWG, the system is required to address a number of key areas. 
These include:  
1. Services delivering care, treatment & recovery (Statutory & voluntary sectors) – ensuring 
valid real time information is available to inform clinical governance, clinical decision making 
and care planning as well as revalidation of staff 
2. Commissioners of services (ADPs, NHS & Local Authority commissioners) – ensuring 
commissioners have access to meaningful information flows to allow adequate planning and 
commissioning of services [monitoring of SOAs & HEAT] and demonstration of effectiveness 
(including cost-effectiveness).  
 
Any system should also aim to supply valid information to improve potential for active involvement 
in academic research and audit activity, building on existing achievements. 
An essential element of the proposal is the development of local capacity to deliver the required 
elements in a sustainable way. 
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In March 2010, NHS Tayside Strategic Plan 2010-2015 was published. It states: “The first financial 
challenge is to assess the relative cost effectiveness of our services.  Once this information is 
available an even greater challenge will be to change long established practices in order to increase 
overall efficiency, improve productivity and maximise health gain.  This may involve reducing 
services which are shown to be the least cost effective and redirecting resources into services which 
achieve greater health gain.  This process will be facilitated through the use of appropriate economic 
analysis techniques.” The message is clear that any information development project must ensure 
that some form of health economic evaluation is integral to the delivery plan. 
The current proposal describes a time-limited delivery project which has been developed through a 
process of meetings with key partners including ADP and Local Authority leads, NHS clinical and IT 
staff as well as academics from relevant departments in the University of Dundee – the Centre for 
Addiction research & Education, Scotland (CARES), the Health Informatics Centre (HIC) and the 
Dundee Health Economics Group (DHEG). List of participants to date is included in Appendix 2. 
Issues to be addressed 
This proposal aims to achieve agreement for key components of the SUMIT Project which are 
designed to ensure the project delivers the desired result. These components are: a governance 
process; clear deliverables; realistic timelines. 
Governance process 
This project has the potential to be complex and it is therefore essential that a focus  on delivering 
clear objectives on behalf of the key partners responsible for delivering care treatment and recovery 
in Tayside is maintained. To this end, an accountability/reporting framework is proposed (Fig. 1) 
Figure 1. – Governance process. 
 
 
 
 
 
 
 
 
 
 
 
SUMIT Project 
Accountable Steering Group 
Working Group 2. 
Delivery 
Tayside Alcohol & Drug 
Coordinating committee 
Working Group 3. 
Analysis & research 
Working Group 1. 
Dataset (time limited) 
SUMIT Project Team 
(TSMS Project Manager, CARES 
Coordinator & support) 
Project Lead 
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Tayside Alcohol & Drug Coordinating Committee 
The project is commissioned by the NHST HAF. This group has close links with the Tayside 
Coordinating Committee ensuring stakeholder input is maximised. ThisCommittee will receive project 
update reports at agreed intervals. 
Project Steering (Accountable) Group  
It is essential that the project is overseen by an appropriate group of stakeholders who carry 
relevant accountability to their respective organisations. From the discussions to date this should 
include the budget holder (NF); ADP/LA reps from all three areas [requirement will be judged by 
ADPs and depend on degree of CPP integration of ADPs]; TSMS lead (BK); IT lead (JB). UoD lead 
(KM/BG).  A Project Lead will be agreed. NHST will appoint a project coordinator (Band 6 clinician) to 
oversee delivery of the clinical systems. The project coordinator will be managed by TSMS Clinical 
Governance Lead. UoD (CARES) will appoint & manage a lead researcher to coordinate delivery. Their 
work plans will be set by the SUMIT steering group.  
Working groups 
Specific areas of work are required to deliver the optimal system. These include:  
Working Group 1. – Dataset workstream (time limited) 
A group to ensure the data collection tools and linkages proposed are capable of responding to the 
needs of ongoing clinical governance (staff & team performance; impact of interventions); 
monitoring of service performance (HEAT & SOA etc); commissioning of services (needs assessment, 
cost effectiveness & best value etc). The group will be very active in the early stages (<3/12) to 
ensure project is appropriately focussed. If required this group could be reconvened at a later stage 
to consider issues raised in the delivery phase including any refinement of data collection tools to 
ensure data are useful and of high quality. This group could also address sustainability. 
Key output will be that the project agrees a clearly defined valid dataset. 
Inputs required will include those setting strategic objectives (NHST; ADPs; LA SOA leads); those 
leading clinical delivery (service delivery leads); academics (CARES); technical advisers with 
experience in managing data or systems development (ADP Info officer; HIC; DHEG; NHST Lead 
Pharmacist). 
Working Group 2. – Delivery workstream 
A group to ensure the system functions optimally. This group will address such issues as agreeing 
systems (technical or manual); delivering training and support for clinical staff; putting data 
management systems in place (quality assurance; security; data entry). The group will initially set up 
systems and will then govern their delivery and effectiveness. 
Key output will be that the project collects high quality data timeously 
Inputs required will include operational managers/clinical leads; technical support staff; 
administration managers & those with data handling expertise. 
307 
 
 
Working Group 3. – Analytical & research workstream 
This group has two areas of focus. One is to ensure that the data collected is available for reporting 
as required by commissioners (NHST, ADPs, SOAs – including cost-effectiveness); clinical services 
(clinical governance; revalidation). A second is that it works to maximise value of these data for audit 
and research purposes. This work may be directed by existing  activities (eg Drug Death data – on 
behalf of DRD Group; Outcomes data – such as the Tayside Methadone Cohort etc). Specific datasets 
will allow objective assessment of the cost effectiveness of new service delivery models – eg new 
HITS service post RIE. This group will also bring forward proposals to maximise academic use of these 
data within acceptable ethical constraints. Examples will include data linkage to NHS datasets 
(hospital admissions; labs; death; GP prescribing) and potentially to others (eg child development; 
criminal justice) depending on data sharing agreements. This linkage would allow additional 
outcomes to be taken into consideration within the cost-effectiveness analysis and also ensure that 
the long term cost effectiveness of activities (changes in long-term outcomes) can be assessed. 
Key output will be that the project’s data handling can answer key strategic questions  
Inputs required will include ADPs (through information officer), Local Authority SOA development, 
NHS data handling (HIC) and academics (CARES, DHEG etc). 
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Deliverables 
Figure 2. contains a schematic of the proposed SUMIT system. 
Clinical Effectiveness: 
All services are systematically collecting realtime patient information at key points in the care 
pathway which can demonstrate the patients’ treatment costs & progress towards recovery.  
Cost Effectiveness: 
Academic 
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Dual diagnosis) 
 
DHEG 
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- Data entry 
- Data 
management 
- Data linkage 
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Timely reports to NHS 
committees and Clinical 
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of activity and outcomes 
delivered by TSMS and 
partners. 
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LES governance 
 
Information to inform 
investment/ 
disinvestment processes 
 
ADPs & LAs 
Timely reporting of  
performance indicators 
and outcome measures 
as required for SOA 
reporting. 
Realtime 
clinical 
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NHS: 
TOPAS 
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[Prescribing] 
MIDIS 
[Outcomes] 
 
Local 
Authority 
Inputs from 
databases to 
demonstrate 
activity, 
outputs and 
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Voluntary 
sector 
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When completed, the SUMIT project will deliver: 
 A fully functioning information system which collects high quality activity & outcomes data 
from the care, treatment and rehabilitation pathway across Tayside. 
 Data sets will have been designed to meet the needs of key stakeholders 
 Data will be analysed to allow reporting on various aspects of service delivery including 
commissioning, performance management and clinical governance as well as revalidation of 
clinicians. 
 Tailored/bespoke reports will be available in a timely way for stakeholders 
 
In addition, the system will aim to build local capacity to excel in this work by forming a link with 
existing local academic partnerships, allowing it to: 
 Address questions of cost-effectiveness and health economic analyses 
 Develop data linkage processes – allowing relationships to be explored and long term cost-
effectiveness and performance to be evaluated (eg links with hospital admissions, deaths). 
 Bid for additional resources through academic channels to test and evaluate treatment 
strategies with potential for improved cost-effectiveness. This will support exit strategy. 
 
Effective local clinical/academic partnerships are already in place in substance misuse. Examples 
include: active support from NHS Boards to support development of UoD CARES – which has 
delivered the drug deaths collaboration with ADPs and the Tayside Methadone Cohort Project; 
Development of a health economics project by Dundee City ADP in collaboration with DHEG. 
Processes are underway to secure funding to further develop research capacity (eg ESRC/MRC 
studentship application). Academic outputs have included a recent high impact publication on drug 
deaths in the BMJ (McCowan, Kidd & Fahey 2009). 
 
Finally, the project will deliver an exit strategy, clearly outlining options for the established system 
to be progressed once the delivery project has been completed. This exit strategy will aim to engage 
ongoing processes within partner agencies (e.g. ADP support; NHS Business Support Unit etc.). 
Opportunities to access research/matched funds are an untapped option to increase support for the 
analytical elements. The aim is to deliver a cost neutral exit strategy. 
Timelines 
The project will be delivered in a coordinated way and is divided into key time periods which aim to 
ensure that the project delivers the required outcome and concludes with an acceptable exit 
strategy.  Milestones are identified. 
Phase 1: Immediate actions and objectives (<3/12 from initiation) 
Initial investment will put basic infrastructure in place and focus on the completion of an agreed set 
of data collection tools to meet stakeholders’ needs. This early stage will be completed in 3 months. 
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Key inputs will be: 
 Agree funding & governance arrangements 
 Appoint NHS Band 6 project manager to lead delivery of clinical information system  
o Ensure hardware & software in place (?gradual/phased roll out) 
o Staff training plans  
 Appoint NHS/UoD researcher coordinating development of academic activities/process 
 Set up working groups and agree workplans  
 Put immediate “quick win” processes in place – eg HIC baseline data entry 
 Develop detailed plans for full project 
 
Key outputs will be: 
 Infrastructure in place and functioning within 3 months of commencing project 
 Working groups in place and workplans agreed 
 “Quick wins” delivered or progressing – eg. Baseline TOP data report; Follow-up Methadone 
Cohort Data; data linkage process developed; Health economics processes agreed. 
 
Phase 2: Main body of project – 3/12-18/12 
From this stage the working groups will bring forward a prioritised programme of work to  
 Refine and develop a quality-assured data handling process 
 Ensure the system meets the reporting needs of all stakeholders 
 Maximise the audit, research & clinical governance potential of the system 
 Evaluate the system 
 
Key inputs and outputs will be developed during Phase 1. 
Phase 3: Exit strategy18-24/12 
Evaluation report will inform appropriate options for exit strategy. This will ensure system is 
sustainable beyond the timeframes for the delivery project. 
In conclusion 
It is proposed that the Tayside Substance Misuse partners agree to the plans outlined above.  
If agreed this will allow the immediate phase to progress  - launching the project, putting in place 
key staff and progressing detailed plans. 
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Appendix 3 Research Governance 
 
This Appendix contains copies of documentation associated with the process of research 
governance for the three elements of the project. This includes: 
 Correspondence with the NHS Tayside Research Ethics Committee 
 Correspondence with the Caldicott Guardian 
 Data management documentation relating to the Health Informatics Centre (HIC) 
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NHS Tayside Research Ethics Committee 
 
From: Coote Liz (NHS Tayside) [liz.coote@nhs.net] 
Sent: 25 November 2010 13:40 
To: Cassie Higgins 
Cc: Kidd Brian (NHS Tayside); Baldacchino Alexander (NHS Fife); c.w.crawford@dundee.ac.uk; 
McKenzie Peter (NHS Tayside); Hunter Stewart (NHS Tayside); Fenton Ian (NHS Tayside); Ackland 
Caroline (NHS Tayside) 
Subject: SUMIT and R&D Approval situation 
 
Dr Kidd 
 
SUMIT and R&D Approval situation (TASC Ref: 2010PY01) 
 
I have now reviewed the documentation submitted to TASC R&D on the above study. I note that this study 
relates to the Development of a system that can receive, manage and process information across the alcohol 
and drug care, treatment and recovery agenda. SUMIT aims to ensure delivery of high quality clinical 
information to support services, reporting of service performance, economic assessment of service, data 
linkage and further academic collaboration. It has been agreed that the SUMIT proposal does NOT therefore 
require TASC R&D approval as the development of the system is not research per se. The proposal should be 
reviewed and approved by the Data protection officers and Caldicott guardians whom I have copied in on this 
email for information. 
Please note however that all research proposals utilising patient data from the system is required to be 
notified to TASC R&D office for review and approval. 
Please find below guidance from IRAS website on NHS management permissions for Databases. This supports 
our decision that R&D approval for the development of the system itself is not required. 
NHS management permission 
 
Under the Research Governance Framework (RGF), there is no requirement for NHS research permission for 
the establishment of research databases in the NHS. Applications to NHS R&D offices through IRAS are not 
required as all NHS organisations are expected to have included management review in the process of 
establishing the database.  
Research permission is also not required by collaborators at data collection centres (DCCs) who provide data 
under the terms of a supply agreement between the organisation and the database. DCCs are not research  
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sites for the purposes of the RGF.  
 
Database managers are advised to provide R&D offices at all DCCs with a copy of the REC application for 
information, together with a copy of the favourable opinion letter when available. All DCCs should be listed in 
Part C of the REC application.  
 
NHS researchers undertaking specific research projects using data supplied by a database must apply for 
permission to R&D offices at all organisations where the research is conducted, whether or not the database 
has ethical approval. Where the data is received in non-identifiable form and the research is covered by the 
terms of generic ethical approval for the database, no further REC application is required but the database 
should list the project in its annual report to the REC. 
 
I hope this clarifies matters with respect to R&D/NHS management approval. Please feel free to contact me 
should you wish to discuss this further. 
 
Liz Coote 
R&D Manager 
Tayside Medical Sciences Centre,  
Ninewells Hospital & Medical School 
TASC Research & Development Office 
Residency Block, Level 3, George Pirie Way,  
Dundee, United Kingdom 
DD1 9SY 
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Caldicott Guardian Approval 
User Details   
Sponsor Details 
Name: Dr Brian Kidd  Name: Dr Andrew Russell 
Position: Consultant Psychiatrist / Senior 
Lecturer 
 Position: Medical Director 
Organisation: NHS Tayside  Organisation:  NHS Tayside 
Address: Constitution House 
55 Constitution House 
Dundee DD1LB 
 Address: Kings Cross 
Clepington Road 
Dundee DD3 8EA 
Tel: 01382 424512  Tel: 01382 424176 
Data Protection Reg. 
No. 
Z8537226 
Data Requested : 
A Data Processing 
Specification must also be 
completed. 
Pilot Update to Tayside Methadone Cohort – Audit & Research Plans. 
Original approval Dr Mutch July 2005 
Co-Users of the Data : 1. Data will be used by NHS Tayside Substance Misuse Lead Clinician – Dr Brian 
Kidd - to support process of performance improvement. 2. Data may also be used 
by clinical governance staff under supervision of Dr Kidd (eg 
administrative/research staff associated with the clinical governance office 
TSMS/CARES UoD). 3. Anonymised data [supplied by TSMS] may be used by 
attached medical students to support their requirement to undertake research 
projects under supervision of Dr Kidd 
Intended use of data 
(inc. publications) : 
Initial project will support reports addressing changes in patient outcomes from 
original audit in 2005. It will be the intention to disperse relevant research papers 
more widely through peer-reviewed journals.If students use anonymised data these 
will be included in their UoD research reports 
User’s Declaration 
I declare that I understand and undertake 
to abide by the rules for confidentiality, 
security and release of data received from 
NHS Tayside. 
 Sponsor’s Declaration (to be signed by a consultant if 
patient data is requested and the applicant is not of that 
status or is not medically qualified) 
I declare that the above named user of the data is a bona fide 
worker engaged in a reputable project and that the data 
requested can be entrusted to this person in the knowledge 
that they will conscientiously discharge their obligations in 
regard to confidentiality of the data. 
Signature  Signature 
Date 12
th
 February 2010  Date 
 
 
 
 
315 
 
RULES ON CONFIDENTIALITY, SECURITY AND RELEASE OF INFORMATION 
 
FOR USERS OF NHS PATIENT DATA 
 
1) If the data received from NHS Tayside are to be held on computer, the signatory of this 
request, or the organisation (s)he represents, should have an appropriate registration 
with the Office of the Data Protection Registrar.  Details of the registration number 
should be entered on this document. 
 
2) Data received from NHS Tayside must not be used for any purpose other than for the 
intended use specified on this document. 
 
3) Data received from NHS Tayside must not be divulged to any person who is not 
specified as a ‘co-user of the data’ on this document. 
 
4) Proper safeguards should be applied in keeping the data and destroying it on completion 
of the work/project declared to prevent any breach of confidentiality. 
 
5) Any misuse or loss of these data should be notified immediately to the Information 
Governance Officer for NHS Tayside at AshludieHospital, Monifieth (01382-527920). 
 
6) Recipients of information supplied by NHS Tayside are reminded that the data has been 
supplied for the purposes stated in the approved study only. Further submission for 
approval will be required for any other uses of that data. 
 
7) Any statistics or results of research based on data received from NHS Tayside should 
not be made available in a form which: 
a) directly identifies individual data subjects 
b) is not covered by the ‘intended use of data’ specified 
 
Information Governance 
AshludieHospital 
Monifieth 
DD5 4HQ 
 
 
Telephone : 01382 527920 
Fax : 01382 527808 
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CALDICOTT APPROVAL - DATA PROCESSING SPECIFICATION 
To be submitted with application for Caldicott Approval 
For each separate source of patient identifiable data that you intend to access in support of 
your study please provide the following information.  
Data Source: (Medical Records/System Name) 
Medical records 
 
Data Items: (list the data items that you will require from the named data source) 
Outcome data  (TOP) Maudesley Addiction 
Profile (MAP) 
Urine/oral fluid drug 
screens 
Information from 
contemporaneous 
clinical record 
indicating progress in 
treatment – listed 
below 1-3 
1. Evidence of drug 
use and risk 
behaviours eg 
overdose etc. 
2. Evidence of 
housing & family 
stability 
3. Evidence of criminal 
justice involvement 
 
 
Data Source Contact Details: (who have you agreed access to the source data with?) 
Name: Dina Ajeda Designation: TSMS Clinical Governance Lead 
Base: Constitution House Tel No: 07803671870 
Email address: dinaajeda@nhs.net  
 
Data Storage Arrangements: (where arrangements are described in a supplied study protocol then 
reference to the relevant sections of the protocol can be used) 
Location: (NHS Tayside, University, etc.) 
Data will be stored in a bespoke computer database The 
computer is password protected and the data is encrypted 
(process supervised by HIC technical staff). When not in 
use the computer will be stored in a locked drawer in a 
filing cabinet in the CARES office, Dept of Psychiatry, 
UoD, Ninewells. 
Device to be held on(desktop, laptop, network 
storage, etc.) 
Laptop computer. Password protected. Data 
encrypted. 
 
Access Controls (how will the data be protected from 
unauthorised access?) 
Password protected computer. Encrypted data 
Encryption: (will encryption be used to protect the data?) 
 
Yes 
Anonymisation: (how will the identity of individuals be 
protected) 
Data will be identifiable in the main database by Chi 
number. Names will not be retained 
Format (spreadsheet, database, etc.) 
 
SPSS version 12 
 
If you intend to make contact with patients identified through the processing of this data, indicate how this 
will be done and how you will ensure that it is appropriate to contact them. 
It is recommended that contact with patients is through correspondence signed by the patient’s GP/Clinician 
or Head of Clinical Service. 
At this stage it is NOT intended to contact patients for this follow up audit. Future processes which 
are dependent on available resources may require patient interviews. In such circumstance Dr 
Kidd will require a further Caldicott approval. 
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Health Informatics Centre 
 
 
HIC Data User Agreement 
 
Approved Data User- is the project Principal Investigator (PI) or a person who is authorised by the PI to 
also have access tothe Project Dataset at an approved location. The Approved Data User must be an 
employee of NHS Tayside, NHS Fife or the University of Dundee. All project collaborators must sign and 
agree to abide by the terms of the HIC Data User Agreement.  
Where a data user is not such an employee but is an external project collaborator, then they will be 
logged on the HIC Project Management System as an Approved Data User subject to the following: 
a) The HIC Data User Agreementmust also be signed by an authorised signatory from their 
organisation. 
HIC may choose to make the project data available to the Approved Data User by hosting the data on a 
HIC server, within HIC’s Safe Haven environment and providing secure remote access to the server, 
rather than releasing the data externally. 
 
Data User Responsibilities 
 
All Approved Data Users are expected to maintain the security and confidentiality of their project 
datasets in accordance with this agreement and the Data Protection Principles (see Appendix A). HIC 
expectsApproved Data Users to report significant events that are in breach of the terms of the HIC Data 
User Agreement. Contact the HIC Operations Manager in the first instance to report the incident, who 
will initiate a Significant Event Report. 
 
1) Approved Data Users will not reuse the data for purposes outside the scope of each project; 
share it with colleagues who are not named project Approved Data Users; attempt to link it to 
other datasets; or to de-anonymise it.  
2) Approved Data Users will only keep the data on a secure password-protected and encrypted 
hard drive partition or remotely access their centrally-held data within the HIC Safe Haven. 
Data is not permitted to be stored or transferred on unencrypted removable devices, e.g. 
unencrypted USB keys. HIC can offer advice and install encrypted partitions to researcher’s 
hardware, if required. 
3) Further transfer of data between named project Approved Data Userswill only be of encrypted 
data, usually directly from an access controlled FTP server to the FTP client but data may also 
be sent via email using encrypted data files. HIC can offer advice and provide encryption tools, 
to help meet this requirement. 
318 
 
4) Approved Data Userswill notify HIC when the project is complete and arrange for the return of 
the data and the analysis syntax used for archiving, deleting all local copies. HIC will require 
written confirmation that all locally-held data has been deleted. 
5) Approved Data Users will ensure that HIC and the Health Board responsible for initially 
providing data are acknowledged as data sources in all resulting reports and publications. Eg. 
“We acknowledge the support of  the Health Informatics Centre, University of Dundee for 
managing and supplying the anonymised data and NHS ‘XXX’, the original data source” 
Signatures 
a) Approved Data User 
 
By signing and dating below you confirm that you have read, understood and will abide by this HIC Data 
User Agreement and the Data Protection Principles in relation to data being provided to you from 
HIC.Any breach of this agreement will result in your access to HIC data being reviewed by the HIC 
Executive Committee 
Name:  
 
Position: 
 
 
Signature 
 
 
Date signed: 
 
 
b) Student Supervisor 
(Note: Where the Approved Data User is a student, this Declaration must be signed by the student’s 
supervisor.) 
By signing and dating below you confirm that you will ensure the above named ApprovedData User has 
read, understood and will abide by this HIC Data User Agreement and the Data Protection Principles in 
relation to data being provided to him/her by HIC. 
 
Name: 
 
 
Position: 
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Signature 
 
 
Date signed: 
 
c) Project Collaborators/External Organisations 
 
External project collaborators (Approved Data Users who are not employees of University of Dundee, 
Tayside Health Board or Fife Health Board) must have this section signed by an authorised signatory 
from their organisation. 
Authorised Signatory for Project Collaborator’s Institution to sign the following declaration: 
“We declare that the above named researcher is a bona fide employee of this Institution engaged in a 
reputable project for which all relevant required permissions have been granted, and that the data 
requested can be entrusted to this person in the knowledge that they will conscientiously discharge 
their obligations in regard to the confidentiality of the data. This Institutionagrees to abide by the terms 
of this agreement and takes responsibility for ensuring that researchers are knowledgeable of, and 
compliant with required statutory and regulatory permissions and Data Protection requirements, and 
will provide a secure working environment and suitable technical resources to meet this obligation.” 
We declare that we understand that any breach of this agreement will lead to the withdrawal of access 
to HIC data for this Institution and its staff, and that HIC has a duty to report serious legal or regulatory 
breaches to the appropriate authorities (such as the Data Protection Commissioner and professional 
regulatory bodies).” 
Name:  
 
Position: 
 
 
Signature 
 
 
Date signed: 
 
 
For and On behalf of:_______________________________________  
    (Name of Institution) 
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Appendix A:  The 8 Data Protection Principles 
 
1.  Personal data shall be processed fairly and lawfully 
 must not deceive or mislead 
 must state the purpose of the processing  
 must provide your identity 
 must have consent of the data subject – cannot infer this from a lack of response 
 must specify time period of consent 
 must have appropriate safeguards for data 
 must obtain consent from data subjects for processing if data provided by a third party 
 
2.  Personal data shall be obtained only for one or more specified and lawful purposes, and shall not 
be further processed in any manner incompatible with that purpose or purposes 
 Must identify purposes for which data is being processed 
 Must ensure purposes are compatible with information given to data subjects and to the Office 
of the Information Commissioner (www.ico.gov.uk) 
 Must not further process if purposes are not compatible with consent or notification to OIC 
without resolving conflicts 
 
3. Personal data shall be adequate, relevant, and not excessive in relation to the purpose or purposes 
for which they are processed 
 Must establish what is collected and why 
 Must audit data holding against need – minimum information must be collected – do not 
collect ‘just in case’ 
 Must establish effective data retention and disposal policies 
 Must establish policies and procedures to test new and modified data collection against the 
principles 
 
4. Personal data shall be accurate and, where necessary, kept up to date 
 Must establish methods to validate the source of data 
 Must establish policies and procedures to keep data up–to-date 
 Must establish policies and procedures to correct or mark as incorrect any disputed data 
 
5. Personal data processed for any purpose or purposes shall not be kept for longer than is necessary 
for that purpose or those purposes 
 Must establish policies and procedures review why you are retaining data – eg current use, 
audit/ legal purposes, research purposes 
 Must delete data that is no longer needed 
 
6. Personal data shall be processed in accordance with the rights of data subjects under this Act 
 Rights of data subjects include: 
o Right to be told that their personal data is being processed and for what purpose 
o Right to obtain a copy of their personal data 
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o Right to prevent the use of their data for direct marketing purposes 
o Right to be told to whom the data will be disclosed 
o Right to prevent processing which may cause substantial damage or distress to he 
data subject 
o Right to have explained the logic behind any decision taken on the basis of the 
processing of the data 
 Must manage operations to ensure that data subjects can exercise their rights properly and 
fully 
 
7.  Appropriate technical and organisational measures shall be taken against unauthorised or unlawful 
processing of personal data and against accidental loss or destruction of, or damage to, personal 
data 
 practical steps to compliance include: 
o do not allow staff to share password 
o site PCs where the screen cannot be seen by unauthorised staff or the public and 
do not leave information on the screen when you are not there 
o when using external agencies ensure processing is carried out under written 
contracts 
o block access to systems by former staff 
o vet all prospective employees  
o react to allegations of access to unauthorised data 
o do no leave files unattended in the open 
o shred personal data rather than bin it 
o do not design documents/ write papers in ways that reveal personal data 
o physical and electronic security 
o staff training 
o measures to prevent accidental loss, damage or destruction of data 
 
8. Personal data shall not be transferred to a country or territory outside the European Economic 
Area (25 EU Member States + Iceland, Lichtenstein & Norway) unless that country or territory 
ensures an adequate level of protection for the rights and freedoms of data subjects in relation to 
the processing of personal data 
 must not transfer data by any means (including electronic) if in doubt 
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Data release agreement -HIC 
Project 1013 – Substance Misuse in Tayside (SUMIT) 
Data User: Brian Kidd/ Cassie Higgins / Colin McCowan 
 
 
Date Released: 8th June 2011 
 
SQL tables:   Work..tt_1013_presc    Prescribing imported from PSD_Flow on ATHENA 
   ATHENA.SUMIT..tt_1013_cohort  Cohort on Athena to allow extraction of ATOPs 
Data Requirement Filename Notes No. of records 
extracted 
Demography Demog.txt Demography including anon date of birth, and date of death. 
Note that 20 patients were lost from the original methadone baseline dataset due 
to invalid CHI numbers. 
731 
(627 unique) 
ATOPS ATOPS_Alcohol Liason.txt 
ATOPS_AlcoholServiceCommunity.txt 
ATOPS_DrugService_AISS.txt 
ATOPS_DrugService_DTTO.txt 
ATOPS_DrugService_ISP.txt 
ATOPS_DrugService_TARS.txt 
ATOPs data for the cohort. 
Refer to supplied metadata files for lookups. 
Note: HIC does not have paper copies of the Alcohol Liason or DrugService_ISP 
forms so unsure what each columns are (ie no metadata for these files) 
No results. 
6 
157 
23 
2 
39 
Anonymised: Yes 
PROCHI: bmz 
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ATOPS_TimeTayChange.txt 271 
SMR00 SMR00.txt All outpatient records for the cohort from 2005 to 31/Mar/2010 
Note: seems to be missing SMR00 data 01/Jan/2009 – 30/06/2009, HIC to 
request from ISD, was never received. 
23,057 
SMR01 SMR01.txt All hospital admissions for the cohort from 2005 to 30/Sep/2010 907 
Ward Data TOPAS_Ward.txt Ward data from 01/Oct/2010 to 31/Dec/2010 to supplement SMR01 above 44 
SMR04 SMR04.txt All psychiatric admissions for the cohort from 2005  to 31/Mar/2010 133 
Methadone Methadone_baseline.txt 
Methadone_followup.txt 
Anonymous Methadone baseline and follow-up database supplied by Cassie. 627 
467 
GRO GRO.txt GRO deaths for the cohort 45 
Biochemistry Biochem.txt Biochemistry from 2005 for the codes: 
BENZ : BENZODIAZEPINES (URINE) 
METH : METHADONE (URINE) 
OPIA : OPIATES (URINE) 
AMPH : AMFETAMINES (URINE) 
BARB : BARBITURATES (URINE) 
COCN : COCAINE (URINE) 
UCAN : CANNABINOIDS (URINE) 
OTOX : OPIATE CONFIRMATION (URINE)  
84,634 
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UTOX : TOXICOLOGY (URINE)   
UALC : ALCOHOL (URINE) 
CRU : URINE CREATININE 
Prescribing Presc.txt 
Presc_items.txt 
HIC Prescribing for the cohort, plus directions entered for certain drug groupings.  
Note that (additional methadone ones to be done separately to capture 
information such as quantity, days, total, supervised, frequency). 
Use res_seqno to link between the 2 files. 
117,746 
2,318 
A&E AandE.txt 
AandE_accompany.txt 
AandE_diag.txt 
AandE_drugs.txt 
Accident and Emergency data for the cohort.  The file AandE.txt represents the 
actual admission to the A&E department.  Accompany links to this via CHI and 
Attendance_Number and shows who was with the patient at their attendance (ie 
mother, police, prison officer, teacher etc).  There can be more than one person 
accompanying the patient. 
The diag and drugs files show what decision was made on the diagnosis and any 
treatment given.  
710 
714 
723 
118 
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Date Released: 28th  June 2011 
SQL tables:   ATHENA.SUMIT..tt_1013_cohort  Cohort on Athena to allow extraction of ATOPs 
   Work..baseline_xxxxx, (11 files ) 
Data Requirement Filename Notes No. of records 
extracted 
Baseline data 
Methadone cohort 
baseline_ADHD.txt 
baseline_CORE.txt 
baseline_Chronic_Pain.txt 
baseline_Demographic.txt 
baseline_GHQ.txt 
baseline_Injecting_Risk_Behaviour.txt 
baseline_MAP.txt 
baseline_PTSD.txt 
baseline_Social_Phobia.txt 
baseline_Sweating.txt 
baseline_TPQ.txt 
 623 
620 
625 
623 
626 
625 
625 
623 
621 
624 
621 
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University of Dundee Research and Innovation Services 
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Appendix 4 – Additional tables of results – Chapter 6 
 
This Appendix contains the additional results tables for which no significant associations 
were demonstrated once the Bonferroni correction was applied – 2009 casenote follow up  
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Table A1.  Impact of gender on process and 4 year outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics 
 
Gender 
 
No significant impacts 
demonstrated 
Retention (Yes 156) Chi square X2(1)=0.168; 
p=0.682 
If NOT= +ve or –ve discharge 
(n=139) 
Chi square X2(6)=7.220; 
p=0.301 
Drug screen done Chi square X2(2)=0.890; 
p=0.641 
Methadone dose KWH X2(1)=0.317; p=0.574 
Diazepam dose KWH X2(1)=0.606; p=0.436 
Dependent (Outcome) 
variable 
 
Employment status Chi square X2(1)=0.057; 
p=0.812 
Family stability Chi square X2(2)=1.147; 
p=0.564 
Any illicit drug use reported Chi square X2(3)=1.728; 
p=0.631 
Heroin use reported Chi square X2(3)=0.720; 
p=0.868 
Heroin days Chi square X2(8)=8.526; 
p=0.384 
Heroin route Chi square X2(4)=0.618; 
p=0.961 
Illicit Diazepam use Chi square X2(3)=2.591; 
p=0.459 
Illicit Diazepam days Chi square X2(8)=8.959; 
p=0.346 
Illicit Methadone use  Chi square X2(3)=2.672; 
p=0.445 
Illicit Methadone days Chi square X2(6)=4.774; 
p=0.573 
Illicit painkillers **25 cases Chi square X2(3)=2.558; 
p=0.564 
+ve opiates tests Chi square X2(4)=2.946; 
p=0.567 
+ve benzodiazepine tests Chi square X2(3)=1.159; 
p=0.763 
Acute admissions reported 
(18) 
KWH X2(1)=0.007; p=0.932 
Psych admissions reported 
(14) 
KWH X2(1)=0.274; p=0.600 
Prison reported (48) KWH X2(1)=1.055; p=0.304 
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Table A2.  Impact of NHS Deprivation score (SIM-D) on process and 4 year outcomes 
Independent (predictor) 
Variable 
Dependent (process) 
Variable 
Statistics 
 
SIM-D quintile (local) 
 
NO significant impacts 
identified 
Retention  Chi square X2(4)=5.516; 
p=0.238 
Pos/neg discharge Chi square X2(12)=10.760; 
p=0.550 
Drug screen done Chi square X2(8)=3.592; 
p=0.892 
Methadone dose KWH  X2(4)=2.981; p=0.561 
Diazepam dose KWH X2(4)=5.901; p=0.207 
Dependent (Outcome) 
variable 
 
Employment status Chi square X2(4)=7.188; 
p=0.126 
Family stability Chi square X2(8)=8.357; 
p=0.399 
Any drug use reported ?? 
Heroin use  Chi square X2(12)=11.842; 
p=0.458 
Heroin days Chi square X2(32)=26.819; 
p=0.726 
Heroin route Chi square X2(16)=9.363; 
p=0.898 
Illicit Diazepam use Chi square X2(12)=8.271; 
p=0.764 
Illicit diazepam days Chi square X2(32)=24.497; 
p=826 
Illicit methadone use Chi square X2(12)=8.905; 
p=0.711 
Illicit methadone days Chi square X2(24)=16.290; 
p=0.877 
Illicit painkillers  Chi square X2(12)=10.039; 
p=0.613 
Illicit painkiller days Chi square X2(16)=12.767; 
p=0.690 
+ve opiate Chi square X2(16)=7.592; 
p=0.960 
+ve benzos Chi square X2(12)=8.720; 
p=0.727 
Acute admissions reported 
(18) 
KWH X2(4)=5.641; p=0.228 
Psych admissions reported 
(14) 
KWH X2(4)=5.885; p=0.208 
Prison reported (48) KWH X2(4)=3.296; p=0.510 
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Table A3.  Impact of social stability – time at address - at baseline on process and 4 year 
outcomes 
Independent Variable Dependent (process) 
Variable 
Statistics 
 
Time at address 
 
No significant impacts 
identified 
Retention  Chi square X2(5)=2.772; 
p=0.735 
Pos/neg discharge Chi square X2(5)=6.878; 
p=0.230 
Drug screen done Chi square X2(10)=7.625; 
p=0.665 
Methadone dose KWH X2(5)=2.055; p=0.841 
Diazepam dose KWH X2(5)=2.182; p=0.823 
Dependent (outcome) 
variable 
 
Employment status Chi square X2(25)=16.319; 
p=0.905 
Family stability Chi square X2(10)=8.270; 
p=0.603 
Any illicit drug use reported Chi square X2(15)=18.521; 
p=0.236 
Heroin use reported; days; 
route 
Chi square X2(15)=18.168; 
p=0.254 
Heroin days Chi square X2(15)=31.601; 
p=0.826 
Heroin route Chi square X2(20)=21.416; 
p=0.373 
Illicit Diazepam use Chi square X2(15)=12.447; 
p=0.645 
Illicit diazepam days Chi square X2(40)=31.353; 
p=0.834 
Illicit methadone use Chi square  X2(15)=11.979; 
p=0.681 
Illicit methadone days Chi square X2(25)=18.525; 
p=0.819 
Illicit painkillers use Chi square X2(15)=13.556; 
p=0.559 
Illicit painkillers days Chi square X2(20)=17.854; 
p=0.597 
+ve opiates; Chi square X2(15)=8.168; 
p=0.917 
+ve benzos Chi square X2(15)=6.641; 
p=0.967 
Acute admissions reported  KWH X2(5)=2.870; p=0.720 
Psych admissions reported  KWH X2(5)=2.349; p=0.799 
Prison reported  KWH X2(5)=4.074; p=0.539 
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Table A4.  Impact of Social stability – living circumstances -  on process and 4 year 
outcomes 
Independent Variable Dependent (process) 
Variable 
Statistics 
 
Lives alone or not 
 
No significant impacts 
identified 
Retention  Chi square X2(5)=6.491; 
p=0.261 
Pos/negative discharge Chi square X2(5)=5.873; 
p=0.319 
Drug screen done Chi square X2(10)=6.875; 
p=0.737 
Methadone dose KWH X2(1)=0.819; p=0.365 
Diazepam dose KWH X2(4)=4.982; p=0.289 
Dependent (outcome) 
variable 
 
Employment status Chi square X2(25)=14.071; 
p=0.960 
Family stability Chi square X2(10)=13.430; 
p=0.201 
Any illicit drug use reported Chi square X2(15)=16.142; 
p=0.373 
Heroin use reported; days; 
route 
Chi square X2(15)=12.430; 
p=0.646 
Heroin days Chi square X2(40)=28.477; 
p=0.913 
Heroin route Chi square X2(20)=23.698; 
p=0.256 
Illicit Diazepam use Chi square X2(15)=21.012; 
p=0.136 
Illicit diazepam days Chi square X2(40)=30.383; 
p=0.864 
Illicit methadone use  Chi square X2(15)=15.264; 
p=0.433 
Illicit methadone days Chi square X2(30)=20.278; 
p=0.909 
Illicit painkillers use Chi square X2(15)=13.336; 
p=0.576 
Illicit painkillers days Chi square X2(20)=17.043; 
p=0.650 
+ve opiates Chi square X2(20)=15.828; 
p=727 
+ve benzos Chi square X2(15)=13.186; 
p=0.588 
Acute admissions reported  KWH (4)=5.810; p=0.214 
Psych admissions reported  KWH X2(4)=6.168; p=0.187 
Prison reported  KWH X2(4)=4.039; p=0.401 
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Table A5.  Impact of Social stability – living with children - on process and 4 year outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics 
 
Lives with kids 
 
No significant impacts 
identified 
Retention  Chi square X2(1)=0.143; 
p=0.706 
Pos/neg discharge Chi square X2(1)=0.053; 
p=0.819 
Drug screen done Chi square X2(1)=0.477; 
p=0.490 
Methadone dose KWH X2(1)=0.807; p=0.369 
Diazepam dose KWH X2(1)=0.641; p=0.423 
Dependent (outcome) 
variable 
 
Employment status Chi square X2(5)=2.620; 
p=0.758 
Family stability Chi square X2(2)=1.147; 
p=0.563 
Any illicit drug use reported Chi square X2(2)=0.077; 
p=0.962 
Heroin use reported Chi square X2(3)=1.281; 
p=0.734 
Heroin days Chi square X2(8)=7.014; 
p=0.535 
Heroin route Chi square X2(4)=2.487; 
p=0.647 
Illicit Diazepam use Chi square X2(3)=1.710; 
p=0.635 
Illicit diazepam days Chi square X2(7)=5.654; 
p=0.581 
Illicit methadone use  Chi square X2(3)=4.545; 
p=0.208 
Illicit methadone days Chi square X2(6)=4.671; 
p=0.587 
Illicit painkillers  Chi square X2(3)=1.898; 
p=0.594 
Illicit painkillers days Chi square X2(4)=1.223; 
p=0.874 
+ve opiates Chi square X2(4)=6.219; 
p=0.183 
+ve benzos Chi square X2(3)=0.669; 
p=0.880 
Acute admissions reported  KWH X2(1)=0.015; p=0.902 
Psych admissions reported KWH X2(1)=0.275; p=0.600 
Prison reported  KWH X2(1)=0.163; p=0.686 
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Table A6.  Impact of employment on process and 4 year outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics 
 
Days in paid work/30 
 
No significant impact 
identified 
Retention  LDA X2(1)=1.153; p=0.283 
Pos/neg discharge LDA X2(1)=0.838; p=0.360 
Drug screen done LDA  X2(1)=0.757; p=0.384 
Methadone dose QRA  t(1)=0.147; p=0.883 
Diazepam dose QRA t(1)=0.865; p=0.387 
Dependent (outcome) 
variable 
 
Employment status LDA  X2(1)=2.404; p=0.121 
Family stability LDA  X2(1)=1.463; p=0.226 
Any illicit drug use reported LDA X2(1)=1.210; p=0.271 
Heroin use reported LDA  X2(1)=0.000; p=0.995 
Heroin days QDA X2(6)=2.520; p=0.866 
Heroin route LDA  X2(1)=0.069; p=0.793 
Ill Diazepam use LDA  X2(1)=1.506; p=0.220 
Ill meth use LDA X2(1)=1.688; p=0.194 
Illicit painkillers  used LDA X2(1)=0.068; p=0.795 
+ve opiates LDA  X2(1)=0.011; p=0.918 
+ve benzos LDA X2(1)=2.141; p=0.143 
Acute admissions reported  LRA t(1)=1.043; p=0.298 
Psych admissions reported  LRA t(1)=1.044; p=0.297 
Prison reported  LRA  t(1)=1.068  p=0.280 
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Table A7.  Impact of MAP physical health score on process and 4 year outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics 
 
Baseline MAP physical 
health score 
 
No significant impact 
identified 
Retention  LDA X2(1)=0.000; p=0.995 
Pos/neg discharge LDA X2(1)=1.243; p=0.265 
Drug screen done LDA  X2(1)=0.176; p=0.675 
Methadone dose LRA t(1)=0.212; p=0.832 
Diazepam dose LRA t(1)=-0.098; p=0.922 
Dependent (outcome) 
variable 
 
Employment status LDA X2(1)=2.092; p=0.148 
Family stability LDA X2(1)=0.560; p=0.454 
Any illicit drug use reported LDA  X2(1)=0.438; p=0.508 
Heroin use reported; days; 
route 
LDA X2(1)=0.593; p=0.441 
Heroin days LDA X2(6)=7.330; p=0.291 
Heroin route LDA X2(1)=2.271; p=0.132 
Illicit Diazepam use LDA  X2(1)=0.002; p=0.968 
Illicit diazepam days QDA  X2(6)=9.237; p=0.161 
Illicit methadone use LDA X2(1)=0.894; p=0.344 
Illicit methadone days QDA  X2(4)=5.132; p=0.274 
Illicit painkillers  use LDA  X2(1)=1.959; p=0.581  
Illicit painkillers days QDA X2(2)=4.049; p=0.132 
+ve opiates LDA X2(1)=1.033; p=0.310 
+ve benzos LDA X2(1)=0.350; p=0.554 
Acute admissions reported  LRA t(1)=0.033; p=0.974 
Psych admissions reported  LRA t(1)=0.025; p=0.980 
Prison reported  LRA t(1)=0.168; p=0.866 
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Table A8.  Impact of MAP psychological health score on process and 4 year outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics 
 
Baseline MAP psychological 
health score 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  LDA X2(1)=0.302; p=0.583 
Pos/neg discharge LDA X2(1)=0.550; p=0.458 
Drug screen done LDA  X2(1)=0.670; p=0.413 
Methadone dose QRA t(1)=1.271; p=0.204 
Diazepam dose QRA t(1)=-1.295; p=0.196 
Dependent (outcome) 
variable 
 
Employment status LDA X2(1)=0.527; p=0.468 
Family stability LDA X2(1)=0.003; p=0.956 
Any illicit drug use reported LDA  X2(1)=0.244; p=0.621 
Heroin use reported LDA X2(1)=1.205; p=0.272 
Heroin days QDA X2(5)=2.780; p=0.734 
 
Heroin route LDA X2(1)=0.662; p=0.416 
Illicit Diazepam use LDA  X2(1)=4.049; p=0.044 
>score predicts  benzo use 
Illicit diazepam days QDA  X2(5)=4.886; p=0.430 
Ill meth use; days;  LDA X2(1)=0.690; p=0.406 
Illicit methadone days QDA  X2(4)=6.511; p=0.089 
Illicit painkillers  LDA  X2(1)=1.840; p=0.175 
+ve opiates LDA X2(1)=0.045; p=0.832 
+ve benzos LDA X2(1)=1.474; p=0.225 
Acute admissions reported LRA t(1)=0.548; p=0.584 
Psych admissions reported LRA t(1)=0.545; p=0.586 
Prison reported  LRA t(1)=0.645; p=0.519 
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Table A9.  Impact of baseline heroin days used on process and 4 year outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics 
 
Heroin use days 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  LDA X2(1)=0.072; p=0.789 
Drug screen done LDA X2(1)=0.124; p=0.724 
Methadone dose LRA t(1)=1.821; p=0.069 
Diazepam dose LRA t(1)=-0.316; p=0.752 
Dependant (outcome) 
variable 
 
Employment status LDA X2(1)=1.482; p=0.224 
Family stability LDA X2(1)=0.303; p=0.582 
Any illicit drug use reported LDA X2(1)=2.991; p=0.084 
Heroin use reported LDA X2(1)=5.231; p=0.022 
More days predicts no use 
Heroin days LDA X2(5)=4.931; p=0.424 
Heroin route LDA X2(1)=2.308; p=0.129 
Ill Diazepam use LDA X2(1)=2.263; p=0.132 
Illicit diazepam days LDA X2(5)=3.727; p=0.589 
Illicit methadone use LDA X2(1)=3.497; p=0.061 
Illicit methadone days LDA X2(3)=0.283; p=0.963 
Illicit painkillers  use LDA X2(1)=0.100; p=0.751 
Illicit painkillers days LDA X2(1)=0.970; p=0.325 
+ve opiates LDA X2(1)=2.832; p=0.092 
+ve benzos LDA X2(1)=0.157; p=0.692 
Acute admissions reported  LRA t(1)=-0.199; p=0.843 
Psych admissions reported  LRA t(1)=0.211; p=0.833 
Prison reported  LRA t(1)=0.272; p=0.786 
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Table A10. Impact of baseline diazepam illicit use on process and 4 year outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics 
Benzodiazepine use  - test 
 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
Retention  Chi square X2(2)=0.034; 
p=0.983 
Drug screen done Chi square X2(4)=0.856; 
p=0.931 
Methadone dose KWH X2(1)=2.163;  p=0.141 
Diazepam dose KWH X2(1)=0.579;  p=0.447 
Dependent (outcome) 
variables 
 
Employment status Chi square X2(12)=5.629; 
p=0.934 
Family stability 
Negative predicts stability 
Chi square 
X2(4)=10.699;p=0.030 
 
Any illicit drug use reported Chi square X2(6)=12.494 
p=0.052 
Heroin use reported; days Chi square X2(6)=6.266; 
p=0.394 
Heroin days 
Negative predicts more 
heroin use 
Chi square 
X2(16)=28.293p=0.029 
 
Heroin route Chi square X2(8)=3.647; 
p=0.887 
Illicit Diazepam use Chi square X2(6)=6.805; 
p=0.339 
Illicit diazepam days Chi square X2(16)=18.766; 
p=0.281 
Illicit methadone use  Chi square X2(6)=5.010;  
p=0.543 
Illicit methadone days Chi square X2(12)=11.820; 
p=0.460 
Illicit painkillers use Chi square X2(6)=5.218; 
p=0.516 
Illicit painkillers days Chi square X2(18)=6.401; 
p=0.602 
+ve opiates Chi square X2(8)=8.656; 
p=0.372 
+ve benzos Chi square X2(6)=8.664; 
p=0.193 
Acute admissions reported  KWH X2(1)=0.002;  p=0.968 
Psych admissions reported  KWH X2(1)=0.012;  p=0.912 
Prison reported  KWH X2(1)=0.037;  p=0.848 
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Table A11.  Impact of injecting risk (baseline  IRQ total score) on process and 4 year 
outcomes 
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics 
 
Risk taking – injecting  
total score 1-17 in IRQ  
(71 of 87 IV cases/537) 
 
No significant impact 
identified 
 
Retention  LDA X2(1)=1.003; p=0.317 
Drug screen done Chi square X2(4)=6.389; 
p=0.172 
Methadone dose LRA t(1)=-1.125; p=0.267 
Diazepam dose LRA t(1)=0.531; p=0.598 
Dependent (outcome) 
variable 
 
Employment status LDA X2(1)=0.047; p=0.828 
Family stability LDA X2(1)=0.136; p=0.712 
Any illicit drug use reported LDA X2(1)=0.134; p=0.715 
Heroin use reported; days; 
route  
LDA X2(1)=0.134; p=0.715 
Heroin days LDA X2(2)=1.324; p=0.516 
Heroin route LDA X2(1)=1.286; p=0.257 
Illicit Diazepam use LDA X2(1)=0.727; p=0.394 
Illicit diazepam days LDA X2(3)=3.431; p=0.330 
Ill meth use; days;  Not tested 
Illicit painkillers use Not tested 
Illicit painkiller days Not tested 
+ve opiates Chi square X2(8)=11.926; 
p=0.155 
+ve benzos Chi square X2(8)=11.043; 
p=0.087 
Acute admissions reported  LRA t(1)=-1.015; p=0.316 
Psych admissions reported  LRA t(1)=-1.013; p=0.317 
Prison reported  LRA t(1)=-1.008; p=0.319 
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Table A12.  Impact of Pain and its characteristics on process  
Independent (Predictor) 
Variable 
Dependent (Process) 
variable 
Statistics 
 
Pain 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
 
1. Present  - No 
associations 
2. Duration -  No 
associations 
3. Chronic (12/12) –  
4. Intensity   
5. Intensity quintiles  
Retention : 
High intensity 
(score)predicts poor 
retention 
 
1.Chi square 
X2(1)=0.033;p=0.856 
2.LDA X2(1)=0.238; p=0.626 
3. Chi square 
X2(1)=0.055;p=0.815 
4.LDA X2(1)=6.301; p=0.012 
5. Chi square 
X2(4)=6.208;p=0.184 
Pos/neg discharge : 
More severe 
(quintiles)predicts negative 
discharge 
1.Chi square 
X2(1)=0.548;p=0.459 
2.LDA X2(1)=0.003; p=0.958 
3. Chi square 
X2(1)=0.001;p=0.979 
4.LDA X2(1)=0.748; p=0.387 
5. Chi square 
X2(4)=13.151;p=0.011 
 
Drug screen done:  
Higher intensity (score) 
=less likely to be screened 
 
1.Chi square 
X2(2)=0.869;p=0.647 
2. LDA X2(1)=0.022; p=0.883 
3. Chi square 
X2(2)=0.254;p=0.881 
4.LDA X2(1)=4.874; p=0.027 
5. Chi square 
X2(8)=10.979;p=0.203 
Methadone dose 1. KWH X2(1)=0.810; p=0.368 
2.LRA t(1)=0.284; p=0.777 
3. KWH X2(1)=0.145; p=0.704 
4.LRA t(1)=1.598; p=0.111 
5. KWH X2(4)=6.887; p=0.142 
Diazepam dose 1. KWH X2(1)=0.010; p=0.920 
2.LRA t(1)= 1.189; p=0.236 
3. KWH X2(1)=0.107; p=0.744 
4.LRA t(1)=1.503; p=0.134 
5. KWH X2(4)=3.739; p=0.442 
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Table A13. Impact of Pain and its characteristics on 4 year outcomes 
Independent (Predictor) Variable Dependent (Outcome) variable Statistics 
 
 
Pain 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
 
1. Present  - No associations 
2. Duration -  No associations 
3. Chronic (12/12)  
4. Intensity   
5. Intensity quintiles   
 
Employment status 
 
1.Chi square X2(6)=8.002; p=0.238 
2. LDA X2(1)=0.001; p=0.972 
3. Chi square X2(6)=7.645; p=0.265 
4.LDA X2(1)=0.370; p=0.543 
5. Chi square X2(24)=36.718; p=0.047 
 
Family stability 1.Chi square X
2(2)=0.634; p=0.729 
2. LDA X2(1)=0.914; p=0.339 
3. Chi square X2(2)=2.713; p=0.258 
4.LDA X2(1)=1.455; p=0.228 
5. Chi square X2(8)=9.062; p=0.337 
Any illicit drug use reported 1.Chi square X
2(2)=0.851; p=0.654 
2. LDA X2(1)=0.160; p=0.689 
3. Chi square X2(2)=0.063 p=0.969 
4.LDA X2(1)=3.206; p=0.073 
5. Chi square X2(8)=10.368; p=0.240 
Heroin use reported; days; route  1.Chi square X
2(3)=2.632; p=0.452 
2. LDA X2(1)=0.045; p=0.831 
3. Chi square X2(2)=0.843; p=0.656 
4.LDA X2(1)=0.295; p=0.587 
5. Chi square X2(8)=8.142; p=0.420 
Heroin days: 
Chronic pain predicts moredays 
 
1.Chi square X2(7)=11.644; p=0.113 
2. LDA X2(3)=4.308; p=0.230 
3. Chi square X2(6)=12.942; p=0.044 
4.LDA X2(5)=8.747; p=0.120 
5. Chi square X2(24)=35.542; p=0.061 
Heroin route 1.Chi square X
2(4)=1.573; p=0.814 
2. LDA X2(1)=0.508; p=0.476 
3. Chi square X2(4)=1.211; p=0.876 
4.LDA X2(1)=0.012; p=0.913 
5. Chi square X2(16)=16.987; p=0.386 
Ill Diazepam use 1.Chi square X
2(3)=1.594; p=0.661 
2. LDA X2(1)=0.389; p=0.533 
3. Chi square X2(2)=0.682; p=0.711 
4.LDA X2(1)=1.268; p=0.260 
5. Chi square X2(8)=6.744; p=0.564 
Illicit diazepam days 1.Chi square X
2(8)=3.880; p=0.868 
2. LDA X2(1)=1.756; p=0.882 
3. Chi square X2(8)=7.728; p=0.460 
4.LDA X2(5)=7.772; p=0.169 
5. Chi square X2(32)=27.901; p=0.674 
Illicit methadone use;  1.Chi square X
2(3)=3.952; p=0.267 
2. LDA X2(1)=0.334; p=0.563 
3. Chi square X2(2)=0.443; p=0.802 
4.LDA X2(1)=2.791; p=0.095 
5. Chi square X2(8)=6.274; p=0.617 
Illicit methadone days 1.Chi square X
2(6)=3.958; p=0.682 
2. LDA X2(3)=0.409; p=0.938 
3. Chi square X2(6)=1.293; p=0.972 
4.LDA X2(3)=2.047; p=0.563 
5. Chi square X2(24)=23.425; p=0.495 
Illicit painkillers use 1.Chi square X
2(3)2.188; p=0.534 
2. LDA X2(1)=1.387; p=0.239 
3. Chi square X2(2)=0.422; p=0.810 
4.LDA X2(1)=0.153; p=0.696 
5. Chi square X2(8)=11.023; p=0.200 
+ve opiates 1.Chi square X
2(4)=4.019; p=0.403 
2. LDA X2(1)=0.249; p=0.618 
3. Chi square X2(4)=0.703; p=0.951 
4.LDA X2(1)=2.164; p=0.141 
5. Chi square X2(16)=18.961; p=0.271 
+ve benzos 1.Chi square X
2(3)=0.245; p=0.970 
2. LDA X2(1)=0.546; p=0.460 
3. Chi square X2(3)=0.579; p=0.901 
4.LDA X2(1)=1.660; p=0.198 
5. Chi square X2(12)=16.202; p=0.182 
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Acute admissions reported 
(18)More intense=more 
admissions 
 
1.ANOVA F(1,9)=-0.012; p=0.912 
2. LRA t(1)=-0.339; p=0.735 
3.KWH  X2(1)=0.000; p=0.993 
4.LRA   t(1)=2.366; p=0.018 
5. KWH X2(4)=5.495; p=0.240 
Psych admissions reported 
(14)More intense=more 
admissions 
 
1.ANOVA F(1,9)=-0.014; p=0.905 
2. LRA t(1)=-0.341; p=0.734 
3. KWH X2(1)=0.044; p=0.834 
4. LRA  t(1)=2.391; p=0.017 
5. KWH X2(4)=5.961; p=0.202 
Prison reported (48) 
More intense=more admissions 
 
1.ANOVA F(1,9)=-0.054; p=0.816 
2. LRA t(1)=-0.338; p=0.736 
3KWH X2(1)=0.158; p=0.691 
4LRA   t(1)=2.367; p=0.018 
5.KWH X2(4)=6.690; p=0.153 
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Table A14. Impact of Social Phobia  (SPDQ) on process and 4 year outcomes 
538 screened of whom 215 socially phobic, 323 not. 
Independent (Predictor) Variable Dependent (Process) variable Statistics 
 
Social phobia (SPDQ) 
 
1. Diagnosis y/n 
2. Social phobia total 
score 
 
No significant impact 
identified 
Retention  1.Chi square X
2
(1)=2.293; p=0.130 
2.LDA X
2
(1)=2.219; p=0.136 
Pos/neg discharge 1.Chi square X
2
(1)=0.140; p=0.708 
2.LDA X
2
(1)=0.117; p=0.732 
Drug screen done 1.Chi square X
2
(2)=2.203; p=0.332 
2.LDA X
2
(1)=0.445; p=0.505 
Methadone dose 1.KWH X
2
(1)=0.151; p=0.697 
2.LRA  t(1)=0.-1.188; p=0.235 
Diazepam dose 1.KWH X
2
(1)=1.804; p=0.179 
2.LRA t(1)=-1.575; p=0.116 
Dependent (Outcome) variable  
Employment status 1.Chi square X
2
(6)=12.212; p=0.057 
2.LDA X
2
(1)=2.623; p=0.203 
Family stability 1.Chi square X
2
(2)=2.744; p=0.254 
2.LDA X
2
(1)=0.237; p=0.626 
Any illicit drug use reported 1.Chi square X
2
(2)=2.954; p=0.228 
2.LDA X
2
(1)=1.056; p=0.304 
Heroin use reported  1.Chi square X
2
(3)=3.672; p=0.299 
2.LDA X
2
(1)=0.403; p=0.525 
Heroin days 1.Chi square X
2
(8)=7.784; p=0.455 
2.LDA X
2
(5)=8.082; p=0.152 
Heroin route 1.Chi square X
2
(1)=4.627; p=0.328 
2.LDA X
2
(1)=3.744; p=0.053 
Illicit Diazepam use 1.Chi square X
2
(3)=3.482; p=0.323 
2.LDA X
2
(1)=0.003; p=0.955 
 
Illicit diazepam days 1.Chi square X
2
(8)=10.829; p=0.212 
2.LDA X
2
(5)=6.093; p=0.297 
Illicit methadone use  1.Chi square X
2
(3)=5.177; p=0.159 
2.LDA X
2
(1)=1.557; p=0.212 
Illicit methadone days 1.Chi square X
2
(6)=8.628; p=0.196 
2.QDA X
2
(3)=4.713; p=0.194 
Illicit painkillers  use 
 
1.Chi square X
2
(3)=3.678; p=0.298 
2.LDA X
2
(1)=1.697; p=0.193 
+ve opiates 1.Chi square X
2
(4)=2.658; p=0.617 
2.LDA X
2
(1)=0.002; p=0.966 
+ve benzos 1.Chi square X
2
(3)=3.057; p=0.383 
2.LDA X
2
(1)=1.238; p=0.266 
Acute admissions reported 1.KWH X
2
(1)=1.705; p=0.192 
2.LRA t(1)=-1.512; p=0.131 
Psych admissions reported  1.KWH X
2
(1)=2.104; p=0.147 
2.LRA t(1)=-1.520; p=0.129 
Prison reported  1.KWH X
2
(1)=3.205; p=0.073 
2.LRA t(1)=-1.446; p=0.149 
 
Social phobia as measured by SPDQ at baseline has no significant impact on 2009 
outcomes  
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Table A15.  Impact of ADHD symptoms (CSS) on process and 4 year outcomes. 368 of 
original cohort screened. Of these: 51 had Inattentive symptoms; 28 had 
hyperactive/impulsive symptoms; 20 combined 59 had “any ADHD” symptoms – 31 
inattentive; 8 hyperactive; 20 combined 
Independent (Predictor) Variable Dependent (Process) variable Statistics 
 
1. ADHD symptoms 
2. ADHD types 
3. Impairment (19) 
 
Significant impact set at 
thep<0.05 level 
Significant impact at the 
appropriate level once 
Bonferroni Correction 
applied 
 
 
Retention 1. Chi square X2(1)=0.423; p=0.515 
2. Chi square X2(2)=4.248; p=0.120 
3. Chi square X2(1)=0.046; p=0.529 
Pos/neg discharge 1. Chi square X2(1)=1.347; p=0.246 
2. Chi square X2(1)=0.022; p=0.881 
3. Chi square X2(1)=0.063; p=0.802 
Drug screen done 1.Chi square X2(2)=0.304; p=0.859 
2.Chi square X2(2)=2.813; p=0.245 
3. Chi square X2(2)=0.081; p=0.960 
Methadone dose 1.KWH X2(1)=3.369; p=0.066 
2.KWH X2(2)=0.291; p=0.865 
3. KWH X2(1)=2.022; p=0.155 
Diazepam dose 1.KWH X2(1)=3.327; p=0.068 
2.KWH X2(2)=1.273; p=0.529 
3. KWH X2(1)=2.304; p=0.129 
Dependent (outcome) variable  
Employment status 1.Chi square X2(6)=3.980; p=0.679 
2.Chi square X2(6)=7.274; p=0.296 
3. Chi square X2(6)=9.714; p=0.137 
Family stability 1.Chi square X2(2)=1.140; p=0.566 
2.Chi square X2(4)=5.282; p=0.260 
3. Chi square X2(2)=0.438; p=0.803 
Any illicit drug use reported 1.Chi square X2(3)=0.732; p=0.866 
2.Chi square X2(4)=5.323; p=0.256 
3. Chi square X2(2)=1.968; p=0.374 
Heroin use reported 1.Chi square X2(3)=2.478; p=0.479 
2.Chi square X2(4)=4.316; p=0.365 
3. Chi square X2(3)=0.142; p=0.986 
Heroin days 1.Chi square X2(8)=11.767; p=0.162 
2.Chi squareX2(14)=17.946; p=0.209 
Heroin route 1.Chi square X2(4)=7.981; p=0.092 
2.Chi square X2(8)=9.334; p=0.315 
Illicit Diazepam use 1.Chi square X2(3)=5.481; p=0.140 
2.Chi square X2(4)=5.310; p=0.257 
3. Chi square X2(3)=0.279; p=0.964 
Illicit diazepam days 1.Chi square X2(8)=7.371; p=0.497 
2.Chi square X2(12)=14.980; p=0.243 
Illicit methadone use  1.Chi square X2(3)=2.672; p=0.445 
2.Chi square X2(4)=7.488; p=0.112 
3. Chi square X2(3)=0.179; p=0.981 
Illicit methadone days 1.Chi square X2(5)=6.091; p=0.297 
2.Chi square X2(8)=7.404; p=0.494 
Illicit painkillers use: 
ADHD predicts painkiller use 
1.Chi square X2(3)=8.804; p=0.032 
2.Chi square X2(4)=6.483; p=0.166 
3. Chi square X2(3)=0.244; p=0.970 
+ve opiates 1.Chi square X2(3)=3.199; p=0.362 
2.Chi square X2(6)=7.108; p=0.311 
3. Chi square X2(4)=0.360; p=0.986 
+ve benzos 1.Chi square X2(3)=1.388; p=0.708 
2. Chi square X2(6)=3.998; p=0.677 
3. Chi square X2(3)=0.693; p=0.875 
Acute admissions reported (18) 1.KWH X2(1)=0.525; p=0.469 
2.KWH X2(2)=4.833; p=0.089 
3. KWH X2(1)=0.006; p=0.940 
Psych admissions reported (14) 1.KWH X2(1)=0.236; p=0.627 
2.KWH X2(2)=3.248; p=0.197 
3. KWH X2(1)=0.014; p=0.905 
Prison reported (48) 1.KWH X2(1)=0.088; p=0.767 
2.KWH X2(2)=3.273; p=0.195 
3. KWH X2(1)=0.012; p=0.911 
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Appendix 5 – Additional tables of results – Chapter 7 
 
This Appendix contains the additional results tables for which no significant associations 
were demonstrated  - HIC data linkage univariate analyses  
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Table A16. Impact of Area lived in on outcomes 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
Area 
 
No significant impacts 
identified 
Out-patient appointments 
SMR00 sessions 2005/10 
KWH X2(2)=4.800; p=0.091 
Acute Services Contacts  
Ambulance service call-outs 
SAS attendances 2008/11 
KWH X2(2)=0.700; p=0.705 
Naloxone administrations 
2008/11 
KWH X2(2)=2.506; p=0.286 
A&E attendances <2008 KWH X2(2)=1.904; p=0.386 
General Hospital Admissions  
SMR01 admissions (acute) - 
ALL 
KWH X2(2)=0.816; p=0.665 
SMR01 duration(nights)  - 
ALL 
KWH X2(2)=1.374; p=0.503 
Psychiatric Admissions  
SMR04 admissions(psych) 
2005/11 
KWH X2(2)=0.611; p=0.737 
SMR04 total days KWH X2(2)=1.176; p=0.556 
Registrar General Death 
Data GROS dead/alive 
Chi square X2(2)=0.387; 
p=0.824 
 
Table A18.  Impact of deprivation score on outcomes 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
SIMD quintile 
 
No significant impacts 
identified 
Out-patient appointments 
SMR00 sessions 2005/10 
KWH X2(4)=7.343; p=0.119 
Acute Services Contacts 
Ambulance service call outs 
SAS attendances 2008/11 
KWH X2(4)=5.036; p=0.284 
Naloxone administrations 
2008/11 
KWH X2(4)=4.090; p=0.394 
A&E attendances <2008 KWH X2(3)=5.289; p=0.152 
General Hospital Admissions 
SMR01 admissions (acute) - 
ALL 
KWH X2(4)=5.346; p=0.254 
SMR01 duration(nights)  - 
ALL 
KWH X2(4)=3.072; p=0.546 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
KWH X2(4)=6.280; p=0.179 
SMR04 total days KWH X2(4)=3.881; p=0.422 
Registrar General Death 
Data GROS dead/alive 
Chi square X2(4)=2.188; 
p=0.701 
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Table A17. Impact of time at current address on outcomes 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
Time at address 
 
No significant impacts 
identified 
Out-patient attendances 
SMR00 sessions 2005/10 
KWH X2(5)=1.634; p=0.897 
Acute services contacts 
Ambulance Service Call-outs 
SAS attendances 2008/11 
KWH X2(5)=2.342; p=0.800 
Naloxone administrations 
2008/11 
KWH X2(5)=5.784; p=0.328 
A&E attendances <2008 KWH X2(5)=7.540; p=0.183 
Acute Hospital Admissions 
SMR01 admissions (acute) - 
ALL 
KWH X2(5)=7.732; p=0.172 
SMR01 duration(nights)  - 
ALL 
KWH X2(5)=2.903; p=0.715 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
KWH X2(5)=1.416; p=0.923 
SMR04 total days KWH X2(5)=2.360; p=0.797 
Registrar General Death 
Data GROS deaths 
Chi square X2(5)=8.238; 
p=0.144 
 
Table A19.  Impact of Living arrangements on outcome 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
Lives alone  or not 
 
No significant impacts 
identified 
Out-patient Attendances 
SMR00 sessions 2005/10 
KWH X2(1)=0.017; p=0.896 
Acute Services Contacts 
Ambulance service Call-outs 
SAS attendances 2008/11 
KWH X2(1)=0.211; p=0.646 
Naloxone administrations 
2008/11 
KWH X2(1)=0.020; p=0.886 
A&E attendances <2008 KWH X2(4)=0.011; p=0.918 
Acute Hospital Admissions  
SMR01 admissions (acute) - 
ALL 
KWH X2(1)=0.093; p=0.760 
SMR01 duration(nights)  - 
ALL 
KWH X2(1)=0.218; p=0.641 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
KWH X2(1)=0.572; p=0.449 
SMR04 total days KWH X2(1)=1.211; p=0.271 
Registrar general Death 
Data GROS deaths 
Chi square X2(5)=1.416; 
p=0.923 
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Table A20.  Impact of having children at baseline on outcomes 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
Has children 
 
No significant impacts 
identified 
Out-patient attendances 
SMR00 sessions 2005/10 
MWU=18524; p=0.699 
Acute services contacts 
Ambulance service Call-outs 
SAS attendances 2008/11 
MWU=236.0; p=0.850 
Naloxone administrations 
2008-11 
MWU=63.5; p=0.604 
A&E attendances <2008 MWU=72.0; p=0.796 
Acute Hospital Admissions 
SMR01 admissions (acute) - 
ALL 
MWU=19459; p=0.821 
SMR01 duration(nights)  - 
ALL 
MWU=4187; p=0.580 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
MWU=144.5; p=0.654 
SMR04 total days MWU=204.5; p=0.530 
Registrar General Death 
Data GROS deaths 
Chi square X2(1)=0.140; 
p=0.709 
 
Table A21.  Impact of living with children at baseline on outcomes 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
Living with children 
 
No significant impact 
identified 
Out-patient attendances 
SMR00 sessions 2005/10 
MWU=14542.0; p=0.323 
Acute services contacts 
Ambulance service Call-outs 
SAS attendances 2008/11 
MWU=255.0; p=0.917 
Naloxone administrations 
2008-11 
MWU=34.0; p=0.261 
A&E attendances <2008 MWU=86.5; p=0.867 
Acute Hospital admissions 
SMR01 admissions (acute) - 
ALL 
MWU=3719.5; p=0.860 
SMR01 duration(nights)  - 
ALL 
MWU=3511.5; p=0.497 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
MWU=92.0; p=0.746 
SMR04 total days MWU=85.0; p=0.530 
GROS deaths Chi square X2(1)=1.847; 
p=0.174 
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Table A22. Impact of Educational level achieved on outcome 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
Educational level achieved 
 
No significant impact 
identified 
Out-patient attendances 
SMR00 sessions 2005/10 
KWH X2(4)=7.491; p=0.112 
Acute Services Contacts 
Ambulance service call-outs 
SAS attendances 2008/11 
KWH X2(4)=6.043; p=0.196 
Naloxone administrations 
2008-11 
KWH X2(4)=0.768; p=0.857 
A&E attendances <2008 KWH X2(4)=1.412; p=0.494 
Acute Hospital Admissions 
SMR01 admissions (acute) - 
ALL 
KWH X2(4)=1.817; p=0.769 
SMR01 duration(nights)  - 
ALL 
KWH X2(4)=3.297; p=0.509 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
KWH X2(4)=5.036; p=0.284 
SMR04 total days KWH X2(4)=5.418; p=0.247 
Registrar General Death 
DataGros death 
Chi square X2(4)=2.380; 
p=0.666 
 
Table A23.  Impact of baseline MAP Psychological Health Score on outcome 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
MAP Psychological Health 
Score 
 
No significant impact 
identified 
SMR00 sessions 2005/10 LRA t(1)=1.895; p=0.059 
Emergency Service Contacts 
Ambulance service Call-outs 
SAS attendances 2008/11 
LRA t(1)=-0.427; p=0.671 
Naloxone administrations 
2008-11 
LRA t(1)=-0.026; p=0.979 
A&E attendances <2008 LRA t(1)=1.120; p=0.270 
Acute Hospital Admissions 
SMR01 admissions (acute) - 
ALL 
LRA t(1)=0.645; p=0.519 
SMR01 duration(nights)  - 
ALL 
LRA  t(1)=-0.096; p=0.924 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
LRA t(1)=0.557; p=0.580 
SMR04 total days LRA t(1)=0.634; p=0.529 
Registrar General Death 
Data GROS death 
LDA  X2(1)=0.041; p=0.840 
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Table A24.  Impact of baseline diazepam dosage on outcome 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
Diazepam dose 
 
No significant impact 
identified 
Out-patient attendances 
SMR00 sessions 2005/10 
LRA t(1)=-1.803; p=0.072 
Emergency Service contacts  
Ambulance service Call-outs 
SAS attendances 2008/11 
LRA t(1)=-0.489; p=0.626 
Naloxone administrations 
2008-11 
LRA t(1)=-0.700; p=0.489 
A&E attendances <2008 LRA t(1)=0.596; p=0.555 
Acute Hospital Admissions 
SMR01 admissions (acute)  LRA t(1)=-0.222; p=0.825 
SMR01 duration(nights)   LRA t(1)=-0.535; p=0.593 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
LRA t(1)=-0.460; p=0.647 
SMR04 total days LRA t(1)=-0.613; p=0.541 
Registrar general Death 
Data GROS death 
LDA X2(1)=2.570; p=0.109 
 
Table A25.  Impact of route of baseline heroin use (injecter/non-injector) on outcome 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
Heroin route 
 
No significant impact 
identified 
Out-patient attendances 
SMR00 sessions 2005/10 
MWU=7581.500; p=0.277 
Emergency Service Contacts 
Ambulance service call-outs 
SAS attendances 2008/11 
MWU=122.500; p=0.885 
Naloxone administrations 
2008-11 
MWU=17.000; p=0.571 
A&E attendances <2008 MWU=14.500; p=0.435 
Acute Hospital Admissions 
SMR01 admissions (acute)  MWU=1798.000; p=0.712 
SMR01 duration(nights)   MWU=1677.500; p=0.392 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
MWU=25.500; p=0.053 
SMR04 total days MWU=30.500; p=0.121 
Registrar general Death 
Data GROS death 
Chi square  X2(2)=0.468; 
p=0.791 
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Table A26.  Impact of baseline illicit diazepam use on outcome 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
IV DV Stats 
 
Diazepam use at baseline 
 
No significant impact 
identified 
Out-patient attendances 
SMR00 sessions 2005/10 
MWU=5959.000; p=0.259 
Emergency Service Contacts 
Ambulance Service Call-outs 
SAS attendances 2008/11 
MWU=74.000; p=0.888 
Naloxone administrations 
2008-11 
MWU=2.500; p=0.286 
A&E attendances <2008 MWU=26.500; p=0.763 
Acute Hospital Admissions 
SMR01 admissions (acute) - 
ALL 
MWU=1528.000; p=0.562 
SMR01 duration(nights)  - 
ALL 
MWU=1590.500; p=0.823 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
MWU=34.000; p=0.113 
SMR04 total days MWU=27.500; p=0.052 
Registrar General Death 
Data 
GROS death 
Chi square  X2(2)=0.511; 
p=0.774 
 
Table A27. Impact of baseline risk taking (IRQ total score) on outcome 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
Risk taking – injecting  
total score 1-17 in IRQ  
(71 of 87 IV cases/537) 
 
No significant impact 
identified 
 
Out-patient attendances 
SMR00 sessions 2005/10 
LRA t(1)=-0.322; p=0.748 
Emergency Services Contacts 
Ambulance Service Call-outs 
SAS attendances 2008/11 
LRA t(1)=-0.410; p=0.696 
Naloxone administrations 
2008-11 
Not tested (numbers) 
A&E attendances <2008 LRA t(1)=-0.447; p=0.685 
Acute Hospital admissions 
SMR01 admissions (acute) LRA t(1)=-0.336; p=0.739 
SMR01 duration(nights)   LRA t(1)=-0.221; p=0.827 
Psychiatric Hospital Admissions 
SMR04 admissions(psych) 
2005/11 
Not tested (numbers) 
SMR04 total days Not tested (numbers) 
Registrar General Death 
Data GROS death 
LDA X2(1)=0.160; p=0.689 
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Table A28.  Impact of baseline social phobia (SPDQ) on outcome 
Independent (Predictor) 
Variable 
Dependent (Process or 
outcome) Variable 
Statistics 
 
SPDQ diagnosis and score 
 
No significant impact 
identified 
Out-patient attendances 
SMR00 sessions 2005/10 
1.MWU=27971.000; p=0.298 
2.LRA t(1)=1.384; p=0.167 
Ambulance Service Call-outs 
SAS attendances 2008/11 
1.MWU=392.000; p=0.393 
2.LRA t(1)=0.323; p=0.748 
Naloxone administrations 
2008-11 
1.MWU=122.500; p=0.631 
2.LRA t(1)=0.089; p=0.930 
A&E attendances <2008 1.MWU=105.000; p=0.560 
2.LRA t(1)=1.019; p=0.316 
Acute Hospital Admissions 
SMR01 admissions (acute) - 
ALL 
1.MWU=6686.000; p=0.539 
2.LRA t(1)=-0.366; p=0.715 
SMR01 duration(nights)  - 
ALL 
1.MWU=6731.000; p=0.709 
2.LRA t(1)=0.146; p=0.884 
Psychiatric Admissions 
SMR04 admissions(psych) 
2005/11 
1.MWU=262.000; p=0.629 
2.LRA t(1)=0.960; p=0.342 
SMR04 total days 1.MWU=264.000; p=0.684 
2.LRA t(1)=1.784; p=0.081 
Registrar general death 
Data 
GROS death 
1.Chi square X2(1)=1.261; 
p=0.262 
2 LDA X2(1)=1.807; p=0.179 
 
  
353 
 
Appendix 6 – Cross Validation demonstration of method 
 
This appendix contains a description of a “test” regression analysis and cross validation 
exercise, undertaken to confirm the effectiveness of the cross validation approach taken 
in Chapter 9. 
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Introduction 
 
In order to demonstrate the validity of the cross validation method used, an exercise was 
undertaken using test data. The exercise aimed to demonstrate cross-validation of a 
predictive model derived from Group a data to Group b. A test dataset was generated using 
the MATLAB programme. Overall, the data fitted y=2.1x+3.5. The total dataset was split into 
two elements - Group a split fitted y=2.0x+3.5; Group b split fitted y=2.1x+3.4. [Complete 
data used are attached in Appendix 6. Figure 1.]  
 
Method 
 
A multiple linear regression was undertaken using Group a data. SPSS outputs are shown 
(Tables 1-3). The R square was 0.816 – i.e. the model predicted 81.6% of the variance (Table 
1). F is very high (therefore very unlikely to occur by chance) Accordingly, the significance 
level for the ANOVA is less than 0.001 (Table 2).  
 
The model generated coefficients (Table 3) - B1 (the gradient of the line) and B0 (the Y 
intercept of line). These coefficients were incorporated into the equation y= bo + bx + 3.5 to 
generate a new variable “ca” – the predicted outcome (“y”) using the Group a model. This 
was then correlated with the Group b observed outcome (“y2b”).  These were highly 
correlated  (Table 4  and scatterplot 1) – demonstrating that the predicted outcome “ca” 
correlates closely with (predicts) the observed outcome in the novel dataset “y2b”. The 
model is generalizable. 
 
Table 1. SPSS output 1 - model summary – Group a data 
Model R R square Adjusted R 
Square 
Standard error of 
estimate 
1.  .903 .816 .814 .273 
 
Table 2. SPSS output 2 - ANOVA 
Model Sum of 
Squares 
df Mean 
Square 
F Significance 
Regression 
Residual 
Total 
32.309 
7.292 
39.601 
1 
98 
99 
32.309 
.074 
434.185 .000 
 
Table 3. SPSS output 3 - Coefficients 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 3.517 .058  60.406 .000 
group a x values 2.027 .097 .903 20.837 .000 
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Cross validation 
Coefficients  from regression a, were used to compute variable “ca”. “ca” was then 
correlated with variable y2b (from dataset B). 
Table 4. SPSS output 4 - Correlations 
 
Predicted outcome 
(calculated c using a model) 
Observed outcome 
gp b - y values with noise 
calculated c using a model Pearson Correlation 1 .917
**
 
Sig. (2-tailed)  .000 
N 100 100 
group b y values with noise Pearson Correlation .917
**
 1 
Sig. (2-tailed) .000  
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
SPSS Output 5.  Scatterplot 1. 
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Repeat test 
 
A further multiple linear regression was undertaken using Group b data. SPSS outputs are 
shown (Tables 5-7). The R square was 0.840 – i.e. the model predicted 84% of the variance 
(Table 5). F is very high (therefore very unlikely to occur by chance) Accordingly, the 
significance level for the ANOVA is less than 0.001 (Table 6).  The model generated 
coefficients (Table 7) - B1 (the gradient of the line) and B0 (the Y intercept of line).  
 
Table 5. SPSS output - model summary – Group b data 
Model R R square Adjusted R 
Square 
Standard error of 
estimate 
1.  .917 .840 .839 .262 
 
Table 6. SPSS output - ANOVA 
Model Sum of 
Squares 
df Mean 
Square 
F Significance 
Regression 
Residual 
Total 
35.320 
6.709 
42.029 
1 
98 
99 
35.320 
.068 
515.898 .000 
 
Table 7. SPSS output - Coefficients 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 3.449 .051  67.548 .000 
group b x values 2.141 .094 .917 22.713 .000 
 
These coefficients were incorporated into y= bo + bx + 3.5 to generate a new variable “cb” – 
the predicted outcome (“y”) using the Group b model. This was then correlated with the 
Group a observed outcome (“y2a”).  These were highly correlated (Table 8 and scatterplot 
2) – demonstrating that the predicted outcome “cb” correlates closely with (predicts) the 
observed outcome in the novel dataset “y2a”. The model is generalizable. 
Table 8. SPSS Output  - Correlations 
 
Observed outcome 
group a y values with 
noise 
Predicted outcome 
calculated c using b 
model 
group a y values with noise Pearson Correlation 1 .903
**
 
Sig. (2-tailed)  .000 
N 100 100 
calculated c using b model Pearson Correlation .903
**
 1 
Sig. (2-tailed) .000  
N 100 100 
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SPSS Output.  Scatterplot 2. 
  
 
Conclusions 
This exercise shows that the method of cross-validation undertaken is effective at demonstrating the 
predictive value of the model generated by regression analysis on novel datasets. 
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Figure 1. Data used in cross validation test exercise  
xa xb y2a y2b x y y2 
1. .9501 .5828 5.3400 4.5259 .9501 4.9003 5.3400 
2. .2311 .4235 3.8023 4.3955 .2311 3.4623 3.8023 
3. .6068 .5155 4.5279 4.2928 .6068 4.2137 4.5279 
4. .4860 .3340 4.3370 4.2652 .4860 3.9720 4.3370 
5. .8913 .4329 5.1758 3.9151 .8913 4.7826 5.1758 
6. .7621 .2259 5.1157 4.0230 .7621 4.5242 5.1157 
7. .4565 .5798 4.0327 4.8605 .4565 3.9129 4.0327 
8. .0185 .7604 3.0751 5.4830 .0185 3.0370 3.0751 
9. .8214 .5298 5.1014 4.8102 .8214 4.6428 5.1014 
10. .4447 .6405 4.7593 5.0210 .4447 3.8894 4.7593 
11. .6154 .2091 5.1651 3.8500 .6154 4.2309 5.1651 
12. .7919 .3798 4.8483 4.3939 .7919 4.5839 4.8483 
13. .9218 .7833 5.0039 5.3697 .9218 4.8436 5.0039 
14. .7382 .6808 5.3493 4.4456 .7382 4.4764 5.3493 
15. .1763 .4611 3.5904 4.8677 .1763 3.3525 3.5904 
16. .4057 .5678 4.4572 5.0516 .4057 3.8114 4.4572 
17. .9355 .7942 5.8378 5.1904 .9355 4.8709 5.8378 
18. .9169 .0592 5.4987 3.3719 .9169 4.8338 5.4987 
19. .4103 .6029 4.6909 5.0792 .4103 3.8205 4.6909 
20. .8936 .0503 4.7972 3.6139 .8936 4.7873 4.7972 
21. .0579 .4154 3.2528 4.5634 .0579 3.1158 3.2528 
22. .3529 .3050 4.5245 4.0322 .3529 3.7057 4.5245 
23. .8132 .8744 5.0565 5.7101 .8132 4.6263 5.0565 
24. .0099 .0150 3.9100 3.1021 .0099 3.0197 3.9100 
25. .1389 .7680 4.0127 5.0893 .1389 3.2778 4.0127 
26. .2028 .9708 4.0929 5.2337 .2028 3.4055 4.0929 
27. .1987 .9901 3.7436 5.8381 .1987 3.3974 3.7436 
28. .6038 .7889 4.3736 4.9135 .6038 4.2076 4.3736 
29. .2722 .4387 3.7000 4.5575 .2722 3.5444 3.7000 
30. .1988 .4983 3.5887 4.0501 .1988 3.3976 3.5887 
31. .0153 .2140 3.4530 3.7846 .0153 3.0305 3.4530 
32. .7468 .6435 5.3495 4.7853 .7468 4.4936 5.3495 
33. .4451 .3200 4.3804 4.0745 .4451 3.8902 4.3804 
34. .9318 .9601 5.6796 5.4827 .9318 4.8636 5.6796 
35. 4660 .7266 4.3928 5.0699 .4660 3.9320 4.3928 
36. .4186 .4120 4.2947 3.9372 .4186 3.8373 4.2947 
37. .8462 .7446 5.1431 5.3874 .8462 4.6924 5.1431 
38. .5252 .2679 4.4625 4.2904 .5252 4.0503 4.4625 
39. .2026 .4399 4.3069 4.6710 .2026 3.4053 4.3069 
40. .6721 .9334 4.3499 5.6817 .6721 4.3443 4.3499 
41. .8381 .6833 4.9736 5.0367 .8381 4.6762 4.9736 
42. .0196 .2126 3.0884 3.6260 .0196 3.0393 3.0884 
43. .6813 .8392 5.0557 4.9516 .6813 4.3626 5.0557 
44. .3795 .6288 4.4091 4.8838 .3795 3.7590 4.4091 
45. .8318 .1338 5.6466 3.8044 .8318 4.6636 5.6466 
46. .5028 .2071 4.5583 3.4738 .5028 4.0056 4.5583 
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47. .7095 .6072 4.8190 4.3034 .7095 4.4189 4.8190 
48. .4289 .6299 4.0566 4.5311 .4289 3.8578 4.0566 
49. .3046 .3705 4.2344 4.1500 .3046 3.6092 4.2344 
50. .1897 .5751 4.1127 4.6243 .1897 3.3793 4.1127 
51. .1934 .4514 3.7627 4.8118 .1934 3.3869 3.7627 
52. .6822 .0439 4.3743 3.6840 .6822 4.3644 4.3743 
53. .3028 .0272 4.0254 3.3833 .3028 3.6055 4.0254 
54. .5417 .3127 4.8370 4.1036 .5417 4.0833 4.8370 
55. .1509 .0129 4.0956 3.6229 .1509 3.3017 4.0956 
56. .6979 .3840 5.3158 3.9294 .6979 4.3958 5.3158 
57. .3784 .6831 4.6015 5.1957 .3784 3.7567 4.6015 
58. .8600 .0928 5.0878 4.1418 .8600 4.7200 5.0878 
59. .8537 .0353 5.3281 3.6662 .8537 4.7073 5.3281 
60. .5936 .6124 4.9184 4.2535 .5936 4.1871 4.9184 
61. .4966 .6085 4.1870 5.0292 .4966 3.9931 4.1870 
62. .8998 .0158 5.7044 3.6416 .8998 4.7995 5.7044 
63. .8216 .0164 5.2125 3.7342 .8216 4.6433 5.2125 
64. .6449 .1901 4.9216 3.4723 .6449 4.2898 4.9216 
65. .8180 .5869 4.8704 4.5987 .8180 4.6359 4.8704 
66. .6602 .0576 4.8692 3.4907 .6602 4.3205 4.8692 
67. .3420 .3676 4.6155 3.9013 .3420 3.6839 4.6155 
68. .2897 .6315 3.9146 5.0961 .2897 3.5795 3.9146 
69. .3412 .7176 4.3379 5.2739 .3412 3.6824 4.3379 
70. .5341 .6927 4.4601 4.8370 .5341 4.0682 4.4601 
71. .7271 .0841 5.0815 4.1248 .7271 4.4542 5.0815 
72. .3093 .4544 4.3177 4.0559 .3093 3.6186 4.3177 
73. .8385 .4418 5.0742 4.7536 .8385 4.6770 5.0742 
74. .5681 .3533 4.5498 4.4759 .5681 4.1361 4.5498 
75. .3704 .1536 4.3960 3.7514 .3704 3.7408 4.3960 
76. .7027 .6756 5.2431 4.9719 .7027 4.4055 5.2431 
77. .5466 .6992 4.4648 5.3501 .5466 4.0931 4.4648 
78. .4449 .7275 4.3150 5.0950 .4449 3.8898 4.3150 
79. .6946 .4784 4.9838 4.2041 .6946 4.3891 4.9838 
80. .6213 .5548 4.8084 4.4624 .6213 4.2426 4.8084 
81. .7948 .1210 5.3062 3.4300 .7948 4.5896 5.3062 
82. .9568 .4508 5.4250 4.3922 .9568 4.9137 5.4250 
83. .5226 .7159 4.8216 4.8410 .5226 4.0452 4.8216 
84. .8801 .8928 5.2496 5.2492 .8801 4.7603 5.2496 
85. .1730 .2731 3.5318 4.1571 .1730 3.3459 3.5318 
86. .9797 .2548 5.6601 3.5807 .9797 4.9595 5.6601 
87. .2714 .8656 4.5256 5.0455 .2714 3.5429 4.5256 
88. .2523 .2324 4.3113 4.0731 .2523 3.5047 4.3113 
89. .8757 .8049 5.4551 4.7848 .8757 4.7515 5.4551 
90. .7373 .9084 4.9596 5.4378 .7373 4.4746 4.9596 
91. .1365 .2319 3.3877 3.7097 .1365 3.2730 3.3877 
92. .0118 .2393 3.6884 4.0660 .0118 3.0235 3.6884 
93. .8939 .0498 5.1532 3.6056 .8939 4.7878 5.1532 
94. .1991 .0784 3.5383 3.6215 .1991 3.3983 3.5383 
95. .2987 .6408 4.1642 4.8230 .2987 3.5974 4.1642 
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96. .6614 .1909 5.1459 4.3241 .6614 4.3229 5.1459 
97. .2844 .8439 4.2428 5.0295 .2844 3.5688 4.2428 
98. .4692 .1739 4.9379 3.7496 .4692 3.9384 4.9379 
99. .0648 .1708 4.0912 3.6493 .0648 3.1296 4.0912 
100.9883 .9943 5.0355 5.4002 .9883 4.9767 5.035 
101.  .5828 4.1656 4.5259  
102    .4235 3.8470 4.3955  
       103    .5155 4.0310 4.2928 
       104    .3340 3.6679 4.2652 
       105    .4329 3.8658 3.9151 
       106    .2259 3.4519 4.0230 
       107    .5798 4.1596 4.8605 
       108    .7604 4.5207 5.4830 
       109    .5298 4.0596 4.8102 
       110    .6405 4.2811 5.0210 
       111    .2091 3.4181 3.8500 
       112    .3798 3.7596 4.3939 
       113    .7833 4.5667 5.3697 
       114    .6808 4.3617 4.4456 
       115    .4611 3.9222 4.8677 
       116    .5678 4.1357 5.0516 
       117    .7942 4.5884 5.1904 
       118    .0592 3.1184 3.3719 
       119    .6029 4.2057 5.0792 
       120    .0503 3.1005 3.6139 
       121    .4154 3.8307 4.5634 
       122    .3050 3.6100 4.0322 
       123    .8744 4.7487 5.7101 
       124    .0150 3.0300 3.1021 
       125    .7680 4.5359 5.0893 
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       126    .9708 4.9417 5.2337 
       127    .9901 4.9802 5.8381 
       128    .7889 4.5777 4.9135 
       129    .4387 3.8773 4.5575 
       130    .4983 3.9966 4.0501 
       131    .2140 3.4279 3.7846 
       132    .6435 4.2870 4.7853 
       133    .3200 3.6401 4.0745 
       134    .9601 4.9202 5.4827 
       135    .7266 4.4533 5.0699 
       136    .4120 3.8239 3.9372 
       137    .7446 4.4891 5.3874 
       138    .2679 3.5359 4.2904 
       139    .4399 3.8798 4.6710 
       140    .9334 4.8668 5.6817 
       141    .6833 4.3667 5.0367 
       142    .2126 3.4251 3.6260 
       143    .8392 4.6785 4.9516 
       144    .6288 4.2576 4.8838 
       145    .1338 3.2675 3.8044 
       146    .2071 3.4143 3.4738 
       147    .6072 4.2144 4.3034 
       148    .6299 4.2598 4.5311 
       149    .3705 3.7410 4.1500 
       150    .5751 4.1503 4.6243 
       151    .4514 3.9028 4.8118 
       152    .0439 3.0878 3.6840 
       153    .0272 3.0544 3.3833 
       154    .3127 3.6254 4.1036 
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       155    .0129 3.0257 3.6229 
       156    .3840 3.7679 3.9294 
       157    .6831 4.3662 5.1957 
       158    .0928 3.1857 4.1418 
       159    .0353 3.0707 3.6662 
       160    .6124 4.2248 4.2535 
       161    .6085 4.2171 5.0292 
       162    .0158 3.0315 3.6416 
       163    .0164 3.0327 3.7342 
       164    .1901 3.3801 3.4723 
       165    .5869 4.1738 4.5987 
       166    .0576 3.1152 3.4907 
       167    .3676 3.7351 3.9013 
       168    .6315 4.2629 5.0961 
       169    .7176 4.4353 5.2739 
       170    .6927 4.3853 4.8370 
       171    .0841 3.1682 4.1248 
       172    .4544 3.9087 4.0559 
       173    .4418 3.8837 4.7536 
       174    .3533 3.7065 4.4759 
       175    .1536 3.3072 3.7514 
       176    .6756 4.3513 4.9719 
       177    .6992 4.3984 5.3501 
       178    .7275 4.4550 5.0950 
       179    .4784 3.9568 4.2041 
       180    .5548 4.1097 4.4624 
       181    .1210 3.2421 3.4300 
       182    .4508 3.9015 4.3922 
       183    .7159 4.4318 4.8410 
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       184    .8928 4.7857 5.2492 
       185    .2731 3.5462 4.1571 
       186    .2548 3.5095 3.5807 
       187    .8656 4.7312 5.0455 
       188    .2324 3.4647 4.0731 
       189    .8049 4.6097 4.7848 
       190    .9084 4.8168 5.4378 
       191    .2319 3.4638 3.7097 
       192    .2393 3.4786 4.0660 
       193    .0498 3.0995 3.6056 
       194    .0784 3.1568 3.6215 
       195    .6408 4.2816 4.8230 
       196    .1909 3.3818 4.3241 
       197    .8439 4.6877 5.0295 
       198    .1739 3.3478 3.7496 
       199    .1708 3.3416 3.6493 
       200    .9943 4.9886 5.4002 
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Appendix 7 – Multicollinearity diagnostic tests 
This appendix contains the tables of outputs from the multicollinearity tests undertaken 
during the multiple regression analyses. 
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Introduction 
In the case of the binary regression analyses undertaken to develop predictive models, all 
factors were inserted into a multiple regression as suggested by Field (2009). Outputs were 
recorded – the tolerance levels and Variance Inflation Factor (VIF). Menard (1995) proposes 
that a tolerance level of <0.1 implies there is a significant issue with collinearity of the  
independent variables. Myers (1990) suggests that a VIF of >10 implies significant 
collinearity.  
The outputs below reflect the tests undertaken for the final proposed models. 
Coefficients – Dependent variable = dead 
 
Model 
Collinearity statistics 
Tolerance VIF 
Age .973 1.028 
Screen done .999 1.001 
Number of admissions .974 1.027 
 
Coefficients – Dependent variable = positive drug tests 
 
Model 
Collinearity statistics 
Tolerance VIF 
Methadone dose .990 1.010 
Diazepam dose .982 1.018 
Where treated .989 1.011 
 
Coefficients – Dependent variable = self-report of drug use 
 
Model 
Collinearity statistics 
Tolerance VIF 
Treatment setting 1.000 1.000 
Route of heroin use 1.000 1.000 
 
Coefficients – Dependent variable = Family stability 
 
Model 
Collinearity statistics 
Tolerance VIF 
Age .937 1.067 
Area lived in .697 1.435 
Treatment setting .907 1.102 
Has children .956 1.046 
Has support from external agency .893 1.120 
Prescribed diazepam .909 1.101 
Illicit diazepam use .772 1.295 
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Appendix 8 - Media coverage 
This Appendix contains example screenshots of online headlines/articles covering the 
political debate around methadone prescribing in Scotland in 2012 
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Shocking picture shows woman licking 
methadone from pavement in front of 
child 
31 Jan 2012 00:00 
THIS shocking picture showing a woman licking methadone from a pavement as a child looks on has 
sparked fury. 
 
THIS shocking picture showing a woman licking methadone from a pavement as a child looks on has 
sparked fury. 
The photograph was taken by a stunned onlooker outside Edinburgh’s Wester Hailes shopping centre 
after the woman dropped the heroin substitute. 
The woman, in her 30s, had gone to a chemist for her weekly prescription for methadone. She was 
accompanied by her friend and a young girl. She was on her way home when she dropped the liquid. She 
then kneeled down and licked it from the dirty pavement. 
The image has sparked outrage in the area, where the woman is a well-known addict. 
Mum-of-four Debbie Notman, 28, said: “People are disgusted anyone would do this in front of a child. 
“My pal took the photo on Saturday. He couldn’t believe what he was seeing. “She was so oblivious she 
didn’t even notice the picture was being taken.” 
Campaigners say the woman needs help and should not be vilified. John Arthur, director of Edinburgh 
drugs group Crew 2000, said: “Addicts can go to extraordinary lengths to get their substances due to the 
cravings they can experience. “This is surely deserving of compassion rather than ridicule.” 
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 By Dailyrecord.co.uk 
Methadone is waste of money 
and failure as a treatment, says 
expert 
20 Aug 2012 06:30 
The destruction of Scotland’s working base by Margaret Thatcher’s Tories left a generation out of work 
and bereft of a future. The Heroin Age had begun. 
 
IN the 1970s, I was on the drugs squad in Glasgow, dealing largely with LSD and cannabis users bringing 
drugs in from Amsterdam and North Africa, usually student types returning from holidays. 
There were so few heroin users in Glasgow then that the head of the squad reckoned he knew every one 
personally. 
The subsequent destruction of Scotland’s working base by Margaret Thatcher’s Tories, however, left a 
generation out of work and bereft of a future. The Heroin Age had begun 
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 By John Ferguson  
Methadone madness: Users slam 
claim that drug is being used to 
cure addiction 
21 Aug 2012 06:30 
MANY addicts we spoke to openly admitted to using methadone AND heroin – a combination that has 
resulted in hundreds of drug deaths. 
Methadone 
A CONSTANT stream of addicts file into Houlihan Pharmacy for their daily hit of methadone. 
The shop sits in one of Glasgow’s poorest areas and comprises a needle exchange on the left and a 
chemist shop, where the heroin substitute is handed out, on the right. 
The chemist on Saracen Street, Possilpark, is Scotland’s biggest single supplier of methadone, taking in 
£856,255 from 2006 to 2011. 
Addicts we spoke to made a nonsense of the claim that the Class A drug is being used to cure their 
addiction 
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 By John Ferguson, David Clegg  
Methadone probe launched by 
Scottish Government after Daily 
Record reveals £36m-a-year 
heroin substitute scandal 
5 Sep 2012 06:30 
THE SNP's Community Safety Minister Roseanna Cunningham has initiated a probe into the controversial 
heroin substitute on the back of the Daily Record's campaign. 
MSP Roseanna Cunningham speaks to the Daily Record's John Ferguson at the Scottish Parliament in 
Edinburgh 
THE Scottish Government are carrying out an urgent inquiry into Scotland’s £36million methadone 
scandal demanded by the Daily Record. 
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 By John Ferguson  
Cycle of death and misery caused 
by black market methadone.. and 
it's all funded by the taxpayer 
4 Sep 2012 06:30 
PRESCRIPTION methadone is traded for street heroin leaving hundreds like teenager Danielle Scott dead. 
Danielle Scott was one of many killed by methadone 
DRUG addicts are selling NHS methadone to buy the heroin it’s meant to wean them off. 
Hundreds have died taking methadone sold by addicts in a taxpayer-funded cycle of misery. 
Victims include angel-faced Danielle Scott, 17, who was fed the heroin substitute by a dealer who got 
gallons of it on prescription. 
Gallons of NHS-funded methadone are being sold in a deadly black market which costs hundreds of lives 
every year. 
Almost half of all drug deaths in Scotland last year were linked to the heroin substitute – and most of the 
casualties had not been prescribed methadone 
 
